

AUTHOR INDEX*

Volume 56

A

Aaltonen, L. A., 3331
 Abbaszadegan, M. R., 5435
 Abbolito, M. R., 5293
 Abdel-Wahab, Z., 2368
 Abe, J., 1828, 2368
 Abe, S., 3220
 Abe, T., 2776
 Abrahams, P. J., 2621
 Abreu-Goris, M., 2556
 Achille, A., 3808
 Adachi, D., 3075
 Adachi, M., 1751
 Adams, D. J., 1063
 Adams, G., 2199
 Adams, G. P., 113
 Adams, J., 4936
 Addivinola, F. J., 3634
 Adler-Moore, J. P., 2066
 Adluri, S., 3315
 Aebi, S., 3087, 4881
 Aeppli, D. M., 2199
 Aerssens, J., 2655
 Afridi, N., 2277
 Afting, M., 4362
 Agarwal, C., 1794
 Agarwal, R., 1023
 Ager, J. W., 121
 Aggarwal, B. B., 5156
 Agnarsson, B. A., 3663
 Ahn, H.-J., 44
 Ahrendt, S., 3630
 Ahrendt, S. A., 4119, 5720
 Akagi, K., 5741
 Akahani, S., 4530
 Akamatsu, H., 4541
 Akaza, H., 4154
 Akie, K., 5557
 Akimoto, S., 2213
 Akino, K., 77
 Akiyama, S., 480
 Akiyama, S.-i., 4124
 Akiyama, Y., 4595
 Akizawa, T., 2535
 Akslen, L. A., 1184
 Alabaster, O., 5339
 Alakhov, V., 3626
 Alarcon, R. M., 4315
 Alas, L., 783
 Alati, T., 2331
 Albanell, J., 1503
 Albertini, R. J., 1405, 2393, 5692
 Albertsen, H., 2157
 Albrecht, S., 2949
 Albright, K. D., 3993
 Aldape, K., 3192
 Aldaz, C. M., 5605
 Alder, H., 2472
 Alemany, R., 3047
 Alexander, R. A., 2900
 Aliaga, C., 2314
 Alldersea, J., 1974
 Allen, C., 3421
 Allen, J. C., 182, 1939
 Almquist, K. C., 3307
 Alpan, R. S., 4358
 Alpaugh, R. K., 113
 Alpert, L., 2949, 3651, 4865
 Alsner, J., 5475
 Alston, K. L., 4970

Altura, R. A., 3837
 Alvord, W. G., 5211
 Aman, P., 4871
 Amaya, H., 2671
 Ames, B. N., 4267
 Amici, C., 210
 Amin, S., 316, 1970, 2979
 Amini, S. B., 3042
 Amiot, M., 1909
 Ammons, J. R., 3670
 Amor-Gueret, M., 515
 Amoroso, A. R., 113
 Amos, C. I., 2596
 An, B., 438
 Anaraki, F., 3069
 Andersen, I., 4782
 Andersen, J. A., 855, 5098
 Anderson, I. C., 715
 Anderson, J., 3220
 Anderson, L., 2059
 Anderson, P. M., 4998
 Anderson, R. C., 5217
 Andersson, L. C., 3230
 Ando, J., 457
 Ando, S., 5165
 Andreeff, M., 3010
 Andrew, S. D., 1241
 Andrews, J. L., 4654
 Angelopoulou, R., 4096
 Angulo, J., 1654
 Anholts, J. D. H., 582
 Annab, L., 5238
 Ansel, J. C., 2191
 Antalis, T. M., 2510
 Anthoney, D. A., 1374
 Antonia, S., 4831
 Anzick, S. L., 3446
 Aoki, T., 2707
 Aoki, Y., 5356, 5741
 Aono, T., 2229
 Aoyagi, K., 2809
 Aoyagi, M., 1828
 App, H., 3540
 Appelbaum, F. R., 2123
 Arai, K., 3004
 Arakawa, S., 2440
 Araki, R., 4424
 Aral, B., 4509
 Arason, A., 3663
 Arbogast, J. G., 3670
 Arcelloni, C., 1210
 Archer, P. G., 4673
 Arcuri, R., 5293
 Arioka, H., 789
 Arita, N., 1440
 Arkins, S., 339
 Arlinghaus, R. B., 3426, 5120
 Armier, J., 5450
 Arming, S., 3134
 Armstrong, C. A., 2191
 Arnold, A., 599
 Arredondo, M. A., 4715
 Arrick, B. A., 4578
 Arteaga, C. L., 1098
 Arthur, D. C., 1418
 Artus, J.-C., 4758
 Aruga, J., 377
 Arwert, F., 2621
 Asami, S., 2546
 Asbell, S. O., 2827
 Asch, B. B., 4841

Asch, H. L., 4841
 Askin, F. B., 2224
 Assmann, G., 4556
 Atkin, N. B., 197
 Atweh, G. F., 1445
 Au, J. L.-S., 2086
 Auer, G., 4219
 August, J. T., 21
 Auricchio, F., 4516
 Avilion, A. A., 645

B

Baas, I. O., 2224
 Babcock, K., 2992
 Babel, K. M., 5217
 Babinet, C., 5659
 Bacchetti, S., 645
 Bacci, G., 2434
 Bacic, G., 3344
 Back, T. C., 1131
 Bäckdahl, M., 4219
 Bader, S., 1487
 Bae, I., 840
 Bae, S.-K., 2281
 Baens, M., 2655
 Baer, M. R., 1418
 Baffa, R., 268, 978, 2472, 3173
 Bahnson, R. R., 1690
 Bai, R., 4398
 Bai, S., 2662
 Baik, S.-C., 1279
 Bailey, L., 1974
 Bailly, C., 471
 Baird, S., 280
 Bajenova, O., 4805
 Baker, E., 5238
 Baker, J., 1118
 Baker, S. M., 4836
 Baker, T. S., 5179
 Bakker, P. J. M., 563
 Balansky, R., 1642
 Baldi, A., 2003
 Baldini, N., 2434, 4570
 Bale, A. E., 4599
 Bale, S. J., 4599
 Baley, P. A., 3359
 Bálint, E., 1648
 Balkwill, F., 190
 Balkwill, F. R., 3610
 Ball, E. D., 3763
 Ballinger, S. W., 5692
 Balsara, B., 4297
 Balsari, A., 2082
 Bamberg, M., 1075
 Bammler, T. K., 2306
 Ban, N., 3577
 Banáth, J. P., 4460
 Band, V., 3129, 3371, 4620
 Bandera, C. A., 2738
 Bandiera, A., 1896
 Banerjee, D., 4142
 Bani, M. R., 3075
 Bankert, R. B., 3743
 Bao, J.-J., 3642
 Bapat, B., 2289, 3842
 Bapat, B. V., 2922
 Barbanti-Brodano, G., 2726, 4820
 Barbin, A., 1267
 Bardi, G., 855, 5098
 Bar-Eli, M., 254
 Barkardottir, R. B., 3663
 Barleon, B., 2299
 Barnhill, R. L., 5023
 Barnouin, K., 988
 Barra, J., 5659
 Barrett, J. C., 241, 2539, 4387, 5238
 Barrett, M. T., 4351
 Barrios, B., 5590
 Barrios, R. J., 4096
 Barsky, S. H., 3560
 Bartek, J., 3630, 5475
 Bartels, C. J., 1761
 Barth, H., 2268
 Bartkova, J., 5475
 Bartram, C. R., 1413
 Bartsch, H., 1267
 Bartus, R. T., 3998
 Barzan, L., 1146
 Baserga, R., 3165, 4013, 4044, 5087
 Basolo, F., 3118
 Basse, B., 4782
 Basse, P., 1599, 3516
 Bassily, N. H., 5012
 Bastert, G., 1988
 Bataille, R., 1909
 Batchu, R. B., 5299
 Bates, S. E., 3010, 3737
 Batra, R. K., 1315
 Battaglia, M., 2566
 Battista, S., 1896
 Bauer, K. D., 1457
 Bauer, S., 3961
 Baughman, T. M., 4171
 Baumann, R. G., 5246
 Bautch, V. L., 1324
 Bauza, G., 3461
 Bax, C. M. R., 2059
 Baxter, L. T., 3771
 Baylin, S. B., 616, 722, 973, 3655
 Bazaz, R., 1902
 Beamer, W. G., 1509
 Beames, B., 1126
 Bean, J. M., 941
 Beard, R. L., 1794
 Beart, R. W., 2375
 Beattie, B., 1352, 4087
 Beauchamp, R. D., 733
 Beaudry, G. A., 5384
 Beazer-Barclay, Y., 679
 Becich, M. J., 1690
 Beck, J. D., 2171
 Beck, W. T., 2573, 3010
 Beck, Y., 2368
 Becker, J. C., 1707
 Becker, K., 3244
 Becker, K.-F., 49
 Becker, S. A., 5092
 Becker, W. K., 527
 Bedi, A., 4551
 Bedi, G. C., 2484
 Bednarik, K., 1118
 Beerepoot, L. V., 3747
 Begent, R. H. J., 3293
 Beger, H. G., 2703
 Behbakht, K., 2738
 Behr, T. M., 1805
 Beidler, D. R., 345
 Beijnen, J. H., 2112, 4709
 Beketic-Oreskovic, L., 1091
 Belair, C. D., 2886
 Belanich, M., 783

* For title of article and coauthors, see listing in Contents of Volume 56 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 56

- Belgaid, C. E., 589
 Belinsky, S. A., 3655
 Bell, D. A., 2501, 4108
 Bellamy, W. T., 5435
 Bellon, T., 1991
 Bellone, M., 11, 1210
 Ben-David, Y., 3075
 Bender, J. R., 3211
 Benedict, M., 5734
 Benedict, W. F., 2245
 Benetatos, C. A., 2584
 Benhamou, S., 251
 Benini, S., 4570
 Benjamin, I., 2738
 Ben-Jonathan, N., 5403
 Bennett, W. P., 4917
 Benoit, A., 5450
 Benson, P. J., 3495
 Bentz, M., 3803
 Bepler, G., 1695
 Beran, M., 1445
 Berard, C. W., 3010
 Berchuck, A., 4590
 Berdel, W. E., 3583
 Bergemann, C., 4686, 4694
 Berger, B., 2094
 Berger, G., 1863
 Berger, M. S., 2405
 Berger, R., 848, 4679
 Bergeron, A., 908
 Berggren, M., 5765
 Bergsagel, P. L., 4370
 Bergthorsson, J. T., 3663
 Berk, T., 2289
 Berkowitz, R., 1250
 Berkowitz, R. S., 2501
 Berman, D. B., 1997, 3409
 Bernard, O., 848
 Bernasconi, B., 4493
 Bernassola, F., 4213
 Bernhard, E. J., 1727
 Bernhard, H., 1756
 Bernstein, C., 1480
 Bernstein, H., 1480
 Bernstein, I. D., 2123
 Bertagnolli, M. M., 2556
 Bertelsen, A. H., 5384
 Bertino, J. R., 4142
 Bertolini, F., 2566
 Bertoni, F., 2434
 Berzofsky, J. A., 3967
 Besedovsky, H. O., 4278
 Best, B., 4362
 Bestilny, L. J., 3796
 Bewley, J. R., 2331
 Bhakoo, K. K., 4630
 Bhalla, K., 4743
 Bhatia, K. G., 969
 Bianco, J. A., 105
 Biasi, M. O., 3808
 Bible, K. C., 4856
 Bicknell, R., 2515, 4799
 Bièche, I., 3886
 Biedler, J. L., 3737
 Biegel, J. A., 3421
 Biegion, A., 4328
 Bieler, C. A., 2025
 Bienstock, R. J., 2539
 Bignami, G. S., 637
 Bigner, D. D., 4970
 Bigsby, R. M., 5403
 Bikle, D. D., 2789
 Bilancio, A., 4516
 Binderup, L., 3570
 Bird, R. P., 2382, 2896
 Birnbaum, D., 471, 3216
 Birnie, G. D., 916
 Birrer, M., 3486
 Birrer, M. J., 305
 Bischoff, E. D., 5566
 Bischoff, P., 49
 Bishop, M. J., 1695
 Bishop, R. E., 3670
 Bitonti, A. J., 359
 Bjerknes, M., 2922, 3842
 Björnstedt, M., 4407
 Black, A. R., 700, 3207
 Black, F. J., 1382
 Black, K. L., 4027
 Blagosklonny, M. V., 1851
 Blakey, D. C., 3287
 Blamey, R. W., 5484
 Blasberg, R., 1352
 Blasberg, R. G., 4087
 Blavier, L., 2891
 Blay, J.-Y., 5499
 Blaydes, B., 2052
 Blijham, G. H., 1111
 Bloch, C., 5734
 Block, A. W., 1418
 Block, N. L., 651
 Blom, M. J., 299
 Blom, R. J. J., 3782
 Blomhoff, H. K., 40
 Bloomer, W. D., 964
 Bloomfield, C. D., 1418
 Blum, J., 1770
 Blumberg, P. M., 2105
 Blumenthal, R. D., 3508
 Blunt, D. G., 3998
 Bockmühl, U., 5325
 Bodell, W., 5410
 Bodell, W. J., 53
 Boden, J. A., 3293
 Boden, R., 3293
 Bodine, D. M., 3186
 Boege, F., 2573
 Boettger-Tong, H. L., 3954
 Boggio, L., 4887
 Boggs, S. S., 3516
 Bogina, G., 3808
 Bögl, O., 5079
 Bohlander, S. K., 1413
 Böhm, S., 689
 Bohr, V. A., 2931
 Boice, J. D., Jr., 1564
 Boiocchi, M., 1146
 Bojanowski, K., 789
 Bojes, H. K., 1
 Boland, C. R., 1237, 3087
 Bolis, P., 4493
 Boltz-Nitulescu, G., 4679
 Bom, V. J. J., 3948
 Bonavida, B., 1874
 Bondy, M. L., 1484, 3975
 Bone, E. A., 2815
 Bongcam-Rudloff, E., 241
 Bonham, M. J., 5146
 Bonilla, F., 1219
 Boolbol, S. K., 2556
 Boone, C. W., 4910
 Borg, A., 2497, 2912, 3663, 4871
 Borg, A. L., 511
 Borgnetto, M. E., 1855
 Borgström, P., 4032
 Børresen-Dale, A.-L., 4778
 Bostwick, D. G., 2411, 4475
 Botella, R., 2191
 Bouchardy, C., 251
 Boucher, R. C., 1315
 Boucher, Y., 964, 4264
 Bouck, N., 4887
 Bouck, N. P., 5684
 Boudier, T. G., 5692
 Bouisson, M., 1742
 Bouterfa, H., 1571
 Bova, G. S., 218, 663, 2527, 3091, 3814, 4387
 Bowers, B., 1974
 Bowman-Gram, T. A., 1724
 Box, G. M., 2815
 Boxer, G. M., 3293
 Boyce, B. F., 4096
 Boyd, D., 5369
 Boyd, J., 2738
 Boyer, L. A., 5023
 Boyer, S. N., 4620
 Boyett, J. M., 3010, 3837
 Boynton, K. A., 1917, 4483
 Bozik, M. E., 3516
 Bradbury, E. M., 3551
 Bradley, A., 1179
 Brady, J. N., 1367
 Brandt, B., 4556
 Brandt, R. M. P., 582
 Brat, D. J., 5217
 Brauch, H., 2927
 Braun, R. D., 5522
 Bravo, L. E., 3238
 Brawley, O., 5547
 Breakefield, X. O., 5423
 Brem, H., 5217
 Brenner, W., 2927
 Brent, T. P., 2029, 5615
 Brentani, R. R., 1682
 Brentnall, T. A., 1237
 Brents, L. A., 4370
 Bresalier, R. S., 4354
 Bresciani, G. L., 689
 Bressac-de-Paillerets, B., 3216
 Brewster, M., 4328
 Briand, P., 2039
 Briane, D., 515
 Brieht, M. M., 5765
 Brien, S., 2475
 Bright, R. K., 1126
 Bringuier, P. P., 3234, 4154
 Brinkmann, O., 4556
 Brinkmann, U., 1346
 Brissette-Storkus, C. S., 3516
 Britts, N. J., 4137
 Brizel, D. M., 941, 5347
 Brizuela, L., 2973
 Broadus, A. E., 1043, 4056
 Brock, J. W., 4694
 Brock, P., 2655
 Brockmüller, J., 3915, 3961, 4965
 Brodeur, G. M., 3421
 Brodie, A. M. H., 4956
 Bronner, M. P., 1237
 Bronte, V., 2832
 Brook, J. D., 5484
 Brooks, J. D., 3814
 Brophy, N. A., 3010
 Brothman, A. R., 2157
 Brown, C. B., 3796
 Brown, L. F., 172
 Brown, P. D., 2815
 Brown, R., 1374
 Brown, T. R., 2964
 Broxterman, H. J., 3010
 Brummett, R. E., 706
 Brunda, M. J., 1131
 Bruneau, P., 984
 Brunelli, B. T., 544
 Bruner, J. M., 1484
 Bryan, E. J., 719, 3534
 Buchdunger, E., 100
 Buchholz, N., 27
 Buchholz, U., 988
 Büchler, M. W., 4876
 Buckley, L. A., 4666
 Buckwalter, C. A., 1674
 Buetler, T. M., 2306
 Bullrich, F., 728
 Buluwela, L., 1155
 Bulyk, M. L., 5023
 Bumol, T. F., 4171
 Bunn, P. A., 831, 5198
 Buraggi, G., 4493
 Burgart, L. J., 4836
 Burgess, A. C., 2263
 Burk, R. D., 197, 3967
 Burke, P. J., 3287
 Bürkle, A., 2715
 Burrell, M., 235
 Burt, R. W., 955, 1382
 Burtis, W. J., 1043
 Buscail, L., 1823
 Bush, T. L., 359
 Buttafoco, P., 3883
 Butterworth, B. E., 4270
 Buys, C. H. C. M., 4853
 Byrd, J. C., 4354

C

- Caday, C. G., 3859
 Cai, H., 802
 Cai, J., 2017
 Cai, J. C., 3842
 Cai, J.-C., 2922
 Cairncross, J. G., 2748
 Cairns, P., 1493, 1892, 2527, 3630, 5044
 Calabresse, C., 3461
 Calabretta, B., 1179, 4332
 Califano, J., 2488, 3630, 5720
 Califano, J. A., 1151
 Caligiuri, M. A., 1418
 Callahan, R., 1775
 Calvo, F., 3461
 Calvo, S., 3118
 Cam, L. L., 3451
 Camellini, L., 3883
 Camoirano, A., 1533
 Campa, M. J., 1695
 Campanacci, M., 2434
 Campbell, I. G., 719, 741, 3534
 Campo, E., 1746
 Camus, A., 5659
 Canaan, E., 1179, 1766
 Candidus, S., 49
 Canevari, S., 5443
 Cannon-Albright, L. A., 1382
 Cano, A., 5391
 Canzian, F., 3331
 Cao, J., 4171
 Capella, C., 4493
 Capella, G., 1823, 5713
 Caperell-Grant, A., 5403
 Capes, A. G., 1241
 Capranico, G., 1855
 Carbone, D. P., 3038, 3967
 Carbone, M., 4044
 Carcelain, G., 362
 Cardonick, A., 2738

* For title of article and coauthors, see listing in Contents of Volume 56 beginning on page i at the end of this index issue.

- Carinci, P., 4820
 Cariuk, P., 1256
 Carlson, B. A., 2973
 Carmichael, P. L., 66, 1475, 5342
 Carner, K., 3021
 Carr, A., 5165
 Carrasquillo, J. A., 3788
 Carrera, C. J., 5653
 Carrington, M., 3967
 Carroll, M. W., 2832
 Carroll, P. R., 3091
 Carson, D. A., 2116, 5653
 Carson, D. D., 2856
 Carter, B. S., 3814
 Casale, V., 5293
 Casamassimi, A., 1896
 Casciani, C. U., 5293
 Cascorbi, I., 3915, 3961, 4965
 Casella, I., 1991
 Caserini, C., 556
 Casero, R. A., Jr., 2527
 Casorati, G., 1210
 Cass, L., 434
 Castedo, M., 2033
 Castle, V. P., 5734
 Castoria, G., 4516
 Castresana, J. S., 5023
 Cats, A., 523
 Cavaliere, F., 5293
 Cavallo, F., 467
 Cavanagh, L. L., 2607
 Cavenee, W. K., 1426, 2405, 3859, 5079
 Cawley, H. M., 4917
 Celis, A., 4782
 Celis, E., 582
 Celis, J. E., 4782
 Cenni, B., 3087, 4881
 Cesano, A., 3021, 4444
 Cesarone, C. F., 1533
 Cha, H.-J., 2281
 Cha, R. S., 4927
 Chadburn, A., 2556
 Chadwick, R. B., 3331
 Chae, Y.-H., 1970, 2052
 Chakraborty, N. G., 2479
 Chamberlain, R. S., 2832
 Chambers, A. F., 2748, 3142
 Chambers, W. H., 3516
 Chammas, R., 1682
 Chan, B. M. C., 3142
 Chan, D. C., 5198
 Chan, H. S. L., 3010
 Chan, K. W. K., 1719
 Chan, M. F., 5039
 Chan, W., 182
 Chandra, R., 4159
 Chandra, S., 4302
 Chandraratna, R. A. S., 1794
 Chandrasekharappa, S., 5272
 Chang, A. E., 2677, 3399
 Chang, H., 1137
 Chang, J.-Y., 345
 Chang, K.-J., 1695
 Chang, K.-T., 206, 794, 1068
 Chang, M.-J., 886
 Chang, R. L., 3695
 Chan-Tack, K., 663
 Chao, C., 959, 4811
 Chapman, A. E., 2584
 Charbonnier, F., 5728
 Charles, H. C., 5347
 Chastre, E., 1823
 Chatterjee, D., 1621
 Chatzaki, E., 2059
 Chau, T., 3142
 Chen, C. H., 4116
 Chen, C.-F., 3168
 Chen, C.-Y. M., 3659
 Chen, D., 1331
 Chen, E. Y., 3436
 Chen, F., 4453
 Chen, F.-A., 3743
 Chen, H., 3038
 Chen, I., 3540
 Chen, J., 4862
 Chen, J.-Y., 206, 794, 1487
 Chen, L., 1331
 Chen, L. B., 538, 544, 551, 3617, 3634
 Chen, M.-H., 206, 794
 Chen, P.-L., 3168
 Chen, S., 3451
 Chen, S.-H., 1737, 3758
 Chen, T., 5605
 Chen, W., 2616, 4142
 Chen, Y., 3168
 Chen, Y.-M., 794
 Chen, Z., 5224
 Chen, Z.-H., 1083
 Chen, Z.-P., 2475
 Chenevix-Trench, G., 3622, 5238
 Cheng, C.-C., 1068
 Cheng, H., 2922, 3842
 Cheng, L., 3638, 3975, 4103
 Cheng, Y.-c., 345, 1674, 4187
 Cheon, J., 4614
 Cher, M. L., 3091
 Cherian, S. P., 1237
 Ches, M., 4370
 Cheung, S.-T., 2721
 Chiappetta, C., 3954
 Chiappetta, G., 1896
 Chiarodo, A., 5547
 Chiarugi, V. P., 2697
 Chidambaram, A., 4599
 Chieco-Bianchi, L., 5466
 Chihara, K., 2440
 Chikramane, S., 182
 Chilvers, E. R., 4255
 Chin, K.-V., 3490
 Chinadurai, G., 2506, 3879
 Chintapalli, J., 1253
 Chiodoni, C., 2531
 Chiu, H.-C., 2738
 Chmura, S. J., 2711
 Cho, C., 3350
 Cho, K. R., 669, 2527
 Cho, M.-J., 1279
 Choi, C.-I., 772
 Choi, P. H. K., 3225
 Choi, S.-W., 4662
 Chou, P., 5684
 Chou, T.-C., 5198
 Chresta, C. M., 1834
 Christen, R. D., 3087, 3993, 4881
 Christensen, J. G., 574
 Christian, M., 569
 Chu, R., 4846
 Chuang, T. C. Y., 3842
 Chuaqui, R. F., 5380
 Chun, S.-B., 2662
 Chung, F.-L., 452, 772
 Chung, G. T. Y., 1609
 Chung, K.-C., 2662
 Chung, K.-N., 1498
 Chung, L. W. K., 4614
 Chung, M.-H., 1279
 Chung, Y.-F., 2721
 Chung, Y.-J., 4662
 Ciernik, I. F., 3038
 Ciliberto, G., 4213
 Cirisano, F. D., 4590
 Citron, M., 783
 Civin, C. I., 973
 Claffey, K. P., 172
 Clark, A. J. L., 3276
 Clark, J. I., 113
 Clarke, A. C., 4811
 Clarke, E., 105
 Clarke, J., 4625
 Clarke, M. F., 1965, 5734
 Clarkin, K. C., 2940
 Claudio, P. P., 2003
 Clayman, G., 2488, 2519
 Clerici, M., 3967
 Cline, J. M., 5098
 Co, M. S., 1118
 Cobbs, C. S., 3192
 Cochran, C., 3338
 Coderre, J. A., 4302
 Coffey, D. S., 218, 3682
 Cohen, A. J., 831
 Cohen, H., 1939
 Cohen, S. M., 4269
 Cohen, Z., 2289
 Colacci, A., 2434
 Colburn, N. H., 483
 Colclitz, G. A., 4862
 Cole, C. E., 710
 Cole, C. N., 4578
 Cole, K., 569
 Cole, S. P. C., 3307
 Coleman, A., 4487
 Coleman, A. B., 1635
 Coleman, C. S., 5136
 Coles, B., 1256
 Collector, M. I., 973
 Collins, A. R., 1291
 Collins, B. J., 4666
 Collins, C., 3441
 Collins, F. S., 5272
 Collins, J. M., 2677
 Collins, S. J., 4942
 Collins, V. P., 5141
 Colnaghi, M. I., 689, 2082, 5443
 Colombo, M. P., 467, 2531
 Commerçon, A., 3689
 Conaldi, P. G., 3118
 Condorelli, G. L., 5113
 Condreay, J. P., 1063
 Conney, A. H., 3695
 Connolly, J. L., 4841
 Connors, M. S., 2550
 Consogno, G., 1210
 Consolino, C. M., 4150
 Constantinou, A. I., 4192
 Contant, C., 3758
 Conti, C. J., 5391
 Contois, D., 3967
 Conway, K., 4773
 Conzen, S. D., 4578
 Cooke, T. G., 3823
 Cooley, A. M., 527
 Coombes, R. C., 1155
 Cooney, K. A., 1142, 4150
 Coons, S., 783
 Cooper, J. D., 4499
 Cooper, S., 3499
 Cope, K. A., 1737
 Copp, H., 816
 Corallini, A., 4820
 Córdón-Cardó, C., 1219, 3010
 Corio, R., 2488
 Corkill, M. E., 4673
 Corless, C., 4159
 Corletto, V., 2472
 Cormier, J. N., 4749
 Cornarotti, M., 689
 Cornelissen-Steijger, P. D. M., 2621
 Corneo, B., 5466
 Correa, P., 3238
 Corrigan, A., 3967
 Corsini, C., 2566
 Cortazzo, M., 1199
 Cosimelli, M., 5293
 Costa, S., 1988
 Costalas, J., 3409
 Costello, J. F., 2405
 Cosyns, J.-P., 2025
 Coticelli, M. G., 978
 Couch, F. J., 2738
 Coufal, F., 5079
 Court, W. J., 2815
 Cowan, K., 1346
 Cox, A. D., 1727
 Cox, G. W., 1131
 Craft, T. R., 4654
 Cramer, D. W., 1250
 Cranston, D., 2515
 Cress, A. E., 5435
 Cresteil, T., 58
 Crevat, A. D., 511
 Crider-Miller, S. J., 1214, 1219
 Criley, S. R., 3682
 Crispin, D. A., 1237
 Crissman, J. C., 1654
 Cristofalo, V. J., 4582
 Croce, C. M., 268, 728, 978, 1179, 1253, 1418, 1766, 2472, 2726, 3173, 4130, 5113
 Crofton-Sleigh, C., 5342
 Cros, S., 5659
 Cryns, V. L., 599
 Cucco, C., 4332
 Cuenca, R. E., 3743
 Cui, X. X., 3695
 Cundiff, D. L., 4887
 Cunningham, J., 1484
 Cunningham, J. M., 4475, 4836
 Curley, S. A., 3642
 Curtis, R. E., 1564
 Cussac, C., 3721
 Czelusniak, B., 121
 Czerwinski, M., 3678

D

- da Costa, L. T., 490
 Daggett, D. A., 3704
 D'Agostini, F., 1533, 1642
 Dai, B., 4111
 Dale, T. C., 4320
 Daley, D., 1382
 Dalton, W. S., 3010, 5435
 Daly, A. K., 4276
 Daly, M., 3409
 D'Ambrosio, C., 4013
 Damen, C. A., 1111
 D'Andrea, E., 5466
 Danhauser-Riedl, S., 3589
 Danielpour, D., 5146
 Danks, M. K., 1664
 Dannenberg, A. J., 2556, 4424
 Dantzig, A. H., 4171
 Darden, T., 2539

AUTHOR INDEX TO VOLUME 56

- Darmay, B. G., 138
Darnowski, J. W., 2522
Darrow, T. L., 2368
Darwiche, N., 4942
Dashwood, R., 4307
Date, M., 2960
Daugherty, B., 4250
Davide, J. P., 2626
Davidson, N. E., 973, 2745
Davies, D., 1155
Davies, D. H., 3287
Davies, Q., 5179
Davis, B. B., 3941
Davis, C. D., 2683
Davis, G. S., 5692
Davis, J. R. E., 3276
Davis, M., 719, 741
Davis, M. A., 3203
Davis, P. A., 569
Davol, P. A., 2522
Dawson, M., 1571
Dawson, M. I., 483, 5055, 5246
Dayananth, P., 3199
Dayer, P., 251
Dayton, M. A., 4236
Deacon, M., 1256
Dean, M., 4599, 5039
Dean, N., 3499
Dean, R. L., 3998
de Andrade, M., 1484
de Bart, A. C. W., 1432
DeBaun, M. R., 5723
Debelenko, L. V., 5272
De Benedetti, V. M. G., 4917
Debiec-Rychter, M., 1517
DeBlasio, T., 3666
deBoer, J. G., 4654
de Bruijn, H. S., 2908
Debruyne, F. M. J., 4154
de Bustros, A., 616
Decaudin, D., 2033
Dechelotte, P., 5728
Decker, H.-J., 2927
DeClerck, Y. A., 2891
DeCosse, J. J., 2556
Deeley, R. G., 3307
Deen, D. F., 154
De Flora, S., 1533, 1642
DeFrank, J. S., 5365
Degani, H., 4328
DeGeorge, G., 1978
Degeorges, A., 3461
De Giovanni, C., 3898, 4503
de Groene, E. M., 299
Dehal, S. S., 1283
Deitz, A. C., 3941
de la Chapelle, A., 235, 3331
del Aguila, L. F., 172
DeLaney, T. F., 2277
Del Buono, R., 5285
Delclos, K. B., 2052
Delcros, J.-G., 5624
Delecluse, H.-J., 5499
Delgado, C. H., 1761
Delia, D., 556
Dellabona, P., 1210
Della Torre, G., 689
Della Torre, P., 4200
Della Valle, V., 848
De Luca, A., 2003
De Luca, L. M., 675, 4942
Demant, P., 2382
Demartis, A., 4213
DeMayo, F. J., 4096
Demers, G. W., 892
De Naro Papa, F., 1533
den Hollander, W., 5179
DeRemer, S., 2677
DeRemer, S. J., 4724
Derry, W. B., 816
Desai, R., 1352
De Santis, M., 3883
de Sousa, G., 1296
de Vere White, R. W., 3042
Devineni, D., 1983
DeVito, B., 4424
Devor, D. E., 4894
de Vree, W. J. A., 2908
de Vries, E. G. E., 523
de Vries, T. J., 1432
Dewey, W. C., 500, 4116
Dewhurst, M. W., 941, 5347, 5522
de Wit, M. J., 4853
Dexter, D. W., 2584
Dhingra, K., 287
di Celle, P. F., 5470
DiCioccio, R. A., 3622
Dickinson, A. J., 4799
Dickinson, J. L., 2510
Di Domenico, M., 4516
Dietel, M., 3010, 5325
DiGiovanna, J. J., 4599
Di Lauro, R., 765
Dillehay, D. L., 3180, 4936
Dilts, C. A., 899
Dinney, C. P. N., 3431
Djeu, J. Y., 3399
Dmitrovsky, E., 1503
Docherty, A. J. P., 715
Dodge, R. K., 5347
Doglioni, C., 1146
Dole, M. G., 5734
Doll, M. A., 3941
Dolnick, B. J., 700, 3207
Donehower, L. A., 4413
Dong, J.-T., 4387
Dong, Q., 5272
Dong, Y., 4841
Dong, Z., 483
Donington, J. S., 4044
Donis-Keller, H., 606
Dörken, B., 4686
Dorovini-Zis, K., 182
Dosaka-Akita, H., 5557
Dosch, J., 3244
Dosik, J., 182
Dotzlaw, H., 4606
Dou, Q. P., 438
Douaud, F., 5624
Dougherty, G. J., 3281, 5647
Dove, W. F., 710
Dowell, R. I., 3287
Doyle, L. A., 2904
Doyle, L. V., 2428
Dragan, Y. P., 2985, 2992
Dransfield, I., 4255
Drazan, K. E., 4891
Driggers, W. J., 1262
Dritschilo, A., 5
Druck, T., 978, 3173
Druker, B. J., 100, 3589
D'Sa-Eipper, C., 2506, 3879
Du, L., 2105
Dubay, M. M., 2973
Dubin, J. A., 434
DuBois, R. N., 733
Duchaud, E., 1400
Dugan, M., 4347
Dugani, A., 3883
Duh, F.-M., 1487
Duh, J.-L., 2954
Dullaart, R. P. F., 523
Dumont, P., 5659
Dumontet, C., 1091
Duncan, D., 91
Dunlop, M. G., 235
Dunn, J. F., 3344
Dunn, R. M., 1805
Dunnick, J. K., 4922
Dunstan, C., 633
Dunstan, C. R., 4063
Duquette, J. G., 3597
Duran, G. E., 1091
Duran, H., 5391
Duray, P. H., 1961, 2411, 5380
Durgam, V. R., 3180
Duro, D., 848
Duthie, S. J., 1291
Dutta, A., 4159
Dvorak, H. F., 172

E

Ealovega, M. W., 1965
Early, J., 1621
Eary, J., 2123
East, S. J., 3287
Easton, D. F., 3663
Eaton, D. L., 2306
Eby, Y., 3630
Eccles, S. A., 2815
Eckelman, W. C., 3788
Eckersley, K. P., 3287
Eckert, R. L., 1794
Edara, S., 5571
Edgehouse, N. L., 3042
Edlin, A. R. M., 1374
Edmiston, S. N., 4773
Edwards, M. J., 507
Efird, J. T., 150
Egilsson, V., 3663
Eguchi, H., 72
Eguchi, Y., 2161
Ehlhardt, W. J., 4171
Eidelman, A., 2336
Eidne, K. A., 2059
Eipers, P., 5734
Eiriksdottir, G., 3663
Eisele, D., 1151
Eisenberg, B. L., 2964
Eisinger, F., 471, 3216
Eissner, G., 5610
Eklund, L. K., 3338
El-Bayoumy, K., 1970, 2052
El-Deiry, W. S., 2250
Elder, D. J. E., 2273
Elia, G., 210
Eling, T. E., 2206
Eliopoulos, A. G., 2178
Elkahloun, A. G., 5141
Ellem, K. A. O., 2510
Elliott, P. J., 3998
Ellis, E. M., 2758
Ellis, I. O., 5484
Ellis, L. M., 3891
Ellwein, L. B., 4269
El-Naggar, A. K., 5600
El-Rifai, W., 3230
Elstner, E., 3570
Emmerich, B., 3589
Emmert-Buck, M. R., 1961, 2411, 5272, 5380
Eng, C., 1241, 2167
Engebraaten, O., 5490
Engchild, J., 4887
Englefield, P., 3534
Enomoto, N., 3004
Ensley, J., 5576
Ensminger, W. D., 2677, 4724
Epperly, M. W., 964
Eppig, J. J., 5047
Epstein, A. L., 4998
Epstein, J. I., 1892, 3091, 3814, 5044
Ercikan-Abali, E. A., 4142
Ergin, M. T., 2479
Ermak, G., 1037
Escudier, B., 362
Esparza, J., 633
Essers, M. C., 2908
Estensen, R. D., 5132
Ethier, S. P., 899, 4049
Eto, H., 2440
Ettenberg, S. A., 4236, 4791
Eugène, M., 3461
Evans, S. M., 405
Ewend, M. G., 5217
Ewing, C. M., 3814
Eyre, H., 783

F

Fabbro, D., 3499
Facchiano, F., 5113
Fagin, J. A., 765
Fair, K. L., 606
Fair, W. R., 4137
Fakhrai, H., 280
Falany, C. N., 1551
Falany, J. L., 1551
Falcone, V., 3118
Faller, D. V., 2277
Fan, H., 4366
Fan, K., 4644
Fan, Y., 2519
Fan, Y.-H., 5128, 5600
Fan, Z., 3666
Fang, G., 4743
Fanjul, A. N., 1571
Fantoni, E., 3883
Faquin, W. C., 4483
Farber, E., 4272
Farmer, A. A., 1719, 3168
Farnebo, L.-O., 4219
Fasco, M. J., 3926
Fasullo, M., 5457
Favaudon, V., 1842
Favre, R. G., 511
Favrot, M. C., 5499
Fedele, M., 1896
Feinberg, A. P., 5723
Feldman, E. L., 4522
Feldman, G. L., 3421
Felton, J. S., 2550
Fendly, B. M., 1457
Feng, Y., 527
Fenoglio-Preiser, C. M., 4267
Fenton, R. G., 5638
Ferber, A., 4013
Ferguson, A. W., 2931
Fernandez, L. E., 5165
Fernandez-Madrid, F., 121
Ferone, R., 3301
Ferrando, A. A., 1746
Ferrara, N., 4032
Ferrari, A., 3883

- Ferrario, A., 2355
 Ferrero, E., 3211
 Ferrero, M. E., 3211
 Fey, G. H., 2171
 Fidanza, V., 1179
 Figg, W. D., 569
 Figge, J., 1037
 Finan, J. B., 5513
 Finegold, M. J., 3758, 4096
 Finette, B. A., 1405
 Fink, D., 3087, 4881
 Fink-Gremmels, J., 299
 Finn, O. J., 3763
 Finn, R., 4087
 Fiore, L., 3118
 Firpo, E. J., 2003
 Fishel, R., 3087
 Fisher, A. M. R., 2355
 Fitton, J. E., 3287
 FitzGerald, D., 926
 Fizzotti, M., 5470
 Flamme, I., 3540
 Flatow, U., 2931
 Flavell, R. A., 5351
 Fleming, T. P., 860
 Fleuren, G. J., 582
 Flick, M. B., 5704
 Florence, C. D., 2411
 Flørenes, V. A., 5490
 Flores, J. F., 5023
 Florian, C. L., 4630
 Flynn, A. A., 3293
 Foà, R., 5470
 Fodstad, O., 5490
 Fojo, A. T., 3010
 Foley, J., 1043, 4056
 Foley, J. F., 4666
 Folkvord, J., 831
 Folli, S., 4758
 Fölsch, U. R., 2641
 Fong, Y., 3225
 Fontana, J. A., 5055, 5246
 Fontanini, G., 3118
 Fontham, E. T. H., 3238
 Fornace, A. J., 1367
 Fornace, A. J., Jr., 840
 Forni, G., 467
 Forssen, E. A., 2066
 Foss, A. J. E., 2900
 Foster, K. A., 3622
 Foulkes, W. D., 719, 741
 Fountain, J. W., 5023
 Fowler, L. C., 3934
 Fox, S. B., 4799
 Frabetti, F., 3898, 4503
 Frackelton, A. R., Jr., 2522
 Frade, R., 254
 Fradet, Y., 908
 Franchi, M., 4493
 Francia, G., 3855
 Frank, I. S., 1471
 Frankel, A. E., 926, 2590
 Franklin, T. J., 984
 Franklin, W., 831
 Franklin, W. A., 4673
 Fraumeni, J. F., Jr., 1564
 Frebourg, T., 5728
 Frederick, M. J., 127, 138
 French, A. J., 4836
 Frenzel, H., 1988
 Fretland, A. J., 527
 Fricke, T., 4694
 Frickin, M., 3486
 Fridman, R., 1654
 Friedlander, D. R., 182, 1939
 Friedman, A. D., 3250
 Friend, S. H., 840
 Frier, M., 5179
 Friess, H., 4876
 Frigerio, L., 4493
 Frilling, A., 2167
 Fryer, A. A., 1974
 Fueyo, J., 694
 Fuggle, S., 2515
 Führer, M., 2171
 Fujii, A., 3196
 Fujii, H., 1493, 5260
 Fujii, Y., 2707
 Fujikake, Y., 480
 Fujiki, H., 3711
 Fujimoto, K., 2666
 Fujimoto, N., 3196
 Fujimoto, S., 5005
 Fujioka, A., 2602
 Fujisawa, K., 4164
 Fujita, K., 434
 Fujitsuka, H., 4904
 Fukata, H., 1104
 Fukuda, M., 789, 2237
 Fukuhara, K., 4205
 Fukumoto, M., 4164
 Fukuoka, M., 1232
 Fukushima, M., 2602
 Fuleihan, N. S., 2277
 Fuller, G. N., 384
 Funa, K., 164
 Furlan, D., 4493
 Furukawa, F., 2767
 Furukawa, K., 2844, 2844
 Furumoto, H., 2229
 Furusato, M., 2738
 Fusco, A., 765, 1896
 Futreal, P. A., 4590
 Futscher, B. W., 5435
 Fuzesi, L., 1892
- G**
- Gabra, H., 950
 Gabrielli, B. G., 2510
 Gabrielson, E., 1493, 2484, 5260
 Gabrilovich, D., 3038
 Gaillani, M. R., 4599
 Gaillard, C., 1296
 Galella, E. A., 5384
 Galili, U., 3069
 Gallagher, C. J., 2059
 Gallagher, W. M., 1374
 Gallahan, D., 1775
 Gallardo, D., 4891
 Gallegos, A., 5765
 Gallez, B., 3344
 Gallice, P. M., 511
 Gallinger, S., 2289, 2922, 3842
 Gallo, J. M., 1983
 Galloway, D. A., 892
 Galloway, S. M., 3257
 Galloway, T. H., 2191
 Games, S., 2033
 Gan, Y., 2086
 Gandhi, V., 4453
 Gangopadhyay, A., 4805
 Gannett, P. M., 3670
 Gansauge, F., 2703
 Gansauge, S., 2703
 Gao, M., 4229
 Gao, Q., 3129
 Gao, Y., 2904
 García, C., 5713
 Garcia, E., 5499
 Gardiner, S., 816
 Garewal, H., 1480
 Garg, P. K., 4970
 Garner, M. M., 5563
 Garr, K., 532
 Garrett, K. E., 1664
 Garrett, P. A., 4773
 Garte, S. J., 4275
 Gascoyne, R. D., 3010
 Gasdaska, J. R., 5765
 Gasdaska, P. Y., 5765
 Gasparotto, D., 1146
 Gately, S., 4887
 Gatenby, R. A., 5745
 Gatter, K. C., 4799
 Gatto, B., 2795
 Gattoni-Celli, S., 3866
 Gauthier, E. R., 1451
 Gawlinski, E. T., 5745
 Gayther, S. A., 3622
 Gaz, R. D., 599
 Gazdar, A. F., 206, 5211
 Gazit, A., 1068, 3540
 Gebbers, J.-O., 1922
 Geiger, T., 3499
 Geil, L., 1487
 Geley, S., 5033
 Geng, Y.-j., 866
 Geradts, J., 3415
 Gerald, T. M., 5246
 Gerald, W. L., 1219
 Gerosa, M., 4820
 Gerrard, B., 4599
 Gerson, S. L., 1880, 5375
 Gerweck, L. E., 1194
 Gespach, C., 1823
 Getz, M. J., 5063
 Getzenberg, R. H., 1690
 Giaccia, A. J., 3436, 4315
 Giaconia, J. M., 3042
 Giancotti, V., 1896
 Giannakakou, P., 3737
 Giarola, M., 556
 Gibbs, J. P., 3678
 Gibson, D. F. C., 2789
 Gibson, J. E., 1012
 Giddings, J., 3499
 Giles, H. D., 4666
 Gilford, J., 1974
 Gill, R. D., 3721
 Gillies, S. D., 1707
 Gilliland, D. G., 1413
 Gilman, L., 831
 Gilmer, T. M., 3659
 Gilmore-Hebert, M., 5704
 Gingras, A.-C., 4382
 Gingrich, J. R., 4096
 Giocanti, N., 1842
 Giordano, A., 2003
 Giovannucci, E., 4862
 Girbes, A. R. J., 3948
 Girolidi, L. A., 3234, 4154
 Girotti, A. W., 4636
 Gize, E. A., 5403
 Glasgow, W. C., 2206
 Glasky, M. S., 4998
 Glazer, P. M., 5754
 Gleeson, C. M., 259
 Glendening, J. M., 5023
 Glick, A. B., 3645
 Glickman, B. W., 4654
 Glinsky, G. V., 5319
 Glinsky, V. V., 5319
 Glover, G. A., 434
 Glover, T. W., 2263, 4347
 Gobl, A., 2561
 Goda, F., 3344
 Godwin, A. K., 1731, 1997, 3409
 Goel, A. S., 5397
 Goggins, M., 5360
 Gohji, K., 3196
 Going, J. J., 916
 Gokaslan, Z. L., 384
 Gold, D. V., 1805
 Gold, L. G., 2998
 Gold, L. S., 4267
 Goldenberg, D. M., 1805, 3508
 Goldspiel, B., 569
 Goldstein, A. M., 4599
 Goldstein, D. J., 2452
 Goldwasser, F., 4430
 Golub, T. R., 1413
 Gomer, C. J., 2355
 Gomes, P., 1155
 Gomez, D. E., 2013
 Gomez-Manzano, C., 694
 Gomm, J. J., 1155
 Goncharova, E. I., 752
 Gonsky, R., 765
 Gonzalez-Zulueta, M., 5039
 Gonzalgo, M. L., 5039
 Good, C. K., 2896
 Goodfellow, P. J., 4499
 Goodman, D., 5765
 Goodrow, T. L., 1137
 Goodtzova, K., 5571
 Goodyer, C. G., 2949
 Gordon, R., 3087
 Gorelick, N. J., 4654
 Gorelik, E., 4464
 Gorospe, M., 31, 475, 3480
 Gosland, M., 4992
 Goto, D., 1512
 Goto, I., 3725
 Gotoh, A., 4614
 Gottardis, M. M., 5566
 Goulette, F. A., 2522
 Gousset, H., 515
 Govers, M. J. A. P., 3270
 Gozes, I., 3486
 Gozes, Y., 3486
 Graber, H. U., 4876
 Graeber, L. A., 3315
 Graeber, T. G., 4315
 Grana, G., 3409
 Grande, J. P., 5063
 Grasso, L., 1991
 Gray, J. W., 3441
 Gray-Goodrich, M., 5211
 Greatens, T. M., 3415
 Greco, M. A., 182
 Green, J. E., 2998, 4894
 Greenall, M., 4625
 Greenberg, B., 2488
 Greenberg, N. M., 4096
 Greenblatt, M. S., 2130
 Greene, G., 5594
 Greenhalgh, D. A., 4413
 Greenwald, E., 4942
 Gregel, C. M., 3244
 Grégoire, M., 5506
 Greider, C. W., 645
 Greil, J., 2171
 Greiner, J. W., 2361, 5293
 Gress, R., 1346
 Gress, T., 3803

AUTHOR INDEX TO VOLUME 56

- Griffin, C. A., 2468
 Griffin, R. J., 5590
 Griffioen, A. W., 1111
 Griffoni, C., 3898, 4503
 Grignon, D., 5071, 5576
 Grignon, D. J., 1654
 Grigorian, M., 5490
 Grillier, I., 3570
 Grimes, S., 880
 Grimm, E. A., 127, 138
 Grindey, G. B., 2331
 Grishko, V. I., 1262
 Griwatz, C., 4556
 Groden, J., 5339
 Groenewegen, G., 1111
 Grogan, T. M., 3010
 Grollman, A. P., 2130
 Groom, A. C., 3142
 Gross, E. A., 1012
 Grosse-Wilde, H., 826
 Grottola, A., 3883
 Grove, K. L., 4187
 Grover, P. L., 5342
 Gruber, G., 4679
 Grudzinskis, J. G., 2059
 Grumet, M., 182, 1939
 Grundy, P., 3837
 Grunt, T., 3350
 Grzesik, W. J., 1948
 Gschwend, J. E., 4137
 Gu, J., 1484, 3975
 Guadagni, F., 5293
 Guan, X.-Y., 3441, 3446
 Guarnieri, F. G., 21
 Gubba, S., 3180
 Gucev, Z. S., 1545
 Gudmundsson, J., 3663
 Guengerich, F. P., 316, 2979, 3926
 Guerra, D., 783
 Guinebretiere, J.-M., 3216
 Guise, T. A., 1043
 Guitjens, S., 706
 Guldberg, P., 5475
 Gumerlock, P. H., 3042
 Gunawardane, R., 1503
 Gunselman, S. J., 5563
 Guo, X., 4876
 Guo, X. J., 2556
 Guo, X. W., 3551
 Gupta, E., 1309
 Gupta, J., 645
 Gupta, V., 3495
 Gürtler, R., 4686
 Guru, S. C., 5272
 Gush, K. A., 802
 Gustafson, C. E., 5238
 Gusterson, B. A., 4320
 Gutiérrez, M. I., 969
 Gutsch, D. E., 3399
 Guyton, K. Z., 3480
- H**
- Ha, T.-Y., 2662
 Haas, A. L., 443
 Haas, M., 500, 2781
 Haas, N., 4686
 Haas-Kogan, D. A., 500
 Haaz, M.-C., 3689
 Hachiya, T., 2945
 Hagerman, L. M., 4200
 Haggitt, R. C., 1237
 Hagiwara, T., 3752
 Hague, A., 2273
- Hahn, S. A., 490, 2527
 Hahnfeldt, P., 1660
 Hailey, J. R., 4922
 Haines, A. M. R., 2123
 Hait, W. N., 3490
 Hakam, A., 1690
 Hákansson, S., 2497
 Hakomori, S.-i., 1932, 5309
 Hakozaki, M., 2776
 Hakura, A., 4343
 Hala, M., 5033
 Halazonetis, T. D., 158
 Haldar, S., 1253
 Hall, I., 3659
 Hall, L. L., 3551
 Hallahan, D., 5150
 Hallahan, D. E., 4311
 Hallek, M., 3589
 Halliday, G. M., 2607
 Halling, K. C., 4836
 Halloran, P. J., 5638
 Haluska, F. G., 5023
 Hamada, H., 1341, 1828
 Hamada, K., 1050, 3047
 Hamaguchi, M., 2936
 Hamann, P., 2123
 Hamann, U., 1988
 Hamazaki, M., 377
 Hamblin, M. R., 1075, 5205
 Hamel, E., 4398
 Hamel, W., 2697
 Hamilton, A. D., 1727
 Hamilton, S. R., 235
 Hamilton, T. C., 1997
 Hammarström, L., 2726, 4130
 Hammerschmidt, W., 5610
 Hammock, B. D., 1471
 Hammoud, Z. T., 4499
 Hampton, G. M., 1426
 Han, E. K.-H., 1389
 Han, W., 1503
 Han, Y., 3859
 Han, Z., 1621
 Hanby, A. M., 3855
 Hand, P., 1974
 Handa, K., 1932
 Handjiski, B., 4438
 Hangan, D., 3142
 Hankey, B. F., 1564
 Hanlon, M. H., 3301
 Hanna, N. N., 4311
 Hanna, R., 3062
 Hannah, S., 4255
 Hansson, G. K., 866
 Hapke, D. M., 2343
 Hara, A., 4904
 Hara, E., 5230
 Hara, I., 2440
 Harada, H., 2417
 Haraguchi, M., 2844
 Harb, J., 5506
 Hardcastle, I. R., 66
 Hardcastle, J. D., 880
 Hardonk, M. J., 523
 Harrelson, J. M., 941, 5347
 Harrington, P., 3622
 Harris, A. L., 2515, 2900, 4320, 4625, 4799
 Harris, C. C., 2130
 Harris, L. C., 2029
 Harris, M. N., 3597
 Hart, A. A. M., 2382
 Hart, I. R., 3855
 Hartman, M., 582
- Hartmann, B. L., 5033
 Hartmann, C., 831
 Hartmann, M., 4362
 Hartmann, O., 362
 Hasan, T., 1075, 5205
 Hasegawa, J.-i., 1713, 2161
 Hashimoto, Y., 5266
 Haskill, J. S., 1303
 Hasleton, P., 1609
 Haslett, C., 4255
 Hassing, I. G. A. M., 299
 Haston, C. K., 2596
 Hata, J.-i., 3320
 Haugen, D. R. F., 1184
 Hauser, S. H., 3129
 Havouis, R., 5624
 Hawke, L., 5238
 Hawkins, A. L., 2468
 Hawkins, D. S., 892
 Hay, K., 2922, 3842
 Hay, N., 2506
 Hayakawa, T., 1440
 Hayashi, H., 2776
 Hayashi, N., 3004
 Hayashi, R., 4307
 Hayes, C. L., 2979
 Hayes, J. D., 1974, 2306, 2758
 Hayward, N. J., 3998
 Hayward, N. K., 5023
 Hazama, S., 2776
 He, A.-G., 4917
 He, M., 294
 Head, D., 3010
 Head, K., 4841
 Heagerty, A. H., 1974
 Healey, C. S., 2167
 Healy, E., 589
 Hearing, V. J., 4464
 Heath, J. E., 4666
 Hecht, S. S., 316, 1970, 2979
 Heck, D. E., 1978
 Hecican, S. P., 663
 Hedrick, L., 669, 2527
 Heidl, S., 4556
 Heim, S., 855, 4778, 5098
 Hein, B., 4782
 Hein, D. W., 527, 3941
 Heine, H. S., 1189
 Heinegård, D., 3902
 Heinen, C. D., 5339
 Heinonen, K., 1418
 Hekele, A., 3134
 Heldin, C.-H., 164
 Helfrich, B., 831
 Helling, F., 3315
 Hellman, S., 4311
 Hellstrand, K., 866
 Helm, K., 831
 Helman, L. J., 1367
 Heltai, S., 1210
 Hembree, J. R., 1794
 Hemminki, A., 3331
 Hemminki, K., 4374
 Henderson, R. A., 3763
 Hendrickson, E. A., 1621
 Henion, T. R., 3069
 Hennequin, C., 1842
 Hennighausen, L., 1775
 Henson, J. W., 150
 Henz, B. M., 4438
 Herberman, R. B., 1599, 4278
 Herbold, C., 1988
 Hercend, T., 362
 Herlyn, M., 757
- Herman, J. G., 616, 722
 Hermann, J., 254
 Hermanson, M., 164
 Hermonat, P. L., 5299
 Herod, J. J. O., 2178
 Herrlich, P., 3134
 Herrmann, F., 4686
 Hertel, L. W., 4453
 Herweg, A., 3583
 Herzig, G. P., 1418
 Hewer, A., 66
 Hewer, A. J., 1475
 Heyman, R. A., 5566
 Hiai, H., 3716
 Hibi, K., 480
 Hickey, E., 2446
 Hickman, J. A., 1834
 Hicks, D. J., 2273
 Hida, T., 3486
 Higashiyama, M., 1751
 Hikida, T., 4164
 Hildesheim, A., 3967
 Hilgarth, M., 4679
 Hill, D., 235
 Hill, T. M., 5397
 Hillan, K. J., 4032
 Hiller, T., 4606
 Hines, S. J., 370
 Hinman, L., 2123
 Hino, O., 429, 2881
 Hinoda, Y., 3605
 Hinoi, T., 2387
 Hipfner, D. R., 3307
 Hiraga, S., 1440
 Hirata, T., 4040
 Hirai, A., 480
 Hirakawa, K., 1828
 Hiraku, Y., 1786, 5172
 Hirano, T., 2546
 Hirashima, T., 1232
 Hirazawa, K., 2776
 Hirohashi, M., 3752
 Hirohashi, S., 268, 330, 2213, 2752
 Hirose, K., 2776
 Hiroumi, H., 5557
 Hirsch, T., 2033
 Hirth, K. P., 3540
 Hirvonen, A., 4108
 Hitchcock, A., 719, 741, 3534
 Hittelman, W. N., 287, 434, 2519, 3047, 3638
 Hixson, D. C., 3934
 Hlatky, L., 1660
 Höckel, M., 4509
 Höcker, P., 4679
 Hockfield, S., 2293
 Hockstra, H. J., 3948
 Hoffman, T., 4992
 Hoffmann, I., 2268
 Höfler, H., 49
 Hofstra, R. M. W., 4853
 Hogan, M. E., 5156
 Hoganson, D. K., 1315
 Hohenberger, P., 4686
 Hohenfellner, R., 2927
 Höhne, A., 1756
 Hoki, Y., 4430
 Holbrook, N. J., 31, 475, 3480
 Hole, K., 4606
 Hollensworth, B. S., 5615
 Hollstein, M. C., 4917
 Holman, P., 5734
 Holmberg, E., 4562
 Holmgren, A., 4407

- Holt, J. T., 1098
Holt, P. R., 2422
Hommura, F., 5557
Honchel, R., 145, 4836
Hong, K., 5522
Hong, W. K., 2519, 3975, 4103, 5128, 5600
Honn, K. V., 1902, 5071
Höög, A., 4219
Hoon, D. S., 5631
Höppener, J. W. M., 4853
Hoque, A. T. M. S., 490
Horai, T., 354
Horbach, G. J., 299
Hori, H., 2116, 5653
Hori, Y., 5653
Horibe, K., 2844
Horio, D., 4307
Horiuchi, T., 2671
Horn, T., 5039
Hornick, J. L., 4998
Hosoe, S., 354
Hosoya, T., 1817
Hou, X., 2616
Houghten, R. A., 3967
Houghton, C., 1241, 2167
Houghton, P. J., 2029, 3010
Houle, B., 4927
Houle, F., 273
Housman, D., 4282
Housman, D. E., 5023
Houweling, A., 2621
Hovig, E., 5490
Howard, C. M., 2003
Howard, R., 3499
Howe, S. R., 4049
Howell, S. B., 3087, 3993, 4881
Howell-Clark, J., 2123
Howley, P. M., 2649
Hoyt, D. G., 4146
Hruban, R. H., 490, 2224, 2527, 5360
Hsieh, J.-T., 3431
Hsieh-Ma, S., 113
Hsing, A. Y., 5146
Hsiung, Y., 91
Hsu, R., 5522
Hsu, S. C., 5684
Hsu, T.-M., 683
Hu, L.-T., 5253
Hu, P., 4998
Hu, R.-H., 3265
Hu, S.-X., 2245
Hu, S.-z., 3055
Hu, X., 2479, 3495
Hua, J., 5279
Huang, Aih., 4324
Huang, Aip., 4366
Huang, C.-l., 1751
Huang, D., 978
Huang, D. P., 2721, 3225
Huang, H.-J. S., 2405, 3859, 5079
Huang, L., 1137, 3926, 4992
Huang, L.-c., 2940
Huang, S., 254
Huang, Y., 4743
Huber, B. E., 1063
Huber, C., 1756, 2927
Hudes, G. R., 2584
Huebner, K., 978, 2472, 3173, 5113
Hueffed, M., 1237
Hugh, J. C., 4244
Huguet, E. L., 4320
Huhn, D., 4686, 4694
Huhnt, W., 4686, 4694
Hui, A. B. Y., 3225
Hui, T. H., 3540
Huibregtse, J. M., 2649
Hulka, B. S., 4773
Hungerford, J. L., 2900
Hunt, C. R., 1770
Hunter, D. J., 4862
Huot, J., 273
Huper, G., 4590
Huryk, R., 4137
Huynh, H., 1509, 3651, 4865
Hwu, P., 2832, 5672
Hyder, S. M., 3954
Hyuga, S., 3366
Hyun, W., 154
- I**
- Iaccheri, L., 4820
Iavarone, A., 1219
Ibrado, A. M., 4743
Ichihara-Tanaka, K., 4541
Ichihashi, M., 3546
Ichimura, K., 5141
Ichiyoshi, Y., 2688
Idle, J. R., 4276
Ieki, Y., 1751
Iezzi, G., 11
Iglehart, J. D., 4590
Iguchi, H., 4040
Ihara, Y., 412
Iida, N., 3711
Iizuka, N., 2776
Ijuhin, N., 412
Ikeda, M., 5741
Ikeda, S., 5741
Ikeguchi, M., 3642
Ikezaki, S., 2767
Iki, M., 2671
Im, S.-Y., 2662
Imai, K., 2707, 3605, 4205
Imai, Y., 3320
Imazeki, F., 5620
Imazu, T., 1713
Imondi, A. R., 4200
Imoto, M., 4978
Imren, S., 2891
Imro, M. A., 1210
Inafuku, S., 4343
Inazawa, J., 1629
Incarbone, M., 2285
Ince, T. A., 2021
Ingvar, C., 2497
Ingvarsson, S., 3663
Inohara, H., 4530
Inomata, M., 2213
Inoue, H., 325, 978
Inoue, M., 4535, 4702
Inskip, A., 1974
Irie, R. F., 5666
Isaacs, J. T., 3404, 4387
Isaacs, W. B., 2527, 3091, 3814, 4387
Isacson, C., 669
Iseda, T., 2881
Ishida, K., 3875
Ishida, T., 789
Ishiguro, T., 875
Ishihara, T., 2776
Ishikawa, T., 3320, 3642
Ishitobi, M., 1341
Isoda, H., 5741
Isogai, Z., 3902
- J**
- Isola, J., 2912, 3441
Isomura, M., 1629
Israel, L., 515
Israel, M. A., 500, 2697, 3192
Issa, J.-P. J., 973, 3655
Itagaki, Y., 4224
Ito, A., 1932
Ito, K., 480
Ito, M., 77
Ito, S., 3546
Ito, T., 3862
Ito, Y., 3004
Itoh, F., 3605
Itoh, H., 2546
Itoh, M., 2535
Itoh, Y., 2161
Itoi, S.-i., 1244
Ittmann, M., 2143
Iuzzolino, P., 4820
Ivanov, B., 1948
Iwamatsu, A., 2752
Iwamoto, K. S., 3862
Iwamoto, S., 2017
Iwasaki, H., 330
Iwase, T., 377
Iwaya, K., 2752
Izbicka, E., 633
Izumi, H., 1512
Izumoto, S., 1440
Izzotti, A., 1533, 1642
- K**
- Kabanov, A., 3626
Kacinski, B. M., 5704
Kadomatsu, K., 5146
Kagamu, H., 4338
Kagan, V. E., 2336
Kagotani, K., 4124
Jensen, S. J., 3421
Jerina, D. M., 3695
Jewett, A., 1874
Jhanwar, S. C., 4297
Jhappan, C., 1775
Ji, B.-Y., 1970
Jiang, H., 3975
Jiang, W., 36
Jiang, X., 3534
Jiao, D., 772
Jiao, J.-J., 2954
Jin, Y., 1978
Jin, Z., 4927
Joab, I., 5499
Johannesdottir, G., 3663
Johannsson, O., 2497
Johannsson, O. T., 3663
Johansson, O., 2912
Johansson, U., 2497
Johns, M. M., III, 1151
Johnson, A. B., 197
Johnson, C., 1731
Johnson, C. S., 886, 4146
Johnson, J. P., 2218
Johnson, K. A., 235
Johnson, T. E., 3257
Johnson, W. D., 1724
Johnson-Thompson, M., 3380
Johnston, D. A., 127, 138, 3642
Joiner, B., 405
Jones, C., 4942
Jones, D. C., 3168
Jones, G., 984
Jones, G. D. D., 1584
Jones, G. M., 419
Jones, J. A., 3866, 3993
Jones, J. B., 264
Jones, P. A., 402, 2375, 2463, 5039
Jones, P. W., 1974
Jones, R. M., 3630
Jones, T. W., 1006
Jong, L., 5055
Jorcano, J. L., 5391
Jorcyk, C. L., 2998
Jordan, M. A., 816
Jordan, P., 27
Jordan, V. C., 2321, 3704
Joseph, I. B. J. K., 3404
Joshi, R., 4087
Jost, M., 3112
Jovanovic, A. S., 1917, 4483
Juarez, J., 5369
Judah, D. J., 2758
JUDGE, J.-G., 969
Judice, S. A., 5692
Julian, M., 5659
Juliano, R., 2302
Jung, G., 5443
Jung, M., 5
Jung, M. O., 1498
Jung, Y.-T., 4662
Junker, R., 4556
Jürgens, B., 5698
Justin, T. A., 880
Juweid, M. I., 1805

AUTHOR INDEX TO VOLUME 56

- Kaina, B., 3244
Kainu, T., 2912
Kakizuka, A., 4164
Kaleem, Z., 4499
Kalkner, K. M., 2561
Kallioniemi, A., 3441
Kallioniemi, O.-P., 3441, 4219, 4778
Kalthoff, H., 1823
Kamada, M., 2229
Kamada, S., 1713, 3546
Kamada, T., 3004
Kamatani, T., 3752
Kamath, N., 4192
Kamb, A., 3199
Kamidono, S., 2440
Kamii, W., 1713, 2161, 4541
Kamino, H., 3597
Kaminsky, L. S., 3926
Kamoto, T., 3716
Kanai, F., 1341, 5620
Kanakura, Y., 412
Kane, K. F., 623
Kanematsu, T., 2348
Kang, H.-S., 2662
Kantarjian, H., 1445
Kantoff, P. W., 3634
Kantor, G. J., 3324
Kantor, J. A., 2361
Kanugula, S., 5571
Kanzawa, F., 789
Kao, C., 4614
Kao, G., 1727
Kao, W. H., 5023
Kao, Y.-C., 3451
Kapelari, K., 5033
Kaplan, C., 955
Karhu, R., 4219, 4778
Kari, C., 3112
Kariya, Y., 1104
Karlsson, C., 241
Karp, J. E., 5547
Karsenty, G., 4614
Karvonen, R. L., 121
Käs, E., 1855
Kasai, H., 1279, 2546
Kasai, Y., 480
Kashanchi, F., 1367
Kashiwagi, M., 4876
Kashiwakuma, T., 4040
Kashuba, V., 1487
Kast, W. M., 582, 3782
Kastan, M. B., 3659
Kastury, K., 978
Katagiri, T., 4575
Katahira, T., 3577
Katayose, D., 1346
Katayose, Y., 4205
Katiyar, S. K., 1023
Kato, D., 1075
Kato, K., 2844
Kato, M., 44, 3752
Kato, N., 5620
Kaufmann, M., 1988
Kaufmann, S. H., 973, 1674, 4856
Kawabe, T., 4124
Kawahara, N., 1512, 5330
Kawai, K., 4649
Kawajiri, K., 72, 3725
Kawakami, M., 538, 4124
Kawakami, Y., 5557
Kawamata, N., 2400
Kawanami, K., 2348
Kawanishi, S., 1786, 5172
Kawano, K., 3004
Kayama, T., 5356
Kaye, A. M., 4328
Kayser, S., 5600
Kazmi, S. M. I., 1056
Keane, M. M., 4236, 4791
Keep, P. A., 3293
Keith, W. N., 3823
Keizer, H. J., 4709
Kelleher, D. K., 2009, 4728
Kelley, K. M., 1545
Kelley, K. W., 339
Kelley, M., 5704
Kelloff, G., 772, 3395
Kelloff, G. J., 710, 1724, 4644, 4910, 5547
Kelly, G. M., 2293
Kelly, P. J., 1939
Kelly, T. M., 4805
Kelsey, K., 4862
Kemppainen, J. A., 4956
Kenemans, P., 5179
Kennedy, A. R., 679
Kennedy, J., 4087
Kennedy, R. C., 1126
Kennedy, T. C., 4673
Kensler, T. W., 3480
Kepler, J. A., 4398
Keppler, D., 988
Kerangueven, F., 471, 3216
Kerb, R., 3915
Kerbel, R. S., 3075
Keri, G., 3540
Kern, S., 1426
Kern, S. E., 490, 2527, 4351, 5360
Kerr, D. J., 2178
Kerr, J., 3622
Kerr, R. G., 802
Kessis, T. D., 669
Kharabanda, S., 3617
Khawli, L. A., 4998
Kheir, A., 5513
Kholodilov, N. G., 197
Kibitel, J., 783
Kida, H., 3743
Kihara, T., 5741
Kijima, T., 354
Kikuchi, A., 2387
Kikuchi, H., 2017
Kim, G., 2045
Kim, H.-C., 2767
Kim, I. S., 3788
Kim, I. Y., 44
Kim, J.-H., 44
Kim, J.-W., 2662
Kim, K. J., 921
Kim, K.-W., 2281
Kim, M.-K., 3788
Kim, P. M., 1526
Kim, S. K., 2519
Kim, S.-J., 3711
Kim, S.-O., 3831
Kim, T.-H., 2837
Kimata, K., 3902
Kimbell, J. S., 1012
Kimura, H., 330, 5522
Kimura, T., 4040
King, C. M., 1517
King, D. J., 2123
King, S. A., 2738
King, T. M., 2596
Kinoh, H., 5678
Kinoshita, I., 5557
Kinoshita, T., 2535
Kinsella, T. J., 2677
Kinzel, V., 2268
Kinzler, K. W., 235, 679, 2936
Kipp, J. B. A., 563
Kiriakova, G., 5319
Kirkin, A. F., 5475
Kisaki, H., 1817
Kishi, K., 5620
Kishida, S., 2387
Kishimoto, T., 354, 5230
Kitadai, Y., 3891
Kitajima, M., 2752
Kitamura, H., 3468
Kitamura, I., 1050, 3986
Kitamura, K., 2945
Kitano, S., 2213
Kjellman, M., 4219
Klaunig, J., 2992
Klecker, R. W., 2677
Kleibuker, J. H., 523, 3270
Klein, G., 1487
Klein, K. M., 3508
Klein, T. W., 3399
Kleiner, D. I., 3431
Klein-Szanto, A., 1983
Klein-Szanto, A. J. P., 1137, 4582
Klimstra, D. S., 2692
Klinger, H. P., 197
Klus, G. T., 4956
Knapp, D., 2199
Knol, J. A., 2677, 4724
Knox, S. J., 4315
Knuth, A., 1756
Knuutila, S., 1418, 3230
Ko, G.-H., 1279
Ko, H.-M., 2662
Ko, S.-C., 4614
Ko, Y.-S., 2662
Kobayashi, H., 3788
Kobayashi, T., 429
Kobits, K., 3474
Kobunai, T., 2809
Koch, C. J., 405
Koch, W., 2484, 2488, 3630, 4119
Koch, W. M., 1151, 5720
Kochi, M., 3986
Koeffler, H. P., 738, 1413, 2400, 3570
Koehl, W., 316
Koff, A., 2003
Kofler, R., 5033
Koh, T., 1244
Kohl, N. E., 2626
Kohn, D. B., 2891
Kohn, E. C., 569
Kohn, K. W., 4430, 5533
Kohno, H., 2752
Kohno, K., 2348, 4124, 4224, 5330
Kohsaka, T., 2368
Kohwi, Y., 457
Kohwi-Shigematsu, T., 457
Koi, M., 3087
Koide, S., 325
Koike, K., 4224
Koike, M., 738
Koiso, K., 4154
Kojima, S., 495
Kokeny, K. E., 899
Kokkinakis, D. M., 2076
Kokura, K., 5230
Komitowski, D., 1988
Komiya, T., 3196
Komori, A., 3711
Kon, K., 5165
Kondo, M., 1886, 5579, 5583
Kondo, S., 2185
Kondoh, G., 4343
Kondratyev, A. D., 1498
Konety, B. R., 1690
Kong, A.-N. T., 2954
Konishi, H., 434
Konishi, Y., 3474
Kono, A., 4040
Kononen, J., 2912
Koo, H.-M., 5211
Koopmann, J., 164
Koops, H. S., 3948
Kopeček, J., 3980
Korbelik, M., 3281, 5647
Korc, M., 4876
Kordon, E., 1775
Kosai, K.-i., 3758
Kosowski, M., 4766
Koster, J. F., 2908
Koths, K., 4530
Koura, A. N., 3891
Koutcher, J., 1352, 4087
Koutsilieris, M., 3123
Kovacic, H. N., 511
Kowbel, D., 3441
Koya, K., 538, 544, 551
Kozaki, K.-i., 3366
Kraeft, S., 3617
Kraft, A. S., 802
Krajewska, M., 2422, 2849
Krajewski, S., 40, 2422, 2849, 3570
Krajcinovic, M., 2733
Kram, J. M., 2191
Krasieva, T. B., 2066
Kratzke, R. A., 3415
Krauss, J. C., 4338
Kraut, M. J., 121
Kreek, M.-J., 1352
Kreil, G., 3134
Kreitman, R. J., 5631
Kris, M. G., 2692
Kristo, P., 3331
Kristofferson, U., 4871
Krizman, D. B., 5380
Kroemer, G., 2033
Kroll, R. A., 706
Kroshoop, J. J., 563
Krosi, G., 3281, 5647
Krosi, J., 3281, 5647
Krtolica, A., 1168
Krystal, G. W., 370
Kuan, H.-Y., 4724
Kubens, B. S., 826
Kubo, A., 1232
Kubo, H., 2368
Kubomura, N., 2752
Kuchibhotla, J., 5150
Kuchler, W. R., 3540
Kudo, R., 5586
Kudo, T., 330, 4205
Kuehl, W. M., 4370
Kuesel, A. C., 2964
Kuettel, M. R., 5
Kufe, D., 3617
Kufe, D. W., 1331
Kuhajda, F. P., 745, 1189, 2745
Kuhns, D. B., 1131
Kuipers, F., 523
Kukreja, S. C., 1043
Kukuvitis, A., 3123
Kumagai, T., 354
Kumar, A., 5397
Kumar, R., 5198
Kung, H.-J., 3042

* For title of article and coauthors, see listing in Contents of Volume 56 beginning on page i at the end of this index issue.

- Kunieda, K., 3743
 Kunz, S., 4391
 Kuo, M. T., 3642
 Kupfer, D., 1283
 Küpper, J.-H., 2715
 Kura, T., 3577
 Kuratsu, J.-i., 1050, 3986
 Kurdi-Haidar, B., 3087
 Kuroda, K., 3366
 Kuroki, D. W., 637
 Kuroki, M., 3747
 Kurtzke, C., 1970
 Kurtzman, S. H., 2479
 Kurz, G., 988
 Kusumoto, H., 2573
 Kutchera, W., 955
 Kuttesch, J. F., 3010
 Kuukasjärvi, T., 3441
 Kuus-Reichel, K., 5397
 Kuwano, M., 1512, 2348, 4124, 4224, 5330
 Kuzmin, I., 1487
 Kwaan, H. C., 4887
 Kyemba, S. M., 3421
 Kyoizumi, S., 3862
 Kyrtisis, A. P., 694, 1484
- L**
- Labrie, C., 4586
 Labrie, Y., 4586
 Labuda, D., 2733
 Lachance, Y., 4586
 Laderoute, K. R., 3436
 Ladisch, S., 4602
 Laissue, J. A., 1922
 Lakshmi, V. M., 3941
 Lam, J. S., 5672
 Lamb, R. F., 916
 Lamborn, K., 154
 Lamph, W. W., 5566
 Lan, K.-H., 1341
 Lan, M. S., 2742
 Land, H., 4630
 Land, S. J., 1517
 Landry, J., 273
 Landsvater, R. M., 4853
 Landuzzi, L., 2434, 3898, 4503
 Laneville, P., 3426
 Langman, M. J. S., 623
 Lankinen, M., 809
 Lansing, T. J., 3659
 Lapointe, J., 4586
 Lapré, J. A., 3270
 Larcher, F., 5391
 Larminat, F., 2931
 Larsen, C.-J., 848
 Larsen, R. H., 1204
 Larson, A. A., 1426
 Larson, R. S., 4378
 Larson, S., 4087
 Larsson, C., 4219
 LaRue, H., 908
 Laskin, J. D., 1978
 Lasko, C. M., 2896
 Laszlo, A., 1770
 LaTemple, D. C., 3069
 Latif, F., 1487
 Latouche, J.-B., 5728
 Latres, E., 1219
 Lau, C. Y., 1056
 Lau, S. S., 1006
 Laughton, C. A., 3451
 Lauridsen, J. B., 4782
 Laval, F., 3721
 Lavarino, C., 689
 LaVoie, E. J., 2795
 Law, K. L., 4171
 Lawler, P., 3967
 Lawrence, E., 955
 Lawrence, J. M. T. S., 2677
 Lawrence, T. S., 3203
 Lawson, M. F., 4255
 Layfield, L. J., 941, 5347
 Lazis, S., 5610
 Lazo, J. S., 4146
 Lazzari, L., 2566
 Lazzarin, L., 4820
 Le, J., 3570
 Le, N., 3788
 Leach, F. S., 235, 2936
 Leach, R. J., 2157
 Lear, J. T., 1974
 Learoyd, D. L., 1241
 LeBlanc, G. A., 574
 Leblanc, T., 848
 Lebowitz, P. F., 2626
 Lechago, J., 1164
 Lechago, L. V., 1164
 LeDoux, S. P., 1262, 5615
 Ledwith, B. J., 3257
 Lee, C., 44
 Lee, C.-C., 1487
 Lee, C.-T., 3038
 Lee, D., 2488
 Lee, H. B., 2662
 Lee, H.-K., 2662
 Lee, H.-Y., 2281
 Lee, J. C. K., 2721, 3225
 Lee, J. J., 434
 Lee, J. S., 5600
 Lee, J.-H., 1222
 Lee, J.-Y., 4662
 Lee, K., 1880
 Lee, K. J., 527
 Lee, L.-F., 1303
 Lee, M. J. A., 2066
 Lee, M.-H., 1214, 1219
 Lee, O.-H., 2281
 Lee, R. Y., 616
 Lee, W.-C., 4297
 Lee, W.-H., 3168
 Lee, W.-K., 1279
 Lee, Y. I., 3831
 Lee, Y.-B., 2662
 Leek, R. D., 4625
 Lefebvre, Y., 2949
 Legha, J., 4453
 Lehnert, M., 3010
 Leier, I., 988
 Leininger, J. R., 1012
 Leith, C. P., 3010
 Leland, P., 5631
 Lemieux, G., 1451
 Lemieux, R., 1451
 Lemke, A.-J., 4686
 Le Moyec, L., 3461
 Lenoir, G. M., 5466
 Lentsch, A. B., 507
 Leonard, C. E., 5198
 Leonard, R. C. F., 950
 Leppert, M. F., 955
 Lerman, M. I., 1487
 Le Roch, N., 5624
 Lertratanakoon, K., 995
 Lester, S., 4159
 Letellier, R., 515
 Leung, D., 4644
 Leung, S.-F., 2721, 3225
 Leunig, M., 4264
 Levi, D. S., 3192
 Levin, V. A., 694, 1484
 Levine, R., 2105
 Levitsky, H. I., 21
 Levitzki, A., 1068, 3540
 Lewin, N. E., 2105
 Lewis, C. E., 4625
 Lewis, C. M., 1382
 Lewis, G. D., 1457
 Lewis, S., 2331
 Leygue, E., 4324, 4606
 Li, B., 783
 Li, C.-W., 2964
 Li, D., 287, 1737, 3638
 Li, H., 3837
 Li, J., 2245
 Li, J. J., 2616
 Li, J.-J., 483
 Li, J.-s., 4956
 Li, M.-f., 4464
 Li, Q., 4343
 Li, R., 4602
 Li, S., 3165, 3626
 Li, S. A., 2616
 Li, X., 4831
 Li, X.-S., 5055, 5246
 Li, Y., 294, 538, 544, 551, 2872
 Li, Y.-Q., 5417
 Liabakk, N.-B., 190
 Liang, L., 4917
 Liang, P., 3634
 Lichter, P., 3803
 Lidereau, R., 3886
 Liggett, W. H., Jr., 4119
 Light, Y., 4735
 Lightman, S., 2900
 Lilge, L., 1075
 Lillehaug, J. R., 1184
 Lim, Y.-P., 3934
 Limacher, J.-M., 5728
 Lin, A. H., 1674
 Lin, F., 4636
 Lin, H., 5079
 Lin, K.-Y., 21
 Lin, L., 4250
 Lin, S.-H., 3431
 Lin, T., 3186
 Lin, Y., 4846
 Lindahl, B., 4374
 Lindblom, A., 4130
 Lindor, N. M., 4836
 Linehan, W. M., 2411, 5380
 Ling, C. C., 4116
 Ling, Y.-z., 4956
 Link, C. J., 569
 Linker-Israeli, M., 3570
 Linnoila, R. I., 305
 Liotta, L. A., 384, 569, 1961, 2411, 5272, 5380
 Lipkin, M., 4644, 4910
 Lipkin, M. L., 2556
 Lipkowitz, S., 4236, 4791
 Lippman, S. M., 5600
 Lippmann, M., 1863
 Lips, C. J. M., 4853
 Lisitsyn, N. A., 2936
 Liskay, R. M., 4836
 Lister, T. A., 448
 Litwin, S., 113
 Liu, E., 294
 Liu, E. T., 4773
 Liu, J., 3426, 5120
 Liu, L., 1880, 4743, 5375
 Liu, L. F., 2795
 Liu, M.-L., 2837, 4894
 Liu, P. C., 2738
 Liu, Q. Y., 1155
 Liu, W., 3891
 Liu, X.-H., 5125
 Liu, X.-L., 3129, 3371
 Liu, Y., 31, 3634, 4992
 Liu, Z., 4297
 Livingston, P. O., 3315
 LiVolsi, V. A., 2738
 Llano, E., 944
 Lloyd, K. O., 3315
 Luis, F., 1823, 5713
 Lo, K.-W., 2721, 3225
 Löchner, K., 2171
 Lock, R. B., 4006
 Loddenkemper, R., 3961
 Lofgren, J. A., 1457
 Lofquist, A. K., 1303
 Loibner, H., 1118
 Lokeshwar, B. L., 651
 Lokeshwar, V. B., 651
 Loktionova, N. A., 1578
 Lollini, P.-L., 3898, 4503, 4570
 Lomo, J., 40
 London, S. J., 4276
 Loney, T. L., 3203
 Longenecker, B. M., 4244
 Longhi, M. P., 1615, 3540
 Longy, M., 471
 Look, A. T., 3837
 López-Beltrán, A., 3526
 López-Otin, C., 944, 1746
 Lord, E. M., 405
 Lorico, A., 5351
 Lorincz, A. T., 3967
 Lotan, R., 2519, 3047, 5128, 5600
 Lothe, R. A., 4778
 Lotz, M. M., 4811
 Loughridge, N. S., 2501
 Louis, D. N., 150, 164
 Love, S. M., 3560
 Love-Schimenti, C. D., 2789
 Lowe, R. M., 1361
 Löwik, C. W. G. M., 1948
 Lowrey, G. A., 4236, 4791
 Lu, J., 5360, 5734
 Lu, J. M., 3980
 Lu, L.-M., 3716
 Lu, M., 4578
 Lu, S.-L., 4595
 Lu, Y., 402, 3666
 Lübke, A. S., 4686, 4694
 Lubensky, I. A., 5272
 Lubet, R. A., 710, 1724
 Luboldt, H.-J., 826
 Lucarelli, E., 3737
 Lucci, J., III, 3967
 Ludlow, J. W., 1168
 Lugo, T. G., 1635, 4487
 Luk, H., 4307
 Lukanidin, E., 5490
 Lukas, J., 5475
 Lukeis, R., 5238
 Lulli, V., 5113
 Lumelsky, N. L., 3909
 Lundgren, E., 4610
 Lundh-Rozell, B., 4562
 Lundy, S. K., 5071
 Luo, L., 2726, 4130
 Luo, W., 4983
 Luo, X.-N., 1445

AUTHOR INDEX TO VOLUME 56

Lupu, R., 3350
 Lydon, N. B., 100
 Lyerly, H. K., 16
 Lynch, H. T., 5360

M

Ma, A., 1291
 Mabry, M., 616
 MacDonald, I. C., 3142
 MacDonald, N. J., 2931
 Mach, J.-P., 4758
 Mackay, J., 950
 Mackey, M. A., 1770
 Macoska, J. A., 1142, 2263
 Maddaus, M. A., 3415
 Madden, S. L., 5384
 Madhukar, B. V., 5403
 Madison, L., 4887
 Madlensky, L., 2289
 Madoc-Jones, H., 3129
 Madsen, M. W., 2039
 Maeda, H., 1868
 Maesawa, C., 612, 3875
 Maestro, R., 1146
 Magalini, A. R., 3808
 Magill-Solc, C., 831
 Magnelli, L., 2697
 Magnuson, S. R., 663
 Magrath, I. T., 969
 Maintz, D., 164
 Mak, K.-F., 2721
 Mak, T. W., 2922, 3842
 Makela, S., 3954
 Makhey, D., 2795
 Maki, C. G., 2649
 Makino, Y., 4224, 5230
 Makita, H., 4904
 Makuuchi, M., 5620
 Malapetsa, A., 2475
 Malé-Brune, R., 2066
 Malfatti, M. A., 2550
 Malins, D. C., 5563
 Man, S., 5484
 Manam, S., 3257
 Manara, M. C., 2434, 4570
 Mandahl, N., 4778
 Mandes, B., 268
 Mandeville, R., 3626
 Manenti, F., 3883
 Maniolelli, G., 1896
 Manfredi, A. A., 1210
 Mani, J.-C., 4758
 Manickam, P., 5272
 Mann, D., 3967
 Mannick, E. E., 3238
 Mannix, R. J., 4146
 Manseau, E. J., 172
 Mantione, J., 3180
 Mao, L., 2519, 5128, 5600
 Marais, R., 4735
 Marcantonio, D., 2475
 Marchetti, D., 2856
 Marchetti, P., 2033
 Margolis, B., 3165
 Mariani, A., 4493
 Marincola, F. M., 4749
 Maring, J. K., 3948
 Marion, R. C., 1664
 Marionnet, C., 5450
 Maris, J. M., 3421
 Mark, E. J., 1961
 Markowitz, S., 5375
 Markowitz, S. D., 2936

Marks, J. R., 4590
 Marmé, D., 2299
 Maroulakou, I. G., 2998
 Marquardt, H., 1471, 2094
 Marquina, G., 5165
 Marre, F., 1296
 Mars, W. M., 2837
 Marschalek, R., 2171
 Marsh, C., 1493, 5260
 Marsh, D. J., 1241
 Marshall, D. J., 710
 Marshall, F. F., 1892, 5044
 Marshall, J. F., 3855
 Marshall, M. A., 3967
 Martin, B. A., 3244
 Martin, B. K., 1303
 Martin, C., 5728
 Martin, F. J., 3743
 Martin, F. L., 5342
 Martin, J., 4735
 Martindale, J. L., 31
 Martinet, M., 1296
 Martini, F., 4820
 Martinotti, S., 1111
 Martiny-Baron, G., 2299
 Martucci, C., 2556
 Maruno, T., 2185
 Marx, S. J., 5272
 Marynen, P., 2655
 Mäsbäck, A., 2497
 Mashal, R. D., 4159
 Mashima, T., 5224
 Mason, T., 294
 Massagué, J., 1214, 1219
 Masters, J. R. W., 1834, 2446
 Masuda, A., 5579, 5583
 Masuda, E., 1868
 Masuda, N., 1232, 4978
 Matei, C., 1352
 Mathupala, S. P., 2468
 Matsuda, H., 1713, 2161, 4541
 Matsui, S.-i., 4715
 Matsukado, K., 4027
 Matsumoto, T., 77
 Matsumoto, Y., 3986
 Matsumura, M., 2671
 Matsuno, S., 1629, 4205
 Matsuno, Y., 2752
 Matsushima, M., 5586
 Matsuyama, M., 3366
 Matsuzawa, A., 3731
 Matsuzawa, Y., 412
 Mattes, M. J., 3062, 3508
 Matthews, D., 2123
 Matthews, W. A., 4044
 Matthews, W. J., 4049
 Matthias, M., 4686
 Matthiessen, U., 4728
 Mauceri, H. J., 4311
 Mauillon, J. L., 5728
 Maurici, D., 4570
 Mauthe, R. J., 2550
 May, R. D., 4666
 Mayer, P., 1118
 Maygarden, S., 294
 Mazué, G., 4200
 Mazure, N. M., 3436
 Mazzoni, A., 5443
 Mazzotti, M., 3898
 Mbalaviele, G., 4063
 McBride, W. H., 4891
 McClay, E. F., 3866, 3993
 McConkey, D. J., 5594
 McCormick, C. L., 706
 McCormick, D. L., 1724
 McCrea, P. D., 5285
 McCurley, T. L., 4378
 McDaid, J., 3287
 McDevitt, T. M., 1256
 McDonald, E. R., III, 2250
 McDonnell, S., 145
 McDonnell, S. K., 4475
 McDonnell, T. J., 694
 McGinnis, P. K., 1965
 McGuigan, J. A., 259
 McIlwraith, A. J., 1374
 McKay, R., 3499
 McKenna, K. A., 4551
 McKenna, W. G., 1727
 McLaughlin, J. P., 2361
 McMahon, G., 3540
 McMahon, J., 91
 McManus, A., 3220
 McMurtrey, A. E., 1457
 McNutt, R. W., 1695
 McQuillan, D. J., 2856
 McWilliams, M. J., 5211
 Mecucci, C., 2655
 Medcalf, A. S. C., 4582
 Medina, D., 4382
 Meeker, A. K., 218
 Meerabux, J., 448
 Meflah, K., 5506
 Meiningner, G., 5720
 Meissner, P., 5610
 Meister, L., 3499
 Melani, C., 467, 2531
 Melder, R. J., 3771
 Meldgaard, P., 1031
 Melief, C. J. M., 582, 3782
 Melino, G., 4213
 Mellado, B., 1503
 Melnyk, O., 921
 Melotti, P., 1179
 Melton, R. G., 3287
 Meltzer, P. S., 2527, 3186, 3441,
 3446, 5141, 5380
 Menanteau, J., 5506
 Ménard, S., 689, 2082
 Mendelsohn, J., 1707, 3666
 Menin, C., 5466
 Menrad, A., 4438
 Menter, D. G., 3103
 Mera, R., 3238
 Merajver, S. D., 1142
 Mercola, D., 280
 Mercurio, A. M., 959, 4811
 Merino, M. J., 1961
 Merkle, K. A., 3695
 Merlino, G., 1775
 Merlo, A., 722
 Merrick, T. A., 4673
 Merrill, A. H., Jr., 4936
 Merrill, F. L., 594
 Mertens, F., 4778, 4871
 Metayer, J., 5728
 Metcalf, J. B., 5319
 Mett, H., 100
 Mettlin, C., 294
 Mew, D. J. Y., 4044
 Meyer, A., 4134
 Meyer, T., 100, 1756
 Mezzananza, D., 5443
 Michaeli, D., 880
 Michalopoulos, G. K., 2837
 Michel, P., 5728
 Midis, G. P., 3870
 Miele, M. E., 1222

Miettinen, M., 3230
 Migliaccio, A., 4516
 Mihatsch, M. J., 27
 Mihich, E., 4282
 Mikami, K., 2823
 Mikheev, A., 5211
 Mikheev, A. M., 4927
 Miki, Y., 4575
 Mikkelsen, T., 5684
 Mikolajczyk, S. D., 5397
 Mikoshiba, K., 377
 Mikulski, S. M., 4180
 Mikuta, J. J., 2738
 Milkie, M. N., 4998
 Millar, L. S., 5397
 Millauer, B., 1615
 Miller, C. M., 3042
 Miller, C. W., 738, 2400
 Miller, F. N., 507
 Miller, J. L., 5205
 Miller, M. J. S., 3238
 Miller, O. J., 5576
 Miller, V. A., 2692
 Miller, Y. E., 831, 4673
 Milligan, A., 2510
 Min, H. Y., 2428
 Mineishi, S., 4142
 Miniero, R., 4503
 Minna, J. D., 1487
 Minty, A., 3583
 Mintz, B., 463
 Miozzo, M., 2285
 Miraglia, L., 3499
 Mirakhor, B., 2256
 Mishina, T., 5557
 Mitchell, B. S., 2343
 Mitchell, M. F., 3047
 Mitchell, S. D., 3855
 Mitelman, F., 4871
 Mitri, A., 2289, 2922
 Mitsudomi, T., 206, 2718, 5583
 Mitze, M., 4509
 Miura, K., 1629
 Miura, Y., 3796
 Mixon, M., 2245
 Miyake, H., 2440
 Miyake, M., 1244, 1751
 Miyamoto, Y., 3004
 Miyao, N., 1932
 Miyashita, T., 556, 1991
 Miyazaki, M., 507
 Miyazaki, T., 2945
 Miyazawa, Y., 5230
 Miyoshi, I., 738
 Mizuno, T., 3862
 Mølandsmo, G. M., 5490
 Mo, Y.-Y., 2633
 Moberger, B., 4374
 Moch, H., 27
 Modica-Napolitano, J. S., 544, 551
 Modzelewski, R. A., 886, 4146
 Moen, C. J. A., 2382
 Moghaddam, A., 4799
 Mohan, S., 384
 Mohanraj, D., 1324
 Mohler, J. L., 4108
 Mohr, G., 2475
 Mohrs, K., 2299
 Mok, S., 1250
 Mok, S. C., 2501
 Molina, I. J., 3526
 Moll, J. F., 3134
 Molpus, K. L., 1075
 Molthoff, C. F. M., 5179

AUTHOR INDEX TO VOLUME 56

- Momburg, F., 1756
 Monaco, C., 2726, 3173
 Monks, A., 5211
 Monks, T. J., 1006
 Monsarrat, B., 58
 Montagna, M., 5466
 Monticello, T. M., 1012
 Montone, K. T., 757
 Moody, T. W., 3486
 Moog-Lutz, C., 3886
 Moon, H., 1961
 Moore, D. C., 925
 Moore, D. H., 3091
 Moore, M. A. S., 1503
 Moorthy, B., 53
 Moran, R. G., 2331
 Moreau, V., 5728
 Morelli, D., 2082
 Morgan, C. J., 594
 Morgan, I., 4229
 Morgan, K. T., 1012
 Morgan, M. A., 2738
 Mori, H., 2767, 4904
 Mori, N., 738, 779
 Mori, S., 1874
 Mori, Y., 1817, 3474
 Morrione, A., 3165
 Morris, T. M., 880
 Morris, V. L., 3142
 Morrison, G. H., 4302
 Morton, R. A., 4096
 Moschel, R. C., 2076
 Moser, A. R., 710
 Mosharaf, M., 1164
 Moskaluk, C. A., 490, 5360
 Moslein, G., 4836
 Moss, B., 2832
 Moss, S. E., 3855
 Moss, S. F., 2422
 Mossine, V. V., 5319
 Mossman, B. T., 5334
 Moulinoux, J.-P., 5624
 Moustacchi, E., 1400
 Mrózek, K., 1418
 Mrozikiewicz, P. M., 3961
 Mücke, C., 3583
 Mueller-Lantzech, N., 4362
 Mukherji, B., 2479
 Mukhtar, H., 1023
 Mulder, A. B., 3948
 Mulder, G. J., 4709
 Muldoon, L. L., 706
 Mullen, C. A., 1361
 Muller, J., 4464
 Müller, J. R., 419
 Müller, M., 100, 2715, 3499
 Müller-Pillasch, F., 3803
 Mulligan, L. M., 1241, 2167
 Mullokandov, M. R., 197
 Mumma, D. L., 4673
 Mundy, G. R., 633, 4063
 Muñoz-Antonia, T., 4831
 Murai, H., 2387
 Murakami, Y. S., 2157
 Murakami-Mori, K., 1874
 Muramatsu, M., 5230
 Muraoka, R., 2671
 Murata, T., 5741
 Murillas, R., 5391
 Murphy, L. C., 4324, 4606
 Murphy-Boesch, J., 2964
 Murray, N., 2191
 Murthy, N., 3954
 Muscat, J. E., 5192
 Muschel, R. J., 1727, 5279
 Musso, K., 2285
 Mutirangura, A., 3530
 Muto, M. G., 1250, 2501
 Muto, T., 875
 Mutter, G. L., 1917, 4483
 Myklebost, O., 5490
 N
 Nadaf-Rahrov, S., 3038
 Nádas, A., 752
 Nadasdy, G. M., 2527
 Nadeau, J. H., 5047
 Nagabhushan, M., 3042
 Nagai, E., 3752
 Nagane, M., 5079
 Nagao, M., 1267
 Nagatake, M., 1886, 2718, 5583
 Nair, J., 1267
 Naito, M., 875, 2823, 5224
 Nakachi, K., 72
 Nakada, T., 5230
 Nakagawa, K., 507, 1232, 3546
 Nakahara, S., 4142
 Nakajima, H., 2368
 Nakajima, M., 875, 3196
 Nakajima, Y., 3474
 Nakamura, H., 480
 Nakamura, J., 4956
 Nakamura, S., 1874
 Nakamura, T., 1179, 1800, 4124, 5230
 Nakamura, Y., 1629, 4575, 5586
 Nakano, H., 3474, 3731
 Nakano, K., 1244, 2602
 Nakano, S., 4027
 Nakano, T., 2771
 Nakase, H., 3004
 Nakashima, M., 77
 Nakatsuru, Y., 3320
 Nakayama, J., 457
 Nakayama, S., 2368
 Namba, H., 77
 Nanda, A., 3859
 Nanni, P., 3898, 4503
 Nannmark, U., 1599
 Nanri, H., 5330
 Naoy, T., 2945
 Naraparaju, V. R., 2827
 Narimatsu, H., 330
 Narumiya, S., 4164
 Nata, M., 5356
 Nath, R. G., 452
 Natoli, F., 4841
 Naud, F., 3123
 Naval, J., 2033
 Navidi, W. C., 4276
 Nawroz, H., 2488, 2527, 3630
 Neal, G. E., 2758
 Nebel, S., 4881
 Neckers, L. M., 1851
 Negendank, W. G., 2964
 Negri, G., 2703
 Negrini, M., 268, 728, 978, 1766, 2472, 2726, 3173, 4130
 Nehmé, A., 4881
 Nelkin, B. D., 616
 Nelson, J. B., 663
 Nelson, R., 105
 Nemoto, H., 2017
 Nepveu, A., 3123
 Neruda, W., 1118
 Nesbit, M., 757
 Neuhaus, C., 2927
 Neuhausen, S. L., 1382
 Neuwelt, E. A., 706
 Neven, P., 1475
 Newberne, P. M., 679
 Newmark, H., 4644, 4910
 Newmark, H. L., 2556
 Newsham, I. F., 2916
 Newton, C. A., 3399
 Newton, M. A., 710
 Nguyen, P., 1851
 Nguyen, P. N., 2105
 Nguyen, S. T., 4679
 Nguyen, T. T., 2375
 Nguyen, V., 87
 Nichols, P. W., 402
 Nichols, W. W., 3257
 Nicklas, J. A., 2393, 5692
 Nicklin, P., 3499
 Nioara, A. E., 511
 Nicoletti, G., 2434, 3898, 4503
 Nicolson, G. L., 384, 2856, 3103, 5369
 Niculescu-Duvaz, I. A., 3287
 Niedobitek, G., 2178
 Niehans, G., 2199
 Niehans, G. A., 3415
 Nielsen, K. V., 2039
 Niewoehner, D. E., 3415
 Niitsu, Y., 3577
 Nimgaonkar, M. T., 3763
 Nini, G., 2434
 Niranjana, B., 1155
 Nishi, M., 5557
 Nishi, T., 1050
 Nishibori, H., 2752
 Nishihara, S., 330
 Nishikawa, A., 2767
 Nishikawa, M., 4535
 Nishikawa, Y., 3366
 Nishimune, Y., 4343
 Nishimura, M., 2832
 Nishinaka, Y., 5666
 Nishio, K., 789
 Nishio, M., 1886
 Nishiura, T., 412
 Nishizuka, S., 612, 3875
 Nistér, M., 164
 Nitiss, J. L., 91
 Noble, M. D., 4630
 Nobori, T., 2116, 5653
 Noda, K., 3004, 5586
 Nodzenski, E., 2711
 Noffsinger, A., 4267
 Noguchi, T., 471, 3216
 Nogueira, C. P., 2277
 Nojima, T., 3220
 Nomizu, T., 4595
 Nomura, H., 2707
 Nomura, M., 3752
 Nooijen, W. J., 2112
 Nose, T., 2185
 Notkins, A. L., 2742
 Nousiainen, T., 1418
 Novakovic, K., 710
 Nowell, P. C., 5513
 Nuijens, A., 1457
 Nunes, I., 495, 3597
 Nuñez, G., 5734
 Nutt, C. L., 2748
 Nuwaysir, E. F., 3704
 O
 Obata, F., 2368
 Oberberg, D., 3583
 Öberg, K., 2561
 Oberley, L. W., 2864
 O'Brien, T., 2515
 O'Brien, T. S., 4799
 Ocando, J. E., 452
 Ochiai, A., 2213
 O'Connor, P. M., 840, 4430
 O'Connor, T., 2758
 Oda, H., 3320
 Oda, K., 5230
 Oda, S., 2688
 Oda, Y., 2017
 O'Dwyer, P. J., 1731
 Odze, R., 1961
 Oei, C., 16
 Oeler, T. A., 1690
 Oelmann, E., 3583
 Offerhaus, G. J. A., 2224
 Offord, R. E., 809
 Offringa, R., 3782
 Ogasawara, H., 789
 Ogasawara, S., 612, 3875
 Ogawa, A., 2368
 Ogawa, J.-i., 325
 Oh, S.-J., 2662
 Oh, Y., 1545
 O'Hara, J. A., 3344
 O'Hare, M., 4320
 Ohashi, K., 3474
 Ohga, T., 4224
 Oh-hara, T., 2809
 Ohkawa, K., 3004
 Ohkura, T., 3468
 Ohlendorf, D., 4686
 Ohnishi, A., 412
 Ohnishi, T., 1440
 Ohno, R., 2945
 Ohno, S., 2688
 Ohno, T., 1817
 Ohta, M., 978, 3173
 Ohtsuru, A., 77
 Ohuchi, E., 2707
 Oida, H., 4164
 Oie, H. K., 5211
 Oka, K., 2771
 Oka, M., 789, 2776
 Okabe, H., 2602
 Okabe, S., 1341, 3711
 Okada, K., 1599
 Okada, M., 2844
 Okada, Y., 2707, 5678
 Okajima, E., 3474
 Okajima, K., 5590
 Okamoto, M., 4649
 Okawa, J., 3196
 Okazaki, M., 2387
 Oki, E., 2688
 Oku, T., 4087
 Okumura, K., 4124
 Olden, K., 2206, 3380
 Olesiak, M., 1660
 Olive, P. L., 2801, 4460
 Olsen, J. C., 1315
 Olson, T. A., 1324
 Olsson, H., 2497, 2912
 Olufemi, S.-E., 5272
 O'Malley, B. W., Jr., 1737
 Omata, M., 1341, 5620
 Omura, S., 2945
 O'Neill, J. P., 2393
 Ong, E. T., 5522
 Ong, G. L., 3062, 3508
 Ono, K., 2017
 Ono, M., 1512, 4224, 5330

* For title of article and coauthors, see listing in Contents of Volume 56 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 56

- Ono, T., 5356
 Ono, Y., 150
 Oohara, T., 2703
 Ooi, J. Y. T., 3165
 Oosterwijk, E., 3234
 Oppenorth, T. J., 663
 Oppenheimer, S., 3112
 Ordóñez, J., 5055
 Orfi, L., 3540
 Organ, C. P., 370
 Oriana, S., 689
 Orikasa, S., 1932
 Orimoto, K., 429
 Orkiszewski, R. S., 995
 Orlow, I., 1219
 Ørntoft, T. F., 1031, 4782
 Orvis, L., 2116
 Osada, H., 1886, 2718, 5579, 5583
 Osada, T., 2752
 Osaka, T., 354
 Osborne, M. R., 66
 Oshidari, F., 16
 Osipov, A. N., 2336
 Østergaard, M., 4782
 Otsuki, Y., 2161
 Ottone, F., 689
 Owen, J., 3021
 Owen-Schaub, L. B., 3870
 Owlia, A., 4111
 Oyama, K., 2602
 Oyasu, R., 2666, 4649
 Oyzanne, B. W., 3823
 Ozawa, H., 4040
 Ozawa, Y., 4040
 Ozeki, S.-i., 77
 Ozono, K., 4541
- P**
- Padavic-Shaller, K. A., 2964
 Pagel, M. A., 706
 Paggi, M. G., 2003
 Paietta, E., 3010
 Paik, C. H., 3788
 Paillot, B., 5728
 Paine-Murrieta, G. D., 5765
 Palazzo, J., 978
 Palmantier, R., 2206
 Palmieri, G., 4503
 Pan, J., 4846
 Pan, S.-s., 5253
 Panagopoulos, I., 4871
 Panasci, L. C., 2475
 Pandis, N., 855, 4871, 5098
 Pang, K. S., 4709
 Pantazis, P., 1621
 Panzica, M. A., 5012
 Paoletti, E., 16
 Papadimitrakopoulou, V., 2519
 Papahadjopoulos, D., 5522
 Papapoulos, S. E., 1948
 Paradee, W., 4347
 Paraskeva, C., 2273
 Pardee, A. B., 3634, 4358
 Pardi, R., 3211
 Pardoll, D. M., 21
 Parekh, H. K., 2256
 Parenza, M., 467, 2531
 Parham, D. M., 3010
 Park, B. C., 2281
 Park, C.-K., 1279
 Park, J.-G., 3831
 Park, S., 738
 Parker, B. A., 4021
 Parker, M. G., 1556
 Parmiani, G., 467
 Pasquini, S., 4444
 Pass, H. I., 4044, 4049
 Pastan, I., 1346, 3788, 5631
 Pasternack, G. R., 745, 1189, 2745
 Pastor, M., 783
 Pastorfide, G. C., 5023
 Pastorino, U., 2285
 Pataer, A., 3716
 Patchefsky, A. S., 2964
 Patel, N., 2314
 Pathak, D. N., 53
 Patrick, M., 4887
 Patterson, G. A., 4499
 Patz, E. F., Jr, 1695
 Pauley, C. J., 3257
 Pauley, R., 5576
 Paull, K. D., 5211
 Paulson, T. G., 4021
 Paulsson, Y., 241
 Paulus, W., 5423
 Paus, R., 4438
 Päufer, S., 1863
 Pavelic, Z. P., 3010
 Payne, C., 1480
 Pearson, B., 955
 Pedersen, B., 1031
 Pedersen, L., 2539
 Pedersen, P. L., 2468
 Pedersen-Bjergaard, J., 1418
 Pederzoli, P., 3808
 Pedley, R. B., 3293
 Peeters, P., 2655
 Pegg, A. E., 1578, 2076, 3265, 5136, 5571
 Peled, A., 2148
 Pèlegri, A., 4758
 Pellat-Decunynck, C., 1909
 Peltomaki, P., 235
 Peña, J., 3526
 Pendás, A. M., 944
 Peng, D., 3666
 Perego, P., 556
 Perez, C., 3350
 Perez, R., 5165
 Pericoli, M. N., 5293
 Perkins, A. C., 5179
 Perlman, E. J., 5723
 Perng, G.-S., 2245
 Perng, R.-P., 206, 794, 1068
 Perry, J. E., 1539
 Perucho, M., 3808
 Peschle, C., 1991, 5113
 Pestka, S., 4250
 Peters, M. M. C. G., 1006
 Petersen, G. M., 5360
 Petersen, I., 5325
 Petersen, O. W., 2039
 Peterson, C. A., 3980
 Peterson, C. M., 3980
 Petersson, C., 4871
 Petropoulos, D., 1361
 Pettaway, C. A., 5594
 Pettit, G. R., 802, 2105, 4398
 Peyrat, J.-P., 3216
 Pfahl, M., 1571
 Pfreundschuh, M., 4766
 Pham, H. T., 651
 Pham-Nguyen, K., 3758
 Philbrick, W. M., 1043, 4056
 Phillips, D. H., 66, 1475, 5342
 Phillips, K. K., 1222
 Phillips, N. J., 606
 Piantadosi, S., 2488, 3814
 Piatyszek, M. A., 218, 645
 Picci, P., 2434, 4570
 Piccinin, S., 1146
 Piché, L., 1451
 Pickford, I., 916
 Piepmeier, J. M., 359, 2293
 Pierotti, M. A., 556, 689, 2285, 2472
 Pietraszkiewicz, H., 5576
 Pietsch, T., 2949
 Pignatelli, M., 5285
 Pilarski, L. M., 4244
 Pilotti, S., 689, 2285, 2472
 Pin, S. S., 3091, 4387
 Pincioli, G., 4200
 Pind, M. T. L., 2922
 Pinder, P. E., 3287
 Pinedo, H. M., 2621
 Pink, J. J., 2321
 Pinkerton, R., 3220
 Pinn, M. L., 5217
 Pinto, T., 3495
 Pitot, H. C., 2985, 2992, 3704
 Pittman, B., 772
 Pittman, G., 4108
 Piulats, J., 5713
 Pizer, E. S., 745, 1189, 2745
 Plante, R. K., 1056
 Plate, K. H., 1615
 Platz, C. E., 1564
 Plautz, G. E., 4338, 4702
 Plé, P., 984
 Plonka, P., 4438
 Plot, R., 1118
 Plunkett, W., 3030, 4453
 Pluth, J. M., 2393
 Podestà, A., 4200
 Pohlen, U., 1863
 Poisson, L., 2590
 Pojer, R., 1241
 Polascik, T. J., 1892, 5044
 Polissar, N. L., 5563
 Pollak, M., 1509, 3651, 4865
 Polverini, P. J., 5684
 Polyak, K., 235
 Polychronakos, C., 3123
 Pommier, Y., 4430
 Pommier, Y. G., 1674
 Pompei, G., 3883
 Pond, S. M., 3689
 Ponder, B. A. J., 1241, 2167, 3622
 Ponta, H., 3134
 Pontes, J. E., 1654
 Poon, G. K., 1475
 Pop, E., 4328
 Porteous, D. J., 950
 Porter, A. T., 5071
 Porter, S., 1228
 Porumb, H., 515
 Posada, J., 5334
 Posadas, E. M., 3682
 Poseno, T., 1405
 Possinger, K., 4686
 Post, K. D., 2493
 Potapova, O., 280
 Potter, B. V. L., 4950
 Potter, M., 419
 Poulos, N. E., 1719
 Powell, C. T., 4137
 Powell, S. N., 5365
 Powis, G., 5765
 Pozzatti, R. O., 2411
 Pradayrol, L., 1742
 Prados, M., 783
 Prager, D., 779
 Prakash, N. J., 359
 Prasad, S. C., 5
 Prats, A.-C., 1742
 Prehn, R. T., 937
 Prendergast, G. C., 2626
 Prescott, S. M., 955
 Press, O. W., 926, 2123
 Presti, J. C., Jr., 27
 Pretlow, T. G., 3042
 Pretlow, T. P., 527, 3042
 Price, B. D., 246
 Price, J. E., 5319
 Pritchard-Jones, K., 3220
 Prochazka, A., 4673
 Proietti, E., 5113
 Propert, K. J., 4159
 Prosnitz, L. R., 941, 5347
 Protti, M. P., 11, 1210
 Proudfoot, S. P., 4673
 Puente, X. S., 944
 Puri, R. K., 5631
 Purohit, A., 4950
 Purpura, P., 2336
 Puthenveetil, J. A., 2886
 Pyronnet, S., 1742
- Q**
- Qian, J., 4475
 Qu, W., 3967
 Quan, W., 3645
 Queen, C., 1118
 Quigley, M. M., 1690
 Quilliet, X., 5450
 Quintanilla, M., 5391
 Quintans, J., 2711
- R**
- Rabbitts, P. H., 1609
 Rabidou, N., 359
 Rabinovitch, P. S., 1237
 Rademaker, A., 2666
 Radford, D. M., 606
 Radinsky, R., 3891
 Ragupathi, G., 3315
 Rahmani, R., 1296
 Raimondi, S. C., 2573
 Rajaniemi, H., 4374
 Rajaraman, S., 4111
 Rajewsky, M. F., 5615
 Rak, J., 3075
 Ramachandra, N., 3180
 Ramakrishnan, S., 1324
 Rammensee, H.-G., 4766
 Ramonetti, J. T., 2556, 4424
 Rand, R. W., 5631
 Randall, T., 783
 Randerath, K., 53
 Rando, R. F., 5156
 Randolph, A. E., 4522
 Ranganathan, S., 2584
 Ranzani, G. N., 268
 Rao, C. V., 532, 2314, 3395
 Rao, G. N., 3338, 4666
 Rao, J., 5513
 Rao, J. S., 384
 Rao, K. V. N., 1724
 Rao, M. S., 4846
 Rao, S., 5684
 Rappa, G., 5351
 Rappaport, S. M., 5410

AUTHOR INDEX TO VOLUME 56

- Rasio, D., 1766, 2726
Rasmussen, H. H., 4782
Ratain, M. J., 1309
Rathod, B., 5513
Ratnam, A. V., 2789
Ratz, G. P., 4782
Raubitschek, A., 3055
Raue, F., 2167
Raught, B., 4382
Rauscher, F. J., III, 4288
Rav, C. V., 4566
Ravery, V., 1654
Ravindranath, M. H., 5666
Ray, D. W., 3276
Ray, M. E., 3186
Raz, A., 1902, 2960, 4354, 4530
Re, G. G., 2590
Rea, D., 1556
Read, A., 1228
Realpe, J. L., 3238
Reato, G., 5470
Rebane, B. A., 2738
Rebbeck, T. R., 3421
Rebeiz, C. A., 339
Rebeiz, N., 339
Rector, D., 783
Reddish, M. A., 4244
Reddy, B. S., 532, 1970, 2314, 3395, 4566
Reddy, J. K., 4846
Reddy, K. C., 4846
Redgate, E., 3516
Redston, M., 2922, 3842
Reed, A. L., 3630
Reed, E., 569
Reed, J. C., 40, 556, 1991, 2422, 2849, 3570
Reed, M. J., 4950
Rees, J. L., 589
Reese, K. J., 5723
Reese, L., 3021
Reeves, J. R., 3823
Reeves, M. E., 5672
Reeves, S. A., 5423
Regimbald, L. H., 4244
R  gnier, C. H., 3886
Rehman, I., 589
Reichardt, P., 4686
Reichart, D. B., 2781
Reichert, U., 5055
Reid, B. J., 4351
Reid, L. H., 1214
Reifenberger, G., 5141
Reifenberger, J., 5141
Reisfeld, R. A., 1707
Reisman, D., 1648
Reiss, M., 4831
Reist, C. J., 4970
Reiter, A., 4936
Reitmair, A. H., 2922, 3842
Remack, J. S., 2029
Rempel, A., 2468
Remsen, L. G., 706
Resnick, M. I., 3042
Resnicoff, M., 4013, 4044
Resnik, J. L., 2781
Ressing, M. E., 582
Restifo, N. P., 2832
Reszka, R., 1863
Reubi, J. C., 1922, 3486
Reufi, B., 3583
Reyes, G., 5713
Reynolds, A. B., 2633
Reynolds, T. Y., 5754
Reznikoff, C. A., 2886, 4649
Rhee, K-H., 1279
Rhim, J. S., 5
Rhyu, M-G., 4662
Riabowol, K. T., 3796
Rice, G. C., 105
Richards, E. H., 2446
Richardson, A-L., 1241
Richer, C., 2733
Richie, J. P., 4159
Richie, J. P., Jr., 5192
Ridet, A., 1400
Ridings, J. W., 899
Riess, H., 4686, 4694
Rietbroek, R. C., 563
Riffe, M. E., 305
Rifkin, D. B., 495, 3597
Rigas, J. R., 2692
Rigby, H., 589
Righetti, S. C., 556, 689
Rigotty, J., 772
Riley, D., 5384
Rimm, E. B., 4862
Rimsza, L., 3010
Ring, D. B., 113
Rio, M-C., 3886
Riou, J-F., 3689
Risau, W., 1615, 3540
Rishi, A. K., 2904, 5055, 5246
Risio, M., 4910, 5470
Risse, B., 3112
Ritacca, F., 2289
Ritchie, A. J., 259
Reed, A. L., 3630
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413
Roos, J. C., 5179
Roots, I., 3915, 3961, 4965
Rosales, C., 2302
Rose, A., 91
Rose, D. P., 5125
Rose, K., 809
Roselli, M., 5293
Rosen, J. M., 4096, 4382
Rosenbach, M. D., 5653
Rosenberg, S., 2428
Rosenberg, S. A., 2832, 4749, 5672
Rosenfeld, R. G., 1545
Rosenstein, M., 964
Roses, D. F., 3597
Rosin, M. P., 443
Ross, D. D., 2904
Ross, J. S., 1037
Ross, M. A., 1291
Rosselli, F., 1400
Rossi, A., 210
Rossi, I., 3898, 4503
Rossini, F. P., 4910, 5470
Rossman, T. G., 752
Roth, J. A., 694, 3047
Roti Roti, J. L., 1770
Rotter, V., 2148
Rousset, F., 5499
Rovera, G., 4444
Rowe, M., 4610
Royal, R. E., 5672
Royer, I., 58
Roz, L., 1228
Rozenblum, E., 490
Rozenfurt, E., 3895, 5758
Riva, C., 4493
Rivard, S., 5576
Riverson, A., 772, 1970, 3395
Rivera, M. I., 1006
Rivory, L. P., 3689
Ro, J. Y., 1892
Robbins, P. D., 3763
Robbins, T. L., 4200
Robert, B., 4758
Robert, J., 3689
Roberts, J. D., 2206
Robertson, G., 4487
Robertson, G. P., 1635
Robertson, J. M., 2677
Robertson, K. W., 3823
Robertson, L. D., 3796
Robertson, M., 955
Robey, F. A., 1948
Robey, P. G., 1948
Robillard, N., 1909
Robinson, B. G., 1241
Robinson, G., 880, 1775
Robinson, J. C., 3814
Robinson, L., 1037
Robles, A. I., 5391
Rocco, J., 4119
Roche, P. C., 4836
Rockwell, S., 5704, 5754
Rode, C., 5734
Rodeck, U., 3112
Rodgers, Q. E., 2573
Rodolfo, M., 467
Rodov, S., 5704
Rodrigues-Lima, F., 254
Rodr  guez, L. V., 127, 138
Roebroek, A. J., 448
Roemer, K., 4362
Romantsev, F. E., 1189
Roninson, I. B., 3010
Roop, D. R., 4413

AUTHOR INDEX TO VOLUME 56

- Sauter, G., 27
 Sauter, M., 4362
 Savarese, T. M., 1083
 Savelieva, E., 2886
 Savino, R., 4213
 Sawaya, R., 384
 Saya, H., 1050
 Scala, S., 3737
 Scanlon, K. J., 5490
 Scarpa, A., 3808
 Scatolini, L., 1642
 Schäfer, H., 2641
 Schäffer, U., 4509
 Schaid, D. J., 145, 4475
 Schalken, J. A., 3234, 4154, 4387
 Scher, H., 3666
 Scher, H. I., 1503
 Scheving, L. A., 5186
 Schichman, S. A., 1418, 1766
 Schieren, L., 1389
 Schiffer, C. A., 1418
 Schiffman, M. H., 3967
 Schild, H.-J., 4766
 Schiller, J. T., 5087
 Schilli, M. B., 4438
 Schlenger, K., 4509
 Schlom, J., 2361, 4250, 5293
 Schmeiser, H. H., 2025
 Schmelz, E. M., 4936
 Schmidt, E. E., 3142
 Schmidt, P. G., 2066
 Schmidt, R. G., 2964
 Schmidt, W. E., 2641
 Schmitt, H., 4766
 Schmitz-Dräger, B. J., 5698
 Schmutte, C., 2375
 Schnaper, H. W., 4887
 Schobert, I., 4766
 Schoenberg, M., 1892, 5044
 Schold, S. C., Jr., 359, 2076
 Schommer, S., 4362
 Schor, N. F., 1199, 2336
 Schreck, R., 3540
 Schreiber, G., 1695
 Schrenk, D., 1272
 Schreuder, G. M. T., 582
 Schriever, F., 4686
 Schubiger, P. A., 809
 Schuerer-Maly, C.-C., 1303
 Schuller, D. E., 2086
 Schulman, P., 1418
 Schulman, S., 783
 Schulte, T., 1851
 Schultz, D. C., 1997, 3409
 Schulz, W. A., 5698
 Schutrups, J., 4709
 Schutte, M., 490, 2527, 4351, 5360
 Schwartz, B. S., 3909
 Schwartz, G. N., 1346
 Schwartz, M. R., 1737
 Schwartz, R. E., 4398
 Schwartz, S., 3042
 Schwarz, L., 5156
 Schwarz, L. R., 4391
 Schwarzmeier, J. D., 4679
 Schwendel, A., 5325
 Schwerdtle, R. F., 2927
 Sciacca, S., 1533
 Scimeca, J. R., 995
 Scita, G., 4942
 Scotlandi, K., 2434, 4570
 Scott, D. R., 3967
 Scott, I. V., 3622
 Scott, M. A., 4378
 Scott, V., 362
 Scotto, K. W., 2021
 Scotto, L., 3898
 Scudiero, D. A., 840
 Scully, C., 1228
 Scully, S. P., 941, 5347
 Sebt, S. M., 1727
 Secomb, T. W., 5522
 Seely, B. L., 2781
 Seetharaman, K., 1194
 Segain, J.-P., 5506
 Sehgal, I., 3359
 Seibert, K., 4566
 Seidel, N. E., 3186
 Seigne, J., 2245
 Seiki, M., 384, 2281, 2535, 2707, 5678
 Seiler, N., 5624
 Seilkop, S., 1012
 Seinen, W., 299
 Seitz, G., 4362, 4766
 Sekido, Y., 1487
 Sekiguchi, K., 4541
 Sekiya, T., 72
 Seko, A., 3468
 Seliger, B., 1756
 Semjonow, A., 4556
 Sena-Esteves, M., 5423
 Sendo, F., 4278
 Senekowitsch-Schmidtke, R., 5428
 Sengstag, C., 5457
 Senik, A., 2033
 Sensibar, J. A., 44
 Senter, P. D., 1471
 Seo, E.-J., 4662
 Serova, O., 5466
 Serra, M., 2434, 4570
 Sers, C., 2218
 Serve, H., 3583
 Serve, S., 3583
 Seth, P., 1346, 1367
 Sethi, T., 4255
 Sette, A., 582
 Seufferlein, T., 3895, 5758
 Sewell, D., 3630
 Sewell, D. A., 4119
 Seyama, T., 3862
 Seymour, A. B., 490
 Sgambato, A., 1389
 Shamsa, F., 1654
 Shan, A., 4475
 Shan, D., 2123
 Shantz, L. M., 3265, 5136
 Shao, J., 733
 Shao, Z.-M., 5055, 5246
 Shapiro, D. N., 3837
 Shapiro, R. L., 3597
 Shapiro, W., 783
 Sharif, M., 4983
 Sharif, T. R., 4983
 Sharkey, R. M., 1805, 3508
 Sharkis, S. J., 973, 4551
 Sharma, S. K., 3287
 Sharp, R., 1775
 Shastri, P. K., 3670
 Shaw, J. W., 44
 Shaw, L. M., 959
 Shawver, L. K., 1615, 3540
 Shay, J. W., 218, 645
 Shearer, G. M., 3967
 Shearer, M. H., 1126
 Shearer, P., 3837
 Shehata, M., 4679
 Sheikh, M. S., 840
 Shen, C.-c., 5615
 Shen, W., 2289
 Shen, Y., 3870, 5005
 Sheng, H., 733
 Shepard, R. L., 4171
 Sherman, L. S., 3134
 Sherman, M., 3055
 Shi, T., 113
 Shiah, J.-G., 3980
 Shibata, J., 2809
 Shibata, M.-A., 2998, 4894
 Shibuya, M., 2013
 Shiff, B., 1939
 Shih, C., 2331
 Shih, S.-C., 1591
 Shiku, H., 2844
 Shima, D. T., 3747
 Shimada, H., 2891
 Shimada, T., 2979
 Shimazui, T., 3234, 4154
 Shimizu, M., 3731
 Shimizu, S., 1713, 2066, 2161, 3366
 Shimizu, T., 4430
 Shimokata, K., 1886, 2718
 Shimomatsuya, T., 2671
 Shimoyama, S., 2703
 Shinagawa, A., 5678
 Shindo-Okada, N., 5266
 Shinoda, M., 4205
 Shinomura, T., 3902
 Shinozaki, T., 2960
 Shintaku, I. P., 3570
 Shipley, J., 3220
 Shipp, M. A., 715
 Shirai, S., 2185
 Shirakawa, T., 4614
 Shirasaka, T., 2602
 Shiratori, Y., 1341, 5620
 Shirley, M. A., 5566
 Shishido, T., 538
 Shivapurkar, N., 5339
 Shively, J. E., 3055
 Shively, L., 3055
 Shizuta, Y., 3180
 Shochat, D., 2123
 Shridhar, R., 4347, 5576
 Shridhar, V., 4347, 5576
 Shroot, B., 5055
 Shu, S., 4338, 4702
 Shui, C., 1705
 Shuman, M. A., 921, 2428
 Shuttleworth, G., 4320
 Sibbering, M., 5484
 Siddoo-Atwal, C., 443
 Siders, W. M., 5638
 Sidransky, D., 1151, 1493, 1892, 2484, 2488, 2527, 3630, 4119, 5044, 5720
 Siegal, C., 926
 Siegel, E. G., 2641
 Siegel, J. A., 1805
 Siegfried, J. M., 5576
 Siegler, G., 2171
 Siemeister, G., 2299
 Sikes, R. A., 4614
 Sikic, B. I., 1091, 3010
 Silletti, S., 1902
 Silvers, W. K., 463
 Simi, B., 532, 2314
 Simizu, S., 4978
 Simon, C., 5369
 Simon, H.-G., 3112
 Simon, J., 339
 Simoneau, A. R., 5039
 Simons, J. W., 663
 Simpkins, H., 2256
 Simpson, J. F., 2400
 Sims, D. E., 507
 Singer, J. W., 105
 Singh, A., 4950
 Singh, P., 4111
 Singh, R. K., 3891
 Singh, S. V., 3495
 Singleton, J. R., 4522
 Singleton, T. P., 1142
 Sinnamon, D., 2733
 Sirahama, S., 5586
 Sirakusa, T., 2823
 Sirgi, K. E., 4673
 Sæter, G., 4778
 Skog, S., 4407
 Skolnick, M. H., 1382
 Skopek, T. R., 4654
 Skrede, M., 5490
 Slagle, B. L., 5092
 Slater, J., 738
 Slattery, J. T., 3678
 Slebos, R. J. C., 2224
 Sleeman, J. P., 3134
 Sliwkowski, M. X., 1457
 Sloan, J. M., 259
 Sloan, P., 1228
 Slominski, A., 925
 Sluiter, W., 2908
 Sluiter, W. J., 523
 Small, E. J., 3091
 Smeland, E. B., 40
 Smith, A., 809, 1974
 Smith, A. P., 599
 Smith, D. E., 4724
 Smith, D. I., 4347, 5576
 Smith, D. R., 4302
 Smith, G., 3823
 Smith, G. H., 1775
 Smith, H. S., 402
 Smith, K., 4320
 Smith, M. L., 840
 Smith, R. A., 190
 Smyth, J. F., 950
 Snel, C. A. W., 4709
 Snell, L., 4606
 Snoy, P., 5631
 Snyderwine, E. G., 2683
 Soballe, P. W., 757
 Sobol, H., 471, 3216
 Söderkvist, P., 3338
 Soff, G. A., 4887
 Sohr, R., 4686
 Soligo, D., 2566
 Solinas-Toldo, S., 3803
 Solomayer, E.-F., 1988
 Somjen, D., 4328
 Sommerfeld, H.-J., 218
 Sommers, R. L., 1426
 Somoano, J. R., 1164
 Son, C., 4956
 Sone, H., 1267
 Sonenberg, N., 4382
 Song, C. W., 5590
 Song, I. S., 2191
 Song, J.-M., 4662
 Song, K., 2422
 Sonnier, M., 58
 Sopwith, M., 5179
 Souhami, R. L., 3721
 Sourla, A., 3123
 Soutter, W. P., 5285

AUTHOR INDEX TO VOLUME 56

- Sozzi, G., 2285, 2472
Sparreboom, A., 2112
Spatti, G., 689
Spaulding, D., 434
Speight, P., 1228
Spengler, B. A., 3737
Spiegel, A. M., 5272
Spiegelman, D., 4862
Spila, A., 5293
Spirin, K. S., 2400
Spirio, L. N., 955
Spittler, A., 4679
Spitz, D. R., 273
Spitz, M. R., 3638, 3975, 4103
Spohn, W. C., 2856
Spooner, R. A., 4735
Sporn, J. R., 2479
Spreafico, F., 2531
Springer, C. J., 3287, 4735
Spruck, C. H., III, 5039
Spyrou, G., 4407
Sriram, P., 53
Sriramarao, P., 4032
Sriuranpong, V., 3530
Srivastava, D. K., 3010
St. Clair, D. K., 2864
Stack, M. S., 4887
Stacker, S. A., 393
Stadler, W. M., 2886
Stähle-Bäckdahl, M., 4562
Stamberg, J., 5253
Stampfer, M. J., 4862
Stanbridge, E. J., 1719
Stancel, G. M., 3954
Stang, M. T., 5063
Stanton, P. D., 3823
Star, W. M., 2908
Staretz, M. E., 316
Starling, J. J., 4171
Starr, T. B., 1012
Stary, A., 5450
Staveley-O'Carroll, K. F., 21
Stec, D., 4137
Steck, K. D., 694
Steck, P. A., 694, 5684
Steege, P. S., 2931
Steel, C. M., 950
Steele, V., 772, 3395
Steele, V. E., 1724, 4644, 4910
Steenvoorden, D. P. T., 4709
Steger, K. A., 1091
Stegmaier, K., 1413
Stegmann, A. P. A., 2343
Stein, R., 3508
Steinbach, G., 434
Steinberg, S. M., 305, 4044
Steinbrueck, T., 606
Steiner, G., 5044
Steinmetz, R., 5403
Steller, M. A., 1761, 5087
Stemmermann, G. N., 4267
Stenman, G., 241
Stenner, F., 4766
Sternlicht, M. D., 3560
Stetson, P. L., 2677, 4724
Steven, K., 5039
Stolz, D. B., 2837
Stone, S., 3199
Stoppacciaro, A., 2531
Stoppa-Lyonnet, D., 471, 1400, 3216
Störkel, S., 2927
Straight, R. C., 3980
Strange, R. C., 1974
Strasser-Wozak, E. M. C., 5033
Stratton-Thomas, J. R., 2428
Strauss, B., 2781
Strawn, L. M., 1615, 3540
Ströbinskiene, L., 4006
Stride, B. D., 3307
Strout, M. P., 1418
Strup, S. E., 2411
Studzinski, G. P., 264, 925, 5513
Stumper, B., 1118
Stutman, O., 1591
Su, Y. A., 3186
Subbaramaiah, K., 4424
Subramanian, T., 2506, 3879
Sueoka, E., 3711
Sugamura, K., 2590
Suganuma, M., 3711
Sugimachi, K., 2688, 5330
Sugimoto, Y., 2809
Sugimura, H., 377
Sulfaro, S., 1146
Sullivan, C., 3380
Sullivan, S. J., 1770
Sullivan, T. M., 4200
Sulman, E. P., 3421
Sumantran, V. N., 1965
Sun, Y., 3980
Sundaresan, R. S., 4499
Sundaresan, V., 1609
Sung, C., 4180
Supino, R., 556
Supiyaphun, P., 3530
Susin, S. A., 2033
Susini, C., 1823
Sutter, T. R., 2979
Suzuki, H., 2185, 4387
Suzuki, K., 1629, 3004
Suzuki, M., 4205, 5586
Suzuki, T., 2776
Suzuki, Y., 612
Svensson, H. P., 1471
Swartz, H. M., 3344
Svenberg, J. A., 1012
Swensen, J., 1382
Symanski, E., 5410
Symonds, E. M., 5179
Szabo, E., 305
Szallasi, Z., 2105
Szekeres, K., 1902, 5071
Szumel, R., 5260
- ## T
- Tabassi, K., 5217
Tachibana, I., 354
Taghian, A., 3853
Taghian, A. G., 2277
Tahara, H., 599
Taillandier, E., 515
Taioli, E., 4275
Takabayashi, K., 2116
Takada, M., 1232, 4978
Takagaki, M., 2017
Takagi, H., 480
Takagi, K., 5579
Takagi, S., 3366
Takagi, Y., 2718
Takahara, J., 1232
Takahashi, H., 2738
Takahashi, M., 2767, 2776, 3474
Takahashi, N., 675
Takahashi, S., 4475
Takahashi, T., 1886, 2718, 5579, 5583
Takahashi, Y., 3577
Takai, S., 377
Takano, S., 2185
Takasuna, K., 3752
Takata, M., 589
Takatsuka, J., 675
Takayama, T., 3577
Takebayashi, H., 4164
Takechi, T., 2602
Takeda, S., 2602
Takehana, K., 2960
Takenaka, K., 5330
Takeshima, H., 1050
Takeuchi, J., 3902
Takeuchi, K., 5266
Takeuchi, S., 738, 1413, 2400
Takeyama, H., 1817
Taki, T., 1244, 1440, 1751
Takiguchi, M., 2368
Takino, T., 2535, 5678
Talbot, I., 190
Talib, S., 16
Tallett, A., 4255
Tampe, R., 1756
Tamura, G., 612, 3875
Tamura, T.-a., 5230
Tan, J., 3399
Tan, R. S.-P., 2417
Tan, T.-H., 2954
Tanaka, K., 2945
Tanaka, S., 3391, 4040
Tanaka, T., 1341, 4904, 5330
Tanaka, Y., 2666, 5741
Tanakamaru, Z.-y., 2767
Tang, C., 3540
Tang, C. K., 3350
Tang, K., 5071
Tang, S.-H., 765
Tang, W., 5365
Tang, Z., 5339
Tangir, J., 1250, 2501
Tangoku, A., 2776
Tani, M., 5266
Tanigawa, N., 2671
Taniguchi, K., 2348, 4124
Taniguchi, N., 412, 2771
Taniguchi, T., 2417
Tanimoto, M., 4224
Tanio, Y., 354
Tanizawa, A., 1674
Tanner, M. M., 3441
Taramelli, R., 4493
Tartaglia, J., 16
Tateishi, T., 316
Tatematsu, N., 4904
Tatoud, R., 3461
Tatsuta, N., 538
Taubert, H., 4134
Taylor, C. W., 5765
Taylor, J. A., 294, 4108
Taylor, K. J., 950
Taylor, R., 1609
Tedesco, M., 5293
Teicher, B. A., 715
Teixeira, M. R., 855, 5098
Tekmal, R. R., 3180
Telang, N., 4424
Temoshok, L. R., 4278
Tennenbaum, T., 4942
Teplitz, R. L., 3551
Terada, T., 2809
Terasawa, K., 2229
Terashima, M., 612, 3875
ter Harmsel, W. B., 582
Terleth, C., 2621
Termont, D. S. M. L., 3270
Terry, N. H. A., 434
Teshigawara, K., 1104
Testa, J. R., 4297
Tester, D. J., 4475, 4836
Tew, K. D., 2584
Thakker, N., 1228
Thalmeier, K., 2566
Thelin, S., 4871
Thews, O., 2009, 4728
Thiagalingam, S., 2936
Thibodeau, S. N., 145, 4475, 4836
Thiel, E., 3583
Thiele, C. J., 3737
Th'ng, J. P. H., 3551
Thomale, J., 5615
Thomas, B. A., 1471
Thomas, E. J., 3534
Thomas, G. A., 2167
Thomas, P., 4805
Thomas, W., 2815
Thompson, C. B., 5734
Thompson, J. S., 5723
Thompson, N. L., 3934, 5012
Thompson, S., 5192
Thompson, T. C., 3359
Thorgeirsson, S. S., 2137
Thorgeirsson, U. P., 2013
Thraves, P. J., 5
Thurman, R. G., 1
Tian, Y., 1978
Tibiletti, M. G., 4493
Timar, J., 1902, 5071
Tindall, D. J., 1539
Tinelli, S., 1855
Ting, J. P.-Y., 1303
Tiraby, G., 5659
Tirkkonen, M., 3441
Tirona, R., 4709
Tischfield, J. A., 955
Tisdale, M. J., 1256
Tjuvajev, J., 1352
Tjuvajev, J. G., 4087
Tlsty, T. D., 3659
Toda, K., 3180
Toda, N., 5620
Todorov, P. T., 1256
Toes, R. E. M., 3782
Toftgård, R., 4562
Tognazzi, K., 172
Tognon, M., 4820
Togo, G., 5620
Toh, Y., 2688
Tokino, T., 1629
Tokuyama, S., 1932
Tolbert, D. M., 3324
Toma, H., 5266
Tomasetto, C., 3886
Tomida, A., 2823
Tomioka, Y., 2546
Tomisaki, S., 2688
Tomoda, M., 2688
Tong, W. P., 2692
Tong, Y., 4142
Toninelli, E., 3211
Toniolo, A., 3118
Tornielli, S., 2472
Toro, M., 3526
Toso, J. F., 16
Toth, M., 1654
Touhalisky, J. E., 4338
Touitou, R., 5499
Tovari, J., 1902

* For title of article and coauthors, see listing in Contents of Volume 56 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 56

- Tran, P., 5653
 Tran, Y. K., 2916
 Trauzold, A., 2641
 Travassos, L. R., 1682
 Travis, E. L., 2596
 Travis, L. B., 1564
 Trent, J. M., 3075, 3186, 3441, 3446, 5380
 Trepel, J., 1851
 Trewyn, R. W., 594
 Triebel, F., 362
 Trikha, M., 1902, 5071
 Trimbo, B. J., 582
 Trirakan, S., 3530
 Tritton, T. R., 5334
 Trivers, G. E., 4917
 Tromberg, B. J., 2066
 Trubia, M., 4493
 Trybus, T. M., 2263
 Tryfiates, G. P., 3670
 Tsai, C-M., 206, 794, 1068
 Tsai, Y. C., 402, 5039
 Tchang, Y-S., 2721
 Tsuchiya, H., 429, 2881
 Tsuji, T., 3902
 Tsuji, Y., 2844
 Tsujii, M., 733
 Tsujimoto, Y., 1713, 2161, 3546
 Tsujiuchi, T., 3474
 Tsukui, T., 3967
 Tsunozuka, Y., 5678
 Tsunoda, M., 2368
 Tsunoda, R., 1828
 Tsuruo, T., 875, 2809, 2823, 5224
 Tsutsumi, M., 3474
 Tsuyama, N., 3862
 Tujimura, T., 3004
 Tureci, O., 4766
 Turley, H., 4799
 Tursz, T., 4917
 Tutsch, K., 710
 Twardowski, P., 4887
 Twentyman, P. R., 3010
 Tyler, B. M., 5217
- U**
- Uchida, A., 1104
 Uchida, J., 2602
 Uchida, K., 1886, 2718, 5579, 5583
 Ueda, T., 1800
 Uehara, H., 1352
 Ueki, K., 150
 Ueng, Y-F., 316
 Ueno, K., 354
 Ueoka, R., 3986
 Ugwumadu, A. H. N., 1475
 Uhlman, D. L., 2199
 Uhlmann, E. J., 2506
 Ukai, T., 538
 Ullrich, A., 1615, 3540
 Ulmer, H. U., 1988
 Umezawa, K., 4978
 Umiel, T., 3570
 Unden, A. B., 4562
 Unemi, N., 2602
 Uniyal, S., 3142
 Upadhyaya, P., 1970
 Ushio, Y., 1050, 3986
 Ushiro, S., 1512
 Utsugi, T., 2809
 Utsumi, K., 4535
 Uyeno, S., 5356
- V**
- Vaccari, M., 2434
 Vagliani, M., 467, 2531
 Vagner, S., 1742
 Vahlquist, A., 589
 Vahrmeijer, A. L., 4709
 Vaidyanathan, G., 1204
 Vaillant, J-C., 1823
 Vaitkevicius, V. K., 4347
 Valentine, M., 3837
 Valentini, B., 3165
 Valiente, O., 5165
 Valle, P., 3737
 Valteau, D., 362
 Valtieri, M., 5113
 Van, N. T., 3431
 van Amstel, H-K. P., 4853
 van Bree, C., 563
 Van den Bergh, H., 2655
 van der Eb, A. J., 2621
 van der Meer, J., 3948
 Van der Meer, R., 3270
 van der Pluijm, G., 1948
 van der Riet, P., 2488
 van der Valk, M. A., 2382
 Vanderveer, L., 1997
 van der Voort, E., 3782
 van de Velde, C. J. H., 4709
 Van de Ven, W. J. M., 448
 Vande Woude, G. F., 5211
 van Dierendonck, J. H., 4709
 van Driel, W. J., 582
 van Ginkel, R. J., 3948
 van Haaften-Day, C., 1303
 van Hasselt, A., 2721
 van Hof, A. C., 5179
 van Muijen, G. N. P., 1432
 van Tellingen, O., 2112
 van Ypersele de Strihou, C., 2025
 Varghese, S. P., 5
 Varhaug, J. E., 1184
 Varki, N. M., 1707
 Varnum, D. S., 5047
 Varro, A., 880, 4111
 Vasandani, V. M., 4180
 Vasavada, R., 1043
 Vasquez, M., 1118
 Vassy, J., 515
 Vaughan, A. T. M., 4192
 Vaughn, J. P., 4590
 Vaultier, M., 5624
 Vaupel, P., 2009, 4509, 4728
 Vaysse, N., 1742, 1823
 Vecchione, A., 5293
 Velasco, G., 944, 1746
 Venitt, S., 5342
 Venne, A., 3626
 Ventura, A. M., 1682
 Verheijen, J. H., 1432
 Verheijen, R. H. M., 5179
 Verma, A., 710
 Veronese, M. L., 728, 2472
 Vidair, C. A., 500, 4116
 Vieira, K. B. L., 2452
 Viglietto, G., 1896
 Vikse, C. M., 4460
 Villa, A., 3211
 Villa, E., 3883
 Villa, L. L., 2452
 Villanueva, A., 5713
 Villegas, C., 4366
 Vincent-Salomon, A., 471
 Visconti, V., 1056
 Visonneau, S., 3021, 4444
 Vitelli, L., 5113
 Vitt, C. R., 2428
 Vloedgraven, H. J. M., 1948
 Vnencak-Jones, C. L., 4378
 Vocke, C. D., 2411
 Voest, E. E., 3747
 Vogelstein, B., 235, 2936
 Vogler, W. J., 294
 Vogt, P. K., 4229
 Vojta, P. J., 241
 Volpert, O., 4887
 Volpert, O. V., 5684
 von Ballestrem, C., 3142
 von Brevin, M-C., 4917
 von Deimling, A., 150, 164
 Vonk, R. J., 3270
 von Roemeling, R. W., 2964
 von Schweinitz, D., 2949
 Voorzanger, N., 5499
 Voravud, N., 3530
 Vore, M., 4992
 Vofechovsky, I., 2726, 3173, 4130, 4562
 Vortmeyer, A. O., 1961
 Vousden, K. H., 5285
 Vrana, J. A., 5063
 Vuilhorgne, M., 3689
 Vujanovic, N. L., 1599
 Vukanovic, J., 3404
 Vukosavljevic, T., 1146
- W**
- Wada, M., 2348, 4124, 5330
 Wada, S., 2440
 Wagner, A. J., 2506
 Wagner, L. K., 3257
 Wagner, R. J., 527
 Wagner, S., 1863
 Wagoner, M. A., 5566
 Waha, A., 164
 Wahl, G. M., 2940, 4021
 Waibel, C., 3350
 Wajchman, H. J., 5513
 Wakabayashi, Y., 1512
 Wakamatsu, T., 5230
 Waki, H., 5165
 Wakimoto, H., 1341, 1828
 Waldman, F. M., 27
 Waldman, T., 2250
 Walker, C. L., 4044, 4049
 Walker, G. J., 5023
 Walker, S. C., 2677
 Walker, V. E., 4654
 Wallrapp, C., 3803
 Waltham, M. C., 4142
 Wands, J. R., 3391
 Wang, F-L., 3634
 Wang, H., 538
 Wang, J., 154
 Wang, L., 4354
 Wang, M., 287, 3638
 Wang, Q. M., 264
 Wang, S., 4610, 5012
 Wang, X., 1309, 4347
 Wang, X. Q., 2510
 Wang, X-J., 4413
 Wang, Y., 3634
 Ward, J. M., 2998, 4894
 Warmuth, M., 3589
 Warnke, R., 3010
 Warrell, R. P., Jr, 2692
 Warren, S., 2832
 Warwick, J., 2178
 Wasan, E., 1880
 Waser, B., 1922
 Wasserman, P., 783
 Watanabe, H., 2960
 Watanabe, K., 3371, 4087
 Watanabe, M., 1817
 Watanabe, Y., 5678
 Waterman, J. L. F., 158
 Waterman, M. J. F., 158
 Waters, C., 2590
 Watkins, P. J., 1063
 Watkins, S., 1599, 3516
 Watkins, S. C., 3763
 Watson, J. E. V., 950
 Watson, M., 4108
 Watson, M. A., 860
 Watson, P. H., 4324, 4606
 Watson, R. H., 719, 3534
 Watson, S. A., 880
 Wattenberg, E. V., 637
 Wattenberg, L. W., 5132
 Waxman, D. J., 1331
 Wayne, J. D., 4311
 Wazer, D. E., 3129, 3371, 4620
 Webb, S. K., 4936
 Webber, K. O., 3788
 Weber, B. L., 2738
 Weber, J., 5428
 Weber, J. L., 259
 Weber, L., 2446
 Weber, W., 5428
 Weber-Hall, S., 3220
 Weber-Hall, S. J., 4320
 Webster, A. D. B., 2726, 4130
 Webster, N. J. G., 2781
 Wechsler-Reya, R., 2626
 Weeks, R. S., 105
 Weghorst, C. M., 36
 Wehbe, T., 3934
 Wei, L. L., 1222
 Wei, M-H., 1487
 Wei, Q., 1484, 3638, 3975, 4103
 Wei, S-J. C., 3695
 Wei, Y-q., 1104
 Weibel, B., 5457
 Weichselbaum, R., 3617
 Weichselbaum, R. R., 2711, 4311
 Weidle, U. H., 1432
 Weidt, E., 2927
 Weinbach, J., 5659
 Weinberg, W. C., 3645
 Weindell, K., 2299
 Weiner, L. M., 113
 Weinfeld, M., 1584
 Weinhold, K. J., 16
 Weinstein, C. L., 490, 2527, 5360
 Weinstein, I. B., 36, 1389
 Weinstein, R., 3010
 Weir, E. C., 1043
 Weisberg, E. L., 544, 551
 Weissman, B. E., 1214, 1219, 1222
 Weksler, B. B., 4424
 Welch, D. R., 1222
 Welch, W. R., 2501
 Wells, P. G., 1526
 Wendell, K., 816
 Wennmalm, A., 866
 Werlen, R. C., 809
 Werner, S., 4391
 West, A., 1214
 Westendorf, J., 2094
 Westerdahl, J., 2497
 Westermarck, B., 164, 241
 Westman, L., 2336
 Westra, W., 2484, 2488
 Westra, W. H., 1151, 2224, 3630, 5720

AUTHOR INDEX TO VOLUME 56

- Westwood, M., 4799
Wetzel, J. C., 1142, 4150
Wewer, U. M., 959
Whipple, D. O., 1664
White, A., 783, 3276
White, C. M., 1303
White, P. S., 3421
White, R., 955, 2872
White, R. L., 2157
Whitehouse, R., 4625
Whiteside, T. L., 1599
Wicha, M. S., 1965
Wick, M. J., 4475
Wientjes, M. G., 2086
Wierzbka, K., 2809
Wiessler, M., 2025
Wiestler, O. D., 164
Wigginton, J. M., 1131
Wigglesworth, K., 5047
Wigler, M. H., 2936
Wijdenes, J., 1909
Wilding, J., 5285
Wiley, J., 2985, 2992
Wilhelm, A. J., 5179
Wilke, C., 4347
Wilkinson, K., 190, 3021
Wilks, A. F., 393
Will, P., 2336
Willett, W. C., 4862
Willheim, M., 4679
Williams, B. A., 5615
Williams, G. R., 623
Williams, J. A., 5217
Williams, L. E., 3055
Williams, M. D., 2105
Williams, P. J., 4063
Williams, S. R., 4630
Willingham, M. C., 2590
Willman, C. L., 3010
Willson, J. K. V., 2936
Wilson, E. L., 3597
Wilson, E. M., 4956
Wilson, G., 616
Wilson, G. L., 1262, 5615
Wilson, K., 2224
Wilson, L., 816
Wilson, P. J., 5238
Wilson-Rawls, J., 3426
Wiltrout, R. H., 1131
Wiltshire, R., 3075
Wimley, W. C., 87
Winski, P. J., 3866, 3993
Winstead, M. V., 955
Winston, J. S., 4841
Winterborn, C. J., 4950
Wiseman, R., 2539
Wiseman, R. W., 3338
Wlodarska, I., 2655
Wojno, K. J., 1142, 2263, 4150
Wolf, D. A., 5012
Wolf, E. J., 113
Wolf, H., 1031, 4782, 5443
Wolf, K-J., 1863
Wolff, T., 4391
Woloschak, M., 2493
Wong, A. J., 1997
Wong, C. S., 5417
Wong, C-Q., 3695
Wong, J. Y. C., 3055
Wong, S., 2355
Wong, W-K., 3634
Woo, J. K. S., 2721
Woo, L. W. L., 4950
Woo, S. L. C., 1737, 3758
Wood, F. D., 745, 1189, 2745
Wood, T., 4111
Woodworth, C. D., 1761
Woollatt, E., 5238
Worland, P. J., 2973
Wörner, W., 1272
Worzalla, J. F., 2331
Wosikowski, K., 3737
Wright, A. F., 3287
Wright, F. A., 4021
Wright, J. A., 4366
Wright, M., 58
Wrzosek, C., 4715
Wu, A. M., 3055
Wu, C. L., 1228
Wu, G. S., 2250
Wu, H-Y., 2795
Wu, I-H., 3645
Wu, J., 616
Wu, L-H., 206, 1068
Wu, S., 3038
Wu, T-C., 21
Wu, Y., 5120
Wu, Y-N., 4180
Würfl, P., 4134
Wyble, C., 5150
Wyche, J. H., 1621
Wyllie, A. H., 235
Wynder, E. L., 5192
Wynn, T-T., 532
Wysolmerski, J. J., 1043, 4056
- ## X
- Xia, H., 3495
Xia, L., 2289
Xiao, J., 2493
Xie, H., 2742
Xie, K., 254
Xie, K. C., 3030
Xie, S., 3426
Xu, B., 3758
Xu, F., 4464
Xu, H-J., 2245
Xu, J., 3446
Xu, Y-H., 2985
Xynos, F. P., 606
- ## Y
- Yager, J. W., 5410
Yagi, H., 3695
Yamabe, K., 2161
Yamada, K., 377
Yamada, M., 2823
Yamada, Y., 2809, 2844, 3004, 3716
Yamaguchi, M., 4164
Yamaguchi, R., 2546
Yamaguchi, Y., 3004
Yamakawa, N., 3902
Yamamoto, A., 3731
Yamamoto, H., 3605
Yamamoto, K., 2776
Yamamoto, M., 72, 384, 3004, 3725
Yamamoto, N., 2827
Yamamoto, Y., 2017
Yamamura, K., 3546
Yamanishi, D. T., 3560
Yamasaki, H., 4192
Yamashiro, S., 1050, 2844
Yamashita, K., 3468
Yamashita, S., 77
Yamauchi, T., 1800
Yamauchi, Y., 330
Yamazaki, H., 316, 2979
Yan, T., 2864
Yanagisawa, J., 457
Yanagisawa, K., 5579
Yang, A. S., 2375
Yang, J. C., 2832
Yang, J-M., 3490
Yang, K., 4644, 4910
Yang, N-S., 3399
Yang, W., 2904
Yang, X-F., 1509
Yang, Z., 2677, 4724
Yano, H., 77
Yano, T., 1179
Yanofsky, R. A., 3421
Yao, K., 2896
Yao, K-S., 1731
Yao, S-L., 4551
Yarborough, A., 683
Yarosh, D., 783
Yaspo, M-L., 448
Yatabe, Y., 5583
Ychou, M., 4758
Yeager, T. R., 2886
Yeh, P., 3436
Yeldandi, A. V., 4846
Yen, R-W. C., 616
Yengi, L., 1974
Yenrudi, S., 3530
Yeo, C. J., 490, 5360
Yeo, K-T., 172, 3747
Yeowell-O'Connell, K., 5410
Ying, Z., 1805
Yokoi, T., 3752
Yokomizo, A., 5330
Yokota, J., 1426, 5266
Yokota, N., 377
Yoneda, S., 3725
Yoneda, T., 4063
Yonezawa, S., 3468
Yoo, T. M., 3788
Yoshida, H., 2945
Yoshida, S., 1512
Yoshida, Y., 1341
Yoshihara, H., 3004
Yoshii, Y., 2185
Yoshiji, H., 2013
Yoshikawa, A., 1232
Yoshikawa, K., 3004
Yoshimoto, T., 5356
Yoshimura, K., 2440
Yoshimura, M., 412
Yoshimura, T., 1050
Yoshizato, K., 1050
Youle, R. J., 4180
Youmell, M. B., 246
Youn, H-S., 1279
Younes, M., 1164
Young, B. D., 448
Young, L. S., 2178
Young, P. C. M., 5403
Yount, G. L., 500
Yu, A., 2493
Yu, C., 2795
Yu, H., 3399
Yu, J. S., 5423
Yu, R., 2954
Yuan, Z-M., 3617
Yuasa, Y., 4595
Yun, A., 4998
Yun, Z., 3103
Yung, W. K. A., 694
Yurkow, E. J., 2045
Yuspa, S. H., 3645, 4942
- ## Z
- Zabarovsky, E., 1487
Zachary, J. F., 339
Zagzag, D., 182, 1939
Zaloudik, J., 2726
Zalutsky, M. R., 1204, 4970
Zamboni, G., 3808
Zamzami, N., 2033
Zandonella, C. L., 2428
Zanella, C. L., 5334
Zang, E., 772, 3395
Zanker, K. S., 4556
Zaphiropoulos, P. G., 4562
Zarama, G., 3238
Zarbl, H., 4927, 5211
Zaren, H. A., 3495
Zbar, B., 1487
Zehnbauer, B. A., 973
Zeidler, R., 5610
Zeki, K., 765
Zelner, D. J., 44
Zeng, W. R., 3123
Zenser, T. V., 3941
Zeuthen, J., 5475
Zewald, R. A., 4853
Zhan, Q., 840, 1367
Zhan, S., 1367
Zhang, C., 2245
Zhang, C-H., 1805
Zhang, F., 5513
Zhang, H., 1083, 3446
Zhang, L., 1367
Zhang, M., 4358
Zhang, R., 802
Zhang, S., 3315
Zhang, S-Y., 1137
Zhang, W-C., 4595
Zhang, W-W., 3047, 3431
Zhang, X., 802
Zhang, X. F., 1770
Zhang, X-J., 3238
Zhang, Y-J., 683
Zhang, Z-F., 2692
Zhang, Z-Y., 3926
Zhao, H., 802
Zhao, X., 1104
Zheng, H., 2801, 3087, 4881
Zhong, W., 2864
Zhou, B-s., 345
Zhou, D., 3451
Zhou, P., 36, 1389
Zhou, W., 5260
Zhou, Y., 1352, 2245
Zhou, Y-Z., 5092
Zhu, H., 3771
Zhu, S. M., 4917
Zhuang, S-M., 3338
Zhuang, Z., 1961, 5272
Zia, H., 3486
Zibera, C., 2566
Ziegler, M. R., 606
Ziel, R., 3499
Zimmermann, A., 4876
Zimmermann, G., 4244
Zimmermann, J., 100
Zipori, D., 2148
Zlotnikov, G., 402
Znati, C. A., 964
Zocchi, M. R., 3211
Zogopoulos, G., 2949
Zou, Z., 1761, 5087
Zucker, S., 3610
Zunino, F., 556, 689, 1855
Zwaveling, J. H., 3948

SUBJECT INDEX

Volume 56

A

19A211

superficial bladder tumor-associated CEA glycoform identification, 908

AACR: see American Association for Cancer Research

Aberrant crypts

colonic

NAT2-dependent formation, congenic Syrian hamsters, 527
suppression by sphingomyelin, CF1 mice, 4936

foci

colonic, microsatellite instability, 5339
genetic susceptibility, mice, 2382

Abl protein-tyrosine kinase

inhibition by 2-phenylaminopyrimidine derivative, 100

A549 cells

flavopiridol-induced cell death, 4856
methylthioadenosine phosphorylase chemosensitivity, 5653

2-Acetylaminofluorene

-induced apoptosis
inhibition by tumor promoters, rat hepatocytes, 1272

N-Acetylation

benzidine, 3941

Acetylators

genotype (NAT2)

-dependent aberrant crypt formation, congenic Syrian hamsters, 527

N-Acetylcysteine

chemoprevention effects
against air particulate extracts, 1526
against mitochondrial DNA adducts, rat organs, 1642
chemopreventive effects, lung tumorigenesis, 772

N-Acetylglucosamine

bisecting
and natural killer sensitivity, K562 cells, 412

Acetyltransferase

mRNAs, histological localization, 1517

N-Acetyltransferase

expression
and food-derived heterocyclic amines, mammary gland, 2683

N-Acetyltransferase 1

benzidine N-acetylation, 3941

N-Acetyltransferase 2

arylamine
bladder cancer risk modulation, 3915
benzidine N-acetylation, 3941
-dependent aberrant crypt formation, congenic Syrian hamsters, 527
genotype, lung cancer susceptibility factor, 3961

Acromegaly

colonic epithelial cell proliferation, 523

Actin

fragmentation by oxidants
HSP27 phosphorylation-mediated resistance, 273

Activin

growth inhibition, mammary epithelial cells, 1155

Adenocarcinoma

Barrett's esophagus
clonal precursors, 1961
microsatellite alterations, 259
colonic

GlcNAc:β1→3 and GlcNAc:β1→4 galactosyltransferase activities, 3468

inhibition by sphingomyelin, CF1 mice, 4936

mucinous, GS-7 cells, 3508

colorectal

Bak expression, 2422

bcl-2 family gene expression, 2422

esophageal

chromosome 4q sequence loss, 4499

DPC4 allelic loss and mutations, 4351

gastric

chromosome 5q allele loss, 612

chromosome 11 loss of heterozygosity, 268

lung

toxin gene therapy, 1315

mucinous

colon, GS-7 cells, 3508

prostatic

allelic imbalance and microsatellite instability, 4475

Adenoids

B-cells

proliferation response to Epstein-Barr virus infection, 5610

Adenoma

colon

genetic susceptibility, mice, 2382

parathyroid

allelotype, 599

spontaneous intestinal

piroxicam chemoprevention, *Apc*^{Min} mouse, 710

Adenomatous polyposis

familial

β-catenin expression, 2213

tumor formation prevention by sulindac, murine model, 2556

Adenomatous polyposis coli

APC gene

somatic mutations, sporadic hepatoblastomas, 3320

attenuated

secretory PLA₂ gene mutations, 955

gene locus

loss of heterozygosity, Barrett's esophagus, 1961

-mediated intestinal tumorigenesis

MSH2 deficiency and, Min mice, 2922

Adenosine-N⁶-diethylthioether-N-pyridoximine-5'-phosphate

circulating tumor marker, 3671

Adenovirus

antisense IGF-Ir expressing

antitumor effects, 3038

-mediated gene therapy

CEA-producing gastric carcinoma, 1341

-mediated p53 transfer

generalized apoptosis, glioma cells, 694

-mediated wild-type p53 transfer

cervical cancer, 3047

ovarian tumor radiosensitization, 4891

melanoma-specific, 5638

Rep78

Sp1 binding, 5299

replication-deficient

modified retinoblastoma gene therapy, 2245

ADEPT: see Antibody-directed enzyme pro-drug therapy

Adhesion molecules

C-CAM1 gene expression, bladder cancer, 3431

CD40

-induced growth arrest, myeloma cells, 1909

disialosyl galactosylgloboide, renal cell carcinoma, 1932

endothelial intercellular, 1

MUC1 adhesion ligand, 4244

suppression, human malignancies, 1111

neural cell, L1

gene expression, malignant glioma, 1440

glioma invasion, 1440

platelet endothelial cell, 2

and TNFα-induced vascular leakage, 3211

Adipocytes

-type fatty acid binding protein
loss, bladder transitional cell carcinomas, 4782

Adrenocortical tumors

genetic aberrations, comparative genomic hybridization, 4219

Adriamycin

N-(2-hydroxypropyl)methacrylamide copolymer-bound

combined with photodynamic therapy, ovarian carcinoma, 3980

sensitivity

increase by GST-π antisense cDNA, colon cancer cells, 3577

Aflatoxin B₁

biotransformation

olipraz-mediated changes, rat liver, 2306

genotoxicity, *S. cerevisiae*, 5457

oxidative DNA damage, rat liver and human oral mucosal cells, 683

African-Americans

CYP1A1 polymorphism

lung cancer risk and, 4275

nevoid basal cell carcinoma syndrome patients

PTCH mutations, 4599

AH130 cells

energy metabolism regulation by nitric oxide, 4535

AIDS

-associated Kaposi's sarcoma

resistance to Fas-mediated apoptosis, 1874

Airflow

obstruction, sputum cytology, 4673

Air particulate extracts

N-acetylcysteine chemoprevention against, 1526

A/J mice

lung carcinoma

chemoprevention by myo-inositol and dexamethasone, 5132

O⁶-Alkylguanine-DNA alkyltransferase

O⁶-benzylguanine resistance, 5571

point mutations

and O⁶-benzylguanine sensitization to BCNU killing, 1578

Alkyltransferase

cellular

O⁶-benzylguanine insensitive, 1578

mismatch repair mutations and, temozolomide resistance, 5375

prognostic value, carmustine-treated brain tumor patients, 783

sensitivity to O⁶-benzylguanine, mouse model, 1880

ALL: see Leukemia, acute lymphoblastic

Allelic deletions

chromosome 11p15.5, non-small cell lung carcinomas, 2916

chromosome 11q13, MEN1 tumors, 5272

chromosome 17p13.3, early ovarian cancer, 606

Allelic imbalance
 chromosome 6, colorectal cancer, 145
 chromosome 3p, oral dysplastic lesions, 1228
 chromosome 13q, sporadic breast cancer, 1988
NME1, colorectal carcinoma, 916
 prostatic adenocarcinoma, 4475

Allelic loss: see also Loss of heterozygosity
ATM, breast cancers, 5484
 chromosome 1p, chromophobe renal cell carcinoma, 2927
 chromosome 2p, chromophobe renal cell carcinoma, 2927
 chromosome 5q, gastric carcinoma, 612
 chromosome 6p, chromophobe renal cell carcinoma, 2927
 chromosome 7q, pancreatic carcinoma, 3808
 chromosome 8p, Chinese hepatocellular carcinoma, 5092
 chromosome 8p12-21, prostate carcinomas, 2411
 chromosome 10, prostate adenocarcinoma, 2143
 chromosome 10p
 chromophobe renal cell carcinoma, 2927
 prostate cancer, 2263
 chromosome 10q, prostate cancer, 2263
 chromosome 13q
 chromophobe renal cell carcinoma, 2927
 prostate cancer, 1142
 chromosome 17p, chromophobe renal cell carcinoma, 2927
 chromosome 21q, chromophobe renal cell carcinoma, 2927
c-myc, myeloma cells, 4370
DPC4
 esophageal adenocarcinoma, 4351
FHIT, breast cancers, 5484
 human leukocyte antigen, advanced renal cell carcinoma, 826

Allelotypes
 cutaneous melanoma and benign melanocytic nevi, 589
 esophageal adenocarcinoma, 4499
 lymphoma, B6C3F1 mice, 3338
 microsatellites
 distal nephron renal tumors, 1892
 unstable, endometrial precancers and cancers, 4483
 parathyroid adenoma, 599
 salivary gland tumors, 1151

Allelotyping
 genetic alterations, metastatic prostate cancer, 3091

Allogeneic tumor cells
 antitumor immunity, 3782

Alopecia
 chemotherapy-induced
 calcitriol and, mice, 4438

Alveolar hyperplasia
 atypical
 K-ras mutations, 2224

American Association for Cancer Research
 NIEHS/AACR Task Force on the Advancement of Minorities in Science
 model program, 3380

4- β -Aminoalkyl-4'-*O*-demethyl-4-desoxypodophyllotoxin: see TOP-53

δ -Aminolevulinic acid
 oxidative DNA damage, 1786
 tumor necrosis induction, 339

2-Amino-3-methylimidazo[4,5-*f*]quinoline
 -induced colon tumors
 apoptosis inhibition, rat, 4307

2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine
 -induced lymphoma
 inhibition by oltipraz, 3395
 metabolism, rat colon tissue, 2550

AML: see Leukemia, acute myeloid

Amniotic tumor
 human
 bone formation induction, 633

Amplicons
 chromosome 12q13-q15
 mapping, malignant gliomas, 5141

Androgen
 -dependent and relapsed prostate cancer, 3042
 -independent prostate cancer
 genetic alterations, comparative genomic hybridization and allelotyping, 3091
 novel synthesis inhibitors
 growth inhibition, prostate cells, 4956
 proliferating cell nuclear antigen regulation, LNCaP cells, 1539

Angiogenesis
 and gastric carcinoma progression, 2671
 inhibition
 anti-VEGF antibody, intravital videomicroscopy, 4032
 chromosome 10, glioblastoma, 5684
 irsogladine, 1512
 urokinase receptor antagonists, 2428
 VEGF-toxin conjugate, 1324
 inhibitor angiostatin
 plasminogen converting enzyme, prostate carcinoma cells, 4887
 inhibitor TNP-470
 and glioma temozolomide uptake, rat model, 1983
 and interstitial hypertension, 4264
 uveal melanoma, 2900

Angiogenic factors
 endothelial ICAM-1 suppression, human malignancies, 1111
 expression, breast cancer, 2013
 midkine
 expression, bladder cancer, 2515
 thymidine phosphorylase/platelet-derived endothelial cell growth factor
 expression, bladder cancers, 4799

Angiogenin
 expression, pancreatic cancer, 2703

Angiostatin
 plasminogen converting enzyme, prostate carcinoma cells, 4887

Annexin VI
 expression, melanoma, 3855

Antibodies: see also Monoclonal antibodies
 anti-CEA antibody fragment
 rapid targeting, xenografts, 3055
 anti-human endogenous retroviruses Env protein
 specificity, germ cell tumors, 4362
 anti-Lewis Y, humanized, 1118
 anti-p53
 circulating, esophageal cancer, 4917
 anti-VEGF
 angiogenesis inhibition, intravital videomicroscopy, 4032
 autoantibodies
 cysteine sulfinic acid decarboxylase, 5230
 bispecific anti-CEA and TNF α
 cytokine targeting, 4758
 bispecific anti-gp40 and human transferrin receptor 1A10
 binding characteristics and antitumor properties, 113
 CTMO1
 engineered human, ovarian cancer, 5179

GS-7 cell penetration, mice, 3508
H. pylori gastritis effects, 3238
 lymphotoxin fusion protein
 growth inhibition, melanoma, 1707
 processing, B-cell lymphomas, 3062

Antibody-directed enzyme prodrug therapy
 ZD2767 system, colorectal tumor xenografts, 3287

Anticancer agents
 MKT-077 activity, 538
 TNF- α expression inhibition, 3711

Anticancer vaccines
 recombinant
 costimulation enhancement, 2832

Antiestrogens
 estrogen receptor regulation, breast cancer cells, 2321
 response
 estrogen receptor type and, 3883
 tamoxifen
 phase II enzyme expression response, rat liver, 3704
 vitamin D₃ analogue effects potentiation, breast cancer, 2789

Antigens
 2B1, identification, 3902
 carcinoembryonic
 anti-CEA and TNF α bispecific antibody, 4758
 anti-CEA antibody fragment, rapid targeting, 3055
 bladder cancer-associated glycoform, identification by 19A211, 908
 -expressing tumors, radioimmunodetection and radioimmunotherapy, 1805
 gene transduction, rhabdomyosarcoma, 4503
 -induced cytokine expression, Kupffer cells, 4805
 -producing gastric carcinoma, adenovirus-mediated gene therapy, 1341
 vaccinia vaccine, combined with interleukin-2, 2361
 HLA-A 0201-restricted E7-encoded epitope
 HPV16-positive cervical lesions against, virus-specific memory CTLs, 582
 HLA-B27
 cell cycle-dependent expression, breast cancer cells, 4358
 Lewis Y
 antibodies, humanized, 1118
 melanoma
 gp100, immunization against, 4749
 inhibition, MHC class I gene-transfected B16BL6 melanoma cells, 4464
 T-cell recognition, 2368
 MHC class I
 presentation, malignant renal cells, 1756
 presenting cell-based vaccine, MAGE-1 peptide-loaded
 CTLp frequency enhancement, melanoma, 2479
 processing, transporter in
 cell cycle-dependent expression, breast cancer cells, 4358
 deficiencies, renal cell carcinoma, 1756
 proliferating cell nuclear
 regulation by androgens, LNCaP cells, 1539
 sialyl-Tn
 expression, neoplastic transformation, 2229
 T, SV40 early region
 brain tumors, 4820
 T, SV40 large
 brain tumors, 4820
 gene inoculation, tumor immunity induction, 1126

- prostatic intraepithelial neoplasia and prostate carcinoma, transgenic mice, 4894
- Tn**
expression, neoplastic transformation, 2229
- trivalent**
-binding construct, preparation with polyoxime chemistry, 809
- tumor**
HOM-MEL-40, *SSX-2* codes, 4766
MHC class II presentation, vaccine that enhances, 21
mucin, human dendritic cells engineered to express, 3763
tumor-associated
immunoglobulin-like TuAg.I, rat liver, 3934
tumor-associated, melanoma gene, transduced dendritic cells, 5672
tumor-associated carbohydrate, possible roles, 2237
very late, 2
postextravasation cell movement function, RD cells, 3142
- Antimetabolites**
cytotoxic
fatty acid synthase target, HL60 cells, 745
- Antioxidants**
effects, *H. pylori* gastritis, 3238
supplementation
protective effects, lymphocytes, 1291
- Antisense**
antifos
breast cancer inhibition, nude mice, 1098
gastrin
RNA expression, antitumorogenicity, 4111
insulin-like growth factor I receptor
adenovirus expressing, antitumor effects, 3038
and mesothelioma, 4044
oligodeoxynucleotides
multidrug resistance reversal, 4332
oligonucleotides
PKC- α inhibitor, tumor growth inhibition, 3499
parathyroid hormone-related peptide inhibition, and malignant pituitary tumor, 77
RNA
p18 expression inhibition, leukemic cells, 1445
- Antitumor effector cells**
zinostatin stimalamer-induced, 1868
- Antitumor immunity**
augmentation by superantigen staphylococcal enterotoxin B, 3731
induced by allogeneic tumor cells, 3782
induction by SV40 large T antigen gene inoculation, 1126
- AP-1**
inhibition by retinoids, 483
upregulation
and polyploidization, HL60 cells, 5513
- AP-2**
binding activity, HTLV-I cells, 779
- APL: see Leukemia, acute promyelocytic**
- APO-1**
-induced apoptosis
interleukin 1 β -converting enzyme-mediated p34^{cdc2} activation, 4551
- Apoptosis: see also Cell death**
B-cell
Mcl-1 expression and, 40
Bcl-x_s and, neuroblastoma cells, 5734
bile acid-induced, colorectal mucosa, 1480
c-Myc-mediated
modulation *in vivo*, 4315
colonic tumorigenesis, mouse, 4910
CPP-32 activation, ovarian carcinoma cells, 5224
drug-resistant tumor cells, 1374
enediye-induced
potentiation by Bcl-2, 1199
etoposide-induced
functional p53 and, hypersensitive testicular tumors, 1834
Fas-induced
CPP32/Yama(-like) protease effects, 1713
interleukin 1 β -converting enzyme-mediated p34^{cdc2} activation, 4551
resistance, AIDS-associated Kaposi's sarcoma cells, 1874
GADD153/CHOP effects, myeloid cells, 3250
generalized
adenovirus-mediated p53 transfer, glioma cells, 694
H. pylori gastritis, 3238
HSV-tk/ganciclovir-mediated, bystander cells, 2697
induction
adenovirus-mediated wild-type p53 gene transfer, cervical cancer, 3047
bcl-x_s gene therapy, mammary tumors, 1965
benzene metabolites, 5172
cytokine-stimulated cells, leukemic cells, 866
dominant negative IGF-I receptor, 4013
erbstatin, small cell lung carcinoma cells, 4978
fatty acid synthesis inhibition, breast cancer cells, 2745
hypoxia, 2161
IL-6 receptor superantagonists, myeloma cells, 4213
interleukin 1 β -converting enzyme, glioma cells, 5423
KH 1060 and 9-*cis*-retinoic acid, HL-60 cells, 495
protein kinase C inhibition, 2711
Taxol, HeLa cells, 816
TGF- β 1, prostatic epithelial cells, 5146
tyrosine kinase inhibitors, small cell lung cancer cells, 4255
inhibition
2-amino-3-methylimidazo[4,5-*f*]quinoline-induced rat colon tumors, 4307
bcl-2 nonconserved region deletion, 2506
Bcl-2 or Bcl-x_L, HL-60 cells, 4743
bcl-x_L, murine myeloma cells, 1451
mammary tumor progression, transgenic mice, 2998
mutant EGFR, glioblastoma, 5079
signaling, myeloid cells, 3909
tumor promoters, rat hepatocytes, 1272
and lesion grade, cervical neoplasia, 669
lipophilic hormone-induced, 4164
mitochondrial function and, 2033
p53-dependent
myeloid cells, 2148
suppression by *bfl-1*, 3879
p53-independent
mammary tumor progression, transgenic mice, 2998
myeloid cells, 2148
postmitotic
induced by X-irradiation, rec-myc cells, 4116
prevention
IGF-I receptor, neuroblastoma, 4522
radiation-induced
oligodendrocytes, adult rat spinal cord, 5417
and radiosensitivity, ataxia telangiectasia, 1400
resistance
HL-60 cell variant, isolation and characterization, 1621
metastatic LNCaP cells, 5594
retinoblastoma protein cleavage by ICE-like protease, 438
taxol-induced
Bcl-2, Raf-1 requirement, 1851
bcl-2-expressing cells, prostate cancer, 1253
TGF- β 1-induced
insulin receptor substrate 1 protection against, hepatocellular carcinoma cells, 3391
regulation, prostatic epithelial cells, 5146
TNF-mediated
cell cycle-dependent, 1591
1- β -D-Arabinofuranosylcytosine
-induced CPP32/Yama protease
inhibition by Bcl-2 or Bcl-x_L, HL-60 cells, 4743
sensitivity
ras and, 5211
1- β -D-Arabinofuranosylcytosine 5'-triphosphate
intracellular
measurement *in vivo*, 1800
Ara-C: see 1- β -D-Arabinofuranosylcytosine
Arginine-rich protein
gene mutations, cancers, 5576
Aristolochic acid
DNA adducts, renal tissue, 2025
Aromatase
gene overexpression
mammary hyperplasia induction, transgenic mice, 3180
inhibitors, binding characteristics, 3451
Arylalkyl isothiocyanates
chemopreventive effects, lung tumorigenesis, 772
Arylamine
N-acetyltransferase 2
bladder cancer risk modulation, 3915
-exposed workers
p53 mutations, bladder tumors, 294
genotoxic
acetyltransferases that acetylate, mRNA, histological localization, 1517
Asbestos
mitogen-activated protein kinase signal transduction stimulation, 5334
Ascites tumors
energy metabolism
regulation by nitric oxide, 4535
Ascorbate radicals
production
and tumor size, 5741
5-[²¹¹At]Astatato-2'-deoxyuridine, 1204
Astrocytes
BCNU resistance
wild-type p53 and, 2748
Astrocytoma
anaplastic
topotecan-treated, topoisomerase I redistribution, 1664
malignant
circularly permuted IL4-toxin, 5631
substance P-induced mitogenesis, 4983
tenascin-C expression, 182
Ataxia-telangiectasia
apoptosis and radiosensitivity, 1400
ATM gene
allele loss, breast cancers, 5484
and breast cancer susceptibility, 2726
mutations, cancer families, 4130

interferon β -inducible protein elevation, 443

ATM
allele loss, breast cancers, 5484
and breast cancer susceptibility, 2726
mutations, cancer families, 4130

Autoantibody
cysteine sulfinic acid decarboxylase, 5230

Autocrine motility factor
integrin regulation, metastatic melanoma cells, 1902
tumor cell, 2960

Autoimmunity
collagen, lung cancer, 121

Automated fluorescent DNA sequencer
microsatellite length analysis, 2688

B

2B1
identification, 3902

B7.1
expression, tumor cells
and *in vivo* maintenance of CTLs, 11

Bacteria
7 α -dehydroxylase
intestinal, fat effects, 2314

Bak
expression
colorectal adenocarcinoma, 2422
in vivo patterns, 2849

Barrett's-associated adenocarcinoma
esophageal
microsatellite alterations, 259

Barrett's esophagus
adenocarcinoma
clonal precursors, 1961

Basal cell carcinoma
cutaneous
risk, *GSTM3* polymorphism and, 1974
PTCH mutations, 4562, 4599

Batimastat
metastasis control, rat mammary carcinoma, 2815

Bax:Bcl-2 ratio
high, hypersensitive testicular tumors, 1834

BB-94: see Batimastat

B cells: see B lymphocytes

B16 cells
growth inhibition by bryostatins, 2105
sublines
differentially expressed genes with different metastatic potentials, 875

B16BL6 cells
MHC class I gene-transfected, melanoma antigen inhibition, 4464

bcl-2 protein
apoptosis inhibition
epithelial tumor cells, 4006
HL-60 cells, 4743
apoptosis prevention, 2161
Ara-C-induced CPP32/Yama inhibition, HL-60 cells, 4743
chromosome 18q21 locus
hypermethylation, lung cancers, 1886
deficiency
melanocytes, mice, 3546
enediayne-induced apoptosis potentiation, 1199
expression
colorectal adenocarcinoma, 2422
inhibition by KH 1060 and 9-*cis*-retinoic acid, HL-60 cells, 495
ovarian carcinoma, 2178
nonconserved region deletion, 2506
taxol-induced apoptosis and phosphorylation prostate cancer, 1253
Raf-1 requirement, 1851

bcl-X protein
expression, colorectal adenocarcinoma, 2422

bcl-X_L protein
apoptosis inhibition
HL-60 cells, 4743
murine myeloma cells, 1451
apoptosis prevention, 2161
Ara-C-induced CPP32/Yama inhibition, HL-60 cells, 4743

bcl-X_S
apoptosis enhancement, neuroblastoma cells, 5734
apoptosis inhibition, mammary tumors, 1965

BCNU: see 1,3 Bis(2-chloroethyl)-1-nitrosourea; N,N'-Bis(2-chloroethyl)-N-nitrosourea

Bcr
c-Abl/Bcr-abl tyrosine kinase inhibition, 5120

Bcr-abl
Src kinase activation, myeloid cells, 3589
tyrosine kinase
inhibition by Bcr, 5120

Benzene
metabolites
DNA damage and apoptosis, 5172

Benzydine
N-acetylation, 3941

Benzo(a)pyrene
-induced pulmonary carcinogenesis
myo-inositol and dexamethasone chemoprevention, female A/J mice, 5132
UDP-glucuronosyltransferase genoprotection against, 1526

Benzo(a)pyrene diol epoxide
DNA adducts
susceptibility marker, lung cancer, 3638
-induced chromosomal aberrations and lung cancer risk, 3975

Benzo(c)phenanthrene diol epoxides
mutagenesis, 3695

Benzoquinazoline
thymidylate synthase inhibitors
uptake, anabolism and cellular retention, 3301

O⁶-Benzyl-2'-deoxyguanosine
combined with BCNU
antitumor activity, brain tumor xenografts, 2076

O⁶-Benzylguanine
insensitive cellular alkyltransferase, 1578
resistance, 5571

bfl-1
p53-induced apoptosis suppression, 3879

Bile acids
-induced apoptosis, colorectal mucosa, 1480
secondary
precipitation by milk calcium, 3270

Bile duct carcinoma
immunotherapy
MUC1-specific targeting, xenografts, 4205

Biomarkers
laryngeal
immunohistochemical staining, 2199
loss, bladder transitional cell carcinomas, 4782
lung
alterations, air particulate extracts, 1526
styrene and styrene-7,8-oxide exposure, workers, 5410

Bis(7-amino-4-azaheptyl)dimethylsilane
tumor cell growth inhibition, 5624

1,3-Bis(2-chloroethyl)-1-nitrosourea: see also Carmustine
combined with O⁶-benzyl-2'-deoxyguanosine
antitumor activity, brain tumor xenografts, 2076
liposome-encapsulated
intrathecal chemotherapy, meningeal gliomatosis, 3986

resistance
mismatch repair mutations and, 5375
wild-type p53 and, mouse astrocytes, 2748
-treated brain tumor patients
alkyltransferase, prognostic value, 783

N,N'-Bis(2-chloroethyl)-N-nitrosourea
killing
O⁶-benzylguanine sensitization, O⁶-alkyl-guanine-DNA alkyltransferase point mutations and, 1578

Bis(7-ethylamino-4-azaheptyl)dimethylsilane
tumor cell growth inhibition, 5624

Blacks: see African-Americans

Bladder
TBHQ-glutathione conjugate toxicity, 1006

Bladder carcinoma
-associated nuclear matrix proteins, 1690
blood group ABO gene transcription, 1031
C-CAM1 gene expression, orthotopic model, 3431
chromosome 9 tumor suppressor loci, 5039
EGF-responsive and -refractory, rat, 2666
invasive
TIMP-2 expression, 1654
midline expression, 2515
risk
modulation by polymorphic enzymes, 3915
thymidine phosphorylase/PDECGF expression, 4799
transitional cell
adipocyte-type fatty acid binding protein loss, 4782

Bladder tumors
blood group ABO gene transcription, 1031
cadherin-associated molecules, prognostic value, 4154
p53 mutations, arylamine-exposed workers, 294
superficial
-associated CEA glycoform, identification by 19A211, 908

Bleomycin
-induced pulmonary fibrosis
genetic model, 2596
prevention, *Sh ble* transgenic mice, 5659

Bleomycin hydrolase
human
cloning and expression analysis, 1746

Blood, peripheral
B lymphocytes
apoptosis, Mcl-1 expression and, 40
isolation of prostate-derived cells from, 4556
lymphocytes
benzo(a)pyrene diol epoxide-DNA adducts, cancer susceptibility markers, 3638
IL-2 production, human papillomavirus response, 3967
V(D)J recombinase-mediated *HPRT* mutations, children, 1405
SV40 early region and large T antigen, 4820

Blood-brain barrier
opening by RMP-7, rat, 3998

Blood flow
erythropoietin effects, 4728
fluctuation
transient hypoxia and, murine breast cancer, 5522

Blood flow modifiers
combined with radioimmunotherapy, colorectal xenografts, 3293

Blood groups
ABO
gene transcription, bladder carcinomas, 1031

Blood perfusion

- tumor
- and pO₂, after X-rays, 3344

B lymphocytes: see also Lymphocytes

- acute lymphoblastic leukemia
- p16* inactivation by chromosome translocation, 848
- adenoid
- proliferation response to Epstein-Barr virus infection, 5610
- apoptosis
- Mcl-1 expression and, 40
- lymphoma
- antibody processing, 3062
- and lymphotoxin fusion protein growth inhibition, melanoma, 1707
- Mcl-1 levels
- upregulation by latent membrane protein 1, 4610
- murine antihuman B-cell mAb Lym-1
- chimeric Lym-1/IL-2 fusion protein, 4998
- pre-B lymphoma
- resistance genes, MSM/Ms mouse, 3716

BMS-181174

- activation, 3495

Bone

- breast carcinoma metastasis
- E-cadherin expression, 4063
- cell adhesion
- inhibition by bone sialoprotein peptides, breast cancer, 1948
- formation
- induction by human amniotic tumor, 633
- metastasis, lung cancer cell model, 4040

Bone marrow

- purging
- adenovirus-mediated, breast tumor cells, 1346

Bone sialoprotein peptides

- cell adhesion inhibition, breast cancer, 1948

Borderline ovarian tumors

- epithelial
- microsatellite instability, 2501

Boron neutron capture therapy

- malignant brain tumors, 2017
- quantitative ion imaging, brain tumor model, 4302

p-Boronophenylalanine

- hydroxylforms
- boron neutron capture therapy, malignant brain tumors, 2017

Bowman-Birk inhibitor

- carcinoma suppression, Min mice intestines, 679

Bradykinin

- permeability mediation, brain tumors, 4027

Brain

- endothelial cells
- tenascin-C expression, 182
- peritumoral edema
- corticotropin-releasing factor treatment, 1352

Brain-derived neurotrophic factor

- chemosensitivity effects, neuroblastoma cells, 3737

Brain enriched hyaluronan binding

- expression, glioma, 2293

Brain tumors

- O⁶-benzyl-2'-deoxyguanosine and BCNU
- antitumor activity, xenografts, 2076
- boron neutron capture therapy, quantitative ion imaging, 4302
- carboplatin uptake
- RMP-7 and, rat, 3998
- carmustine treatment
- alkyltransferase, prognostic value, 783
- cell migration, 1939

immunotherapy

- superantigen-activated T cells, 4702
- inhibition by MDL101731, 359
- malignant
- boron neutron capture therapy, 2017
- membrane-type matrix metalloprotease
- expression and gelatinase A activation, 384
- manganese superoxide dismutase expression, 3192
- metastatic
- local chemotherapy, 5217
- microvessel permeability
- mediation by bradykinin, 4027
- serum and tumor tissue VEGF levels, 2185
- SV40 early region and large T antigen, 4820

BRCA1

- amino-terminal zinc ring domain molecular modeling, 2539
- mutations
- 185delAg, Jewish women with ovarian cancer, 1250
- germline, and histoprogenic grade, 471
- germline, Italian cancer families, 5466
- germline, mRNA *in situ* hybridization detection, 2912
- protein expression and phosphorylation, 3168
- protein truncation, hereditary breast cancers, 3216
- splice variants, mammary epithelial cells, 4578

BRCA2

- cell cycle control, 4590
- chromosome 13q allelic imbalance, sporadic breast cancer, 1988
- mutations
- 999del5, Icelandic breast and ovarian cancer patients, 3663
- germline, sporadic pancreatic carcinomas, 5360
- hepatocellular carcinoma, 4575
- Jewish Ashkenazi and non-Jewish individuals, 3409
- ovarian carcinoma, 2738
- sporadic ovarian cancer, 3622

BrdUrd: see Bromodeoxyuridine

Breast

- epithelial cells
- BRCA1 splice variants, 4578
- cyclin E overexpression, mouse, 1389
- growth inhibition by activin, 1155
- immortalization by mutant *p53*, 3129
- malignant transformation, 2039
- sulfotransferase expression, 1551
- transformed, cyclooxygenase-2 transcription, 4424
- epithelium
- monoclonality, 402
- Fas expression and function, 4791
- lipid, genotoxicity, 5342
- malignant cells
- Fas expression and function, 4791
- proliferative disease
- FHIT and PTPRG deletions, 4871
- secretory differentiation
- truncated *Int3* and, 1775
- tissues
- aromatic DNA adducts, 287
- karyotypic heterogeneity, 855, 5098

Breast carcinoma: see also Carcinoma, breast

- adjacent tissues
- aromatic DNA adducts, 287
- karyotypic heterogeneity, 855, 5098
- α - and β -catenin gene mutations, 49
- angiogenic factors, 2013

apoptosis

- induction by fatty acid synthesis inhibition, 2745
- arginine-rich protein gene mutations, 5576
- BRCA1
- amino-terminal zinc ring domain molecular modeling, 2539
- 185delAg mutations, Jewish women with ovarian cancer, 1250
- germline mutations, and histoprogenic grade, 471
- germline mutations, Italian cancer families, 5466
- germline mutations, mRNA *in situ* hybridization detection, 2912
- protein expression and phosphorylation, 3168
- splice variants, mammary epithelial cells, 4578
- BRCA2
- cell cycle control, 4590
- chromosome 13q allelic imbalance, 1988
- 999del5 mutations, Icelandic patients, 3663
- germline mutations, sporadic pancreatic carcinomas, 5360
- mutations, hepatocellular carcinoma, 4575
- mutations, Jewish Ashkenazi and non-Jewish individuals, 3409
- mutations, ovarian carcinoma, 2738
- mutations, sporadic ovarian cancer, 3622
- BT-20 cells
- p18 variant, 4586
- cell adhesion
- inhibition by bone sialoprotein peptides, 1948
- regulation, 2206
- cell cycle-dependent TAP1, TAP2, and HLA-B27 expression, 4358
- cell proliferation
- inhibition by interleukin 13, 3583
- regulation by 4-HPR, 1056
- vitamin D₃ analogue effects, potentiation by antiestrogen, 2789
- c-erbB-2, quantitative estimation, 3823
- chemoprevention
- LGD1069, 5566
- chromosome 20q amplification, 3441
- chromosome 20q11-q13.2 amplified genes, isolation, 3446
- chromosome 17q11-q21 amplified regions, 3886
- cyclin-dependent kinase 2 and CDK4 inhibition by flavopiridol, 2973
- cyclooxygenase-1 and cyclooxygenase-2
- expression and regulation, 5125
- DEP-1 expression, 4236
- epidermal growth factor receptor, quantitative estimation, 3823
- erbB receptors, 899
- estrogen receptor
- regulation, models, 2321
- variant mRNAs, 4324
- FHIT gene at 3p14.2, 3173
- gangliosides, 5165
- gelsolin loss, 4841
- genetic divergence, 1493
- growth inhibition
- antifos, nude mice, 1098
- flavopiridol, 2973
- interferon, RAR- γ and, breast cancer, 1571
- interleukin 13, 3583
- retinoic acid-induced, mediation by IGFBP-3, 1545
- retinoid, RAR- γ and, breast cancer, 1571
- transforming growth factor- β 2-induced,

mediation by IGFBP-3, 1545

hereditary

- histoprogenic grade, BRCA1 germ line mutations and, 471
- truncated BRCA1 protein, 3216

β -hexachlorocyclohexane estrogenic action, 5403

hormone-independent

- heregulin- β 2 and, 3350

insulin receptor promoter repression by p53, 2781

invasive

- grade I tubular, *FHIT* and *ATM* allele loss, 5484
- macrophage infiltration, 4625
- psoriasis expression, 4606
- tumor stroma tissue factor, 5063

karyotypic heterogeneity, 855, 5098

linomide chemoprevention, rodents, 3404

MAGE-1-specific CTLs, 16

mammaglobin expression, 860

matrix attachment region-binding activity, 457

MCF-7 cells

- estrogen receptor exon 5 variant effects, 1556

MDA-MB-435 cells

- human retinoic acid receptor α gene regulation, 5246
- metastasis-suppressor gene, chromosome 11, 1222

metastasis

- batimastat control, rat, 2815
- inhibition by synthetic glycoamines, nude mice, 5319
- integrin α 6 β 1 function, 959

metastasis to bone

- E-cadherin expression, 4063
- microsatellite instability, 4021
- MT4-MMP gene (*MMP-17*) cloning, 944
- MUC1 adhesion ligand, 4244
- NMU-induced
- H-ras* promoter conformation alterations, 4927

p21^{WAF1/CIP1}, posttranscriptional regulation, 5055

p27/*Kip1* mutations, 2400

P450-based gene therapy, 1331

prognostic factors

- motility-related protein-1, 1244

progression

- regulation by dominant *trans*-acting factors, somatic cell hybridization studies, 3560
- serine protease-like gene down-regulated in, 3371

psoriasis expression, 4606

RBI

- chromosome 13q allelic imbalance, sporadic breast cancer, 1988

SKBR-3 cells

- human retinoic acid receptor α gene regulation, 5246

sporadic

- chromosome 13q allelic imbalance, 1988
- sulfatase and, 4950
- sulfotransferase expression, 1551

susceptibility

- ATM* gene and, 2726

transformed phenotype

- reversal by dominant-negative thioredoxin mutant, 5765

transient hypoxia, murine, 5522

vascular endothelial growth factor expression, 2013

vasoactive intestinal peptide receptors, 3486

xenografts in *lit/lit* hosts

- growth reduction, 1509

Breast carcinoma *in situ*

ductal

- chromosome 16q deletion mapping, 5605
- genetic progression, 5260
- non-comedo, *FHIT* and *ATM* allele loss, 5484
- psoriasis expression, 4606

Breast tumors: see also Mammary tumors

adenovirus-mediated gene transfer

- gene therapy and bone marrow purging, 1346

apoptosis

- induction by *bcl-x_i* gene therapy, 1965

growth

- pregnancy-dependent, IGF-II overexpression and, 3651
- regulation by heregulin, erbB2 effects, 1457

interleukin 6 expression and response, 3118

liver-enriched inhibiting protein expression, 4382

mammary-derived growth inhibitor gene silencing by epigenetic changes, 4865

progression

- apoptosis suppression, transgenic mice, 2998
- WNT-2* expression, 4320

Bromodeoxyuridine

- S-phase cell labeling
- histone H3 mRNA *in situ* hybridization and, rat colonic epithelium, 434

5-Bromo-2'-deoxyuridine

- colorectal liver metastases and liver, 2677
- regional pharmacokinetics, dogs, 4724

Bronchial mucosa

- microsatellite alterations, lung cancer, 2285

Bryostatin 1

- pharmacokinetics, 802

26-epi-Bryostatin 1

- mechanism, 2105

Bryostatins

- cell growth inhibition, B16/F10 cells, 2105

BT-20 cells

- p18 variant, 4586

Burkitt's lymphoma

- mutant *p53* transcription, 1648

Busulfan

- glutathione conjugate
- catalysis by glutathione S-transferase, 3678

1,3-Butadiene

- induced lymphoma
- allele analysis, B6C3F1 mice, 3338

Butylated hydroxytoluene hydroperoxide

- mitogen-activated protein kinase activation, 3480

tert-Butyl-hydroquinone

- glutathione conjugates, toxicity, 1006

Bystander cells

- apoptotic death
- HSV-tk/ganciclovir-mediated, 2697

Bystander effect

- toxin gene effects, lung adenocarcinoma, 1315

C

CAAT/enhancer binding protein

- activity
- GADD153/CHOP effects, myeloid cells, 3250

c-Abl

- tyrosine kinase, inhibition by Bcr, 5120

Cachexia

- inducing tumors
- protein-degrading factor and, 1256

Caco-2 cells

- growth

activation by estradiol, 4516

Cadherin

- associated molecules
- prognostic value, bladder tumors, 4154
- expression, renal cell carcinoma, 3234

E-Cadherin

- catenin complex
- EGF receptor downregulation and invasive phenotype reversal, HPV-transfected keratinocytes, 5285
- expression, breast cancer metastasis to bone, 4063

Caffeine

- and ultraviolet light sensitivity, p53-null cells, 5365

CA 72-4 immunoassay

- tumor-associated glycoprotein 72 levels, colorectal patients, 5293

Cain Memorial Award

- Fifteenth, lecture, 5533

Calcitriol

- and chemotherapy-induced alopecia, mice, 4438

Calcium

- influx
- cytostatic inhibitor, refractory cancers, 569
- milk
- colonic cytotoxicity inhibition, 3270
- peptide-induced flux
- modulation by neutral endopeptidase, 831

Camptothecin

- cytotoxicity
- S and G₂ breakpoints and, colon carcinoma cells, 4430
- prodrug
- rat serum carboxylesterase-mediated activation, 1471
- resistance
- and topoisomerase I expression, epidermoid cancer cells, 2348
- topoisomerase I-independent, 345

Canalicular multispecific organic anion transporter

- human, cisplatin-resistant cancer cells, 4124

Cancer: see Carcinoma

Cancer genes: see Genes; Oncogenes

Cancer-preventive agents

- TNF- α* expression inhibition, 3711

Cancer-prone syndromes

- hereditary
- abnormal SOS-like response, inheritance, 2621

CAPL

- anti-CAPL (*mts1*) ribozyme
- metastatic phenotype reversal, tumor cells, 5490

Carbogen breathing

- combined with hyperthermia
- radiosensitization, 5590

Carbohydrates

- tumor-associated antigens, possible roles, 2237

Carbonyl

- reducing enzymes
- regulation by chemoprotectors, rat liver, 2758

Carboplatin

- ototoxicity
- thiosulfate rescue, 706
- uptake into brain tumors
- RMP-7 and, rat, 3998

Carboxyamido-triazole

- refractory cancers, 569

Carboxylesterase

- serum
- prodrug activation role, rat, 1471

- Carboxypeptidase G2**
combined with mustard prodrug
gene-directed enzyme prodrug therapy,
4728
- Carcinoembryonic antigen**
anti-CEA and TNF α bispecific antibody
targeting, 4758
anti-CEA antibody fragment
rapid targeting, xenografts, 3055
bladder cancer-associated glycoform, identi-
fication by 19A211, 908
-expressing tumors
radioimmunodetection and radioimmuno-
therapy, 1805
gene transduction, rhabdomyosarcoma, 4503
-induced cytokine expression, Kupffer cells,
4805
-producing gastric carcinoma
adenovirus-mediated gene therapy, 1341
vaccinia vaccine
combined with interleukin-2, immunother-
apy, 2361
- Carcinogenesis: see also Tumorigenesis**
English sole model
DNA base modifications and liver lesions,
5563
- Carcinogenicity**
2',3'-dideoxycytidine, mice, 4666
- Carcinogens**
chemical
activation by human P450 1B1, 2979
colon
6-nitrochrysene, metabolism and DNA
binding, 2052
-induced gene amplification
potentiation by poly(ADP-ribosyl)ation
inhibition, SV40-transformed Chinese
hamster cells, 2715
induction
mitochondrial DNA adducts, rat organs,
1642
phenolphthalein effects, experimental mod-
els, 4922
Phlp
metabolism, rat colon tissue, 2550
- Carcinoid tumors**
somatostatin receptor scintigraphy *vs in situ*
hybridization, 2561
- Carcinoma**
DNA methylation errors and, 2463
erythrocytes
sodium transport, 511
glucose catabolism, 2468
Glut1 expression, 1164
inhibition by MKT-077, 538
mitochondria
MKT-077 toxicity, 544
mutator phenotype
inter-Alu polymerase chain reaction detec-
tion, 2733
radioimmunoconjugate metabolism and re-
tention, 2123
refractory
cytostatic calcium influx inhibitor, 569
suppression by Bowman-Birk inhibitor, Min
mice intestines, 679
TAI/E16 expression, 5012
tamoxifen methiodide anticancer activity,
rodents, 4328
- Carcinoma, basal cell**
cutaneous
risk, *GSTM3* polymorphism and, 1974
PTCH mutations, 4562, 4599
- Carcinoma, bile duct**
immunotherapy
MUC1-specific targeting, xenografts, 4205
- Carcinoma, bladder**
-associated nuclear matrix proteins, 1690
blood group ABO gene transcription, 1031
C-CAM1 gene expression, orthotopic model,
3431
chromosome 9 tumor suppressor loci, 5039
EGF-responsive and -refractory, rat, 2666
invasive
TIMP-2 expression, 1654
midkine expression, 2515
risk
modulation by polymorphic enzymes,
3915
thymidine phosphorylase/PDEC GF expres-
sion, 4799
- Carcinoma, breast**
adjacent tissues
aromatic DNA adducts, 287
 α - and β -catenin gene mutations, 49
angiogenic factors, 2013
apoptosis
induction by fatty acid synthesis inhibi-
tion, 2745
arginine-rich protein gene mutations, 5576
BRCA1
amino-terminal zinc ring domain molecu-
lar modeling, 2539
185delAg mutations, Jewish women with
ovarian cancer, 1250
germ line mutations, and histoprogenetic
grade, 471
germline mutations, Italian cancer fami-
lies, 5466
protein expression and phosphorylation,
3168
splice variants, mammary epithelial cells,
4578
BRCA2
cell cycle control, 4590
chromosome 13q allelic imbalance, 1988
999del5 mutations, Icelandic patients,
3663
germline mutations, sporadic pancreatic
carcinomas, 5350
mutations, hepatocellular carcinoma, 4575
mutations, Jewish Ashkenazi and non-
Jewish individuals, 3409
mutations, ovarian carcinoma, 2738
mutations, sporadic ovarian cancer, 3622
BT-20 cells
p18 variant, 4586
cell adhesion
inhibition by bone sialoprotein peptides,
1948
regulation, 2206
cell cycle-dependent TAP1, TAP2, and
HLA-B27 expression, 4358
cell proliferation
inhibition by interleukin 13, 3583
regulation by 4-HPR, 1056
vitamin D $_3$ analogue effects, potentiation
by antiestrogen, 2789
c-erbB-2, quantitative estimation, 3823
chemoprevention
LGD1069, 5566
chromosome 20q amplification, 3441
chromosome 20q11-q13.2 amplified genes,
isolation, 3446
chromosome 17q11-q21 amplified regions,
3886
cyclin-dependent kinase 2 and CDK4 inhibi-
tion by flavopiridol, 2973
cyclooxygenase-1 and cyclooxygenase-2
expression and regulation, 5125
DEP-1 expression, 4236
epidermal growth factor receptor, quantita-
tive estimation, 3823
erbB receptors, 899
- estrogen receptor
regulation, models, 2321
variant mRNAs, 4324
FHIT gene at 3p14.2, 3173
gangliosides, 5165
gelsolin loss, 4841
genetic divergence, 1493
growth inhibition
antifos, nude mice, 1098
flavopiridol, 2973
interferon, RAR- γ and, breast cancer,
1571
interleukin 13, 3583
retinoic acid-induced, mediation by IG-
FBP-3, 1545
retinoid, RAR- γ and, breast cancer, 1571
transforming growth factor- β 2-induced,
mediation by IGFBP-3, 1545
- hereditary
histoprogenetic grade, *BRCA1* germ line
mutations and, 471
truncated *BRCA1* protein, 3216
 β -hexachlorocyclohexane estrogenic action,
5403
hormone-independent
heregulin- β 2 and, 3350
insulin receptor promoter repression by p53,
2781
invasive
grade 1 tubular, *FHIT* and *ATM* allele
loss, 5484
macrophage infiltration, 4625
psoriasis expression, 4606
tumor stroma tissue factor, 5063
karyotypic heterogeneity, 855, 5098
linomide chemoprevention, rodents, 3404
MAGE-1-specific CTLs, 16
mammaglobin expression, 860
matrix attachment region-binding activity,
457
MCF-7 cells
estrogen receptor exon 5 variant effects,
1556
MDA-MB-435 cells
human retinoic acid receptor α gene regu-
lation, 5246
metastasis-suppressor gene, chromosome
11, 1222
metastasis
inhibition by synthetic glycoamines, nude
mice, 5319
integrin α 6 β 1 function, 959
metastasis to bone
E-cadherin expression, 4063
microsatellite instability, 4021
MT4-MMP gene (*MMP-17*) cloning, 944
MUC1 adhesion ligand, 4244
NMU-induced
H-ras promoter conformation alterations,
4927
p21^{WAF1/CIP1}, posttranscriptional regulation,
5055
p27/*Kip1* mutations, 2400
P450-based gene therapy, 1331
prognostic factors
motility-related protein-1, 1244
progression
regulation by dominant *trans*-acting fac-
tors, somatic cell hybridization studies,
3560
serine protease-like gene down-regulated
in, 3371
- RB1**
chromosome 13q allelic imbalance, spo-
radic breast cancer, 1988
- SKBR-3 cells**
human retinoic acid receptor α gene regu-
lation, 5246

- sporadic
 chromosome 13q allelic imbalance, 1988
 sulfatase and, 4950
 sulfotransferase expression, 1551
 susceptibility
ATM gene and, 2726
 transformed phenotype
 reversal by dominant-negative thioredoxin mutant, 5765
 transient hypoxia, murine, 5522
 vascular endothelial growth factor expression, 2013
 vasoactive intestinal peptide receptors, 3486
 xenografts in *lit/lit* hosts
 growth reduction, 1509
- Carcinoma, cecum**
 sporadic
 transforming growth factor β type II receptor gene mutations, 5620
- Carcinoma, cervical**
 adenovirus-mediated wild-type *p53* gene transfer, 3047
 chromosome loss of heterozygosity, 197
 genomic alterations, 197
 human papillomavirus tumor status, 197
 insulin-like growth factor I receptor overexpression, 1761
 malignant progression
 tumor hypoxia and, 4509
 microsatellite instability, 1427
 radiation therapy
 manganese superoxide dismutase expression, 2771
 replication error phenotypes, 1427
 virus-specific memory CTLs, 582
- Carcinoma, colon**
 camptothecin cytotoxicity
S and *G₂* breakpoints and, 4430
 cell cycle arrest
 ZD1694-induced, 4715
 cell density
 vascular endothelial growth factor regulation, 3891
 cell proliferation
 gastrin gene expression and, 4111
 inhibition by 9-*cis*-retinoic acid, colon cancer cells, 623
 inhibition by vitamin D₃, 623
 cyclooxygenase-2 inhibitor chemopreventive properties, 4566
 DNA methylation mechanisms, 2375
 drug sensitivity
 increase by GST- π antisense cDNA, 3577
 hereditary nonpolyposis
 genomic instability, 2733
 inhibition
 exogenous *NF1* gene, 2872
 gastrin, 880
 sphingomyelin, CF1 mice, 4936
 late-stage
 and diet, Sprague-Dawley rats, 2896
 metastasis
 gelatinase B secretion, autocrine stimulation by TGF- β 1, 3366
 hepatic, suicide and cytokine gene therapy, 3758
 mitomycin C sensitivity
 DT-diaphorase determinant, 2823
 mucin
 galactin-3 binding, 4354
 nitric oxide biosynthesis
 suppression by 5-fluorouracil, 1978
 somatostatin receptor gene expression, 1823
TA1/E16 expression, 5012
 1 M tegatur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxanate antitumor activity, 2602
- Carcinoma, colorectal**
 chromosome 6 allelic imbalance, 145
 chromosome 8p22-23 tumor suppressor gene, functional evidence, 5238
 familial
hMLH1 mutations, 5728
FHIT gene evaluation, 2936
 genetic heterogeneity and unmapped genes, 1382
 hereditary nonpolyposis
 TGF- β *R11* mutations, 4595
 high mobility group protein HMGI(Y) expression, 1896
 invasive
 integrin $\alpha_6\beta_4$ functions, 4811
 matrix metalloproteinase 2 and matrix metalloproteinase 9, 190, 3610
 metastasis
 cell adhesion regulator mRNA expression and, 3605
MRP and γ -*GCS* expression, 3642
 mycophenolic acid resistance, 984
NME1 allelic imbalance, 916
 nonfamilial
 microsatellite instability, 5470
 risk
 methylenetetrahydrofolate reductase polymorphism and, 4862
 TNF α allelic frequency, 145
 tumor-associated glycoprotein 72 levels, quantitative CA 72-4 immunoassay, 5293
 ubiquitin-conjugated proteins, 2752
- Carcinoma, endometrial**
 gonadotropin-releasing hormone expression, 2059
 monoclonal precursors, uteri, 1917
 precursor lineages, 4483
- Carcinoma, epidermoid**
 topoisomerase I expression
 saintopin resistance and, 2348
- Carcinoma, epithelial ovarian**
 chromosome 11q23.3-q24.3 loss of heterozygosity, 950
 intraperitoneal photodynamic therapy, xenograft murine model, 1075
- Carcinoma, esophageal**
 anti-p53 antibodies, circulating, 4917
H19 imprinting loss, 480
- Carcinoma, gastric**
 α - and β -catenin gene mutations, 49
 carcinoembryonic antigen-producing adenovirus-mediated gene therapy, 1341
 chromosome 5q allele loss, 612
 glandular
 vitamin D₃ chemoprevention, rats, 2767
 intestinal
 microsatellite instability-associated mutations, 4664
 mitomycin C sensitivity
 DT-diaphorase determinant, 2823
 progression
 angiogenesis and, 2671
- Carcinoma, head and neck**
 squamous cell
 arginine-rich protein gene mutations, 5576
 chromosomal alterations, comparative genomic hybridization, 5325
 chromosome 13q deletion mapping, 1146
DPC4 mutations, 2519
FHIT abnormalities, 5128
 genetic progression model, 2488
p16 growth suppressor, 4119
p16 inactivation, 3630
p16 β growth suppressor, 4119
 radiosensitization by paclitaxel, 5198
 radiotherapy, 13-*cis*-retinoic acid/ α -2a-IFN, 2277
- telomerase activity, 3530, 5600
 telomerase activity, oral rinses, 5720
- Carcinoma, hepatocellular**
 -activated cysteine sulfinic acid decarboxylase, 5230
BRCA2 mutations, 4575
 chromosome 8p allele loss, China, 5092
 hereditary
 etheno-DNA adducts, copper-dependent formation, LEC rats, 1267
 insulin-like growth factor I receptor gene expression, 3831
 megesterol treatment
 response, estrogen receptor type and, 3883
 tamoxifen treatment
 response, estrogen receptor type and, 3883
 TGF- β 1-induced apoptosis, insulin receptor substrate 1 protection against, 3391
 thioredoxin overexpression, 5330
 vascular permeability factor/VEGF expression, 3004
- Carcinoma, intestinal**
 spontaneous, *Msh2*-deficient mice, 3842
 suppression by Bowman-Birk inhibitor, Min mice, 679
- Carcinoma, invasive**
 bladder
 midline expression and, 2515
 TIMP-2 expression, 1654
 breast
 grade I tubular, *FHIT* and *ATM* allele loss, 5484
 tumor stroma tissue factor, 5063
 colorectal
 integrin $\alpha_6\beta_4$ functions, 4811
 prostate
 progression, SV40 T_{AG} transgenic mice, 4894
 ursolic acid anti-invasive activity, HT1080 cells, 2281
- Carcinoma, lung**
 A549 cells
 flavopiridol-induced cell death, 4856
 methylthioadenosine phosphorylase chemosensitivity, 5653
 Ad-IGF-Ir/ as antitumor effects, 3038
 arginine-rich protein gene mutations, 5576
bcl-2 chromosome 18q21 locus hypermethylation, 1886
 bone metastasis model, 4040
 chemoprevention
 arylalkyl isothiocyanates and *N*-acetylcysteine, Fischer rats, 772
myo-inositol and dexamethasone, female A/J mice, 5132
 chemotherapy
 CT1746 and cyclophosphamide combination, murine Lewis, 715
 cJun expression, 305
 collagen autoimmunity, 121
CYP1A1 polymorphisms and *p53* mutations, 72
 DNA repair capacity, 4103
DPC4 somatic alterations, 2718
FHIT alterations, 5579
 α -1,3-fucosyltransferase expression, 325
 IA-2 neuroendocrine marker, 2742
JV18-1 somatic alterations, 5583
 microsatellite alterations, bronchial and sputum specimens, 2285
 neutral endopeptidase expression and inactivation, 831
 non-small cell
 p16 and retinoblastoma protein status, 5557
 risk
 benzo(a)pyrene diol epoxide-induced

- chromosomal aberrations and, 3975
CYP1A1 polymorphisms risk, African-Americans, 4275
 retinoic acid catabolism and, 2692
 tobacco, CYP2D6 activity and, 251
- small cell
 apoptosis induction by erbstatin, 4978
 mitogen-activated protein kinase stimulation, 5758
- susceptibility
 benzo(a)pyrene diol epoxide-DNA adducts and, 3638
CYP1A1 C4887A polymorphism and, 4965
NAT2 genotype and, 3961
 TOP-53 antitumor activity, 2809
- Carcinoma, medullary thyroid**
RET mutations, 1241, 2167
- Carcinoma, Merkel cell**
 aberrant *FHIT* transcripts, 2472
- Carcinoma, nasal**
 formaldehyde-induced, 1012
- Carcinoma, nasopharyngeal**
 chromosome 11 long arm loss of heterozygosity, 3225
p16 gene hypermethylation, 2721
- Carcinoma, non-small cell lung**
 chemosensitivity enhancement by tyrphostin Ag825, 1068
 chemotherapy
 gemcitabine-containing regimens, 794
 chromosome 11p15.5 allelic deletions, 2916
 chromosome 12p loss of heterozygosity, 738
CYP1A1 and *GSTM1* polymorphisms, 1974
HER-2/neu expression and chemoresistance, 206
KAI1/CD82 expression, 1751
p16 and retinoblastoma protein status, 5557
- Carcinoma, oral**
 combination gene therapy, murine model, 1737
 inhibition by flavonoids, rat, 4904
 risk
 smoking and, gender differences, 5192
- Carcinoma, ovarian**
 advanced
p53 status and response to therapy, 689
 apoptotic cells
 CPP-32 activation, 5224
bcl-2 and *p53* expression, 2178
 bispecific mAb-based treatment
 CD3-CD28 costimulation, 5443
BRCA1
 185delAg mutations, Jewish women, 1250
 germline mutations, Italian cancer families, 5466
BRCA2
 999del5 mutations, Icelandic patients, 3663
 mutations, 2738
 cell invasion
 hypoxic, 1168
 charged photoimmunoconjugates and, 5205
 chemotherapy
 combined with photodynamic therapy, 3980
 fatty acid synthase inhibition, xenograft model, 1189
 chromosome 11q loss of heterozygosity, 741
 chromosome 22q loss of heterozygosity, 729
 cisplatin resistance, 556
 phenotype expression, chromosome segregation, 2256
 deletions, minimal region, 5586
 early
 chromosome 17p13.3 allelic deletion, 606
 engineered human CTMO1 biodistribution, 5179
- IL-8 expression
 Taxol-dependent activation, 1303
 malignancy
 second, 1565
p53 mutations, 556
 sporadic
BRCA2 mutations, 3622
- Carcinoma, pancreatic**
 angiogenin expression, 2703
 chromosome 7q allelic losses, 3808
 chromosome 18q21.1 homozygous deletion map, 490
 comparative genomic hybridization, 3803
DPC4 inactivation, 2527
KAI1 expression, 4876
 metastasis
 hyaluronate-independent, 3134
 orthotopic xenografts, 5713
p16/MTS-1 alterations, 1137
PRG1, 2641
 somatostatin receptor gene expression, 1823
 sporadic
 germline *BRCA2* mutations, 5360
- Carcinoma, pancreatic cell**
p16, *MTAP*, and *IFN* deletion and chemosensitivity, 1083
- Carcinoma, papillary thyroid**
 CD44 mRNA splicing, 1037
 c-erbB-3 and c-erbB-4 expression, 1184
- Carcinoma, prostate**
 advanced
 endothelin-1 production and endothelin B receptor expression, 663
 androgen-dependent and relapsed, 3042
 androgen-independent
 genetic alterations, comparative genomic hybridization and allelotyping, 3091
 arginine-rich protein gene mutations, 5576
 chaotic oscillations, cultured rat cells, 3682
 chromosome 6q deletions, 4150
 chromosome 8p12-21 allelic loss, 2411
 chromosome 10p allelic loss, 2263
 chromosome 10q allelic loss, 2263
 chromosome 13q allelic loss, 1142
 cyclin expression, 4159
 differentially expressed genes, 3634
 DU145 cells
 p27^{Kip1}-mediated G₁ arrest, 3666
 DU147 cells
 β -L-(-)-dioxolane-cytidine uptake and metabolism, 4180
 hyaluronidase levels, 651
 α IIb β 3 integrin expression, 5071
 invasive
 progression, SV40 T_{AG} transgenic mice, 4894
KAI1 dysregulation, 4387
 linomide chemoprevention, rodents, 3404
 LNCaP cells
 proliferating cell nuclear antigen regulation by androgens, 1539
tpc/hpr fusion transcript, 728
 metastatic
 genetic alterations, comparative genomic hybridization and allelotyping, 3091
 TGF- β 1 effects, 3359
 TRAMP model, 4096
p53 alterations, 3814
 plasminogen-angiotensin converting enzyme, 4887
 prevention
 investigational approaches and opportunities, 5547
 R-3327 cells
 invasion and metastasis inhibition by PKC- ζ , 4137
- taxol-induced *bcl-2* phosphorylation and apoptosis, 1253
 TGF- β receptor-1 genetic change, 44
 TGF- β 1 insensitivity, 44
 tubulin isotype levels, 2584
 vitamin D receptor gene polymorphisms, 4108
- Carcinoma, renal**
 inhibition by IL-12 cDNA injection, murine model, 3399
- Carcinoma, renal cell**
 advanced
 human leukocyte antigen loss of allele expression, 826
 cadherin expression, 3234
 chromophobe
 loss of heterozygosity pattern, 2927
 comparative genomic hybridization, 27
 disialosyl galactosylglycoside adhesion molecules, 1932
 malignant progression by FGF-2 transfection, mouse, 2440
 transporter associated with antigen processing and low molecular weight protein deficiencies, 1756
 VEGF expression
 reversion by von Hippel-Lindau protein, 2299
- Carcinoma, renal collecting duct**
 chromosome 1q high-density mapping, 5044
- Carcinoma, seminal vesicle**
 linomide chemoprevention, rodents, 3404
- Carcinoma, skin**
 human skin grafted to SCID mice, 757
 MGMT protection against, transgenic mice, 3244
p53 loss, transgenic mice, 4413
 vascular endothelial growth factor/vascular permeability factor upregulation, 5391
- Carcinoma, small cell lung**
 apoptosis
 induction by erbstatin, 4978
 cisplatin and topoisomerase inhibitors NB-506 and SN-38 synergism, 789
c-kit and stem cell factor, 370
 δ opioid receptors, characterization, 1695
 glucocorticoid receptor, 3276
 mitogen-activated protein kinase stimulation, 5758
 Myc-overexpressing, gene therapy, 354
 p70^{src} phosphorylation
 inhibition by rapamycin, 3895
 topoisomerase II α point mutations, 1232
 tumor suppressor gene region
 600-kb cosmid contig, 1489
- Carcinoma, sporadic**
 breast
 chromosome 13q allelic imbalance, 1988
 cecum
 transforming growth factor β type II receptor gene mutations, 5620
 pancreatic
 germline *BRCA2* mutations, 5360
- Carcinoma, squamous cell**
 esophageal
 advanced-stage, *p16/CDKN2* inactivation, 3875
 interleukin 6 serum levels, 2776
 head and neck
 arginine-rich protein gene mutations, 5576
 chromosomal alterations, comparative genomic hybridization, 5325
 chromosome 13q deletion mapping, 1146
DPC4 mutations, 2519
FHIT abnormalities, 5128
 genetic progression model, 2488
 growth suppressors, *p16* and *p16 β* , 4119
p16 inactivation, 3630

- radiosensitization by paclitaxel, 5198
radiotherapy, 13-*cis*-retinoic acid/ α -2a-IFN, 2277
telomerase activity, 3530, 5600
telomerase activity, oral rinses, 5720
parathyroid hormone-related protein gene expression
and hypercalcemia, athymic mice, 1043
radiation
tumor hypoxia reduction and repair inhibition by nicotinamide, SCCVII murine tumors, 2801
- Carcinoma, thyroid**
differentiated
mAb JT-95, production, 1817
thyroid peroxidase reexpression
wild-type p53 and, 765
- Carcinoma, transitional cell**
bladder
adipocyte-type fatty acid binding protein loss, 4782
- Carcinoma, urothelial**
DNA methylation, 5698
recurrence
serum MMP-2:TIMP-2 ratio, 3196
- Carcinoma in situ**
breast
psoriasis expression, 4606
ductal
chromosome 16q deletion mapping, 5605
genetic progression, 5260
non-comedo, *FHIT* and *ATM* allele loss, 5484
- Cardiotoxicity**
doxorubicin-induced
dexrazoxane dose-response relationship, mice, rats, and dogs, 4200
- Carmustine**; see also 1,3-Bis(2-chloroethyl)-1-nitrosourea
-treated brain tumor patients
alkyltransferase, prognostic value, 783
- Catabolism**
retinoic acid
and lung cancer risk, 2692
- Catenin**
E-cadherin complex
EGF receptor downregulation and invasive phenotype reversal, HPV-transfected keratinocytes, 5285
- α -Catenin**
gene mutations, gastric and breast carcinomas, 49
prognostic value, bladder tumors, 4154
- β -Catenin**
expression, familial adenomatous polyposis, 2213
gene mutations, gastric and breast carcinomas, 49
prognostic value, bladder tumors, 4154
- γ -Catenin**
prognostic value, bladder tumors, 4154
- Caucasians**
nevroid basal cell carcinoma syndrome patients
PTCH mutations, 4599
- CCAAT/enhancer-binding protein**
tumor growth inhibition, 1063
- CCAAT/enhancer-binding protein β**
translationally regulated dominant-negative expression, mammary neoplasia, 4382
- C-CAM**; see Cell adhesion molecules
- C6 cells**
growth inhibition by antisense-VEGF, 393
- CD3**
costimulation with CD28
bispecific mAb-based treatment, ovarian carcinoma, 5443
- CD9**; see Motility-related protein-1
- CD11a**
and CD40-induced growth arrest, myeloma cells, 1909
- CD18**
and CD40-induced growth arrest, myeloma cells, 1909
- CD28**
costimulation with CD3
bispecific mAb-based treatment, ovarian carcinoma, 5443
- CD40**
-induced growth arrest, myeloma cells, 1909
- CD43**
expression, nonhematopoietic tumor cells, 3526
- CD44**
mRNA splicing, papillary thyroid carcinoma, 1037
variant-expressing pancreatic carcinoma cells
hyaluronate-independent metastasis, 3134
- CD82**
expression, non-small cell lung cancer, 1751
- CD102**
and CD40-induced growth arrest, myeloma cells, 1909
- cdc25-c**
activation
prevention by 1 Gy radiation, HeLa cells, 2268
- CDK**; see Cyclin-dependent kinase
- CEA**; see Carcinoembryonic antigen
- Cecum carcinoma**
sporadic
transforming growth factor β type II receptor gene mutations, 5620
- Cell adhesion**
galectin-3 and Mac-2-binding protein interactions and, 4530
inhibition by bone sialoprotein peptides, breast cancer, 1948
regulation, breast carcinoma, 2206
- Cell adhesion molecules**
C-CAM1
gene expression, bladder cancer, 3431
melanoma-associated MUC18/MCAM regulation by phorbol ester and cyclic AMP, 2218
neural, L1
gene expression, malignant glioma, 1440
glioma invasion, 1440
platelet endothelial, 2
and TNF α -induced vascular leakage, 3211
X-ray-induced, 5150
- Cell adhesion regulator**
mRNA expression
and metastasis, colorectal cancer, 3605
- Cell-cell contact**
gelatinase B expression induction, tumors, 5506
- Cell cycle**
arrest
G₁-phase, induction by flavopiridol, 2973
G₂-phase, and camptothecin cytotoxicity, 4430
p53-dependent, *scid* mouse fibroblasts, 2940
reversible p16-mediated, protection from chemotherapy, 3199
S-phase, and camptothecin cytotoxicity, 4430
ZD1694-induced, colon carcinoma cells, 4715
colchicine-induced disturbance
hepatocarcinoma enhancement, rats, 3474
control
BRCA2, 4590
- TNF- α and, keratinocytes, 2452
-dependent TAP1, TAP2, and HLA-B27 expression, breast cancer cells, 4358
-dependent TNF apoptosis, 1591
- G₁ phase**
arrest, induction by flavopiridol, 2973
arrest, p27^{KIP1}-mediated, prostate cancer cells, 3666
delay, cyclooxygenase-2 overexpression, 733
p53 and radiosensitivity, 500
- G₂ phase**
arrest, and camptothecin cytotoxicity, 4430
late delay, and p16 accumulation response to UV irradiation, 2510
- G₁-S phase**
1,25-dihydroxyvitamin D₃-induced block, HL60 cells, 264
p16^{INK4}-induced block, bicistronic expression vector, 1719
- metaphase**
premature exit, staurosporine, 3551
- M phase**
kinase activation, heat shock, 1770
- progression**
hypoxia and, ovarian carcinoma, 1168
-regulated proteins
expression, prostate cancer, 4159
- S phase**
arrest, and camptothecin cytotoxicity, 4430
BrdUrd labeling, histone H3 mRNA *in situ* hybridization and, rat colonic epithelium, 434
late delay, and p16 accumulation response to UV irradiation, 2510
- Cell death**; see also Apoptosis
etoposide-induced, epithelial tumor cells, 4006
flavopiridol-induced, A549 cells, 4856
multiple
induction by IL-6 receptor superantagonists, myeloma cells, 4213
oxidative stress-induced
HSP27 phosphorylation-mediated resistance, 273
prostaglandin A₂-mediated
p21 and, 475
- Cell density**
vascular endothelial growth factor regulation, colon carcinoma, 3891
- Cell differentiation**
DEP-1 expression, breast cancer, 4236
enediynes-induced
potentiation by Bcl-2, 1199
erythroid
commitment, topoisomerase II α and, 4192
hematopoietic
ALL-1 gene and, 1179
regulation by TGF- β , HL-60 cells, 495
secretory
truncated *Int3* and, mammary epithelium, 1775
telomerase activity
loss, 3796
tumor cells, 1503
thyroid carcinoma
mAb JT-95, production, 1817
- Cell growth**; see also Cell proliferation; Tumor growth
activation by estradiol, Caco-2 cells, 4516
autocrine
insulin-like growth factor I receptor and, cervical carcinoma, 1761
breast cancer xenografts in *lit/lit* hosts, 1509
CD40-induced arrest, myeloma, 1909

- inhibition
 activin, mammary epithelial cells, 1155
 androgen synthesis inhibitors, prostate cells, 4956
 antisense oligonucleotide PKC- α inhibitor, mice, 3499
 antisense-VEGF, C6 cells, 395
 bis(7-amino-4-azaheptyl)dimethylsilane and bis(7-ethylamino-4-azaheptyl)dimethylsilane, 5624
 bryostatins, B16/F10 cells, 2105
 chromosome 6, melanoma, 1635
 cyclin E overexpression and, mouse mammary cells, 1389
 DEP-1, breast cancer, 4236
 flavopiridol, breast carcinoma cells, 2973
 gastrimmune, colon cancer, 880
 interferon, RAR- γ and, breast cancer, 1571
 interleukin 13, breast cancer cells, 3583
 KH 1060 and 9-*cis*-retinoic acid, HL-60 cells, 3570
 lymphotoxin fusion protein, melanoma, 1707
 MKT-077, carcinoma, 538
p16 and *p16 β* , head and neck squamous cell carcinoma, 4119
 9-*cis*-retinoic acid, HL-60 cells, 3570
 retinoic acid, mediation by IGFBP-3, 1545
 retinoid, RAR- γ and, breast cancer, 1571
 salicylate, colorectal tumor cells, 2273
 selenium compounds, lymphocytes, 4407
 transforming growth factor- β 2-induced, mediation by IGFBP-3, 1545
 triple helix-forming oligodeoxyribonucleotides, glioblastoma cells, 5156
 vasoactive intestinal peptide receptor antagonist, breast cancer, 3486
- rate
 and polyploidization, HL60 cells, 5513
- regulation
 erbB receptors, breast cancer cells, 899
 heregulin, erbB2 effects, 1457
 human amniotic tumor, osteoblasts, 633
 peroxisome proliferators, 3257
 thymidylate synthase, *r7S* expression and, 700
 transforming growth factor- β , HL-60 cells, 495
 regulatory genes
 induction by *p53*, 5384
 stimulation
 macrophage colony-stimulating factor receptor, 5704
 toxin gene effects, lung adenocarcinoma, 1315
- Cell proliferation: see also Cell growth; Tumor growth**
 antisense epidermal growth factor receptor transfection and, rhabdomyosarcoma, 3898
 chemoresistance and, non-small cell lung cancer, 206
 colonic epithelial cells, acromegaly, 523
 Epstein-Barr virus infection response, adenoid B-cells, 5610
 gastrin gene expression and, colon cancer cells, 4111
- inhibition
 CCAAT/enhancer-binding protein, 1063
 interleukin 13, breast cancer cells, 3583
 9-*cis*-retinoic acid, colon cancer cells, 623
 retinoic acid metabolism and, 675
 VEGF-toxin conjugate, *KDR/flk-1*-positive endothelial cells, 1324
 vitamin D₃, colon cancer cells, 623
- vitamin D₃ analogues, potentiation by antiestrogen, 2789
 and lesion grade, cervical neoplasia, 669
 mutant EGFR, glioblastoma, 5079
 regulation by 4-HPR vs retinoic acid, breast cancer cells, 1056
 risk factor, doubtful validity, 4267
 thioredoxin transfection and, 5765
 truncated BRCA1 protein and, hereditary breast cancers, 3216
- Cell transformation**
 and choline metabolism alterations, 4630
 cyclooxygenase-2 transcription, mammary epithelial cells, 4424
 human papillomavirus 16 E6 and E7
 IGF-1R and, 5087
 hydrogen peroxide *in vitro*, rat urothelial cells, 4649
 induction by *HhaI* methyltransferase, NIH3T3 cells, 616
 Ras GDP dissociation stimulator like Ras-interacting domain and, NIH3T3 cells, 2387
 reversal by ornithine decarboxylase mutant, 5136
 tumor promoter-induced
 inhibition by retinoids, 483
 urate oxidase-mediated, epithelial cells, 4846
- CEM-C1 cells**
 glucocorticoid resistance, 5033
- Central nervous system tumors**
 manganese superoxide dismutase expression, 3192
- Ceramide**
 production
 protein kinase C inhibition and, 2711
- c-erb-2: see HER2/neu**
- c-erbB-2**
 quantitative estimation, breast cancer, 3823
- c-erbB-4**
 protein expression, papillary thyroid carcinomas, 1184
- Cerebellum**
 granule cells
 Zic expression, 377
- Cervical carcinoma**
 adenovirus-mediated wild-type *p53* gene transfer, 3047
 chromosome loss of heterozygosity, 197
 genomic alterations, 197
 human papillomavirus tumor status, 197
 insulin-like growth factor I receptor overexpression, 1761
 malignant progression
 tumor hypoxia and, 4509
 microsatellite instability, 1427
 radiation therapy
 manganese superoxide dismutase expression, 2771
 replication error phenotypes, 1427
 virus-specific memory CTLs, 582
- Cervical neoplasia**
 cell proliferation and apoptosis, 669
- Cervix**
 ectocervical epithelial cells
 retinoid X receptor-specific retinoids and insulin-like growth factor binding protein-3, 1794
 epithelial cells
 sialyl-Tn and Tn antigen expression, neoplastic transformation, 2229
 pathology
 interleukin 2 response to human papillomavirus and, 3967
- CF1 mice**
 colonic aberrant crypts
 suppression by sphingomyelin, 4936
- 5814
- c-fos**
 antisense
 breast cancer inhibition, nude mice, 1098
- Chalcone**
 oral carcinogenesis inhibition, rat, 4904
- Chemical procarcinogens**
 activation by human P450 1B1, 2979
- Chemoembolization**
 VX2 tumor study
 MRI, rabbit liver, 1863
- Chemoprevention**
 N-acetylcysteine
 against air particulate extracts, 1526
 arylalkyl isothiocyanates and, lung tumorigenesis, 772
 mitochondrial DNA adducts, rat organs, 1642
 cyclooxygenase-2 inhibitor, colon carcinoma, 4566
 dehydroepiandrosterone
 low-dose, rat mammary gland, 1724
 linomide, rodents, 3404
 myo-inositol and dexamethasone
 pulmonary carcinogenesis, female A/J mice, 5132
 sunlight, 925
 vitamin D₃, glandular stomach carcinogenesis, 2767
- Chemopreventive agents**
 phenethyl isothiocyanate
 c-Jun N-terminal kinase 1 activation, 2954
- Chemoprotection**
 reversible p16-mediated cell cycle arrest, 3199
- Chemoprotectors**
 carbonyl-reducing enzymes regulation, rat liver, 2758
- Chemoresistance**
 HER-2/neu expression and, non-small cell lung cancer, 206
- Chemoselectivity**
 p16, MTAP, and IFN deletion and, 1083
- Chemosensitivity**
 brain-derived neurotrophic factor effects, neuroblastoma cells, 3737
 functional p53, testicular tumors, 1834
 methylthioadenosine phosphorylase, A549 cells, 5653
 p53 inactivation and, 892
 tyrphostin Ag825 effects, non-small cell lung cancer cells, 1068
- Chemosensitizers**
 resistance
 cytoplasmic P-glycoprotein and, 5435
- Chemotherapy**
 combined with photodynamic therapy, ovarian carcinoma, 3980
 CT1746 and cyclophosphamide combination, murine Lewis lung carcinoma, 715
 fatty acid synthase inhibition, ovarian cancer, 1189
 gastrointestinal toxicity
 prevention by anti-doxorubicin mAb, 2082
 -induced alopecia
 calcitriol and, mice, 4438
 intrathecal
 liposome-encapsulated 1,3 bis(2-chloroethyl)-1-nitrosourea, meningeal gliomatosis, 3986
 local, metastatic brain tumor models, 5217
 response
 p53 status and, advanced ovarian carcinoma, 689
- Childhood acute lymphoblastic leukemia**
 t(12;21)
 ETV6 and CDKN1B alterations, 2655

- TEL* and *KIP1* mutations, 1413
- Children**
V(D)J recombinase-mediated *HPRT* mutations, peripheral blood lymphocytes, 1405
- Chinese**
hepatocellular carcinoma
chromosome 8p allele loss, 5092
- Chinese hamster cells**
SV40-transformed
gene amplification potentiation by poly-(ADP-ribosyl)ation inhibition, 2715
- Chinese herbs**
nephropathy
aristolochic acid-DNA adducts, renal tissue, 2025
- 2-Chloro-9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)adenine**
DNA synthesis actions, lymphoblastoid cells, 3030
- 5-Chloro-2,4-dihydroxypyridine**
1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxanate
antitumor activity, colon carcinoma, 2602
- Chloroethylnitrosourea**
resistance
ERCC-2 expression and, tumor cells, 2475
- Cholestasis**
 β -estradiol-17 β -D-glucuronide
MDR1 substrates/modulators protective effects against, rat liver, 4992
- Cholesterol epoxides**
tumorigenicity, rat mammary gland, 1970
- Choline**
metabolism
alterations, immortalization and transformation and, 4630
- Chondroitin sulfate proteoglycans**
PG-M/Verscan, identification, 3902
- CHOP**
CAAT/enhancer binding protein activities and apoptosis effects, myeloid cells, 3250
- Chromatin**
condensation
p16/CDKN2 methylation and, gliomas, 2405
topoisomerase II DNA cleavage sites, 1855
- Chromium**
mitogen-activated protein kinase activation, H4 cells, 2045
- Chromosome 1**
cell fusion hybrid effects, 241
- Chromosome 1p**
allelic loss, chromophobe renal cell carcinoma, 2927
- Chromosome 1p22**
deletion mapping, malignant mesothelioma, 4297
- Chromosome 1p35-36**
secretory *PLA₂* genes
mutations, attenuated adenomatous polyposis coli, 955
- Chromosome 1p36**
familial predisposition to neuroblastoma linkage, 3421
- Chromosome 1q**
high-density mapping, renal collecting duct carcinoma, 5044
and hybrid cell clone senescence escape, 241
- Chromosome 2p**
allelic loss, chromophobe renal cell carcinoma, 2927
- Chromosome 3p**
allelic imbalance, oral dysplastic lesions, 1228
- Chromosome 3p14.2**
FHIT
breast carcinoma, 3173
lung cancer cells, 5579
fragile site *FRA3B* breakpoints, pancreatic tumors, 4347
potential gastrointestinal tumor suppressor locus, 978
- Chromosome 3p21.3**
small cell lung cancer *TSG* region
600-kb cosmid contig, 1489
- Chromosome 4q**
sequence loss, esophageal adenocarcinoma, 4499
- Chromosome 5q**
allelic loss, gastric carcinoma, 612
- Chromosome 6**
allelic imbalance, colorectal cancer, 145
cell growth and tumor suppression, melanoma, 1635
- Chromosome 6p**
allelic loss, chromophobe renal cell carcinoma, 2927
- Chromosome 6q**
deletions, prostate cancer, 4150
early activity, surface epithelial ovarian tumors, 4487
- Chromosome 6q27**
minimal deletion region, ovarian cancers, 5586
- Chromosome 7q**
allelic loss, pancreatic carcinoma, 3808
- Chromosome 7q22**
deletion
and *PAI-1* expression, uterine leiomyomas, 3123
- Chromosome 8p**
allele loss, Chinese hepatocellular carcinomas, 5092
- Chromosome 8p12-21**
allelic loss, prostate carcinomas, 2411
- Chromosome 8p22-23**
tumor suppressor gene, colorectal cancer, 5238
- Chromosome 9**
tumor suppressor loci, bladder cancer, 5039
- Chromosome 9p21**
marker deletions, sporadic melanoma, 5023
- Chromosome 9q**
deletion mapping, esophageal squamous cell carcinoma, 1629
- Chromosome 10**
allelic loss, prostate adenocarcinoma, 2143
angiogenesis inhibition, glioblastoma, 5684
malignant phenotype suppression, PPC-1 cells, 2157
- Chromosome 10p**
allelic loss
chromophobe renal cell carcinoma, 2927
prostate cancer, 2263
- Chromosome 10q**
allelic loss, prostate cancer, 2263
- Chromosome 11**
loss of heterozygosity
nasopharyngeal carcinoma, 3225
stomach cancer, 268
malignant melanoma tumor suppressor, 4487
metastasis-suppressor gene, MDA-MB-435 breast carcinoma, 1222
segregation
cisplatin resistance phenotype expression, ovarian carcinoma cells, 2256
- Chromosome 11p15.5**
allelic deletion, non-small cell lung carcinomas, 2916
- Chromosome 11q**
loss of heterozygosity, ovarian cancer, 741
- Chromosome 11q13**
allelic deletions, MEN1 tumors, 5272
- Chromosome 11q23.3-q24.3**
loss of heterozygosity, epithelial ovarian cancer, 950
- Chromosome 12p**
loss of heterozygosity, non-small cell lung cancer, 738
- Chromosome 12q13-q15**
amplicon mapping, malignant gliomas, 5141
- Chromosome 13q**
allelic imbalance, sporadic breast cancer, 1988
allelic loss
chromophobe renal cell carcinoma, 2927
prostate cancer, 1142
deletion mapping, head and neck squamous cell carcinoma, 1146
- Chromosome 14q**
deletions, gastrointestinal stromal tumors, 3230
- Chromosome 16**
segregation
cisplatin resistance phenotype expression, ovarian carcinoma cells, 2256
- Chromosome 16q**
deletion mapping, ductal carcinoma *in situ* of breast, 5605
- Chromosome 17p**
allelic loss, chromophobe renal cell carcinoma, 2927
loss of heterozygosity
and platelet-derived growth factor α receptor expression, malignant glioma, 164
- Chromosome 17p13.3**
allelic deletion, early ovarian cancer, 606
candidate tumor suppressor genes, 1997
- Chromosome 17q11-q21**
amplified regions, breast cancer, 3886
- Chromosome 17q21**
NME1 allelic imbalance, colorectal carcinoma, 916
- Chromosome 17q24-qter**
gains, malignant peripheral nerve sheath tumors, 4778
- Chromosome 18q21**
bcl-2 locus
hypermethylation, lung cancer, 1886
DPC4 somatic alterations, lung cancers, 2718
- Chromosome 18q21.1**
homozygous deletion map, pancreatic cancer, 490
- Chromosome 20q**
amplification, breast cancer, 3441
- Chromosome 20q11-q13.2**
amplified genes, isolation, 3446
- Chromosome 21q**
allelic loss, chromophobe renal cell carcinoma, 2927
- Chromosome 22q**
loss of heterozygosity, ovarian cancer, 729
- Chromosomes**
aberrations
benzo(a)pyrene diol epoxide-induced, and lung cancer risk, 3975
imbalances
comparative genomic hybridization mapping, pancreatic carcinoma, 3803
translocations
t(6;16)(p21;q22), LNCaP cells, 728
t(9;14)(p21-22;q11), *p16* inactivation, B-cell acute lymphoblastic leukemia, 848
t(11;14)(q23;q32), breakpoint, molecular cloning, 448
t(12;21), *ETV6* and *CDKN1B* alterations,

- childhood acute lymphoblastic leukemia, 2655
- C3H10T1/2 cells**
ras-transfected
 queueine modification, 589
- Cigarette smoking**
 8-hydroxyguanine levels and repair activity, leukocytes, 2546
 mitochondrial DNA damage, 5692
- Cisplatin**
 resistance
 acquired, DNA mismatch repair loss, 3087
 human canalicular multispecific organic anion transporter and, 4124
 phenotype expression, chromosome segregation, 2256
 p53 modulation by rIFN- α 2a and, melanoma cells, 2522
 and p53 mutation, ovarian carcinoma cells, 556
 response
 p53 status and, advanced ovarian carcinoma, 689
 sensitivity
 hepatocellular carcinoma, 5330
 increase by GST- π antisense cDNA, colon cancer cells, 3577
 and nm23-transfected tumor cells, 2931
 YB-1 and, 4224
 synergism
 NB-506 and SN-38, small cell lung cancer cells, 789
 Δ^{12} -prostaglandin J₂, malignancies, 3866
- c-Jun**
 comparison with v-Jun, 4229
 protein expression, lung carcinogenesis, 305
- c-Jun N-terminal kinase**
 activation by palytoxin, 637
- c-Jun N-terminal kinase 1**
 activation by phenethyl isothiocyanate, 2954
- c-kit**
 expression, small cell lung cancer, 370
 kinase defective mutants
 tumor suppression, 4343
- Clones**
 adenocarcinoma precursors, Barrett's esophagus, 1961
 breast cancer evolution, genetic divergence, 1493
 hybrid cell
 chromosome 1 effects, 241
 600-kb cosmid contig
 small cell lung cancer *TSG* region, 1489
 killer
 advanced tumor therapy, canines, 3021
 lung tumor evolution, 1609
 multiple head and neck tumor origin, 2484
 tumor-specific Th2
 tumor regression, mice, 5005
- Cloning**
 gene
P. putida L-methioninase, 2116
 human bleomycin hydrolase, 1746
 molecular
 MT4-MMP gene (*MMP-17*), 944
 translocation t(11;14)(q23;q32) breakpoint, 448
- Clonogenic survival**
 bcl-2 and, epithelial tumor cells, 4006
- c-myc**
 p53 interactions, 1991
- c-myc**
 activity
 modulation *in vivo*, 4315
 allelic exclusion, myeloma cells, 4370
 immunoglobulin α recombinations
 detection, mice, 419
- Colchicine**
 -induced cell cycle disturbance
 hepatocarcinoma enhancement, rats, 3474
- Colitis**
 ulcerative
 microsatellite instability, nonneoplastic mucosa, 1237
- Collagen**
 autoimmunity, lung cancer, 121
 type IV
 breast carcinoma cell adhesion regulation, 2206
- Collagenase**
 type IV
 72-kDa, precursor processing by membrane-type 1 matrix metalloprotease, 2535
 matrix metalloprotease 2 and matrix metalloprotease 9, colorectal cancer, 190, 3610
- Colon**
 aberrant crypts
 foci, microsatellite instability, 5339
 NAT2-dependent formation, congenic Syrian hamsters, 527
 suppression by sphingomyelin, CF1 mice, 4936
 carcinogens
 6-nitrochrysene, metabolism and DNA binding, 2052
 cytotoxicity
 inhibition by milk calcium, 3270
 epithelial cells
 β -catenin expression, familial adenomatous polyposis, 2213
 modulation by Western-style diets, 4644
 proliferation, acromegaly, 523
 epithelium
 histone H3 mRNA *in situ* hybridization, rat, 434
 GlcNAc: β 1 \rightarrow 3 and GlcNAc: β 1 \rightarrow 4 galactosyltransferase activities, 3468
 mucosa
 diacylglycerol kinase, fat effects, 2314
 protein kinase C, fat effects, 2314
 Phlp metabolism, rat, 2550
 tissue
 Lewis enzyme, 330
- Colon adenocarcinoma**
 GlcNAc: β 1 \rightarrow 3 and GlcNAc: β 1 \rightarrow 4 galactosyltransferase activities, 3468
 inhibition by sphingomyelin, CF1 mice, 4936
 mucinous
 GS-7 cells, mice, 3508
- Colon adenoma**
 genetic susceptibility, mice, 2382
- Colon carcinoma**
 Caco-2 cells
 growth activation by estradiol, 4516
 camptothecin cytotoxicity
 S and G₂ breakpoints and, 4430
 cell cycle arrest
 ZD1694-induced, 4715
 cell density
 vascular endothelial growth factor regulation, 3891
 cell proliferation
 gastrin gene expression and, 4111
 inhibition by 9-*cis*-retinoic acid, colon cancer cells, 623
 inhibition by vitamin D₃, 623
 cyclooxygenase-2 inhibitor chemopreventive properties, 4566
 DNA methylation mechanisms, 2375
 drug sensitivity
 increase by GST- π antisense cDNA, 3577
- HCT 116 cells
 NAD(P)H:quinone oxidoreductase locus, 5253
 hereditary nonpolyposis
 genomic instability, 2733
 inhibition
 exogenous *NFI* gene, 2872
 gastrimmune, 880
 sphingomyelin, CF1 mice, 4936
 late-stage
 and diet, Sprague-Dawley rats, 2896
 metastasis
 gelatinase B secretion, autocrine stimulation by TGF- β 1, 3366
 hepatic, suicide and cytokine gene therapy, 3758
 mitomycin C sensitivity
 DT-diaphorase determinant, 2823
 mucin
 galactin-3 binding, 4354
 nitric oxide biosynthesis
 suppression by 5-fluorouracil, 1978
 somatostatin receptor gene expression, 1823
 TA1/E16 expression, 5012
 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxanate antitumor activity, 2602
 tumorigenicity
 inhibition by antisense gastrin RNA expression, 4111
- Colon tumors**
 2-amino-3-methylimidazo[4,5-f]quinoline-induced
 apoptosis inhibition, rat, 4307
 apoptosis and mitoses, mouse, 4910
 mitomycin C-treated
 DT-diaphorase transcript splicing and expression, 1731
 promotion by fat types and amount
 male F344 rats, 533
 mechanisms, 2314
- Colorectal adenocarcinoma**
 Bak expression, 2422
 bcl-2 family gene expression, 2422
- Colorectal carcinoma**
 chromosome 6 allelic imbalance, 145
 chromosome 8p22-23 tumor suppressor gene, functional evidence, 5238
 familial
 hMLH1 mutations, 5728
 FHIT gene evaluation, 2936
 genetic heterogeneity and unmapped genes, 1382
 hereditary nonpolyposis
 TGF- β RII mutations, 4595
 high mobility group protein HMGI(Y) expression, 1896
 invasion
 integrin $\alpha_6\beta_4$ functions, 4811
 matrix metalloprotease 2 and matrix metalloprotease 9, 190, 3610
 metastasis
 cell adhesion regulator mRNA expression and, 3605
 MRP and γ -GCS expression, 3642
 mycophenolic acid resistance, 984
 NME1 allelic imbalance, 916
 nonfamilial
 microsatellite instability, 5470
 risk
 methylenetetrahydrofolate reductase polymorphism and, 4862
 TNF α allelic frequency, 145
 tumor-associated glycoprotein 72 levels, quantitative CA 72-4 immunoassay, 5293
 ubiquitin-conjugated proteins, 2752

- Colorectal mucosa**
bile acid-induced apoptosis, 1480
- Colorectal tumors**
growth inhibition by salicylate, 2273
radioimmunotherapy plus blood flow modifiers, xenografts, 3293
ZD2767 ADEPT system, xenografts, 3287
- Comet assay**
tirapazamine tumor response, mice, 4460
- Comparative genomic hybridization**
adrenocortical tumors, 4219
familial Wilms' tumor deletion regions, 3837
genetic alterations, metastatic prostate cancer, 3091
head and neck squamous cell carcinoma, 5325
malignant peripheral nerve sheath tumor genetic changes, 4778
pancreatic carcinoma, 3803
renal cell carcinoma, 27
rhabdomyosarcoma analysis, 3220
- Complement**
C3 component
-cleaving proteinase, metastatic melanoma, 254
- Complementary DNA**
GST- π antisense
drug sensitivity and, colon cancer cells, 3577
interleukin-12
injection, tumor establishment inhibition, 3399
representative library, prostatic intraepithelial neoplasia, 5380
- Copper**
-dependent formation, etheno-DNA adducts, 1267
- Coralyne**
topoisomerase I cytotoxic target, 2795
- Corticotropin-releasing factor**
peritumoral brain edema treatment, 1352
- Cosmid clones**
600-kb contig
small cell lung cancer TSG region, 1489
- CpG**
transition mutations
DNA methylation and, colon carcinoma, 2375
- CPP32**
activation, apoptotic ovarian carcinoma cells, 5224
Ara-C-induced
inhibition by Bcl-2 or Bcl-x_L, HL-60 cells, 4743
Fas-mediated apoptosis effects, 1713
- CPT-11: see Irinotecan**
- c-Raf-1**
signal transduction pathway
taxol-induced apoptosis and phosphorylation, bcl-2, 1851
- Cremonophor EL**
combined with paclitaxel, pharmacokinetics, 2112
- Cryptophycin**
tubulin interactions, 4398
- Crypts**
aberrant
colonic, microsatellite instability, 5339
colonic, NAT2-dependent formation, congenic Syrian hamsters, 527
colonic, suppression by sphingomyelin, 4936
foci, genetic susceptibility, 2382
- CT1746**
combined with cyclophosphamide, murine Lewis lung carcinoma, 715
- CTLs: see Cytotoxic T lymphocytes**
- CTMO1**
engineered human
biodistribution, ovarian cancer, 5179
- Cutaneous basal cell carcinoma**
risk, GSTM3 polymorphism and, 1974
- Cutaneous melanocytic neoplasms**
induction, uPA-deficient mice, 3597
- Cutaneous melanoma**
allelotypes, 589
low-density lipoprotein receptor-related protein and receptor-associated protein expression, 1432
- CWR22**
androgen-dependent and relapsed prostate cancer xenograft, 3042
- Cyclic AMP**
MUC18/MCAM regulation, 2218
- Cyclin D**
p16-cyclin D/Cdk4-pRb pathway, melanoma, 5475
- Cyclin D1**
overexpression
gene amplification enhancement, 36
- Cyclin-dependent kinase**
CDKN1B gene
alterations, t(12;21) childhood acute lymphoblastic leukemia, 2655
inhibitor p27
and 1,25-dihydroxyvitamin D₃-induced G₁-S block, HL60 cells, 264
inhibitor p57^{KIP2}
expression, Wilms' tumors, 5723
soft tissue sarcoma and Wilms' tumors, 1219
- Cyclin-dependent kinase 2**
CDKN2 gene
alterations, glioblastoma, 150
growth suppression, head and neck squamous cell carcinoma cells, 4119
inactivation, advanced-stage esophageal squamous cell carcinoma, 3875
inactivation, head and neck squamous cell carcinoma, 3630
methylation, and chromatin, gliomas, 2405
inhibition by flavopiridol, breast carcinoma cells, 2973
- Cyclin-dependent kinase 4**
inhibition by flavopiridol, breast carcinoma cells, 2973
p16-cyclin D/Cdk4-pRb pathway, melanoma, 5475
- Cyclin E**
overexpression, mouse mammary cells, 1389
- Cyclin E-dependent kinase**
fluoropyrimidine-mediated radiosensitization and, 3203
- Cyclins**
expression, prostate cancer, 4159
pRb2/p130 interactions, functional analysis, 2003
- Cyclooxygenase**
metabolite formation
dietary fat types and amount effects, colon tumor promotion, 533
- Cyclooxygenase-1**
expression and regulation, breast cancer cells, 5125
- Cyclooxygenase-2**
cell cycle progression and, 733
expression and regulation, breast cancer cells, 5125
inhibitor
chemopreventive properties, colon carcinoma, 4566
overexpression
- sulindac blockade, murine familial adenomatous polyposis model, 2556
transcription, transformed mammary epithelial cells, 4424
- Cyclophosphamide**
combined with CT1746, murine Lewis lung carcinoma, 715
sensitization
P450-based gene therapy, breast cancer, 1331
- Cyclosporin A**
irinotecan interactions, 1309
- Cyproterone acetate**
activation by sulfonation, 4391
- Cysteine proteinase**
C3-cleaving, metastatic melanoma, 254
- Cysteine sulfinic acid decarboxylase**
autoantibody, 5230
hepatocellular carcinoma-activated, 5230
- Cytochrome P450**
1A1
polymorphisms, and p53 mutations, 72
polymorphisms, C4887A, 4965
polymorphisms, lung cancer risk and, 4275
polymorphisms, non-small cell lung cancer, 3725
1A1-Ile⁴⁶² and -Val⁴⁶², expression, 3926
1B1
procarcinogen activation, 2979
2D6
activity, and tobacco lung cancer risk, 251
3A
-mediated docetaxel metabolism, 1296
bladder cancer risk modulation, 3915
docetaxel metabolism, 58
gene therapy, breast cancer, 1331
5-methylchrysene and 6-methylchrysene metabolism, 316
ochratoxin A mutagenicity testing, 299
- Cytogenetics**
liver epithelial cells, rat, 2992
- Cytokeratin**
modulation by Western-style diets, colonic epithelial cells, 4644
- Cytokeratin 8**
ubiquitin-conjugated fragments, colorectal carcinomas, 2752
- Cytokine genes**
combined with suicide genes
therapy for hepatic metastases, colon carcinoma, 3758
- Cytokines**
expression
carcinoembryonic antigen-induced, Kupffer cells, 4805
non-Hodgkin's lymphoma, 5499
-stimulated cells
apoptosis induction, leukemic cells, 866
targeting
bispecific antibody anti-CEA and TNF α , 4758
- Cytokinesis-block method**
potential doubling time measurement, tumor xenografts, 1660
- Cytology**
sputum, airflow obstruction, 4673
- Cytosine deaminase**
E. coli suicide genes
autologous tumor vaccine for microscopic pulmonary metastases, 1361
- Cytotoxic antimetabolites**
fatty acid synthase target, HL60 cells, 745
- Cytotoxicity**
antimelanoma
particulate peptides, 1210
camptothecin

- S and G₂ breakpoints and, colon carcinoma cells, 4430
- colonic
inhibition by milk calcium, 3270
- Fas-mediated
resistance, AIDS-associated Kaposi's sarcoma cells, 1874
- gemcitabine-containing regimens, non-small cell lung cancer cells, 794
- natural killer
bisecting *N*-acetylglucosamine and, K562 cells, 412
- Δ^{12} -prostaglandin J₂, malignancies, 3866
- protection against
reversible p16-mediated cell cycle arrest, 3199
- Cytotoxic T lymphocytes:** *see also* **Lymphocytes; T lymphocytes**
- MAGE-1-specific, breast cancer, 16
- major histocompatibility complex nonrestricted
antitumor efficacy, leukemic mice, 4444
- phase I clinical trial, advanced canine tumors, 3021
- melanoma recognition, 2368
- memory
virus-specific, cervical carcinoma, 582
- precursors
frequency enhancement, melanoma, 2479
- tumor-specific
in vivo maintenance, 11
- D**
- Daunorubicin**
liposomal
disposition, fluorescence imaging studies, tumor tissue, 2066
- local hyperthermia and, rat solid tumors, 563
- DaunoXome**
disposition
fluorescence imaging studies, tumor tissue, 2066
- DDATHF:** *see* (6-*R*),5,10-Dideazatetrahydrofolate
- Defects**
c-kit kinase
tumor suppression, 4343
- DNA repair
p21^{WAF1/CIP1} -/- cells, 2250
- Deglycosylation**
vitamin D₃-binding protein
and immunosuppression, 2827
- Dehydroepiandrosterone**
low-dose
chemopreventive activity, rat mammary gland, 1724
- 7 α -Dehydroxylase**
intestinal bacterial
fat effects, 2314
- Deletion mapping**
chromosome 1p22, malignant mesothelioma, 4297
- chromosome 16q, ductal carcinoma *in situ* of breast, 5605
- chromosome 13q, head and neck squamous cell carcinoma, 1146
- esophageal squamous cell carcinoma, 1629
- homozygous
18q21.1, pancreatic cancer, 490
- Deletions:** *see also* **Cancers**
- ALL-1* breakpoint cluster region, acute lymphoblastic T-cell leukemia, 2171
- Bcl-2 nonconserved region, 2506
- chromosome 1q32.1-32.2, renal collecting duct carcinoma, 5044
- chromosome 5 long arm, stomach adenocarcinoma, 612
- chromosome 6q, prostate cancer, 4150
- chromosome 6q27 minimal region, ovarian cancers, 5586
- chromosome 9p21, sporadic melanoma, 5023
- chromosome 11p15.5, non-small cell lung carcinomas, 2916
- chromosome 11q13, MEN1 tumors, 5272
- chromosome 14q, gastrointestinal stromal tumors, 3230
- chromosome 17p13.3, early ovarian cancer, 606
- del(7)(q22)
and PAI-1 expression, uterine leiomyomas, 3123
- exon 13
hMSH2 variant, 2289
- familial Wilms' tumors, regions, 3837
- FHIT*, proliferative breast disease, 4871
- genomic
malathion exposure and, 2393
- interferon (*IFN*)
and chemoselectivity, pancreatic cell carcinoma, 1083
- methylthioadenosine phosphorylase (*MTAP*)
and chemoselectivity, pancreatic cell carcinoma, 1083
- MTS-1*, pancreatic cancer, 1137
- p16*
and chemoselectivity, pancreatic cell carcinoma, 1083
- pancreatic cancer, 1137
- p53*, cancers, 2130
- FTPRG*, proliferative breast disease, 4871
- Dendritic cells**
engineered to express mucin, 3763
- epidermal T lymphocytes
and UV radiation tumorigenesis, 2607
- melanoma tumor-associated antigen gene transduced, 5672
- Deoxycytidine kinase**
overexpression, tumor cells, 2343
- Deoxynucleotide pools**
depletion by Cl-F-ara-A, lymphoblastoid cells, 3030
- DEP-1**
expression, breast cancer cells, 4236
- Dexamethasone**
chemopreventive effects against pulmonary carcinogenesis, female A/J mice, 5132
- Dextrazoxane**
dose-response relationship, doxorubicin-induced cardiotoxicity, 4200
- Diacylglycerol kinase**
colonic mucosal
fat effects, 2314
- Diarrhea**
irinotecan
 β -glucuronidase and, rats, 3752
- (6-*R*),5,10-Dideazatetrahydrofolate
folic acid-enhanced therapeutic activity, 2331
- 2',3'-Dideoxycytidine**
carcinogenicity, mice, 4666
- induced lymphoma
allelotype analysis, B6C3F1 mice, 3338
- Diet**
antioxidants
protective effects, lymphocytes, 1291
- fat types and amount
colon tumor promotion, male F344 rats, 533
- colon tumor promotion, mechanisms, 2314
- flavonoids
oral carcinogenesis inhibition, rat, 4904
- indole-3-carbinol
multidrug resistance reversal, 574
- late-stage colon carcinogenesis and, Sprague-Dawley rats, 2896
- Western-style
-induced tumorigenesis, mouse colon, 4910
- modulation, colonic epithelial cells, 4644
- 2',2'-Difluorodeoxycytidine:** *see* **Gemcitabine**
- Dihydrofolate reductase**
codon 22 and 31 mutations, 4142
- (-)-(1*R*,2*S*,3*S*,4*R*)-3,4-Dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenzo[*c*]phenanthrene
mutational profiles, 3695
- 3,4-Dihydroxytamoxifen**
covalent binding proximate intermediate, 1283
- 1,25-Dihydroxyvitamin D₃**
-induced G₁-S block, HL60 cells, 264
- resistance
cell growth rate and polyploidization, HL60 cells, 5513
- 1 α ,25-Dihydroxyvitamin D₃**
antiproliferative effects, colon cancer cells, 623
- 24*R*,25-Dihydroxyvitamin D₃**
chemopreventive effects, glandular stomach carcinogenesis, 2767
- 3,2'-Dimethyl-4-aminobiphenyl**
NAT2-dependent aberrant crypt formation, congenic Syrian hamsters, 527
- 1,2-Dimethylhydrazine**
colon adenocarcinoma
inhibition by sphingomyelin, CF1 mice, 4936
- β -L-(-)-Dioxolane-cytidine**
uptake and metabolism, DU-145 cells, 4180
- Diphtheria**
fusion toxin DAB₃₈₉IL-2
sensitivity, hematopoietic cells, 2590
- Disialosyl galactosylgloboside**
adhesion molecule, renal cell carcinoma, 1932
- Disulfide**
-stabilized Fv fragment
renal uptake, blockade by L-lysine, 3788
- DNA**
automated fluorescent sequencer
microsatellite length analysis, 2688
- base modifications
and liver lesions, English sole carcinogenesis model, 5563
- binding
6-nitrochrysene, rats, 2052
- gemcitabine excision, 4453
- intraarterial plasmid
electro-gene transfer, 1050
- methylation
errors, 2463
- urothelial carcinoma, 5698
- mismatch repair
loss, acquired cisplatin resistance, 3087
- mutations, temozolomide resistance and, 5375
- and platinum drug resistance, 4881
- mismatch repair genes
hMSH2, expression, 235
- mitochondrial
apoptosis and, 2033
- synthesis
Cl-F-ara-A actions, lymphoblastoid cells, 3030
- synthesis inhibition
oxygen consumption rate, DS cells, 2009
- targeted treatment
history and prospects, Fifteenth Cain Award lecture, 5533

DNA, complementary

- GST- π antisense
 - drug sensitivity and, colon cancer cells, 3577
- interleukin-12
 - injection, tumor establishment inhibition, 3399
- representative library, prostatic intraepithelial neoplasia, 5380

DNA-activated protein kinase

- deficient mouse fibroblasts, p53-dependent cell cycle arrests, 2940

DNA adducts

- aristolochic acid, renal tissue, 2025
- aromatic, breast tissues, 287
- benzo(a)pyrene diol epoxide
 - susceptibility marker, lung cancer, 3638
- etheno
 - copper-dependent formation, LEC rats, 1267
- 4-hydroxytamoxifen, 53
- mitochondrial
 - chemoprevention by *N*-acetylcysteine, rat organs, 1642
- 1,*N*²-propanodexyguanosine
 - endogenous lesions, tissue, 452
- tamoxifen, 53
 - breast cancer, 4374
 - identification, rat liver, 66

DNA damage

- mitochondrial
 - cigarette smoking, 5692
- oxidative
 - AFB₁-treated rat liver and human oral mucosal cells, 683
 - δ -aminolevulinic acid, 1786
 - benzene metabolites, 5172
 - H. pylori*-infected gastric mucosa, 1279
 - 8-hydroxyguanine, levels and repair activity, 2546
 - protective effects of dietary antioxidants against, lymphocytes, 1291
 - repair, XPA cells, 1262
- radiation-induced
 - flow cytometry, glioma cells, 154
- strand breaks
 - etoposide-induced, inhibition by integrins, 4146
 - induction by tirapazamine, 1584
- thiotepa-induced
 - repair, 3721

DNA-damaging agents

- sensitivity

YB-1 and, 4224

DNA methyltransferase

- HhaI*
 - cell lethality and transformation, NIH3T3 cells, 616

DNA polymerase slippage/misalignment model

- confirmation, 2130

DNA repair

- capacity, lung cancer, 4103
- defect, p21^{WAF1/CIP1} -/- cells, 2250
- 8-hydroxyguanine, leukocytes, 2546
- inhibition by nicotinamide, SCCVII murine tumors, 2801
- O*⁶-methylguanine, glial cells, 5615
- mismatch
 - loss, acquired cisplatin resistance, 3087
 - mutations, temozolomide resistance and, 5375
 - and platinum drug resistance, 4881
- mitochondrial, XPA cells, 1262
- p53 domain, 3324
- XPD gene transduction and, trichothiodystrophy cells, 5450

DNA topoisomerase I

- coralyne cytotoxic target, 2795
- distribution
 - RNA synthesis inhibitors and, 1674
- expression
 - saintopin resistance and, epidermoid cancer cells, 2348
- independent camptothecin resistance, 345
- inhibitors NB-506 and SN-38
 - synergism with cisplatin, small cell lung cancer cells, 789
- redistribution, topotecan-treated anaplastic astrocytoma, 1664

DNA topoisomerase II

- cleavage sites, chromatin, 1855
- inhibitors
 - merbarone, -resistant leukemic cells, 2573
- sensitivity, *ras* and, 5211

DNA topoisomerase II α

- erythroid differentiation commitment, mouse erythroleukemia cells, 4192
- mutations, 91
 - point, small cell lung cancer, 1232

Docetaxel

- metabolism by human cytochromes P450, 58

Docetaxel (Taxotere)

- hepatic CYP3A-mediated metabolism, 1296
- ionizing radiation interactions, HeLa and SQ20B cells, 1842

Doubling time

- potential
 - cytokinesis-block measurement, tumor xenografts, 1660

Doxorubicin

- anti-doxorubicin mAb
 - mucositis prevention, mice, 2082
- cardiotoxicity
 - dexrazoxane dose-response relationship, mice, rats, and dogs, 4200
- liposomal
 - tumor suppression, lung tumor xenografts, 3743

DPC4

- allelic loss and mutations, esophageal adenocarcinoma, 4351
- alterations, various tumor types, 2527
- mutations, head and neck squamous cell carcinoma, 2519
- somatic alterations, lung cancer, 2718

Drosophila

- chromatin
 - topoisomerase II DNA cleavage sites, 1855

Drosophila patched

- human homologue (*PTCH*)
 - gene mutations, basal cell carcinoma and Gorlin syndrome, 4562
 - gene mutations, nevoid basal cell carcinoma syndrome, 4599

Drug resistance: see also Multidrug resistance; Resistance

- microsatellite instability, apoptosis, and p53 function, 1374
- platinum
 - DNA mismatch repair and, 4881

Drugs: see also specific drugs

- N*-(2-hydroxypropyl)methacrylamide copolymer-bound
 - combined with photodynamic therapy, ovarian carcinoma, 3980
- liposomal
 - tumor suppression, lung tumor xenografts, 3743
- magnetic targeting
 - clinical experiences, 4686
 - preclinical experiences, 4694
- prodrugs

- adenovirus-mediated gene therapy, CEA-producing gastric carcinoma, 1341
- antibody-directed enzyme prodrug therapy, ZD2767 system, 3287
- gene-directed enzyme prodrug therapy, mustard prodrug/carboxypeptidase G2 combination, 4728
- paclitaxel and camptothecin, rat serum carboxylesterase-mediated activation, 1471

Drug sensitivity: see also Sensitivity

- heat shock protein 27 overexpression and, testis tumor cells, 2446
- increase by GST- π antisense cDNA, colon cancer cells, 3577
- MRP double knockout ant, 5351

DS cells

- oxygen consumption rate, DNA synthesis inhibition, 2009

DT-diaphorase

- mitomycin C sensitivity determinant, colon and gastric carcinoma cells, 2823
- transcript splicing and expression, colon tumors and peripheral mononuclear cells, 1731

DU145 cells

- p27^{Kip1}-mediated G₁ arrest, 3666

DU147 cells

- β -L-(-)-dioxolane-cytidine uptake and metabolism, 4180

Ductal carcinoma in situ

- breast
 - chromosome 16q deletion mapping, 5605
 - genetic progression, 5260
 - non-comedo, *FHIT* and *ATM* allele loss, 5484

Duplications

- partial tandem
 - ALL1*, acute myeloid leukemia, 1418

Dysplastic lesions

- oral
 - chromosome 3p allelic imbalance, 1228

E

E16

- expression, colon carcinoma, 5012

Early-response genes

- PRG1*, pancreatic carcinoma cells, 2641
- radiation-inducible glycosylated, identification and characterization, 1498

Edema

- peritumoral brain
 - corticotropin-releasing factor treatment, 1352

EF5: see 2-Nitroimidazole

Effector cells

- biodistribution in mammals, kinetic model, 3771
- L-selectin-negative, antitumor reactivity, 4338
- xenogeneic
 - TALL-104, leukemic mice, 4444

EGF: see Epidermal growth factor

EJ-ras

- transformed fibroblasts
 - migration, α 6 β 1-integrin and, 1682

Electron paramagnetic resonance oximetry

- combined with gadopentetate dimeglumine dynamic MRI
 - tumor blood perfusion and pO₂ after X-rays, 3344

Electroporation

- gene transfer after, 1050

Embryo fibroblasts

- H-ras-transformed
 - FTI-277 radiosensitization, rat, 1727

Endometrial carcinoma

- gonadotropin-releasing hormone expression,

- 2059
monoclonal precursors, uteri, 1917
precursor lineages, 4483
- Endometriosis**
loss of heterozygosity, 3534
- Endometrium**
tamoxifen-DNA adducts, breast cancer, 4374
tamoxifen genotoxicity, 1475
- Endoperoxide synthase 2**
cell cycle progression and, 733
- Endoradiotherapeutic agents**
 α -particle-emitting 5-[²¹¹At]astato-2'-deoxyuridine, 1204
- Endothelial cell growth factor**
platelet-derived
expression, bladder cancers, 4799
- Endothelial cells**
brain
tenascin-C expression, 182
KDR/flk-1-positive
proliferation inhibition by VEGF-toxin conjugate, 1324
nitric oxide production, 886
tumor-derived
etoposide-induced DNA strand breakage, inhibition by integrins, 4146
- Endothelin 1**
production, advanced prostate cancer, 663
- Endothelin B**
receptor expression, advanced prostate cancer, 663
- Endothelium**
vascular
radiation-induced leukocyte adhesion, mediation by cell adhesion molecules, 5150
- Enediye**
-induced apoptosis
potentiation by Bcl-2, 1199
- Energy**
metabolism
regulation by nitric oxide, ascites tumor cells, 4535
- Enhancer-binding protein**
activity
GADD153/CHOP effects, myeloid cells, 3250
tumor growth inhibition, 1063
- Enhancer-binding protein β**
translationally regulated dominant-negative expression, mammary neoplasia, 4382
- Enterotoxin B**
superantigen staphylococcal
antitumor immunity augmentation, 3731
- Enzyme prodrug therapy**
antibody-directed
ZD2767 system, colorectal tumor xenografts, 3287
gene-directed
mustard prodrug/carboxypeptidase G2 combination, 4728
- Enzymes**
carbonyl-reducing
regulation by chemoprotectors, rat liver, 2758
interleukin 1β -converting
apoptosis induction, glioma cells, 5423
-like protease, retinoblastoma protein cleavage, 438
-mediated p34^{cdc2} activation, Fas-induced apoptosis, 4551
- Lewis
genetic evidence and intracellular localization, colon, 330
phase II
expression, tamoxifen response, 3704
plasminogen-angiotensin converting, prostate carcinoma cells, 4887
- polymorphic
bladder cancer risk modulation, 3915
- 4E-P2 cells**
ornithine decarboxylase regulation, 3265
- Epidermal growth factor**
receptor
anti-EGFR mAb 225, p27^{Kip1} upregulation, prostate cancer cells, 3666
antisense transfection, rhabdomyosarcoma, 3898
downregulation by E-cadherin/catenin complex, HPV-transfected keratinocytes, 5285
mutant, tumorigenicity enhancement, 5079
phosphorylation, MAP kinase signal transduction stimulation by asbestos after, 5334
quantitative estimation, breast cancer, 3823
truncated, tyrphostin AG 1478 selectivity, 3859
-refractory bladder carcinoma, rat, 2666
-responsive bladder carcinoma, rat, 2666
withdrawal
malignant transformation and, breast epithelial cells, 2039
- Epidermal T lymphocytes**
dendritic
and UV radiation tumorigenesis, 2607
- Epidermoid carcinoma**
topoisomerase I expression
saintopin resistance and, 2348
- 4'-Epidoxorubicin**
magnetic drug targeting, advanced solid tumors, 4686
- Epithelial carcinoma**
ovarian
chromosome 11q23.3-q24.3 loss of heterozygosity, 950
intraperitoneal photodynamic therapy, xenograft murine model, 1075
- Epithelial cells**
breast
malignant transformation, 2039
colonic
 β -catenin expression, familial adenomatous polyposis, 2213
modulation by Western-style diets, 4644
proliferation, acromegaly, 523
ectocervical
retinoid X receptor-specific retinoids and insulin-like growth factor binding protein-3, 1794
liver
cytogenetic analysis and correlation with IGF-II expression, 2992
mammary
BRCA1 splice variants, 4578
cyclin E overexpression, mouse, 1389
growth inhibition by activin, 1155
immortalization by mutant p53, 3129
neoplastic transformation, liver-enriched inhibiting protein expression, 4382
sulfotransferase expression, 1551
transformed, cyclooxygenase-2 transcription, 4424
prostate
apoptosis induction by TGF- β 1, 5146
radiation-induced neoplastic transformation, 5
transformation
urate oxidase-mediated, 4846
uterine cervical
sialyl-Tn and Tn antigen expression, neoplastic transformation, 2229
- Epithelial tumors**
bcl-2 and clonogenic survival, 4006
- ovarian
borderline, microsatellite instability, 2501
surface, early chromosome 6q activity, 4487
- Epithelium**
colonic
histone H3 mRNA *in situ* hybridization, rat, 434
mammary
monoclonality, 402
secretory differentiation, truncated *Int3* and, 1775
- Epitope mapping**
QCRL-1, 3307
- Epoxide hydrolase**
microsomal
bladder cancer risk modulation, 3915
- E6 protein**
transformation, 5087
- E7 protein**
transformation, 5087
ubiquitin-dependent Rb degradation induction, 4620
- Epstein-Barr virus**
-associated neoplasia
targeted therapy, 969
infection
proliferative response, adenoid B-cells, 5610
- erbB**
receptors, breast cancer cells, 899
- erbB2**
heregulin-mediated signaling effects, breast and ovarian tumor cells, 1457
- Erbstatin**
apoptosis induction, small cell lung carcinoma cells, 4978
- ERCC-2**
expression
and chloroethylnitrosourea resistance, tumor cells, 2475
- Erythrocytes**
glucose transporter Glu5533
expression, benign and malignant tissues, 1164
sodium transport, cancer patients, 511
- Erythroleukemia**
erythroid differentiation commitment
topoisomerase II α and, mouse cells, 4192
- Erythropoietin**
tumor oxygenation effects, 4728
- Escherichia coli**
cytosine deaminase suicide genes
autologous tumor vaccine for microscopic pulmonary metastases, 1361
formamidopyrimidine-DNA glycosylase
thiotepe-induced DNA damage repair in cells expressing, 3721
- Esophageal adenocarcinoma**
Barrett's-associated
clonal precursors, 1961
microsatellite alterations, 259
chromosome 4q sequence loss, 4499
DPC4 allelic loss and mutations, 4351
- Esophageal carcinoma**
anti-p53 antibodies, circulating, 4917
H19 imprinting loss, 480
squamous cell
advanced-stage, *p16/CDKN2* inactivation, 3875
deletion mapping, 1629
interleukin 6 serum levels, 2776
- Estradiol**
cell growth activation, Caco-2 cells, 4516
and uterine VEGF expression, 3954
- β -Estradiol-17 β -D-glucuronide**
cholestasis

- MDR1 substrates/modulators protective effects against, rat liver, 4992
- Estramustine**
resistance
tubulin isotype levels, prostate carcinoma cells, 2584
- Estrogen**
antiestrogens
estrogen receptor regulation, breast cancer cells, 2321
tamoxifen, phase II enzyme expression response, 3704
vitamin D₃ analogue effects, potentiation, breast cancer, 2789
β-hexachlorocyclohexane action, breast cancer cells, 5403
-induced proto-oncogene and suppressor gene expression, hamster kidney, 2616
receptor
exon 5 variant, effects in MCF-7 cells, 1556
methylation, hematopoietic neoplasms, 973
methylation, lung tumors, 3655
regulation, breast cancer cells, 2321
types, and response to antiestrogen therapy, 3883
variant mRNAs, breast cancer, 4324
- Estrone-3,4-quinone**
tumorigenicity, rat mammary gland, 1970
- Ethanol**
Z. officinale rhizome extract
tumor promotion inhibition, SENCAR mouse skin, 1023
- Etheno**
DNA adducts
copper-dependent formation, LEC rats, 1267
- 7-Ethyl-10-hydroxy-camptothecin: see SN-38**
- Ethyl nitrosourea**
-induced *hprt* and *lacI* mutations, *lacI* transgenic mice, 4654
- Etoposide**
-induced apoptosis
epithelial tumor cells, 4006
functional p53 and, hypersensitive testicular tumors, 1834
-induced DNA strand breakage
inhibition by integrins, 4146
sensitivity
increase by GST-π antisense cDNA, colon cancer cells, 3577
- ETV6**
alterations, t(12;21) childhood acute lymphoblastic leukemia, 2655
- Eukaryotic initiation factor 2α**
upregulation, mammary neoplasia, 4382
- Eukaryotic initiation factor 4E**
-induced cell transformation
reversal by ornithine decarboxylase mutant, 5136
- Ewing's sarcoma**
insulin-like growth factor I receptor-mediated circuit, 4570
- Exocyclic adducts**
endogenous, tissue DNA, 452
- Exposure**
malathion
and genomic deletions, 2393
occupational
arylamines, *p53* mutations, bladder tumors, 294
styrene and styrene-7,8-oxide, biomarkers, 5410
phenolphthalein
carcinogenic effects, experimental models, 4922
- Expression vectors**
bicistronic, 1719
- External beam radiotherapy**
local chemotherapy and, metastatic brain tumor models, 5217
- Extracellular matrix proteins**
brain tumor cell migration, 1939
- Extracellular-signal regulated kinase-1**
signal transduction
stimulation by asbestos, 5334
- F**
- Familial adenomatous polyposis**
β-catenin expression, 2213
tumor formation
prevention by sulindac, murine model, 2556
- Familial colorectal carcinoma**
hMLH1 mutations, 5728
- Familial malignant melanoma**
p16 germline mutations, southern Sweden, 2497
- Familial Wilms' tumor**
deletion regions, comparative genomic hybridization, 3837
- Farnesyltransferase**
inhibitors
FTI-277, radiosensitization, H-ras-transformed rat embryo fibroblasts, 1727
resistance, *ras*-transformed cells, 2626
- Fas**
expression and function, breast cells, 4791
-induced apoptosis
CPP32/Yama(-like) protease effects, 1713
interleukin 1β-converting enzyme-mediated p34^{cdc2} activation, 4551
resistance, AIDS-associated Kaposi's sarcoma cells, 1874
nuclear receptor fusion protein
lipophilic hormone-induced apoptosis, 4164
soluble
levels, nonhematopoietic malignancy, 3870
- Fat**
types and amount
colon tumor promotion, male F344 rats, 533
colon tumor promotion, mechanisms, 2314
- Fatty acid binding protein**
adipocyte-type
loss, bladder transitional cell carcinomas, 4782
- Fatty acids**
intestinal
precipitation by milk calcium, 3270
synthesis inhibition
apoptosis induction, breast cancer cells, 2745
- Fatty acid synthase**
cytotoxic antimetabolite target, HL60 cells, 745
inhibition
chemotherapy, ovarian cancer, 1189
- F10 cells**
growth inhibition by bryostatins, 2105
- Fetus**
-specific growth hormone receptor mRNA
regulation, liver, 2949
- FHIT**
allele loss, breast cancers, 5484
alterations
head and neck cancer cells, 5128
lung cancer cells, 5579
Merkel cell carcinoma, 2472
chromosome 3p14.2, breast carcinoma, 3173
- 5821
- deletions, proliferative breast disease, 4871
evaluation, colorectal cancers, 2936
- Fibrololysis**
systemic
hyperthermic limb perfusion with TNF-α and, 3948
- Fibroblast growth factor**
basic
gene transfection, malignant progression, 2440
- Fibroblasts**
embryo
H-ras-transformed, FTI-277 radiosensitization, 1727
gelatinase B expression
induction by cell-cell contact, 5506
lung
manganese superoxide dismutase overexpression, SV40-transformed cells, 2864
ras
migration, α6β1-integrin and, 1682
queue modification, C3H10T1/2 cells, 589
scid mouse, cell cycle analyses, 2940
senescence, 4582
wortmannin radiosensitization, murine cells, 246
- Fibronectin**
recombinant
overexpression, tumor cells, 4541
- Fibrosarcoma**
HT1080 cells
ursolic acid anti-invasive activity, 2281
transformed phenotypes
suppression by recombinant fibronectin overexpression, 4541
- Fibrosis**
pulmonary
bleomycin-induced, genetic model, 2596
bleomycin-induced, prevention, *Sh ble* transgenic mice, 5659
- Fischer rats**
lung cancer
chemoprevention by arylalkyl isothiocyanates and *N*-acetylcysteine, 772
- Fischer 344 rats**
colon tumors
promotion by fat types and amount, 533
- FJ-776: see MKT-077**
- Flavonoids**
oral carcinogenesis inhibition, rat, 4904
- Flavopiridol**
cyclin-dependent kinase 2, CDK4, and cell growth inhibition, 2973
-induced cell death, A549 cells, 4856
- Flk-1**
tumor growth inhibition, 1615
tumor growth inhibition target, 3540
- Flow cytometry**
radiation-induced DNA damage assay, glioma cells, 154
- Fluids**
interstitial pressure
after radiation, human tumor xenografts, 964
sperm
SV40 early region and large T antigen, 4820
- Fluorescence imaging**
DaunoXome disposition studies, tumor tissue, 2066
- Fluorescent DNA sequencer**
automated
microsatellite length analysis, 2688
- Fluoropyrimidine**
-mediated radiosensitization
and cyclin E-dependent kinase, 3203

5-Fluorouracil

- hematopoietic recovery stimulation by isofylline, 105
- nitric oxide biosynthesis suppression, colon carcinoma cells, 1978
- regional pharmacokinetics, dogs, 4724
- resistance
 - rTS* alternate splicing and overexpression, 3207

Folic acid

- enhanced DDATHF therapeutics, 2331

Food

- derived heterocyclic amines
 - N*-acetyltransferase expression and, mammary gland, 2683

Formaldehyde

- induced nasal cancer, 1012

Formamidopyrimidine-DNA glycosylase

- E. coli*
 - thiotepa-induced DNA damage repair in cells expressing, 3721

6-N-Formylamino-12,13-dihydro-1,11-dihydroxy-13-(β -D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione: see NB-506

F344 rats: see Fischer 344 rats

FTI-277

- radiosensitization, H-ras-transformed rat embryo fibroblasts, 1727

5-FU: see 5-Fluorouracil

α -1,3-Fucosyltransferase

- types IV and VII
 - gene expression, lung cancer, 325

Fusion genes

- tpc/hpr*, LNCaP cells, 728

Fusion proteins

- chimeric Lym-1/IL-2, 4998
- Fas-nuclear receptor
 - lipophilic hormone-induced apoptosis, 4164
- lymphotoxin
 - growth inhibition, melanoma, 1707

Fusion toxins

- diphtheria DAB₃₈₉IL-2
 - sensitivity, hematopoietic cells, 2590

Fv fragment

- ant-carcinoembryonic antigen antibody (single-chain Fv-C_H3)
 - rapid targeting, xenografts, 3055
- disulfide-stabilized
 - renal uptake, blockade by L-lysine, 3788

G

Gadopentetate dimeglumine dynamic magnetic resonance imaging

- combined with electron paramagnetic resonance oximetry
- tumor blood perfusion and pO₂ after X-rays, 3344

Galactose

- anti-galactose
- tumor cell opsonization, 3069

α -Galactosyl

- epitopes
 - synthesis by recombinant α 1,3galactosyltransferase, 3069

Galactosylgloboside

- disialosyl
 - adhesion molecule, renal cell carcinoma, 1932

Galactosyltransferase

- GlcNAc: β 1 \rightarrow 3 and GlcNAc: β 1 \rightarrow 4 activities, colonic adenocarcinomas, 3468

α 1,3Galactosyltransferase

- recombinant
 - α -galactosyl epitope synthesis, 3069

Galectin-3

- colon cancer mucin binding, 4354

- Mac-2-binding protein interactions, 4530

Ganciclovir

- mediated apoptotic death, bystander cells, 2697

Gangliosides

- anti-GM2 mAb, 5666
- breast cancer, 5165
- immunosuppressive neuroblastoma shedding modulation, 4602

Ganglioside α -2,8-sialyltransferase

- gene expression, adult T-cell leukemia, 2844

GAS1

- mutations
 - initial screening, bladder cancer, 5039

Gastric adenocarcinoma

- chromosome 5q allele loss, 612
- chromosome 11 loss of heterozygosity, 268

Gastric carcinoma

- α - and β -catenin gene mutations, 49
- carcinoembryonic antigen-producing adenovirus-mediated gene therapy, 1341
- chromosome 5q allele loss, 612
- glandular
 - vitamin D₃ chemoprevention, rats, 2767
- intestinal
 - microsatellite instability-associated mutations, 4664
- mitomycin C sensitivity
 - DT-diaphorase determinant, 2823
- progression
 - angiogenesis and, 2671

Gastric mucosa

- H. pylori*-infected
 - oxidative DNA damage, 1279

Gastrimmune

- colon cancer inhibition, 880

Gastrin

- antisense RNA expression
- antitumorigenicity, colon cancer cells, 4111

Gastritis

- H. pylori*
 - iNOS, nitrotyrosine, apoptosis, 3238

Gastrointestinal toxicity

- chemotherapy-induced
 - prevention by anti-doxorubicin mAb, 2082

Gastrointestinal tumors

- stromal
 - chromosome 14q deletions, 3230
- suppressor locus, potential, 978

G12 cells

- mutagenesis
 - serum deprivation and, Chinese Hamster, 752

Gelatinase

- inhibitor
 - combined with cyclophosphamide, murine Lewis lung carcinoma, 715

Gelatinase A

- activation, malignant brain tumors, 384
- precursor processing by membrane-type I matrix metalloprotease, 2535

Gelatinase B

- expression
 - induction by cell-cell contact, 5506
- secretion
 - autocrine stimulation by TGF- β 1, murine metastatic colon carcinoma cells, 3366

Gelsolin

- loss, breast cancers, 4841

Gemcitabine

- containing regimens
 - cytotoxic effects, non-small cell lung cancer cells, 794
- excision from DNA, 4453

Gender differences

- smoking and oral cancer risk, 5192

Gene amplification

- chromosome 20q, breast cancer, 3441
- chromosome 20q11-q13.2, isolation, 3446
- chromosome 17q11-q21 regions, breast carcinoma, 3886
- cyclin D1 overexpression and, 36
- poly(ADP-ribosyl)ation inhibition and, SV40-transformed Chinese hamster cells, 2715
- type II hexokinase, tumor cells, 2468

Gene cloning

- P. putida* L-methioninase, 2116

Gene-directed enzyme prodrug therapy

- mustard prodrug/carboxypeptidase G2 combination, 4728

Gene products: see also Tumor suppressor gene products

- p53
 - insulin receptor promoter repression, breast cancer, 2781
- rTS*
 - alternate splicing and overexpression, 5-FU-resistant cells, 3207
- tuberosclerosis (*Tsc2*)
 - transcriptional activation domains, Eker rat model, 429
- VHL*
 - VBP-1 binding, 2881

Genes: see also Metastasis-associated genes; Metastasis suppressor genes; Oncofetal genes; Oncogenes; Proto-oncogenes; Suicide genes; Transgenes; Tumor suppressor genes

- adenomatous polyposis coli (*APC*)
 - loss of heterozygosity, Barrett's esophagus, 1961
- somatic mutations, sporadic hepatoblastomas, 3320

ALL-1

- breakpoint cluster region deletion, acute lymphoblastic T-cell leukemia, 2171
- exon structure, 1766
- and hematopoietic differentiation, 1179
- partial tandem duplication, acute myeloid leukemia, 1418

Annexin VI

- expression, melanoma, 3855
- arginine-rich protein
 - mutations, cancers, 5576

ATM

- allele loss, breast cancers, 5484
- and breast cancer susceptibility, 2726
- mutations, cancer families, 4130

bcl-2

- chromosome 18q21 locus hypermethylation, lung cancers, 1886
- deficiency, melanocytes, 3546
- expression, colorectal adenocarcinoma, 2422
- taxol-induced phosphorylation, prostate cancer, 1253

bcl-X_L

- apoptosis inhibition, murine myeloma cells, 1451

bFGF (FGF-2)

- transfection, malignant progression, 2440

bfl-1

- p53-induced apoptosis suppression, 3879
- bleomycin-resistance (*Sh ble*)
 - protective effects against bleomycin-induced pulmonary fibrosis, transgenic mice, 5659

blood group ABO

- transcription, bladder carcinomas, 1031

BRCA1

- amino-terminal zinc ring domain molecular modeling, 2539

- 185delAg mutations, Jewish women with ovarian cancer, 1250
germline mutations, Italian breast/ovarian cancer families, 5466
germline mutations, mRNA *in situ* hybridization detection, 2912
splice variants, mammary epithelial cells, 4578
- BRCA2**
cell cycle control, 4590
chromosome 13q allelic imbalance, sporadic breast cancer, 1988
germline mutations, sporadic pancreatic carcinomas, 5360
mutations, hepatocellular carcinoma, 4575
mutations, Jewish Ashkenazi and non-Jewish individuals, 3409
mutations, ovarian carcinoma, 2738
mutations, sporadic ovarian cancer, 3622
breast cancer
divergence, 1493
- CAPL**
anti-CAPL (*m1s*) ribozyme, metastatic phenotype reversal, 5490
- α -catenin**
mutations, gastric and breast carcinomas, 49
- β -catenin**
mutations, gastric and breast carcinomas, 49
- C-CAM1**
expression, bladder cancer, 3431
- CD82**
expression, non-small cell lung cancer, 1751
- CDKN1B**
alterations, t(12;21) childhood acute lymphoblastic leukemia, 2655
- CDKN2**
alterations, glioblastoma, 150
growth suppression, head and neck squamous cell carcinoma cells, 4119
inactivation, advanced-stage esophageal squamous cell carcinoma, 3875
inactivation, head and neck squamous cell carcinoma, 3630
methylation, and chromatin, gliomas, 2405
- cell growth regulatory
induction by *p53*, 5384
- c-erbB-2**
quantitative estimation, breast cancer, 3823
- c-myc**
p53 interactions, 1991
- colorectal cancer
heterogeneity, 1382
- cytochrome P450 1A1 (*CYP1A1*)
polymorphisms, and *p53* mutations, 72
polymorphisms, C4887A, 4965
polymorphisms, lung cancer risk and, 4275
polymorphisms, non-small cell lung cancer, 3725
- differentially expressed
melanocytic cells, 3112
normal prostate tissue and carcinoma, 3634
- differentially expressed with different metastatic potentials, melanoma sublines, 875
- DPC4**
allelic loss and mutations, esophageal adenocarcinoma, 4351
alterations, various tumor types, 2527
mutations, head and neck squamous cell carcinoma, 2519
- somatic alterations, lung cancer, 2718
- early-response
PRG1, pancreatic carcinoma cells, 2641
radiation-inducible glycosylated, 1498
- ERCC-2**
expression, and chloroethylnitrosourea resistance, tumor cells, 2475
- estrogen receptor (*ER*)
methylation, hematopoietic neoplasms, 973
- ETV6**
alterations, t(12;21) childhood acute lymphoblastic leukemia, 2655
- expression vectors
bicistronic, 1719
- FHIT**
aberrant transcripts, Merkel cell carcinoma, 2472
abnormalities, head and neck cancer cells, 5128
allele loss, breast cancers, 5484
alterations, lung cancer cells, 5579
chromosome 3p14.2, breast carcinoma, 3173
colorectal cancers, 2936
deletions, proliferative breast disease, 4871
- α -1,3-fucosyltransferase types IV and VII
expression, lung cancer, 325
- ganglioside α -2,8-sialyltransferase (*G_{D3} synthase*)
expression, adult T-cell leukemia, 2844
- γ -glutamylcysteine synthetase
expression, colorectal cancers, 3642
- GSTM1**
polymorphisms, non-small cell lung carcinoma, 3725
- GSTM3**
polymorphism, and cutaneous basal cell carcinoma risk, 1974
- GS-X**
expression, colorectal cancers, 3642
- H19**
loss of imprinting, esophageal cancer, 480
overexpression, MDR cells, 2904
- Ha-ras**
allele sequence variations, minisatellite variant repeat PCR, 4773
- HER2/neu**
chemoresistance and, non-small cell lung cancer, 206
inhibition by triple helix-forming oligonucleotide, 515
- herpes simplex virus thymidine kinase
expression, noninvasive imaging, 4087
- hMLH1**
expression, 4836
mutations, familial colorectal cancer, 5728
- HPRT**
V(D)J recombinase-mediated mutations, peripheral blood lymphocytes of children, 1405
- H-ras1**
promoter conformation alterations, NMU-induced mammary carcinoma and pregnancy, 4927
- human canalicular multispecific organic anion transporter
expression, cisplatin-resistant cancer cells, 4124
- human homologue of *D. patched* (*PTCH*)
mutations, basal cell carcinoma and Gorlin syndrome, 4562
mutations, nevoid basal cell carcinoma syndrome, 4599
- human kallikrein (*hK2*)
expression, mammalian cells, 5397
- 5823
- human melanocyte-stimulating hormone (*hMSH2*)
exon 13 deletion variant, 2289
expression, 4836
expression, normal and neoplastic tissues, 235
- human retinoic acid receptor α
regulation, SKBR-3 and MDA-MB-435 cells, 5246
- hypoxanthine-guanine phosphoribosyl transferase (*hprt*)
mutations, ethylnitrosourea-induced, 4654
- INK4A**
inactivation, head and neck squamous cell carcinoma, 3630
- insulin-like growth factor II (*IGF2*)
loss of imprinting, glioma, 5356
- insulin-like growth factor I receptor
activation by hepatitis B virus X protein, 3831
- Int3**
truncated, and mammary secretory differentiation, 1775
- int-5/aromatase**
mammary hyperplasia induction, transgenic mice, 3180
- interferon (*IFN*)
deletion, and chemoselectivity, 1083
- JV18-1**
somatic alterations, lung cancers, 5583
- KAI1**
dysregulation, prostatic cancer, 4387
expression, non-small cell lung cancer, 1751
expression, pancreatic cancer, 4876
- KDR/flk-1**
-positive endothelial cell proliferation inhibition by VEGF-toxin conjugate, 1324
- KIP1**
mutations, childhood acute lymphoblastic leukemia, 1413
- K-ras**
mutations, atypical alveolar hyperplasia, 2224
- lacI**
mutations, ethylnitrosourea-induced, 4654
- lit**
mutations, breast cancer xenografts in homozygous hosts, 1509
- lysyl oxidase**
regulation by IRF-1, 2417
- mammary-derived growth inhibitor
silencing by epigenetic changes, breast neoplasms, 4865
- melanocyte-stimulating hormone (*Msh2*)
-deficient mice, intestinal carcinomas, 3842
- melanoma tumor-associated antigen (*MART-1*)
transduced dendritic cells, 5672
- metastasis-associated
melanoma, mRNA differential display, 5266
- metastasis suppressor
chromosome 11, MDA-MB-435 breast carcinoma, 1222
- methylthioadenosine phosphorylase (*MTAP*)
deletion, and chemoselectivity, 1083
- MGMT**
transcription inhibition by wild-type *p53*, 2029
- MT4-MMP (*MMP-17*)**
molecular cloning, 944
- MTS-1**
growth suppression, head and neck squamous cell carcinoma cells, 4119

inactivation, head and neck squamous cell carcinoma, 3630
 multidrug resistance protein (*MRP*)
 expression, colorectal cancers, 3642
 knockout, double, 5351
 multiple endocrine neoplasia type 2 (*MEN* 2)
 dominantly transforming *in vivo*, 4853
 neural cell adhesion molecule L1
 expression, malignant glioma, 1440
 neurofibromatosis type 1 (*NF1*)
 exogenous, colon cancer cell suppression, 2872
nm23
 and cisplatin sensitivity, transfected tumor cells, 2931
NME1
 allelic imbalance, colorectal carcinoma, 916
 oncogenes
 activated, integrin signaling to NF- κ B blockade, 2302
 functional aspects, Seventh Annual Pezcoller Symposium, 4282
p15
 loss, sporadic melanoma, 5023
p16
 alterations, glioblastoma, 150
 alterations, pancreatic cancer, 1137
 deletion, and chemoselectivity, 1083
 germline mutations, familial malignant melanoma, 2497
 growth suppression, head and neck squamous cell carcinoma cells, 4119
 hypermethylation, nasopharyngeal carcinoma, 2721
 inactivation, advanced-stage esophageal squamous cell carcinoma, 3875
 inactivation, chromosome translocation, B-cell acute lymphoblastic leukemia, 848
 inactivation, head and neck squamous cell carcinoma, 3630
 loss, pituitary tumors, 2493
 loss, sporadic melanoma, 5023
 methylation, and chromatin, gliomas, 2405
p16 β
 growth suppression, head and neck squamous cell carcinoma cells, 4119
p53
 adenovirus-mediated transfer, generalized apoptosis, glioma cells, 694
 alterations, prostate cancers, 3814
 cell growth regulatory gene induction, 5384
 deletions and insertions, cancers, 2130
 DNA repair domain, 3324
 gain-of-function mutations, and T-cell receptor instability postirradiation, 3862
 loss, transgenic mouse skin carcinoma, 4413
 mutant transcription, Burkitt's lymphoma cells, 1648
 mutations, and response to therapy, advanced ovarian carcinoma, 689
 mutations, arylamine-exposed worker bladder tumors, 294
 mutations, chemoresistance and, non-small cell lung cancer, 206
 mutations, cisplatin resistance and, 556
 mutations, *CYP1A1* polymorphisms and, 72
 mutations, mammary epithelial cell immortalization, 3129
 mutations, *PTHrP* repression, 4056
 transcriptional activation blockade by wortmannin, 246

p57
 characterization, G401 Wilms' tumor assay, 1214
p57^{KIP2}
 expression, Wilms' tumor, 5723
 parathyroid hormone-related peptide and malignant pituitary tumor, rat, 77
 parathyroid hormone-related protein (*PTHrP*)
 expression, and hypercalcemia, 1043
 repression by p53 mutants, 4056
 P-glycoprotein
 transcriptional regulation, 2021
 proprotein convertase (*LPC*)
 location, lymphoma, 448
 protooncogenes
 expression, hamster kidney, 2616
PTC
 mutations, initial screening, bladder cancer, 5039
PTPRG
 deletions, proliferative breast disease, 4871
ras
 and Ara-C sensitivity, 5211
 and topoisomerase II inhibitor sensitivity, 5211
 -transfected cells, queuine modification, 589
ras^{Hla}
 activation, retinoic acid receptor loss and, 4942
 resistance
 pre-B lymphoma, MSM/Ms mouse, 3716
RET
 dominantly transforming *in vivo*, 4853
 mutations, medullary thyroid carcinoma, 2167
 retinoblastoma *RB*
 alterations, glioblastoma, 150
 expression, non-small cell lung tumors, 3415
 retinoblastoma *RB1*
 chromosome 13q allelic imbalance, sporadic breast cancer, 1988
 retinoid receptor-mediated expression regulation by 4-HPR vs retinoic acid, breast cancer cells, 1056
rTS
 expression, and thymidylate synthase activity, 700
 secretory PLA₂
 mutations, attenuated adenomatous polypoidosis coli, 955
 serine protease-like, down-regulated in breast cancer, 3371
 somatostatin receptor (*sst2*)
 expression, pancreatic and colorectal cancer, 1823
SSX-2
 HOM-MEL-40 coding, 4766
 suicide
 E. coli cytosine deaminase, autologous tumor vaccine for metastasis, 1361
 SV40 large T antigen
 inoculation, tumor immunity induction, 1126
TA1/E16
 expression, colon carcinoma, 5012
TAL-1
 T-cell lymphoma, transgenic mice, 5113
TEL
 alterations, t(12;21) childhood acute lymphoblastic leukemia, 2655
 mutations, childhood acute lymphoblastic leukemia, 1413
 toxin

lung adenocarcinoma therapy, 1315
tpc/hpr, LNCaP cells, 728
 transforming growth factor β type II receptor
 mutations, hereditary nonpolyposis colorectal cancers, 4595
 mutations, sporadic cancer, 5620
 promoter mutations, 4831
 tumor necrosis factor α (*TNF- α*)
 expression inhibition by cancer preventive agents, 3711
 tumor suppressor
 chromosome 17p13.3, candidate, 1997
 chromosome 8p22-23, colorectal cancer, 5238
 chromosome 22q, ovarian cancer, 729
 gastrointestinal, potential locus, 978
 kidney expression, hamster, 2616
 MEN1 tumor mapping, 5272
 ovarian candidate, loss of heterozygosity, 3534
 parathyroid adenomas, genomic localization, 599
 small cell lung cancer region, 600-kb cosmid contig, 1489
 unmapped, colorectal cancer, 1382
 vitamin D receptor (*VDR*)
 polymorphisms, prostate cancer, 4108
WNT-2
 expression, breast tumors, 4320
XPD
 DNA repair and mutagenesis and, trichothiodystrophy cells, 5450
Gene therapy
 adenovirus-mediated
 breast tumor cells, 1346
 CEA-producing gastric carcinoma, 1341
bcl-x_s
 apoptosis induction, mammary tumors, 1965
 combination
 oral cancer, murine model, 1737
 combination suicide and cytokine genes
 hepatic metastases, colon carcinoma, 3758
 modified retinoblastoma, 2245
p53, cervical cancer, 3047
 P450-based, breast cancer, 1331
 radiotherapy
 tumor vessel targeting, 4311
 toxic
 osteocalcin promoter-based, osteosarcoma, 4614
Genetic engineering
 human dendritic cells engineered to express mucin, 3763
Genetic models
 bleomycin-induced pulmonary fibrosis, 2596
 head and neck squamous cell carcinoma, 2488
Gene transfer
 adenovirus-mediated
 breast tumor cells, gene therapy and bone marrow purging, 1346
 p53, generalized apoptosis, glioma cells, 694
 wild-type *p53*, cervical cancer, 3047
 wild-type *p53*, ovarian tumor radiosensitization, 4891
 CEA, rhabdomyosarcoma, 4503
 electro-, 1050
 FGF-2
 malignant progression, mouse renal cell carcinoma, 2440
 herpes simplex virus thymidine kinase, non-invasive imaging, 4087
MDR
 stromal layers and continuous flow cul-

- ture, hematopoietic progenitors, 2566
retrovirus-mediated
suppressed phenotype reversion, malignant melanoma, 3186
TIMP-2 overexpression, 2891
- Genomes**
alterations
cervical carcinoma, 197
comparative genomic hybridization
adrenocortical tumors, 4219
familial Wilms' tumor deletion regions, 3837
head and neck squamous cell carcinoma, 5325
malignant peripheral nerve sheath tumor
genetic changes, 4778
metastatic prostate cancer, 3091
pancreatic carcinoma, 3803
renal cell carcinoma, 27
rhabdomyosarcoma analysis, 3220
deletions
malathion exposure and, 2393
instability
hepatocarcinogenesis, 2137
hereditary nonpolyposis colon cancer, 2733
suppression by TGF- β 1, 3645
TGF- β RII, hereditary nonpolyposis colorectal cancers, 4595
- Genoprotection**
UDP-glucuronosyltransferase, 1526
- Genotoxicity**
aflatoxin B₁, *S. cerevisiae*, 5457
mammary lipid, 5342
tamoxifen, endometrium, 1475
- Genotypes**
NAT2
-dependent aberrant crypt formation, congenic Syrian hamsters, 527
lung cancer susceptibility factor, 3961
phenotype correlation, hereditary breast cancers, 3216
- Germ cell tumors**
human endogenous retrovirus-K protein expression and antibody reaction, 4362
- Ginger rhizome**
tumor promotion inhibition, SENCAR mouse skin, 1023
- Glandular stomach carcinoma**
vitamin D₃ chemoprevention, rats, 2767
- Glia cells**
O⁶-methylguanine repair, 5615
- Glioblastoma**
angiogenesis
inhibition by chromosome 10, 5684
CDKN2/p16 or RB alterations, 150
inhibition
MDL101731, 359
triple helix-forming oligodeoxyribonucleotides, 5156
radiosensitivity
p53 and, 500
serum and tumor tissue VEGF levels, 2185
T98G cells
tumorigenic and metastatic phenotype, PDGF-B/*v-sis* and, 280
tumorigenicity
enhancement by mutant EGFR, 5079
- Glioma**
apoptosis
generalized, adenovirus-mediated p53 transfer, 694
induction by ICE, rat model, 5423
brain enriched hyaluronan binding expression, 2293
C6 cells
growth inhibition by antisense-VEGF, 393
- IGF2 loss of imprinting, 5356
invasive
brain enriched hyaluronan binding expression, 2293
neural cell adhesion molecule L1, 1440
malignant
chromosome 12q13-q15 amplicon mapping, 5141
chromosome 17p loss of heterozygosity, PDGF- α receptor expression and, 164
neural cell adhesion molecule L1 gene expression, 1440
membrane-type matrix metalloproteinase expression and gelatinase A activation, 384
meningeal
intrathecal chemotherapy with liposome-encapsulated 1,3 bis(2-chloroethyl)-1-nitrosourea, 3986
p16/CDKN2 methylation and chromatin, 2405
radiation-induced DNA damage, flow cytometric assay, 154
risk
mutagen sensitivity and, 1484
temozolomide uptake, rat model, 1983
truncated EGF receptor-expressing inhibition by tyrphostin AG 1478, 3859
- Gliosarcoma**
9L
NKR-P1⁺ cells, rat, 3516
- Glucocorticoids**
receptor, small cell lung carcinoma cells, 3276
resistance, CEM-C1 cells, 5033
- Glucose**
catabolism, cancer cells, 2468
erythrocyte transporter Glu5533
expression, benign and malignant tissues, 1164
- Glucuronate**
MRP-mediated conjugate export, substrates, 988
- β -Glucuronidase**
and irinotecan diarrhea, rats, 3752
- Glucuronidation**
and mycophenolic acid resistance, colorectal carcinoma cells, 984
- γ -Glutamylcysteine synthetase**
gene expression, colorectal cancers, 3642
- Glutathione**
BMS-181174 activation, 3495
busulfan conjugate
catalysis by glutathione S-transferase, 3678
tert-butyl-hydroquinone conjugate
toxicity, 1006
depletion
methyl-donor deficiency, 995
melphalan conjugation, liver perfusion, 4709
MRP-mediated conjugate export, substrates, 988
- Glutathione S-transferase**
busulfan-glutathione conjugation catalysis, 3678
- Glutathione S-transferase- π**
antisense cDNA
drug sensitivity and, colon cancer cells, 3577
- Glutathione S-transferase M1**
bladder cancer risk modulation, 3915
gene polymorphisms, non-small cell lung carcinoma, 3725
- Glutathione S-transferase M3**
gene polymorphism, and cutaneous basal cell carcinoma risk, 1974
- Glutathione S-transferase T1**
bladder cancer risk modulation, 3915
- Glycoamines**
synthetic
breast cancer metastasis inhibition, nude mice, 5319
- Glycoform**
bladder cancer-associated CEA, identification by 19A211, 908
- Glycoprotein**
membrane
95-kDa, H19 overexpression and, 2904
- Glycoprotein 40**
bispecific 1A10 antibody, binding characteristics and antitumor properties, 113
- Glycoprotein 72**
levels
colorectal patients, quantitative CA 72-4 immunoassay, 5293
phosphorylatable MAB-chB72.3-P, construction, 4250
- Glycoprotein 100**
immunization against, 4749
- Glycosylation**
deglycosylation
vitamin D₃-binding protein, and immunosuppression, 2827
tumor malignancy, 5309
- GM-CSF: see Granulocyte-macrophage colony-stimulating factor**
- Gonadotropin-releasing hormone**
expression, endometrial cancer, 2059
- Gorlin syndrome**
PTCH mutations, 4562
- G₁ phase**
arrest
p27^{KIP1}-mediated, prostate cancer cells, 3666
delay
cyclooxygenase-2 overexpression, 733
p53 and radiosensitivity, 500
- G₂ phase**
arrest
and camptothecin cytotoxicity, colon carcinoma cells, 4430
- Granule cells**
cerebellar
Zic expression, 377
- Granulocyte-macrophage colony-stimulating factor**
antitumor effects, melanoma, 2191
localized treatment
photodynamic therapy and, 3281
vaccine producing IL-4 and, 1828
- Grb10**
insulin-like growth factor I receptor substrate, 3165
- Growth factors**
cytokines, non-Hodgkin's lymphoma, 5499
dependence
and polyploidization, HL60 cells, 5513
epidermal
anti-EGFR mAb 225, p27^{KIP1} upregulation, prostate cancer cells, 3666
antisense receptor transfection, rhabdomyosarcoma, 3898
receptor, mutant, tumorigenicity enhancement, 5079
receptor, quantitative estimation, 3823
receptor downregulation by E-cadherin/catenin complex, HPV-transfected keratinocytes, 5285
receptor phosphorylation, MAP kinase signal transduction stimulation by asbestos after, 5334
-refractory bladder carcinoma, rat, 2666
-responsive bladder carcinoma, rat, 2666
truncated receptor, tyrphostin AG 1478 selectivity, 3859

withdrawal, malignant transformation and, breast epithelial cells, 2039
 hematopoietic, hairy cell leukemia, 4679
 hepatocyte
 activation, rat hepatocytes, 2837
 insulin-like
 binding protein-3, retinoic acid- and TGF- β 2-induced cell growth inhibition mediation, 1545
 binding protein-3, retinoid X receptor-specific retinoids and, 1794
 insulin-like, I
 autocrine loop, and tamoxifen response, 4049
 receptor, and transformation by HPV-16 E6 and E7, 5087
 receptor, apoptosis and neuroblastoma tumorigenesis effects, 4522
 receptor, dominant negative, 4013
 receptor, Grb10 substrate, 3165
 receptor antisense, and mesothelioma, 4044
 receptor antisense, antitumor effects, 3038
 receptor gene activation by hepatitis B virus X protein, 3831
 receptor gene expression, hepatocellular carcinoma cells, 3831
 receptor-mediated circuit, Ewing's sarcoma and primitive neuroectodermal tumors, 4570
 receptor overexpression, cervical carcinoma, 1761
 insulin-like, II
 liver epithelial cells and, rat, 2992
 loss of imprinting, glioma, 5356
 overexpression, pregnancy-dependent mammary tumor growth and, 3651
 P3 promoter regulation by p53, 1367
 platelet-derived, α
 receptor expression, 17p loss of heterozygosity and, 164
 platelet-derived endothelial cell
 expression, bladder cancers, 4799
 transforming, β
 growth and differentiation effects, HL-60 cells, 495
 inhibition by lisofylline, 105
 type I receptor, genetic change, prostate cancer cells, 44
 type II receptor, gene mutations, hereditary nonpolyposis colorectal cancers, 4595
 type II receptor, gene mutations, sporadic cancer, 5620
 type II receptor, gene promoter mutations, 4831
 transforming, β 1
 apoptosis induction, prostatic epithelial cells, 5146
 autocrine stimulation of gelatinase B secretion, murine metastatic colon carcinoma cells, 3366
 effects in metastatic vs primary mouse prostate cancer cells, 3359
 genomic instability suppression, 3645
 -induced apoptosis, inhibition by tumor promoters, rat hepatocytes, 1272
 -induced apoptosis, insulin receptor substrate 1 protection against, 3391
 insensitivity, prostate cancer, 44
 transforming, β 2
 -induced growth inhibition, mediation by IGFBP-3, 1545
 vascular endothelial
 antisense, growth inhibition, C6 cells, 393
 anti-VEGF antibody, angiogenesis inhibition, 4032

expression, breast cancer, 2013
 expression, hepatocellular carcinoma, 3004
 expression, melanoma cells, 172
 expression, uterine, 3954
 inhibition, tumor dissemination suppression, 921
 receptor expression, breast cancer, 2013
 regulation by cell density, colon carcinoma cells, 3891
 regulation by oncogenic transformation and hypoxia, 3437
 reversion by von Hippel-Lindau protein, renal carcinoma cells, 2299
 serum and tumor tissue levels, brain tumor, 2185
 upregulation, mouse skin carcinogenesis, 5391
 upregulation by iron chelators, 3747
Growth hormone
 receptor
 regulation, liver, 2949
Growth inhibitors
 mammary-derived
 gene silencing by epigenetic changes, breast neoplasms, 4865
GS-7 cells
 antibody penetration, mice, 3508
GST: see Glutathione S-transferase
GS-X
 expression, colorectal cancers, 3642
G β 3 synthase
 gene expression, adult T-cell leukemia, 2844
Guanylyl cyclase C
 upregulation, regenerating rat liver, 5186

H

H19
 loss of imprinting, esophageal cancer, 480
 overexpression, MDR cells, 2904
Hair
 regrowth
 calcitriol enhancement, mice, 4438
Hairy cell leukemia
 hematopoietic growth factors, 4679
Ha-ras
 activation
 retinoic acid receptor loss and, mouse skin tumors, 4942
 allele sequence variations, minisatellite variant repeat PCR, 4773
HC11 cells
 cyclin E overexpression, 1389
H4 cells
 chromium-induced mitogen-activated protein kinase activation, 2045
HCT 116 cells
 NAD(P)H:quinone oxidoreductase locus, 5253
Head and neck squamous cell carcinoma
 arginine-rich protein gene mutations, 5576
 chromosomal alterations, comparative genomic hybridization, 5325
 chromosome 13q deletion mapping, 1146
 DPC4 mutations, 2519
 FHIT abnormalities, 5128
 genetic progression model, 2488
 p16 growth suppressors, 4119
 p16 inactivation, 3630
 p16 β growth suppressors, 4119
 radiosensitization by paclitaxel, 5198
 13-cis-retinoic acid/ α -2a-IFN radiotherapy, 2277
 telomerase activity, 3530, 5600
 oral rinses, 5720
Head and neck tumors
 multiple
 clonal origin, 2484

taxol pharmacodynamics, 2086
Heat
 autologous tumor killing induction, tumor cells, 1104
 sensitivity
 heat shock protein 27 overexpression and, testis tumor cells, 2446
Heat shock
 M-phase kinase activation, 1770
Heat shock protein 27
 overexpression, testis tumor cells, 2446
 phosphorylation
 -mediated resistance to actin fragmentation by oxidants, 273
Heat shock protein 70
 and heat induction of autologous tumor killing, 1104
 and PGA $_1$ -induced thermotolerance modulation by quercetin, leukemic cells, 210
Heat shock proteins
 induction by photosensitization, 2355
HeLa cells
 mitotic inducers
 activation prevention by 1 Gy radiation, 2268
 taxoid-ionizing radiation interactions, 1842
 Taxol-induced abnormal mitotic exit and apoptosis, 816
Helicobacter pylori
 gastritis
 iNOS, nitrotyrosine, apoptosis, 3238
 infection
 oxidative DNA damage, gastric mucosa, 1279
Helper T cells
 tumor-specific Th2 clone
 tumor regression, mice, 5005
Hematological malignancies
 antibody processing, 3062
Hematopoiesis
 recovery
 stimulation by lisofylline, 105
Hematopoietic cells
 differentiation
 ALL-1 gene and, 1179
 IL-2 receptor expression and diphtheria fusion toxin DAB $_{389}$ IL-2 sensitivity, 2590
 progenitors
 MDR gene transfer, stromal layers and continuous flow culture, 2566
Hematopoietic growth factors
 hairy cell leukemia, 4679
Hematopoietic neoplasms
 estrogen receptor gene methylation, 973
Heparanase
 regulation, malignant melanoma, 2856
Hepatitis
 hereditary
 etheno-DNA adducts, copper-dependent formation, LEC rats, 1267
Hepatitis B virus X protein
 IGF-I receptor gene activation, 3831
Hepatoblastoma
 sporadic
 APC gene mutations, 3320
Hepatocarcinoma: see also Liver
 enhancement by colchicine-induced cell cycle disturbance, rats, 3474
 multistage
 karyotypic changes, rat model, 2985
 ploidy and karyotypic alterations, transgenic mice, 2137
Hepatocellular carcinoma: see also Liver
 -activated cysteine sulfinic acid decarboxylase, 5230
 apoptosis
 TGF- β 1-induced, insulin receptor sub-

- strate 1 protection against, 3391
BRCA2 mutations, 4575
 chromosome 8p allele loss, China, 5092
 hereditary
 etheno-DNA adducts, copper-dependent formation, LEC rats, 1267
 insulin-like growth factor I receptor gene expression, 3831
 megestrol treatment
 response, estrogen receptor type and, 3883
 tamoxifen treatment
 response, estrogen receptor type and, 3883
 thioredoxin overexpression, 5330
 vascular permeability factor/VEGF expression, 3004
- Hepatocyte growth factor**
 activation, rat hepatocytes, 2837
- Hepatocytes**
 apoptosis
 inhibition by tumor promoters, rat, 1272
 guanylyl cyclase C upregulation, regenerating rat liver, 5186
 hepatocyte growth factor activation, rat cultures, 2837
- Hepatoma**
 ascites cells
 energy metabolism regulation by nitric oxide, 4535
 H4 cells
 chromium-induced mitogen-activated protein kinase activation, 2045
- Herbs**
 Chinese
 nephropathy, aristolochic acid-DNA adducts, 2025
- Hereditary cancer-prone syndromes**
 abnormal SOS-like response, inheritance, 2621
- Hereditary carcinoma**
 breast
 truncated BRCA1 protein, 3216
 colorectal
 nonpolyposis, genomic instability, 2733
 nonpolyposis, TGF- β *R11* mutations, 4595
- Heregulin**
 growth regulation
 erbB2 effects, breast and ovarian tumor cells, 1457
- Heregulin- β 2**
 and hormone-independent breast cancer cells, 3350
- HER2/neu**
 chemoresistance and, non-small cell lung cancer, 206
 inhibition by triple helix-forming oligonucleotide, 515
- Herpes simplex virus thymidine kinase**
 gene therapy
 Myc-overexpressing small cell lung cancer cells, 354
 noninvasive imaging, 4087
 -mediated apoptotic death, bystander cells, 2697
- Heterocyclic amines**
 food-derived
 N-acetyltransferase expression and, mammary gland, 2683
- Heterozygosity, loss of: see also Allelic loss APC**
 Barrett's esophagus, 1961
 cervical carcinoma, 197
 chromophobe renal cell carcinoma pattern, 2927
 chromosome 1p22
 malignant mesothelioma, 4297
 chromosome 11
 stomach cancer, 268
- chromosome 11 long arm
 nasopharyngeal carcinoma, 3225
 chromosome 11q
 ovarian cancer, 741
 chromosome 11q23.3-q24.3
 epithelial ovarian cancer, 950
 chromosome 12p
 non-small cell lung cancer, 738
 chromosome 17p
 and platelet-derived growth factor α receptor expression, malignant glioma, 164
 chromosome 22q
 ovarian cancer, 729
 endometriosis, 3534
 semiautomated assessment, 3331
- β -Hexachlorocyclohexane**
 estrogenic action, breast cancer cells, 5403
- Hexokinase**
 type II
 gene amplification, tumor cells, 2468
- HhaI methyltransferase**
 cell lethality and transformation, NIH3T3 cells, 616
- High mobility group protein**
 HMGI
 expression, hepatocellular carcinoma, 5330
 HMGI(Y)
 expression, colorectal carcinomas, 1896
- Histone H3**
 mRNA *in situ* hybridization, rat colonic epithelium, 434
- HLA: see Human leukocyte antigen**
- HL-60 cells**
 apoptosis
 inhibition by Bcl-2 or Bcl- x_L , HL-60 cells, 4743
 -resistant variant, isolation and characterization, 1621
 Ara-C-induced CPP32/Yama protease inhibition by Bcl-2 or Bcl- x_L , HL-60 cells, 4743
 differentiation
 regulation by TGF- β , 495
 fatty acid synthase, cytotoxic antimetabolite target, 745
 growth
 inhibition by KH 1060 and 9-*cis*-retinoic acid, 3570
 regulation by TGF- β , 495
 G $_1$ -S block
 1,25-dihydroxyvitamin D $_3$ -induced, 264
 vitamin D $_3$ -resistant
 cell growth rate and polyploidization, 5513
- HMG: see High mobility group protein hMLH1**
 expression, 4836
 mutations, familial colorectal cancer, 5728
- HOM-MEL-40**
 SSX-2 codes, 4766
- Hormones**
 gonadotropin-releasing
 expression, endometrial cancer, 2059
 -independent breast cancer cells
 heregulin- β 2 and, 3350
 lipophilic
 -induced apoptosis, 4164
 melanocyte-stimulating
 deficiency, intestinal carcinomas, mice, 3842
 deficiency, intestinal tumorigenesis, 2922
 melanocyte-stimulating, human
 exon 13 deletion variant, 2289
 expression, normal and neoplastic tissues, 235
- expression, tumors, 4836
 parathyroid
 -related peptide, antisense inhibition, 77
 -related protein, bone metastasis, 4040
 -related protein, gene expression, 1043
 -related protein, repression by p53 mutants, 4056
- 4-HPR: see N-(4-Hydroxyphenyl)retinamide**
- HPRT**
 V(D)J recombinase-mediated mutations, peripheral blood lymphocytes of children, 1405
- HPS: see Heat shock proteins**
- H-ras**
 -transformed embryo fibroblasts
 FTI-277 radiosensitization, rat, 1727
- H-ras1**
 promoter
 conformation changes, NMU-induced mammary carcinoma and pregnancy, 4927
- HSV: see Herpes simplex virus thymidine kinase**
- HT1080 cells**
 ursolic acid anti-invasive activity, 2281
- Human endogenous retrovirus-K**
 protein expression
 antibody reaction, germ cell tumors, 4362
- Human leukocyte antigen**
 class I
 loss of allele expression, advanced renal cell carcinoma, 826
- Human leukocyte antigen A**
 0201-restricted E7-encoded epitope
 HPV16-positive cervical lesions against, virus-specific memory CTLs, 582
- Human leukocyte antigen B27**
 cell cycle-dependent expression, breast cancer cells, 4358
- Human papillomavirus**
 interleukin 2 response
 cervical pathology correlation, 3967
 invasive phenotype reversal by E-cadherin/catenin complex, keratinocytes, 5285
 tumor status, cervical carcinoma, 197
 type 16
 E6 protein, transformation, 5087
 E7 protein, transformation, 5087
 E7 protein, ubiquitin-dependent Rb degradation induction, 4620
 -positive cervical lesions, virus-specific memory CTLs, 582
 types
 cell proliferation and apoptosis and, cervical neoplasia, 669
- Human T cell leukemia virus**
 type I
 AP-2 binding activity, 779
- Hyaluronan**
 brain enriched binding
 expression, glioma, 2293
- Hyaluronate**
 -independent metastasis, pancreatic carcinoma cells, 3134
- Hyaluronidase**
 levels, prostate cancer, 651
- Hybrid cell clones**
 chromosome 1 effects, 241
- Hydrogen peroxide**
 erbstatin-induced apoptosis, small cell lung carcinoma cells, 4978
 J558L plasmacytoma killing, mice, 87
 transformation *in vitro*, rat urothelial cells, 4649
- 2-Hydroxychalcone**
 oral carcinogenesis inhibition, rat, 4904
- 8-Hydroxydeoxyguanosine**
 immunoperoxidase detection, AFB $_1$ -treated

I

- rat liver and human oral mucosal cells, 683
- 6-Hydroxydopamine**
adjunctive treatment with Tempol, murine neuroblastoma, 2336
- 8-Hydroxyguanine**
increased levels and repair activity, leukocytes, 2546
- N-(4-Hydroxyphenyl)retinamide**
cell proliferation regulation, breast cancer cells, 1056
- N-(2-Hydroxypropyl)methacrylamide copolymer**
-bound adriamycin/Mce₆, combined with photodynamic therapy, ovarian carcinoma, 3980
- 4-Hydroxytamoxifen**
DNA adducts, 53
- Hydroxytoluene hydroperoxide**
butylated
mitogen-activated protein kinase activation, 3480
- Hypercalcemia**
parathyroid hormone-related protein gene expression and, 1043
- Hypermethylation**
chromosome 18q21 *bcl-2* locus, lung cancer, 1886
p15^{INK4B} inactivation, 722
p16 gene, nasopharyngeal carcinoma, 2721
- Hypermutation**
serum deprivation and, Chinese Hamster, 752
- Hyperplasia**
alveolar
atypical, *K-ras* mutations, 2224
mammary
induction by *int-5*, transgenic mice, 3180
- Hyperresistance**
photodynamic inactivation
hemin effects, leukemia cells, 4636
- Hypersensitivity**
testicular tumors
functional p53, 1834
- Hypersensitization**
pluronic L61, MDR cells, 3626
- Hypertension**
interstitial
angiogenesis and, 4264
- Hyperthermia**
combined with carbogen breathing
radiosensitization, 5590
combined with radiotherapy, soft tissue sarcoma, 5347
limb perfusion with TNF- α
and systemic fibrinolysis, 3948
local
liposomal daunorubicin and, rat solid tumors, 563
- Hypomethylation**
DNA, urothelial carcinoma, 5698
- Hypoxanthine-guanine phosphoribosyl transferase**
gene mutations
ethylnitrosourea-induced, *lacI* transgenic mice, 4654
- Hypoxia**
apoptosis and necrosis induction, 2161
ovarian cancer cell invasion, 1168
synergism with oncogenic transformation and vascular endothelial growth factor modulation, 3437
transient, murine breast cancer, 5522
tumor
and malignant progression, cervical cancer, 4509
reduction by nicotinamide, SCCVII murine tumors, 2801
- IA-2**
neuroendocrine marker, lung cancer cells, 2742
- IACRLRD: see International Association for Comparative Research on Leukemia & Related Diseases**
- ICAM-1: see Intercellular adhesion molecule-1**
- ICE: see Interleukin 1 β -converting enzyme**
- Icelanders**
breast and ovarian cancer patients
BRCA2 999del5 mutations, 3663
- Ifosfamide**
sensitization
P450-based gene therapy, breast cancer, 1331
- IGF: see Insulin-like growth factor**
- Imaging: see also specific modalities**
noninvasive
gene expression, 4087
quantitative ion
boron neutron capture therapy, brain tumor model, 4302
- Imidazoacridinones**
new agents, pharmacological and toxicological aspects, 2094
- Immortal cells**
differentiation
telomerase activity loss, 3796
- Immortalization**
and choline metabolism alterations, 4630
p16, human uroepithelial cells, 2886
- Immune cells**
biodistribution in mammals, kinetic model, 3771
- Immunity**
augmentation by superantigen staphylococcal enterotoxin B, 3731
induced by allogeneic tumor cells, 3782
induction by SV40 large T antigen gene inoculation, 1126
- Immunization**
against glycoprotein 100, 4749
- Immunoassay**
CA 72-4
tumor-associated glycoprotein 72 levels, colorectal patients, 5293
- Immunodeficiency**
severe combined
cell cycle analyses, *scid* mouse fibroblasts, 2940
skin carcinogenesis, SCID mice, 757
- Immunoglobulin α**
c-myc recombinations
detection, mice, 419
- Immunoglobulin G**
anti-galactose
tumor cell opsonization, 3069
- Immunoglobulin-like tumor-associated antigen**
TuAg.1, rat liver, 3934
- Immunohistochemical staining**
laryngeal markers, 2199
- Immunoperoxidase**
8-hydroxydeoxyguanosine detection, AFB₁-treated rat liver and human oral mucosal cells, 683
- Immunosuppression**
deglycosylated vitamin D₃-binding protein and, 2827
- Immunotherapy**
active
anticancer vaccines, costimulation enhancement, 2832
adjuvant interleukin 12, 467
MUC1-specific targeting, bile duct carcinoma, 5828
- noma, 4205
- radioimmunotherapy
carcinoembryonic antigen-expressing tumors, 1805
combined with tumor blood flow-modifying agents, colorectal xenografts, 3293
superantigen-activated T cells
brain tumors, 4702
vaccinia-CEA vaccine and IL-2, 2361
- Immunotoxins**
biology and therapy advances
Fourth International Symposium on Immunotoxins meeting report, 926
- Indium-111**
metabolism and retention by cancer cells, 2123
- Indole-3-carbinol**
multidrug resistance reversal, 574
- Infection**
Epstein-Barr virus
proliferative response, adenoid B-cells, 5610
H. pylori
oxidative DNA damage, gastric mucosa, 1279
- Inositol**
chemopreventive effects against pulmonary carcinogenesis, female A/J mice, 5132
- In situ hybridization**
histone H3 mRNA, rat colonic epithelium, 434
mRNA
BRCA1 germline mutation detection, breast cancer, 2912
somatostatin receptor, carcinoid tumors, 2561
- Insulin**
receptor
promoter repression by p53, breast cancer, 2781
receptor substrate 1
protective effects against TGF- β 1-induced apoptosis, hepatocellular carcinoma cells, 3391
- Insulin-like growth factor I**
autocrine loop
and tamoxifen response, leiomyoma, 4049
receptor
antisense, adenovirus expressing, antitumor effects, 3038
antisense, and mesothelioma, 4044
apoptosis and neuroblastoma tumorigenesis effects, 4522
dominant negative, 4013
gene activation by hepatitis B virus X protein, 3831
gene expression, hepatocellular carcinoma cells, 3831
Grb10 substrate, 3165
-mediated circuit, Ewing's sarcoma and primitive neuroectodermal tumors, 4570
overexpression, cervical cancer cells, 1761
and transformation by HPV-16 E6 and E7, 5087
- Insulin-like growth factor II**
expression
liver epithelial cells and, rat, 2992
loss of imprinting, glioma, 5356
overexpression
pregnancy-dependent mammary tumor growth and, 3651
P3 promoter
regulation by p53, 1367
- Insulin-like growth factor binding protein 3**
retinoic acid- and TGF- β 2-induced growth inhibition mediation, breast cancer cells, 1545

- retinoid X receptor-specific retinoids and, ectocervical epithelial cells, 1794
- Int3**
truncated
and mammary secretory differentiation, 1775
- int-5**
mammary hyperplasia induction, transgenic mice, 3180
- Integrins**
 $\alpha_2\beta_1$ (VLA-2)
postextravasation cell movement function, RD cells, 3142
 $\alpha_{2b}\beta_3$
expression, prostate carcinoma cells, 5071
 $\alpha_6\beta_1$
function, metastatic breast carcinoma cells, 959
and *ras* fibroblast migration, 1682
 $\alpha_6\beta_4$
functions, colorectal carcinoma invasion, 4811
 α_v
brain tumor cell migration and, 1939
 $\alpha_v\beta_3$
liver metastasis, murine RAW117 large cell lymphoma, 3103
 β_1
brain tumor cell migration and, 1939
etoposide-induced DNA strand breakage inhibition, murine tumor-derived endothelial cells, 4146
regulation by autocrine motility factor, metastatic melanoma, 1902
signaling to NF- κ B, monocytic leukemia cells, 2302
- Inter-Alu polymerase chain reaction**
mutator phenotype detection, cancer cells, 2733
- Intercellular adhesion molecule 1**
endothelial
MUC1 adhesion ligand, breast cancer, 4244
suppression, human malignancies, 1111
- Interferon**
cell growth inhibition, breast cancer, 1571
- α -Interferon**
gene deletion
and chemoselectivity, pancreatic cell carcinoma, 1083
interleukin 6 upregulation, 4679
- $\alpha 2a$ -Interferon**
combined with 13-*cis*-retinoic acid
radiotherapy, head and neck squamous cell carcinoma, 2277
recombinant
p53 modulation, cisplatin-resistant melanoma cells, 2522
- β -Interferon**
gene deletion
and chemoselectivity, pancreatic cell carcinoma, 1083
-inducible proteins
elevation, ataxia telangiectasia cells, 443
- γ -Interferon**
nitric oxide production from endothelial cells induction, 886
-stimulated cells
apoptosis induction, leukemic cells, 866
- Interleukin 1 α**
nitric oxide production from endothelial cells induction, 886
- Interleukin 2**
-activated natural killer cells
liver metastases elimination, 1599
chimeric Lym-1/IL-2 fusion protein, 4998
combined with vaccinia-CEA vaccine immunotherapy, 2361
- diphtheria fusion toxin DAB₃₈₉IL-2
sensitivity, hematopoietic cells, 2590
human papillomavirus response
cervical pathology correlation, 3967
-induced hepatic toxicity, mechanisms, 507
receptor
expression, hematopoietic cells, 2590
-transduced tumor cells vaccine
adjuvant interleukin 12, 467
- Interleukin 3**
receptor
p210 Bcr-Abl interactions, 3426
- Interleukin 4**
circularly permuted IL4-toxin, malignant astrocytoma, 5631
GM-CSF and
vaccine producing, 1828
- Interleukin 6**
autologous tumor vaccine expressing, microscopic pulmonary metastases treatment, 1361
expression and response, mammary tumors, 3118
non-Hodgkin's lymphoma, 5499
receptor
superantagonists, myeloma cell apoptosis induction, 4213
serum levels, esophageal squamous cell carcinoma, 2776
upregulation by recombinant IFN- α , 4679
- Interleukin 8**
expression
Taxol-dependent activation, ovarian cancer, 1303
- Interleukin 10**
non-Hodgkin's lymphoma, 5499
- Interleukin 12**
cDNA injection
tumor establishment inhibition, murine renal carcinoma model, 3399
immunotherapy adjuvant, 467
-induced nitric oxide production, 1131
local vs systemic delivery, 2531
- Interleukin 13**
cell growth inhibition, breast cancer cells, 3583
- Interleukin 1 β -converting enzyme**
apoptosis induction, glioma cells, 5423
-like protease
retinoblastoma protein cleavage, apoptosis, 438
-mediated p34^{cdc2} activation, Fas-induced apoptosis, 4551
protease CPP-32
activation, apoptotic ovarian carcinoma cells, 5224
- International Association for Comparative Research on Leukemia & Related Diseases (IACRLRD)**
XVIII Symposium, meeting report, 4288
- International Symposium on Immunotoxins**
Fourth, meeting report, 926
- Interstitial fluid pressure**
after radiation, human tumor xenografts, 964
- Interstitial hypertension**
angiogenesis and, 4264
- Intestinal adenoma**
spontaneous
piroxicam chemoprevention, *Apc*^{Min} mouse, 710
- Intestinal carcinoma**
gastric
microsatellite instability-associated mutations, 4664
spontaneous, *Msh2*-deficient mice, 3842
suppression by Bowman-Birk inhibitor, Min mice, 679
- Intestinal tumors**
MSH2 deficiency and, Min mice, 2922
stromal
chromosome 14q deletions, 3230
suppressor locus, potential, 978
- Intestines**
bacterial 7 α -dehydroxylase and phosphatidylinositol-specific phospholipase C
fat effects, 2314
fatty acids
precipitation by milk calcium, 3270
toxicity
chemotherapy-induced, prevention by anti-doxorubicin mAb, 2082
irinotecan, β -glucuronidase and, 3752
- Intraepithelial neoplasia**
prostatic
progression to invasive carcinoma, SV40 T_{AG} transgenic mice, 4894
representative cDNA library, construction, 5380
- Invasion**
hypoxic, ovarian carcinoma, 1168
inhibition
PD 098059, 5369
retroviral-mediated deoxycytidine kinase overexpression, 2343
phenotype
reversal by E-cadherin/catenin complex, HPV-transfected keratinocytes, 5285
reaction-diffusion model, 5745
stimulation
macrophage colony-stimulating factor receptor, 5704
- Invasive carcinoma**
bladder
midkine expression and, 2515
TIMP-2 expression, 1654
breast
grade I tubular, *FHIT* and *ATM* allele loss, 5484
macrophage infiltration, 4625
psoriasis expression, 4606
tumor stroma tissue factor, 5063
colorectal
integrin $\alpha_6\beta_4$ functions, 4811
prostate
inhibition by PKC- ζ , R-3327 cells, 4137
progression, SV40 T_{AG} transgenic mice, 4894
ursolic acid anti-invasive activity, HT1080 cells, 2281
- Invasive glioma**
brain enriched hyaluronan binding expression, 2293
neural cell adhesion molecule L1, 1440
- Invasive melanoma**
neurotrophin stimulation, 2856
- Iodine-125**
metabolism and retention by cancer cells, 2123
- 5-Iodo-2'-deoxyuridine**
²¹¹At-labeled analogue, 1204
- Ion imaging**
quantitative
boron neutron capture therapy, brain tumor model, 4302
- Ionizing radiation: see Radiation**
- IRF-1**
Lysyl oxidase gene regulation, 2417
- Irinotecan**
cyclosporin A interactions, 1309
diarrhea
 β -glucuronidase and, rats, 3752
plasma metabolite, identification and properties, 3689
- Iron chelators**
vascular endothelial growth factor up-regula-

tion, 3747
Irradiation: *see* **Radiation**
Irsogladine
 tumor growth and neovascularization inhibition, 1512
Italians
 breast/ovarian cancer families
BRCA1 germline mutations, 5466
J
Jewish women
 Ashkenazi
BRCA2 mutations, 3409
 ovarian cancer patients
BRCA1 185delAg mutations, 1250
J558L plasmacytomas
 peroxide killing, mice, 87
JT-95
 production, 1817
JV18-1
 somatic alterations, lung cancers, 5583
K
KAI1
 dysregulation, prostatic cancer, 4387
 expression
 non-small cell lung cancer, 1751
 pancreatic cancer, 4876
Kallikrein
 human
 expression, mammalian cells, 5397
Kaposi's sarcoma
 AIDS-associated
 resistance to Fas-mediated apoptosis, 1874
Karyotypes
 alterations, hepatocarcinogenesis, 2137
 heterogeneity, breast cancer, 855, 5098
 multistage hepatocarcinogenesis, rat model, 2985
K562 cells
 natural killer sensitivity
 bisecting *N*-acetylglucosamine and, 412
 proton nuclear magnetic resonance spectroscopy, 3461
KDR/jk-1
 -positive endothelial cells
 proliferation inhibition by VEGF-toxin conjugate, 1324
Keratinocytes
 cell cycle control
 TNF- α and, 2452
Keratoacanthoma
 melanoma regression and, 937
KH 1060
 combined with 9-*cis*-retinoic acid
 cell growth inhibition, HL-60 cells, 3570
Kidney: *see also* **Renal**
 aristolochic acid-DNA adducts, 2025
 disulfide-stabilized Fv fragment uptake
 blockade by L-lysine, 3788
 gene expression, hamster, 2616
 malignant
 MHC class I antigen presentation, 1756
 TBHQ-glutathione conjugate toxicity, 1006
Kidney tumors
 distal nephron
 microsatellite allelotype, 1892
Killer clones
 advanced tumor therapy, canines, 3021
Kinase
 Abl
 inhibition by 2-phenylaminopyrimidine derivative, 100
 Bcr-abl
 inhibition by Bcr, 5120
 c-Abl
 inhibition by Bcr, 5120

c-Jun N-terminal
 activation by palytoxin, 637
 c-Jun N-terminal, 1
 activation by phenethyl isothiocyanate, 2954
 cyclin-dependent
CDKN2/p16 gene alterations, glioblastoma, 150
 inhibitor p57^{KIP2}, expression, Wilms' tumors, 5723
 inhibitor p57^{KIP2}, soft tissue sarcoma and Wilms' tumors, 1219
 cyclin E-dependent
 fluoropyrimidine-mediated radiosensitization and, 3203
 deoxycytidine
 overexpression, tumor cells, 2343
 DNA-activated protein
 -deficient mouse fibroblasts, p53-dependent cell cycle arrests, 2940
 extracellular-signal regulated, 1
 signal transduction stimulation by asbestos, 5334
 mitogen-activated protein
 activation, and substance P-induced mitogenesis, astrocytoma cells, 4983
 activation, butylated hydroxytoluene hydroperoxide, 3480
 activation, chromium, H4 cells, 2045
 activation, p21^{WAF1/CIP1}, 31
 stimulation, asbestos, 5334
 stimulation, small cell lung cancer cells, 5758
 mitogen-activated protein kinase
 inhibitor PD 098059, invasion and urokinase expression inhibition, 5369
 M-phase activation, heat shock, 1770
 phosphatidylinositol 3
 inhibitor wortmannin, radiosensitization, 246
 protein
 DNA-activated, -deficient mouse fibroblasts, p53-dependent cell cycle arrests, 2940
 stress-activated, activation by palytoxin, 637
 protein, C
 activator bryostatin 1, pharmacokinetics, 802
 breast carcinoma cell adhesion regulation, 2206
 colonic mucosal, fat effects, 2314
 inhibition, apoptosis and ceramide production induction, 2711
 P-glycoprotein interactions, MDR cells, 3490
 protein, C- α
 antisense oligonucleotide inhibitor, tumor growth inhibition, 3499
 protein, C- ζ
 invasion and metastasis inhibition, R-3327 cells, 4137
 Src
 activation by *bcr/abl*, myeloid cells, 3589
 stress-activated protein
 activation by palytoxin, 637
 thymidine, herpes simplex virus
 gene therapy, Myc-overexpressing small cell lung cancer cells, 354
 gene therapy, noninvasive imaging, 4087
 -mediated apoptotic death, bystander cells, 2697
 tyrosine
 inhibitors, apoptosis stimulation, 4255
KIP1
 mutations, childhood acute lymphoblastic leukemia, 1413

K-ras
 mutations, atypical alveolar hyperplasia, 2224
Kupffer cells
 activation by peroxisome proliferators, 1
 carcinoembryonic antigen-induced cytokine expression, 4805
L
L61
 hypersensitizing effects, MDR cells, 3626
lacI
 mutations
 ethylnitrosourea-induced, *lacI* transgenic mice, 4654
Laminin-1
ras fibroblast migration, $\alpha 6 \beta 1$ -integrin and, 1682
Larynx
 neoplastic progression, immunohistochemical markers, 2199
Latent membrane protein 1
 Mcl-1 upregulation, B-cells, 4610
Lectin
 modulation by Western-style diets, colonic epithelial cells, 4644
Leiomyoma
 uterine
 del(7)(q22) and PAI-1 expression, 3123
 tamoxifen response, IGF-I autocrine loop and, 4049
Lesions: *see also* **Neoplasms; Tumors**
 cervical
 HPV16-positive, virus-specific memory CTLs, 582
 endogenous DNA
 1,*N*²-propanodeoxyguanosine adducts, tissue, 452
 liver
 DNA base modifications and, English sole carcinogenesis model, 5563
 oral dysplastic
 chromosome 3p allelic imbalance, 1228
Lethality
 induction by *HhaI* methyltransferase, NIH3T3 cells, 616
Letters to the Editor
 re: Farber, 55: 3759-3762, 4267
 re: Knol *et al.*, 55: 3687-3691, 2677
 re: Liabakk *et al.*, 56: 190-196, 3610
 re: London, *et al.*, 55: 6035-6037, 4275
 re: Studzinski and Moore, 55: 4014-4022, 925
 re: Teixeira *et al.*, 56: 855-859, 5098
Leukemia
 adult T-cell
G_{D3} synthase gene expression, 2844
 apoptosis
 induction by cytokine-stimulated cells, 866
 cell photokilling
 hemin effects, 4636
 hairy cell
 hematopoietic growth factors, 4679
 HL-60 cells
 apoptosis-resistant variant, isolation and characterization, 1621
 1,25-dihydroxyvitamin D₃-induced G₁-S block, 264
 growth and differentiation regulation by TGF- β , 495
 growth inhibition by KH 1060 and 9-*cis*-retinoic acid, 3570
 human T cell leukemia virus type I
 AP-2 binding activity, 779
 K562 cells
 proton nuclear magnetic resonance spectroscopy, 3461

- merbarone-resistant, characterization, 2573
monocytic cells
 integrin signaling to NF- κ B, 2302
pathogenesis and treatment
 molecular aspects, IACRLRD XVIII Symposium meeting report, 4288
p18 expression
 inhibition by antisense RNA, 1445
resistance
 multidrug resistance reversal by antisense oligodeoxynucleotides, 4332
TALL-104 antitumor efficacy, syngeneic mice, 4444
- Leukemia, acute lymphoblastic**
ALL1 gene
 exon structure, 1766
 and hematopoietic differentiation, 1179
 partial tandem duplication, acute myeloid leukemia, 1418
B-cell
 p16 inactivation by chromosome translocation, 848
childhood
 t(12;21), *ETV6* and *CDKN1B* alterations, 2655
 TEL and *KIP1* mutations, 1413
T-cell
 ALL-1 breakpoint cluster region deletion, 2171
 CEM-C1 cells, glucocorticoid resistance, 5033
- Leukemia, acute myeloid**
ALL1 partial tandem duplication, 1418
- Leukemia, acute promyelocytic**
PML-retinoic acid receptor α degradation by all-*trans*-retinoic acid, 2945
- Leukemia, promyelocytic**
HL60 cells
 fatty acid synthase, cytotoxic antimetabolite target, 745
- Leukocytes**
adhesion to vascular endothelium
 radiation-induced, mediation by cell adhesion molecules, 5150
 8-hydroxyguanine levels and repair activity, 2546
- Leukoplakia**
oral
 telomerase activity, 3530
- Lewis enzyme**
colon tissue, 330
lung carcinoma
 CT1746 and cyclophosphamide combination chemotherapy, murine, 715
- Lewis Y antigen**
antibodies, humanized, 1118
- LGDI069**: see **Targretin[®]**
- Limbs**
TNF- α perfusion
 and systemic fibrinolysis, 3948
- Linomide**
chemoprevention, rodents, 3404
- Lipids**
mammary, genotoxicity, 5342
- Lipophilic hormone**
-induced apoptosis, 4164
- Liposomes**
daunorubicin
 disposition, fluorescence imaging studies, tumor tissue, 2066
 local hyperthermia and, rat solid tumors, 563
drug-loaded
 tumor suppression, lung tumor xenografts, 3743
-encapsulated 1,3 bis(2-chloroethyl)-1-nitrosourea
- intrathecal chemotherapy, meningeal gliomatosis, 3986
- Lipoxygenase**
breast carcinoma cell adhesion regulation, 2206
- Lisofylline**
hematopoietic recovery stimulation, 105
- Lit**
mutations
 breast cancer xenografts in homozygous hosts, growth reduction, 1509
- Liver**: see also **Hepatocarcinoma**; **Hepatocellular carcinoma**
aflatoxin B₁-treated
 olipraz-mediated changes, rat, 2306
 oxidative DNA damage, rat, 683
BrdUrd incorporation, 2677
carbonyl-reducing enzymes regulation, rat, 2758
cytochrome P450 enzymes
 5-methylchrysene and 6-methylchrysene metabolism, 316
docetaxel metabolism, CYP3A-mediated, 1296
epithelial cells
 cytogenetic analysis and correlation with IGF-II expression, 2992
etheno-DNA adducts
 copper-dependent formation, LEC rats, 1267
growth hormone receptor mRNA regulation, 2949
MDR1 substrates/modulators protective effects against β -estradiol-17 β -D-glucuronide cholestasis, rat, 4992
metastasis
 colorectal, BrdUrd incorporation, 2677
 elimination by IL-2-activated natural killer cells, 1599
 integrin $\alpha_3\beta_3$, murine RAW117 large cell lymphoma, 3103
 suicide and cytokine gene therapy, colon carcinoma, 3758
perfusion
 melphalan glutathione conjugation, 4709
phase II enzyme expression, tamoxifen response, 3704
RD cells
 postextravasation movement, integrin function, 3142
regenerating
 guanylyl cyclase C upregulation, rat, 5186
tamoxifen-DNA adducts, identification, 53
toxicity
 interleukin-2-induced, mechanisms, 507
 tumor-associated antigen TuAg.1, rat, 3934
tumor promoters
 apoptosis inhibition, rat hepatocytes, 1272
- Liver-enriched inhibiting protein**
expression, mammary neoplasia, 4382
- Liver lesions**
DNA base modifications and, English sole carcinogenesis model, 5563
- Liver tumors**
VX2
 chemoembolization study, MRI, 1863
- LNCaP cells**
metastatic
 apoptosis resistance, 5594
proliferating cell nuclear antigen regulation
 by androgens, 1539
tpc/hpr fusion transcript, 728
- Lometrexol**
folic acid-enhanced therapeutic activity, 2331
- Loss of heterozygosity**: see also **Allelic loss**
APC
- Barrett's esophagus, 1961
cervical carcinoma, 197
chromophobe renal cell carcinoma pattern, 2927
chromosome 1p22
 malignant mesothelioma, 4297
chromosome 11
 stomach cancer, 268
chromosome 11 long arm
 nasopharyngeal carcinoma, 3225
chromosome 11q
 ovarian cancer, 741
chromosome 11q23.3-q24.3
 epithelial ovarian cancer, 950
chromosome 12p
 non-small cell lung cancer, 738
chromosome 17p
 and platelet-derived growth factor α receptor expression, malignant glioma, 164
chromosome 22q
 ovarian cancer, 729
endometriosis, 3534
semiautomated assessment, 3331
- Loss of imprinting**
IGF2, glioma, 5356
- Low-density lipoprotein receptor-related protein**
expression, cutaneous melanoma, 1432
- Low molecular weight protein**
deficiencies, renal cell carcinoma, 1756
- LPC**
location, lymphoma, 448
- 9L s.c. tumors**
2-nitroimidazole and radiation resistance, 405
- Lung**
atypical alveolar hyperplasia
 K-ras mutations, 2224
biomarker alterations
 air particulate extracts, N-acetylcysteine chemoprevention, 1526
cytochrome P450 enzymes
 5-methylchrysene and 6-methylchrysene metabolism, 316
fibrosis
 bleomycin-induced, genetic model, 2596
 bleomycin-induced, prevention, *Sh ble* transgenic mice, 5659
manganese superoxide dismutase overexpression, SV40-transformed fibroblasts, 2864
metastasis
 growth inhibition by lymphotoxin fusion protein, melanoma, 1707
 membrane-type matrix metalloproteinase 1 expression, experimental assay, 5678
 microscopic, autologous tumor vaccine treatment, 1361
- Lung adenocarcinoma**
therapy
 toxin genes, 1315
- Lung carcinoma**
A549 cells
 flavopiridol-induced cell death, 4856
 methylthioadenosine phosphorylase chemosensitivity, 5653
Ad-IGF-Ir/as antitumor effects, 3038
arginine-rich protein gene mutations, 5576
bc1-2 chromosome 18q21 locus hypermethylation, 1886
bone metastasis model, 4040
chemoprevention
 arylalkyl isothiocyanates and N-acetylcysteine, Fischer rats, 772
 myo-inositol and dexamethasone, female A/J mice, 5132

- chemotherapy
 CT1746 and cyclophosphamide combination, murine Lewis, 715
 cJun expression, 305
 collagen autoimmunity, 121
 CYP1A1 polymorphisms and p53 mutations, 72
 DNA repair capacity, 4103
 DPC4 somatic alterations, 2718
 FHIT alterations, 5579
 α -1,3-fucosyltransferase expression, 325
 IA-2 neuroendocrine marker, 2742
 JVI18-1 somatic alterations, 5583
 microsatellite alterations, bronchial and sputum specimens, 2285
 neutral endopeptidase expression and inactivation, 831
 non-small cell
 chemosensitivity enhancement by tyrosin Ag825, 1068
 chemotherapy, gemcitabine-containing regimens, 794
 chromosome 11p15.5 allelic deletions, 2916
 chromosome 12p loss of heterozygosity, 738
 CYP1A1 and GSTM1 polymorphisms, 1974
 HER-2/neu expression and chemoresistance, 206
 KAI1/CD82 expression, 1751
 p16 and retinoblastoma protein status, 5557
 risk
 benzo(a)pyrene diol epoxide-induced chromosomal aberrations and, 3975
 CYP1A1 polymorphisms and, African-Americans, 4275
 retinoic acid catabolism and, 2692
 tobacco, CYP2D6 activity and, 251
 small cell
 apoptosis induction by erbstatin, 4978
 apoptosis induction by tyrosine kinase inhibitors, 4255
 c-kit and stem cell factor, 370
 δ opioid receptors, characterization, 1695
 glucocorticoid receptor, 3276
 mitogen-activated protein kinase stimulation, 5758
 Myc-overexpressing, gene therapy, 354
 p70^{src} phosphorylation inhibition by rapamycin, 3895
 synergism of cisplatin and topoisomerase inhibitors NB-506 and SN-38, 789
 topoisomerase II α point mutations, 1232
 TSG region 600-kb cosmid contig, 1489
 susceptibility
 benzo(a)pyrene diol epoxide-DNA adducts and, 3638
 CYP1A1 C4887A polymorphism and, 4965
 NAT2 genotype and, 3961
 TOP-53 antitumor activity, 2809
Lung tumors
 clonal evolution, 1609
 estrogen receptor methylation, 3655
 non-small cell
 Rb and p16^{INK4a} expression, 3415
 suppression by drug-loaded liposomes, xenografts, 3743
LY335979
 multidrug resistance reversal, 4171
Lymph nodes
 zinostatin stimulator cellular effects, 1868
Lymphoblastoid cells
 DNA synthesis
 Cl-F-ara-A actions, 3030
- Lymphocytes: see also B lymphocytes; Cytotoxic T lymphocytes; T lymphocytes**
 growth inhibition by selenium compounds, 4407
 peripheral
 benzo(a)pyrene diol epoxide-DNA adducts, cancer susceptibility markers, 3638
 IL-2 production, human papillomavirus response, 3967
 V(D)J recombinase-mediated HPRT mutations, children, 1405
 protective effects of dietary antioxidants, 1291
 tumor response to photodynamic therapy, mouse EMT6 tumors, 5647
Lymphokine-activated killer proteins
 M, 65,000
 phosphorylation induction by tumor target binding, 127
 pp65a and pp65b, characterization, 138
Lymphoma
 allelotype analysis, B6C3F1 mice, 3338
 B-cell
 antibody processing, 3062
 Burkitt's
 mutant p53 transcription, 1648
 inhibition by olipiraz, 3395
 non-Hodgkin's
 cytokines, 5499
 pathogenesis and treatment
 molecular aspects, IACRLD XVIII Symposium meeting report, 4288
 pre-B
 resistance genes, MSM/Ms mouse, 3716
 proprotein convertase gene (LPC) location, 448
 RAW117 large cells
 liver metastasis, integrin $\alpha_v\beta_3$, 3103
 T-cell
 transgenic tal-1 mice, 5113
Lymphoproliferative disorders
 posttransplant
 microsatellite analysis, 4378
Lymphotoxins
 fusion protein
 growth inhibition, melanoma, 1707
L-Lysine
 renal disulfide-stabilized Fv fragment uptake blockade, 3788
Lysis
 viral
 Epstein-Barr virus-targeted therapy, 969
Lysyl oxidase
 gene
 regulation by IRF-1, 2417
- M**
- Mac-2-binding protein**
 galectin-3 interactions, 4530
 α_2 -Macroglobulin
 receptor expression, cutaneous melanoma, 1432
Macrophage colony-stimulating factor
 receptor
 invasion and clonogenic growth stimulation, 5704
Macrophages
 infiltration, invasive breast carcinoma, 4625
 nitric oxide production
 IL-12-induced, 1131
MAGE-1
 -loaded antigen presenting cell-based vaccine
 CTLp frequency enhancement, melanoma, 2479
 -specific CTLs, breast cancer, 16
- Magnetic drug targeting**
 clinical experiences, 4686
 preclinical experiences, 4694
Magnetic resonance imaging
 gadopentetate dimeglumine dynamic combined with electron paramagnetic resonance oximetry, 3344
 VX2 tumor chemoembolization study, rabbit liver, 1863
Magnetic resonance spectroscopy
 proton-decoupled phosphorus
 soft tissue sarcoma *in vivo* and *in vitro*, 2964
 proton nuclear
 MDR K562 cells, 3461
Major histocompatibility complex
 class I
 antigen presentation, malignant renal cells, 1756
 gene-transfected B16BL6 cells, melanoma antigen inhibition, 4464
 class II
 tumor antigen presentation, vaccine that enhances, 21
 nonrestricted CTLs
 antitumor efficacy, leukemic mice, 4444
 phase I clinical trial, advanced canine tumors, 3021
Malathion
 exposure
 and genomic deletions, 2393
Malignancy
 astrocytoma
 circularly permuted IL4-toxin, 5631
 brain tumors
 boron neutron capture therapy, 2017
 membrane-type matrix metalloprotease expression and gelatinase A activation, 384
 breast
 Fas expression and function, 4791
 cervical cancer
 tumor hypoxia and, 4509
 dominant conversion, melanoma, 3075
 endothelial ICAM-1 suppression, 1111
 familial melanoma
 p16 germline mutations, southern Sweden, 2497
 glioma
 chromosome 12q13-q15 amplicon mapping, 5141
 chromosome 17p loss of heterozygosity, PDGF- α receptor expression and, 164
 neural cell adhesion molecule L1 gene expression, 1440
 Glut1 expression, 1164
 hematological
 antibody processing, 3062
 melanoma
 chromosome 11 tumor suppressor, 4487
 heparanase regulation, 2856
 suppressed phenotype reversion by retroviral transduction, 3186
 mesothelioma
 chromosome 1p22 deletion mapping, 4297
 multidrug resistance and, osteosarcoma, 2434
 nonhematopoietic
 soluble Fas levels, 3870
 osteosarcoma
 multidrug resistance and, 2434
 ovarian carcinoma
 second, 1565
 peripheral nerve sheath tumors
 genetic changes, comparative genomic hybridization, 4778
 phenotypes

- suppression by chromosome 10, PPC-1 cells, 2157
- pituitary tumor
- parathyroid hormone-related peptide inhibition and, rat, 77
- progression by FGF-2 transfection, mouse renal cell carcinoma, 2440
- Δ^{12} -prostaglandin J_2 cytotoxicity, 3866
- prostate tissue
- telomerase activity, 218
- renal
- MHC class I antigen presentation, 1756
- second
- ovarian carcinoma, 1565
- suppression by noncoding RNA, 4366
- transformation, breast epithelial cells, 2039
- tumor
- 2B1 antigen, identification, 3902
- glycosylation and sphingo(glyco)lipid metabolism, 5309
- Malnutrition**
- esophageal squamous cell carcinoma, 2776
- Mammaglobin**
- expression, breast cancer, 860
- Mammalian cells**
- human kallikrein expression, 5397
- Mammary-derived growth inhibitor**
- gene silencing by epigenetic changes, breast neoplasms, 4865
- Mammary gland**
- N*-acetyltransferase expression and food-derived heterocyclic amines, 2683
- chemoprevention
- low-dose dehydroepiandrosterone, rat, 1724
- cholesterol epoxides and estrone-3,4-quinone tumorigenicity, rat, 1970
- epithelial cells
- BRCA1* splice variants, 4578
- cyclin E overexpression, mouse, 1389
- growth inhibition by activin, 1155
- immortalization by mutant *p53*, 3129
- malignant transformation, 2039
- sulfotransferase expression, 1551
- transformed, cyclooxygenase-2 transcription, 4424
- epithelium
- monoclonality, 402
- hyperplasia
- induction by *int-5*, transgenic mice, 3180
- lipid, genotoxicity, 5342
- neoplasia
- liver-enriched inhibiting protein expression, 4382
- secretory differentiation
- truncated *Int3* and, 1775
- Mammary tumors: see also Breast tumors**
- apoptosis
- induction by *bcl-x_s* gene therapy, 1965
- suppression, transgenic mice, 2998
- interleukin 6 expression and response, 3118
- Manganese superoxide dismutase**
- expression
- central nervous system tumors, 3192
- radiation therapy, 2771
- overexpression, SV40-transformed lung fibroblasts, 2864
- Matrix attachment region**
- binding activity, breast carcinoma, 457
- Matrix metalloproteinase**
- human MT4-MMP gene (*MMP-17*), molecular cloning, 944
- inhibitor
- combined with cyclophosphamide, murine Lewis lung carcinoma, 715
- metastasis control, rat mammary carcinoma, 2815
- membrane-type
- expression, malignant brain tumors, 384
- Matrix metalloproteinase 1**
- membrane-type, 2535
- expression, experimental metastasis assay, 5678
- tissue inhibitor of metalloproteinase 2 complex, 2707
- Matrix metalloproteinase 2**
- colorectal cancer, 190, 3610
- precursor processing by membrane-type I matrix metalloproteinase, 2535
- serum MMP-2:TIMP-2 ratio, recurrence of urothelial cancer, 3196
- Matrix metalloproteinase 9**
- colorectal cancer, 190, 3610
- down-regulation
- metastasis inhibition, rat sarcoma model, 5279
- expression, HT1080 cells, 2281
- Max response element**
- herpes simplex virus thymidine kinase gene containing
- therapy, Myc-overexpressing small cell lung cancer cells, 354
- Mce₆**
- N*-(2-hydroxypropyl)methacrylamide copolymer-bound
- combined with photodynamic therapy, ovarian carcinoma, 3980
- MCF-7 cells**
- estrogen receptor exon 5 variant effects, 1556
- Mcl-1**
- B-cell levels
- upregulation by latent membrane protein 1, 4610
- expression
- and B-cell apoptosis, 40
- MDA-MB-435 cells**
- human retinoic acid receptor α gene regulation, 5246
- metastasis-suppressor gene, chromosome 11, 1222
- MDL101731**
- glioblastoma and neuroblastoma inhibition, 359
- MED-1: see Multiple start site element downstream**
- Medullary thyroid carcinoma**
- RET* mutations, 12¹, 2167
- Medulloblastoma**
- Zic expression, 377
- Meeting reports**
- International Association for Comparative Research on Leukemia & Related Diseases, XVIII Symposium
- leukemia and lymphoma, pathogenesis and treatment, 4288
- International Symposium on Immunotoxins, Fourth
- immunotoxin biology and therapy advances, 926
- Pezcoller Symposium, Seventh Annual cancer genes, functional aspects, 4282
- Sapporo Cancer Seminar, Fifteenth psychoneuroimmunology, 4278
- Megestrol**
- hepatocellular carcinoma treatment response
- estrogen receptor type and, 3883
- Melanocytes**
- bcl-2*-deficient mice, 3546
- differential gene expression, 3112
- Melanocyte-stimulating hormone**
- hMsh2*
- exon 13 deletion variant, 2289
- expression, normal and neoplastic tissues, 235
- expression, tumors, 4836
- Msh2 deficiency**
- intestinal carcinomas, mice, 3842
- intestinal tumorigenesis, Min mice, 2922
- Melanocytic neoplasms**
- induction, uPA-deficient mice, 3597
- Melanocytic nevi**
- benign
- allelotypes, 589
- Melanoma**
- Annexin VI expression, 3855
- antigen
- gp100, immunization against, 4749
- inhibition, MHC class I gene-transfected B16BL6 melanoma cells, 4464
- antimelanoma cytotoxicity
- particulate peptides, 1210
- B16 cells
- growth inhibition by bryostatins, 2105
- B16BL6 cells
- MHC class I gene-transfected, melanoma antigen inhibition, 4464
- cisplatin-resistant
- p53* modulation by rIFN- α 2a, 2522
- cutaneous
- allelotypes, 589
- low-density lipoprotein receptor-related protein and receptor-associated protein expression, 1432
- cytotoxic T lymphocyte precursors, frequency enhancement, 2479
- differential gene expression, 3112
- F10 cells
- growth inhibition by bryostatins, 2105
- GM-CSF antitumor effects, 2191
- growth
- acceleration after stroma destruction, mouse model, 463
- growth inhibition
- chromosome 6, 1635
- lymphotoxin fusion protein, 1707
- invasion
- neurotrophin stimulation, 2856
- malignant
- chromosome 11 tumor suppressor, 4487
- dominant conversion, 3075
- familial, *p16* germline mutations, 2497
- heparanase regulation, 2856
- suppressed phenotype reversion by retroviral transduction, 3186
- metastasis-associated genes, mRNA differential display, 5266
- metastatic
- C3-cleaving proteinase, 254
- integrin regulation by autocrine motility factor, 1902
- p16*-cyclin D/Cdk4-pRb pathway, 5475
- p53* pathway abnormality after ionizing radiation, 840
- regression
- and keratoacanthoma, 937
- specific adenovirus, 5638
- sporadic
- p16*, *p15*, and chromosome 9p21 marker losses, 5023
- sublines
- differentially expressed genes with different metastatic potentials, 875
- T-cell recognition, 2368
- tumor-associated antigen gene (MART-1) transduced dendritic cells, 5672
- uvea
- angiogenesis, 2900
- vascular permeability factor/vascular endothelial growth factor expression
- tumor growth and vascularization and, 172

Melanoma-associated cell adhesion molecules

MUC18/MCAM
regulation by phorbol ester and cyclic AMP, 2218

Melphalan

combined with TNF- α
hyperthermic limb perfusion, and systemic fibrinolysis, 3948
glutathione conjugation, liver perfusion, 4709
sensitivity
increase by GST- π antisense cDNA, colon cancer cells, 3577

Membrane glycoprotein

95-kDa
H19 overexpression and, 2904

Memory cytotoxic T lymphocytes

virus-specific, cervical carcinoma, 582

MEN: see Multiple endocrine neoplasia

Meningeal glioma

intrathecal chemotherapy with liposome-encapsulated 1,3 bis(2-chloroethyl)-1-nitrosourea, 3986

Merbarone

-resistant leukemic cells, characterization, 2573

Merkel cell carcinoma

aberrant FHIT transcripts, 2472

Mesenchymal tumors

somatostatin and vasoactive intestinal peptide receptors, 1922

Mesothelioma

malignant
chromosome 1p22 deletion mapping, 4297
tumorigenesis
inhibition by IGF-IR antisense, 4044

Messenger RNA: see also RNA

acetyltransferase, histological localization, 1517

BRCA1 splice variants, mammary epithelial cells, 4578

CD44

splicing, papillary thyroid carcinoma, 1037

cell adhesion regulator

and metastasis, colorectal cancer, 3605

differential display

metastasis-associated genes, K-1735 melanoma, 5266

differential gene expression, melanocytic cells, 3112

estrogen receptor variant, breast cancer, 4324

growth hormone receptor

regulation, liver, 2949

histone H3

in situ hybridization, rat colonic epithelium, 434

HLA-B27

cell cycle-dependent expression, breast cancer cells, 4358

noncoding

malignant suppression, 4366

ornithine decarboxylase

translational regulation by alternative splicing, 1742

plasminogen activator inhibitor 1

del(7)(q22) and, uterine leiomyomas, 3123

in situ hybridization

BRCA1 germline mutation detection, breast cancer, 2912

TAP1 and TAP2

cell cycle-dependent expression, breast cancer cells, 4358

Metabolism

choline

alterations, immortalization and transfection and, 4630

β -L-(-)-dioxolane-cytidine, DU-147 cells, 4180

docetaxel

hepatic CYP3A-mediated, 1296

human cytochromes P450, 58

energy

regulation by nitric oxide, ascites tumor cells, 4535

methylchrysenes

cytochrome P450 enzymes, 316

6-nitrochrysene, rats, 2052

Phlp, rat colon, 2550

radioimmunoconjugate, cancer cells, 2123

retinoic acid

and cell proliferation inhibition, 675

sphingo(glyco)lipid, tumor malignancy, 5309

Metaiodobenzylguanidine

therapeutic effects, neuroblastoma multicellular tumor spheroids, 5428

Metalloproteinase

tissue inhibitor, 2

expression, invasive bladder cancer, 1654

membrane-type matrix metalloproteinase 1 complex, 2707

retroviral-mediated overexpression, tumors, 2891

Metaphase

premature exit, staurosporine, 3551

Metaplasia

Barrett's esophagus, 1961

Metastasis

bone

E-cadherin expression, breast cancer, 4063

lung cancer cell model, 4040

brain tumor

local chemotherapy, 5217

breast carcinoma

E-cadherin expression, 4063

inhibition by synthetic glycoamines, nude mice, 5319

integrin α 6 β 1 function, 959

spontaneous, batimastat control, 2815

colon carcinoma

gelatinase B secretion, autocrine stimulation by TGF- β 1, 3366

hepatic, suicide and cytokine gene therapy, 3758

colorectal carcinoma

cell adhesion regulator mRNA expression and, 3605

liver, BrdUrd incorporation, 2677

NME1 allelic imbalance, 916

gastric carcinoma

angiogenesis and, 2671

hepatic

BrdUrd incorporation, colorectal carcinoma, 2677

elimination by IL-2-activated natural killer cells, 1599

integrin α β γ , murine RAW117 large cell lymphoma, 3103

suicide and cytokine gene therapy, colon carcinoma, 3758

inhibition

CEA transduction, rhabdomyosarcoma, 4503

matrix metalloproteinase 9 down-regulation, rat sarcoma model, 5279

PKC- ζ , R-3327 cells, 4137

lung cancer

TOP-53 antitumor activity, 2809

lung tumor

suppression by drug-loaded liposomes, xenografts, 3743

lymphoma

hepatic, integrin α β γ , murine RAW117 large cells, 3103

melanoma

C3-cleaving proteinase, 254

integrin regulation by autocrine motility factor, 1902

pulmonary, growth inhibition by lymphotoxin fusion protein, 1707

membrane-type matrix metalloproteinase 1 expression, experimental assay, 5678

pancreatic carcinoma

hyaluronate-independent, 3134

phenotype

PDGF-B/ ν -sis and, T98G cells, 280

reversal by anti-CAPL (*mts1*) ribozyme, tumor cells, 5490

pituitary tumor

parathyroid hormone-related peptide inhibition and, rat, 77

potential

disialosyl galactosylgloboside and, renal cell carcinoma, 1932

prostate carcinoma

genetic alterations, comparative genomic hybridization and allelotyping, 3091

LNCAp cells, apoptosis resistance, 5594

TGF- β 1 effects, 3359

TRAMP model, 4096

pulmonary

growth inhibition by lymphotoxin fusion protein, melanoma, 1707

microscopic, autologous tumor vaccine treatment, 1361

renal cell carcinoma

potential, disialosyl galactosylgloboside and, 1932

rhabdomyosarcoma

inhibition by CEA transduction, 4503

soft tissue sarcoma

tumor oxygenation and, 941

spontaneous

batimastat control, rat mammary carcinoma, 2815

tumor

augmentation by platelet-activating factor, 2662

Metastasis-associated genes: see also Genes

melanoma, mRNA differential display, 5266

Metastasis suppressor genes: see also Genes

chromosome 11, MDA-MB-435 breast carcinoma, 1222

KAI1

dysregulation, prostatic cancer, 4387

expression, pancreatic cancer, 4876

nm23

and cisplatin sensitivity, transfected tumor cells, 2931

1-Methionine- α -deamino- γ -mercaptomethane-lyase

P. putida

gene cloning and characterization, 2116

Methyl

-donor deficiency due to glutathione depletion, 995

Methylation

DNA

errors, 2463

mechanisms, colon carcinoma, 2375

urothelial carcinoma, 5698

estrogen receptor

hematopoietic neoplasms, 973

lung tumors, 3655

hypermethylation

chromosome 18q21 *bcl-2* locus, lung cancer, 1886

p16 gene, nasopharyngeal carcinoma, 2721

- p15^{INK4B}* inactivation, 722
- p16/CDKN2*
and chromatin, gliomas, 2405
- 5-Methylchryse**
metabolism by cytochrome P450 enzymes, 316
- 6-Methylchryse**
metabolism by cytochrome P450 enzymes, 316
- 4-Methylcoumarin-7-O-sulfamate**
in vivo activity, 4950
- Methylenetetrahydrofolate reductase**
polymorphism
and colorectal cancer risk, 4862
- O⁶-Methylguanine**
repair, glial cells, 5615
- O⁶-Methylguanine-DNA methyltransferase**
gene transcription
inhibition by wild-type p53, 2029
protective effects against skin tumor initiation, transgenic mice, 3244
- N-Methyl-N'-nitro-N-nitrosoguanidine**
vitamin D₃ chemopreventive effects against, glandular stomach carcinogenesis, 2767
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone**
-induced pulmonary carcinogenesis
myo-inositol and dexamethasone chemoprevention, female A/J mice, 5132
UDP-glucuronosyltransferase genoprotection against, 1526
- N-Methyl-N-nitrosourea**
EGF-responsive and -refractory bladder carcinoma, rat, 2666
- Methylthioadenosine phosphorylase**
chemoselectivity, pancreatic cell carcinoma, 1083
chemosensitivity, A549 cells, 5653
- MGMT: see O⁶-Methylguanine-DNA methyltransferase**
- MHC: see Major histocompatibility complex**
- Microenvironment**
tumor
genetic instability, 5754
- Microsatellites**
allelotype, distal nephron renal tumors, 1892
alterations
Barrett's-associated esophageal adenocarcinoma, 259
lung cancer, 2285
instability
allelotype mapping, endometrial precancers and cancers, 4483
-associated mutations, intestinal gastric carcinoma, 4664
breast cancer, 4021
cervical carcinoma, 1427
colonic aberrant crypt foci, 5339
drug-resistant tumor cells, 1374
epithelial borderline ovarian tumors, 2501
monoclonal endometrial carcinoma precursors, uteri, 1917
nonfamilial colorectal cancer, 5470
nonneoplastic mucosa, chronic ulcerative colitis, 1237
prostatic adenocarcinoma, 4475
TGF- β type II receptor gene mutations and, sporadic cecum cancer, 5620
tumors, hMSH2 and hMLH1 expression, 4836
- length
analysis by automated fluorescent DNA sequencer, 2688
posttransplant lymphoproliferative disorders, 4378
- Microscopy**
intravital videomicroscopy
anti-VEGF antibody angiogenesis inhibition, 4032
- Microsomes**
epoxide hydrolase
bladder cancer risk modulation, 3915
- Microtumors**
growth inhibition
anti-VEGF antibody, intravital videomicroscopy, 4032
- Microvessels**
blood flow fluctuation
transient hypoxia and, tumors, 5522
counts, uveal melanoma, 2900
permeability
mediation by bradykinin, brain tumors, 4027
- Midkine**
expression, bladder cancer, 2515
- Milk products**
calcium
colonic cytotoxicity inhibition, 3270
- Minibodies**
anti-CEA antibody antibody fragment
rapid targeting, xenografts, 3055
- Minisatellites**
variant repeat PCR
Ha-ras allele sequence variations, 4773
- Min mice**
intestinal carcinoma
suppression by Bowman-Birk inhibitor, 679
intestinal tumors
MSH2 deficiency and, 2922
- Minorities**
NIEHS/AACR Task Force on the Advancement of Minorities in Science
model program, 3380
- Mismatch repair**
loss, acquired cisplatin resistance, 3087
and platinum drug resistance, 4881
- Mismatch repair genes**
hMLH1
expression, 4836
hMSH2
expression, 4836
expression, normal and neoplastic tissues, 235
- Mitochondria**
DNA adducts
chemoprevention by *N*-acetylcysteine, rat organs, 1642
DNA damage, cigarette smoking, 5692
DNA repair, XPA cells, 1262
function
and apoptosis, 2033
impairment by MKT-077, 551
MKT-077 toxicity, 544
- Mitogen-activated protein kinase**
activation
butylated hydroxytoluene hydroperoxide, 3480
chromium, H4 cells, 2045
p21^{WAF1/CIP1}, 31
and substance P-induced mitogenesis, astrocytoma cells, 4983
stimulation
asbestos, 5334
small cell lung cancer cells, 5758
- Mitogen-activated protein kinase kinase**
inhibitor PD 098059
invasion and urokinase expression inhibition, 5369
- Mitogenesis**
substance P-induced, astrocytoma cells, 4983
- Mitomycin C**
analogue BMS-181174, activation, 3495
DT-diaphorase transcript splicing and expression, colon tumors, 1731
resistance
and NAD(P)H:quinone oxidoreductase, HCT 116 cells, 5253
sensitivity
DT-diaphorase determinant, colon and gastric carcinoma cells, 2823
YB-1 and, 4224
- Mitosis**
abnormal exit induction by Taxol, HeLa cells, 816
aflatoxin B₁-induced recombination, yeast, 5457
colonic tumorigenesis, mouse, 4910
inducers
activation prevention by 1 Gy radiation, HeLa cells, 2268
metaphase
premature exit, staurosporine, 3551
postmitotic apoptosis induced by X-irradiation, rec-myc cells, 4116
- Mitosis-promoting factor**
activation
prevention by 1 Gy radiation, HeLa cells, 2268
- MKT-077**
anticarcinoma activity, 538
mitochondrial impairment, 551
mitochondrial toxicity, 544
- MMP: see Matrix metalloproteinase**
- Molecular cloning**
MT4-MMP gene (*MMP-17*), 944
translocation t(11;14)(q23;q32) breakpoint, 448
- Molecular modeling**
BRCA1 amino-terminal zinc ring domain, 2539
- Monoclonal antibodies**
19A211
superficial bladder tumor-associated CEA glycoform identification, 908
anti-doxorubicin
mucositis prevention, mice, 2082
anti-EGFR mAb 225
p27^{Kip1} upregulation, prostate cancer cells, 3666
anti-GM2, 5666
bispecific
CD3-CD28 costimulation, ovarian carcinoma treatment, 5443
JT-95, against differentiated thyroid carcinoma, 1817
multidrug resistance protein-specific
QCRL-1
epitope mapping, 3307
murine antihuman B-cell Lym-1
chimeric Lym-1/IL-2 fusion protein, 4998
radioiodination, 4970
tumor-associated antigen
phosphorylatable MAb-chB72.3-P, construction, 4250
- Monoclonality**
mammary epithelium, 402
- Monocytes**
integrin signaling to NF- κ B, leukemia, 2302
- Mononuclear cells**
peripheral
mitomycin C-treated, DT-diaphorase transcript splicing and expression, 1731
- Motility-related protein-1**
prognostic factor, breast cancer, 1244
- MRI: see Magnetic resonance imaging**
- MRP: see Multidrug resistance protein**
- MRP-1: see Motility-related protein-1**
- MRS: see Magnetic resonance spectroscopy**
- MSH: see Melanocyte-stimulating hormone**
- Mucin**
acidic

- modulation by Western-style diets, colonic epithelial cells, 4644
- colon cancer
galactin-3 binding, 4354
- glycoprotein 72
colorectal patients, quantitative CA 72-4 immunoassay, 5293
- human dendritic cells engineered to express, 3763
- MUC1
adhesion ligand, breast cancer, 4244
-specific targeting immunotherapy, bile duct carcinoma, 4205
synthetic vaccines, mice, 3315
- MUC18/MCAM
regulation by phorbol ester and cyclic AMP, 2218
- Mucinous adenocarcinoma**
colon
GS-7 cells, mice, 3508
- Mucosa**
bronchial
microsatellite alterations, lung cancer, 2285
- colonic
diacylglycerol kinase, fat effects, 2314
protein kinase C, fat effects, 2314
- colorectal
bile acid-induced apoptosis, 1480
- gastric
H. pylori-infected, oxidative DNA damage, 1279
- nonneoplastic
microsatellite instability, chronic ulcerative colitis, 1237
- oral
aflatoxin B₁-treated, oxidative DNA damage, 683
- Mucositis**
prevention by anti-doxorubicin mAb, mice, 2082
- Multicell spheroids**
neuroblastoma
metaiodobenzylguanidine therapeutic effects, 5428
- tirapazamine response
comet assay, mice, 4460
- Multidrug resistance: see also Drug resistance; Resistance**
cytoplasmic P-glycoprotein and, 5435
gene transfer
stromal layers and continuous flow culture, hematopoietic progenitors, 2566
- H19* overexpression, 2904
- hypersensitization, pluronic L61, 3626
- and malignancy, osteosarcoma, 2434
- MDR1 substrates/modulators
protective effects against β -estradiol-17 β -D-glucuronide cholestasis, rat liver, 4992
- methods detection workshop, 3010
- P-glycoprotein and protein kinase C interactions, 3490
- P-glycoprotein-mediated
methods detection workshop, 3010
reversal by LY335979, 4171
- proton nuclear magnetic resonance spectroscopy, K562 cells, 3461
- reversal
antisense oligodeoxynucleotides, 4332
indole-3-carbinol, 574
LY335979, 4171
- Multidrug resistance protein**
gene expression, colorectal cancers, 3642
gene knockout, double, 5351
-mediated conjugate export, substrates, 988
-specific monoclonal antibody QCRL-1, epitope mapping, 3307
- Multiple endocrine neoplasia**
familial type 1
chromosome 11q13 deletions, 5272
- type 2
dominantly transforming oncogene *in vivo*, 4853
- Multiple start site element downstream**
and P-glycoprotein gene transcriptional regulation, 2021
- Multispecific organic anion transporter**
human canalicular, cisplatin-resistant cancer cells, 4124
- Mustard prodrug**
combined with carboxypeptidase G2
gene-directed enzyme prodrug therapy, 4728
- Mutagen**
sensitivity
and glioma risk, 1484
- Mutagenesis**
benzo[c]phenanthrene diol epoxides, 3695
serum deprivation and, Chinese Hamster G12 cells, 752
XPD gene transduction and, trichothiodystrophy cells, 5450
- Mutagenicity**
ochratoxin A, testing, 299
- Mutations: see also Deletions**
 α - and β -catenin gene
gastric and breast carcinomas, 49
- APC*
somatic, sporadic hepatoblastomas, 3320
- ATM*
cancer families, 4130
- BRCA1*
185del Δ g, Jewish women with ovarian cancer, 1250
germline, and histoprogenic grade, hereditary breast cancer, 471
germline, Italian breast/ovarian cancer families, 5466
germline, mRNA *in situ* hybridization detection, 2912
- BRCA2*
999del5, Icelandic breast and ovarian cancer patients, 3663
germline, sporadic ovarian cancer, 3622
germline, sporadic pancreatic carcinomas, 5360
hepatocellular carcinoma, 4575
Jewish Ashkenazi and non-Jewish individuals, 3409
ovarian carcinoma, 2738
somatic, sporadic ovarian cancer, 3622
sporadic ovarian cancer, 3622
- c-kit* kinase defective (W)
tumor suppression, 4343
- codon 22 and 31
dihydrofolate reductase, 4142
- CpG transition
DNA methylation and, colon carcinoma, 2375
- CYP1A1* C4887A polymorphism linkages, 4965
- dihydrofolate reductase
codon 22 and 31, 4142
- (-)-(1R,2S,3S,4R)-3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene profiles, 3695
- DPC4*
esophageal adenocarcinoma, 4351
head and neck squamous cell carcinoma, 2519
- epidermal growth factor receptor
tumorigenicity enhancement, 5079
- GAS1*
initial screening, bladder cancer, 5039
- germline
BRCA1, and histoprogenic grade, hereditary breast cancer, 471
BRCA1, Italian breast/ovarian cancer families, 5466
BRCA1, mRNA *in situ* hybridization detection, 2912
BRCA2, sporadic ovarian cancer, 3622
BRCA2, sporadic pancreatic carcinomas, 5360
p16, familial malignant melanoma, 2497
- hMLH1*
familial colorectal cancer, 5728
- hprt*
ethylnitrosourea-induced, *lacI* transgenic mice, 4654
- hypermutations
serum deprivation and, Chinese Hamster, 752
- Kip1*
breast cancer, 2400
childhood acute lymphoblastic leukemia, 1413
- K-ras*
atypical alveolar hyperplasia, 2224
- lacI*
ethylnitrosourea-induced, *lacI* transgenic mice, 4654
- lit*
breast cancer xenografts in homozygous hosts, growth reduction, 1509
- microsatellite instability-associated, intestinal gastric carcinoma, 4664
- mismatch repair
temozolomide resistance and, 5375
- ornithine decarboxylase
transformation reversal, 5136
- p16
germline, familial malignant melanoma, 2497
pancreatic cancer, 1137
- p27
breast cancer, 2400
- p53
bladder tumors, arylamine-exposed workers, 294
cisplatin resistance and, ovarian carcinoma cells, 556
gain-of-function, and T-cell receptor instability postirradiation, 3862
mammary epithelial cell immortalization, 3129
PTHrP repression, 4056
and response to therapy, advanced ovarian carcinoma, 689
transcription, Burkitt's lymphoma cells, 1648
tumor-derived, dominant wild-type p53 and, 158
type, and soft tissue sarcoma prognosis, 4134
- point
*O*⁶-alkylguanine-DNA alkyltransferase, and *O*⁶-benzylguanine sensitization to BCNU killing, 1578
topoisomerase II α , small cell lung cancer, 1232
- PTC*
initial screening, bladder cancer, 5039
- PTCH*
basal cell carcinoma and Gorlin syndrome, 4562
nevroid basal cell carcinoma syndrome, 4599
- RET*, inherited medullary thyroid carcinoma, 1241

- secretory PLA_2 genes, attenuated adenomatous polyposis coli, 955
- somatic
- APC* gene, sporadic hepatoblastomas, 3320
 - BRCA2*, sporadic ovarian cancer, 3622
 - TEL*, childhood acute lymphoblastic leukemia, 1413
- thioredoxin
- dominant-negative, phenotype reversal, breast cancer cells, 5765
- topoisomerase II α
- human, 91
 - point, small cell lung cancer, 1232
- transforming growth factor β type II receptor
- hereditary nonpolyposis colorectal cancers, 4595
 - sporadic cancers, 5620
- transforming growth factor β type II receptor promoter, 4831
- tumor microenvironment and, 5754
- V(D)J recombinase-mediated *HPRT*, peripheral blood lymphocytes of children, 1405
- Mutator phenotypes**
- inter-Alu polymerase chain reaction, cancer cells, 2733
- Mycophenolic acid**
- resistance, colorectal carcinoma cells, 984
- Myc protein**
- herpes simplex virus thymidine kinase gene containing
 - therapy, Myc-overexpressing small cell lung cancer cells, 354 - overexpressing small cell lung cancer cells gene therapy, 354
 - rec-myc cells
 - postmitotic apoptosis after X-irradiation, 4116
- Myeloid cells**
- apoptosis
 - GADD153/CHOP effects, 3250
 - inhibition, signaling, 3909
 - p53-dependent and p53-independent, 2148 - Src kinase activation by *bcr/abl*, 3589
- Myeloma**
- apoptosis
 - induction by IL-6 receptor superantagonists, 4213 - inhibition by *bcl-X_L*, murine cells, 1451
 - cell growth
 - CD40-induced arrest, 1909 - c-myc* allelic exclusion
- Myo-inositol**
- chemopreventive effects against pulmonary carcinogenesis, female A/J mice, 5132

N

- NAD(P)H:quinone oxidoreductase**
- mitomycin C resistance and, HCT 116 cells, 5253
- Nasal carcinoma**
- formaldehyde-induced, 1012
- Nasopharyngeal carcinoma**
- chromosome 11 long arm loss of heterozygosity, 3225
 - p16* gene hypermethylation, 2721
- NAT: see N-Acetyltransferase**
- National Institute of Environmental Health Sciences**
- NIEHS/AACR Task Force on the Advancement of Minorities in Science model program, 3380
- Natural killer cells**
- cytotoxicity
 - bisecting *N*-acetylglucosamine and, K562 cells, 412

- IL-2-activated
 - liver metastases elimination, 1599
- NB-506**
- synergism with cisplatin, small cell lung cancer cells, 789
- Necrosis**
- induction
 - hypoxia, 2161
- Neoplasia**
- cervical
 - cell proliferation and apoptosis, 669 - Epstein-Barr virus-associated
 - targeted therapy, 969 - hMSH2* expression, 235
 - immunohistochemical markers, larynx, 2199
 - mammary
 - liver-enriched inhibiting protein expression, 4382 - multiple endocrine
 - familial type 1, chromosome 11q13 deletions, 5272
 - type 2, dominantly transforming oncogene *in vivo*, 4853 - prostatic intraepithelial
 - progression to invasive carcinoma, SV40 T_{AG} transgenic mice, 4894
 - representative cDNA library, construction, 5380 - radiation-induced, prostate epithelial cells, 5
 - sialyl-Tn and Tn antigen expression, 2229
- Neoplasms: see also Lesions; Tumors**
- breast
 - mammary-derived growth inhibitor gene silencing by epigenetic changes, 4865 - hematopoietic
 - estrogen receptor gene methylation, 973 - melanocytic
 - induction, uPA-deficient mice, 3597 - second malignant, ovarian carcinoma, 1565
 - skin, *Msh2*-deficient mice, 3842
- Nephropathy**
- Chinese herbs
 - aristolochic acid-DNA adducts, renal tissue, 2025
- neu: see HER2/neu**
- Neural cell adhesion molecule L1**
- gene expression, malignant glioma, 1440
 - glioma invasion, 1440
- Neuroblastoma**
- adjunctive treatment
 - 6-hydroxydopamine with Tempol, murine, 2336 - apoptosis
 - enhancement by Bcl-x_S, 5734 - chemosensitivity
 - brain-derived neurotrophic factor effects, 3737 - familial predisposition
 - chromosome 1p36 linkage, 3421 - immunosuppressive gangliosides
 - shedding modulation, 4602 - inhibition by MDL101731, 359
 - metaiodobenzylguanidine therapeutic effects, multicellular tumor spheroids, 5428
 - T-cell receptor repertoire, 362
 - tumorigenesis
 - enhancement by IGF-I receptor, 4522
- Neuroectodermal tumors**
- primitive
 - insulin-like growth factor I receptor-mediated circuit, 4570
- Neuroendocrine phenotype**
- IA-2 marker, lung cancer cells, 2742
- Neurofibromatosis**
- type 1
 - exogenous gene, colon cancer cell suppression, 2872

- von Recklinghausen's
 - malignant tumors, genetic changes, 4778
- Neuroleukin/phosphohexose isomerase polypeptide**
- tumor cell autocrine motility factor, 2960
- Neurotrophic factor**
- brain-derived
 - chemosensitivity effects, neuroblastoma cells, 3737
- Neurotrophins**
- melanoma cell invasion stimulation, 2856
- Neutral endopeptidase**
- expression and inactivation, lung cancer, 831
- Neutron capture therapy**
- malignant brain tumors, 2017
 - quantitative ion imaging, brain tumor model, 4302
- Neutrophils**
- and photodynamic therapy efficacy, 2908
- Nevi**
- benign melanocytic
 - allelotypes, 589
- Nevoid basal cell carcinoma syndrome**
- PTCH* mutations, 4599
- Nicotinamide**
- tumor hypoxia reduction and repair inhibition, SCCVII murine tumors, 2801
- NIEHS: see National Institute of Environmental Health Sciences**
- NIH3T3 cells**
- cytochrome P450-expressing
 - ochratoxin A mutagenicity testing, 299 - lethality and transformation induction by
 - HhaI* methyltransferase, 616 - transformation
 - Ral GDP dissociation stimulator like Ras-interacting domain and, 2387
- Nitric oxide**
- energy metabolism regulation, ascites tumor cells, 4535
 - mediated bradykinin infusion
 - permeability mediation, brain tumors, 4027 - production
 - endothelial cell, 886
 - IL-12-induced, 1131
 - suppression by 5-fluorouracil, colon carcinoma cells, 1978
- Nitric oxide synthase**
- inducible
 - H. pylori* gastritis, 3238
- 6-Nitrochrysene**
- metabolism and DNA binding, rats, 2052
- 2-Nitroimidazole**
- and radiation resistance, 9L s.c. tumors, 405
- N-7-[2-(4-Nitrophenylidithio)ethyl]mitomycin C: see BMS-181174**
- 4-Nitroquinoline 1-oxide**
- induced oral carcinogenesis
 - inhibition by flavonoids, rat, 4904
- N-Nitrosodiethylamine**
- initiated hepatocarcinoma
 - enhancement by colchicine-induced cell cycle disturbance, rats, 3474
- N-Nitroso-N-methylurea**
- induced mammary carcinoma
 - H-ras* promoter conformation alterations, 4927
- Nitrotyrosine**
- H. pylori* gastritis, 3238
- NKR-P1⁺ cells**
- 9L gliosarcoma, rat, 3516
- nm23**
- and cisplatin sensitivity, transfected tumor cells, 2931
- NME1**
- allelic imbalance, colorectal carcinoma, 916

NMU: *see* N-Nitroso-N-methylurea

Non-Hodgkin's lymphoma

cytokines, 5499

Non-small cell lung carcinoma

chemosensitivity enhancement by tyrphostin
Ag825, 1068

chemotherapy

gemcitabine-containing regimens, 794

chromosome 11p15.5 allelic deletions, 2916

chromosome 12p loss of heterozygosity, 738

CYP1A1 and GSTM1 polymorphisms, 1974

HER-2/*neu* expression and chemoresistance,
206

KAI1/CD82 expression, 1751

p16 and retinoblastoma protein status, 5557

Non-small cell lung tumors

Rb and p16^{INK4a} expression, 3415

Nuclear antigen

proliferating cell
regulation by androgens, LNCaP cells,
1539

Nuclear factor κ B

integrin signaling, monocytic leukemia cells,
2302

Nuclear magnetic resonance spectroscopy

¹H-

transformed Schwann cells, 4630

proton

MDR K562 cells, 3461

Nuclear matrix proteins

bladder cancer-associated, 1690

Nuclear phosphoproteins

BRCA1

expression and phosphorylation, 3168

Nuclear receptor

Fas-nuclear receptor fusion protein
lipophilic hormone-induced apoptosis,
4164

Nuclear signaling

induced by ionizing radiation, 3617

Nucleoid assay

flow cytometric, glioma cells, 154

Nucleoside

toxicity

retroviral deoxycytidine kinase transfer
and, tumor cells, 2343

O

O⁶-Benzylguanine

sensitivity

alkyltransferase, mouse model, 1880

Occupational exposure

arylamine

p53 mutations, bladder tumors, 294

styrene and styrene-7,8-oxide

biomarkers, 5410

Ochratoxin A

mutagenicity testing, 299

Oligodendrocytes

radiation-induced apoptosis, adult rat spinal
cord, 5417

Oligodeoxynucleotides

antisense

multidrug resistance reversal, 4332

Oligodeoxyribonucleotides

triple helix-forming

TNF production and autocrine tumor
growth inhibition, glioblastoma, 5156

Oligonucleotides

antisense

PKC- α inhibitor, tumor growth inhibition,
3499

triple helix-forming

HER2 inhibition, 515

Oltipraz

aflatoxin B₁ biotransformation changes, rat
liver, 2306

lymphoma inhibition, 3395

Oncofetal genes: *see also* Genes

TA1/E16

expression, colon carcinoma, 5012

Oncogenes: *see also* Genes; Proto-oncogenes

activated

integrin signaling to NF- κ B blockade,
leukemic monocytic cells, 2302

c-*erbB*-2

quantitative estimation, breast cancer,
3823

functional aspects

Seventh Annual Pezcoller Symposium,
meeting report, 4282

Ha-ras

allele sequence variations, minisatellite
variant repeat PCR, 4773

HER2/*neu*

chemoresistance and, non-small cell lung
cancer, 206

inhibition by triple helix-forming oligonu-
cleotide, 515

H-ras1

promoter conformation alterations, NMU-
induced mammary carcinoma and preg-
nancy, 4927

K-ras

mutations, atypical alveolar hyperplasia,
2224

multiple endocrine neoplasia type 2 (*MEN*
2)

dominantly transforming *in vivo*, 4853

proto-oncogenes

expression, hamster kidney, 2616

ras

and Ara-C sensitivity, 5211

and topoisomerase II inhibitor sensitivity,
5211

-transfected cells, queuine modification,
589

ras^{Hs}

activation, retinoic acid receptor loss and,
4942

RET

dominantly transforming *in vivo*, 4853

mutations, inherited medullary thyroid
carcinoma, 1241

transformation

synergism with hypoxia, and vascular en-
dothelial growth factor modulation,
3437

Oncoproteins: *see also* Proteins

Bcr-abl

tyrosine kinase, inhibition by Bcr, 5120

p210 Bcr-Abl

IL-3 receptor interactions, 3426

Opioid receptors

δ

lung cancer, characterization, 1695

Opsonization

tumor cell

anti-galactose, 3069

Oral carcinoma

combination gene therapy, murine model,
1737

inhibition by flavonoids, rat, 4904

risk

smoking and, gender differences, 5192

Oral dysplastic lesions

chromosome 3p allelic imbalance, 1228

Oral mucosa

aflatoxin B₁-treated

oxidative DNA damage, 683

Oral rinses

telomerase activity, head and neck squamous
cell carcinoma, 5720

Ornithine decarboxylase

dominant-negative mutant

5838

transformation reversal, 5136

regulation

alternative splicing, 1742

transformed cells, 3265

Oscillations

chaotic, rat prostate cancer, 3682

Osteoblasts

human amniotic tumor growth-regulatory
effects, 633

Osteocalcin

promoter

toxic gene therapy, osteosarcoma, 4614

Osteosarcoma

malignancy

multidrug resistance and, 2434

osteocalcin promoter-based toxic gene ther-
apy, 4614

Otototoxicity

carboplatin-induced

thiosulfate rescue, 706

Ovarian carcinoma

advanced

p53 status and response to therapy, 689

apoptotic cells

CPP-32 activation, 5224

bcl-2 and p53 expression, 2178

bispecific mAb-based treatment

CD3-CD28 costimulation, 5443

BRCA1

185delAg mutations, Jewish women, 1250

germline mutations, Italian cancer fami-
lies, 5466

BRCA2

999del5 mutations, Icelandic patients,
3663

mutations, 2738

cell invasion

hypoxic, 1168

charged photoimmunoconjugates and, 5205

chemotherapy

combined with photodynamic therapy,
3980

fatty acid synthase inhibition, xenograft
model, 1189

chromosome 11q loss of heterozygosity, 741

chromosome 22q loss of heterozygosity, 729

cisplatin resistance, 556

phenotype expression, chromosome segre-
gation, 2256

deletions, minimal region, 5586

early

chromosome 17p13.3 allelic deletion, 606

engineered human CTMO1 biodistribution,
5179

epithelial

chromosome 11q23.3-q24.3 loss of het-
erozygosity, 950

intrapertitoneal photodynamic therapy, xe-
nograft murine model, 1075

IL-8 expression

Taxol-dependent activation, 1303

malignancy

second, 1565

p53 expression, 2178

p53 mutations, 556

sporadic

BRCA2 mutations, 3622

Ovarian teratocarcinoma

spontaneous

genetic traits, LT/Sv mice, 5047

Ovarian tumors

epithelial

borderline, microsatellite instability, 2501

surface, early chromosome 6q activity,
4487

growth regulation by heregulin, erbB2 ef-
fects, 1457

- radiosensitization by wild-type *p53* gene transfer, 4891
- Oxidants**
actin fragmentation
HSP27 phosphorylation-mediated resistance, 273
- Oxidative damage**
AFB₁-treated rat liver and human oral mucosal cells, 683
δ-aminolevulinic acid, 1786
benzene metabolites, 5172
H. pylori-infected gastric mucosa, 1279
8-hydroxyguanine, levels and repair activity, 2546
mitochondrial DNA repair, XPA cells, 1262
protective effects of dietary antioxidants against, lymphocytes, 1291
- Oxidative stress**
-induced cell death
HSP27 phosphorylation-mediated resistance, 273
photodynamic therapy-mediated
heat shock protein induction, 2355
- Oximetry**
gadopentetate dimeglumine dynamic MRI and electron paramagnetic resonance study
tumor blood perfusion and pO₂ after X-rays, 3344
- Oxygenation**
after radiation, human tumor xenografts, 964
reoxygenation
tumor parenchyma, murine breast cancer, 5522
soft tissue sarcoma
radiation therapy and hyperthermia effects, 5347
tumor
erythropoietin effects, 4728
and metastases, soft tissue sarcoma, 941
- Oxygen consumption**
DNA synthesis inhibition, DS cells, 2009
- Oxygen tension**
hyperthermia combined with carbogen and, 5590
interstitial pressure and, after radiation, 964
tumor blood perfusion and, after X-rays, 3344
- P**
- p15^{INK4B}**
inactivation by hypermethylation, 722
- p16^{CDKN2}**
methylation
and chromatin, gliomas, 2405
- p16^{INK4A}**
-induced G₁-2 block, bicistronic expression vector, 1719
- p16^{INK4a}**
expression, non-small cell lung tumors, 3415
- p53/56^{ba}**
activation by *bcr/abl*, myeloid cells, 3589
- p57^{KIP2}**
analysis
G401 Wilms' tumor assay, 1214
soft tissue sarcomas and Wilms' tumors, 1219
expression, Wilms' tumor, 5723
- p59^{hck}**
activation by *bcr/abl*, myeloid cells, 3589
- Paclitaxel: see also Taxol**
abnormal mitotic exit and apoptosis induction, HeLa cells, 816
combined with cremophor EL
pharmacokinetics, mice, 2112
ionizing radiation interactions, HeLa and SQ20B cells, 1842
- prodrug**
rat serum carboxylesterase-mediated activation, 1471
radiosensitization, head and neck squamous cell carcinoma, 5198
resistance mechanisms, sarcoma, 1091
- PAI: see Plasminogen activator inhibitor**
- PALA: see N-Phosphonacetyl-L-aspartate**
- Palytoxin**
stress-activated protein kinase/c-Jun N-terminal kinase activation, 637
- Pancreatic carcinoma**
angiogenesis expression, 2703
chromosome 7q allelic losses, 3808
chromosome 18q21.1 homozygous deletion map, 490
comparative genomic hybridization, 3803
DPC4 inactivation, 2527
KAI1 expression, 4876
metastasis
hyaluronate-independent, 3134
orthotopic xenografts, 5713
p16/MTS-1 alterations, 1137
PRGI, 2641
somatostatin receptor gene expression, 1823
sporadic
germline *BRCA2* mutations, 5360
- Pancreatic cell carcinoma**
p16, *MTAP*, and *IFN* deletion and chemoselectivity, 1083
- Pancreatic tumors**
chromosome 3p14.2 fragile site *FRA3B* breakpoints, 4347
- Papillary thyroid carcinoma**
CD44 mRNA splicing, 1037
c-erbB-3 and c-erbB-4 expression, 1184
- Papillomavirus**
-immortalized keratinocytes
cell cycle control, TNF-α and, 2452
- Parathyroid adenoma**
allelotype, 599
- Parathyroid hormone-related peptide**
antisense inhibition
and malignant pituitary tumor, 77
- Parathyroid hormone-related protein**
bone metastasis, lung cancer model, 4040
gene expression
and hypercalcemia, 1043
repression by p53 mutants, 4056
- Parenchyma**
tumor
reoxygenation, murine breast cancer, 5522
- α-Particles**
-emitting 5-[²¹¹At]astato-2'-deoxyuridine, 1204
- PD 098059**
invasion and urokinase expression inhibition, 5369
- PDECGF: see Platelet-derived endothelial cell growth factor**
- PDGF: see Platelet-derived growth factor**
- PECAM: see Platelet endothelial cell adhesion molecule**
- Peptides**
bone sialoprotein
cell adhesion inhibition, breast cancer, 1948
human papillomavirus-derived
interleukin 2 response, cervical pathology correlation, 3967
-induced calcium flux
modulation by neutral endopeptidase, 831
MAGE-1
-loaded antigen presenting cell-based vaccine, CTLp frequency enhancement, 2479
- MUC1**
synthetic vaccines, mice, 3315
parathyroid hormone-related
antisense inhibition, and malignant pituitary tumor, 77
particulate, antimelanoma cytotoxicity, 1210
synthetic
immunization, immunization against gp100, 4749
vasoactive intestinal
receptor, breast cancer, 3486
receptor, mesenchymal tumors, 1922
- Peripheral blood**
B lymphocytes
apoptosis, Mcl-1 expression and, 40
isolation of prostate-derived cells from, 4556
lymphocytes
benzo(a)pyrene diol epoxide-DNA adducts, cancer susceptibility markers, 3638
IL-2 production, human papillomavirus response, 3967
V(D)J recombinase-mediated *HPRT* mutations, children, 1405
mononuclear cells
mitomycin C-treated, DT-diaphorase transcript splicing and expression, 1731
SV40 early region and large T antigen, 4820
- Peripheral nerve sheath tumors**
malignant
genetic changes, comparative genomic hybridization, 4778
- Peroxide**
J558L plasmacytoma killing, mice, 87
- Peroxisome**
proliferators
growth regulation, 3257
Kupffer cell activation, 1
- Perspectives in Cancer Research**
DNA methylation errors, 2463
tumor-associated carbohydrate antigens, roles, 2237
tumor malignancy
glycosylation and sphingo(glyco)lipid metabolism, 5309
- Pesticides**
β-hexachlorocyclohexane
estrogenic action, breast cancer cells, 5403
- Pezcoller Symposium**
Seventh Annual, meeting report, 4282
- PGA: see Prostaglandin A**
- P-glycoprotein**
cytoplasmic, multidrug and chemosensitizer resistance, 5435
gene
transcriptional regulation, 2021
-mediated multidrug resistance
methods detection workshop, 3010
reversal by LY335979, 4171
protein kinase C interactions, MDR cells, 3490
- PG-M/Versican**
identification, 3902
- pH**
cellular gradient, tumor vs normal tissue, 1194
- 1,10-Phenanthroline**
tumor necrosis induction, 339
- Phenethyl isothiocyanate**
c-Jun N-terminal kinase 1 activation, 2954
- Phenolphthalein**
exposure
carcinogenic effects, experimental models, 4922
- Phenotypes**
cisplatin resistance

- expression, chromosome segregation, 2256
- dominant, melanoma, 3075
- genotype correlation, hereditary breast cancers, 3216
- invasive
- reversal by E-cadherin/catenin complex, HPV-transfected keratinocytes, 5285
- malignant
- suppression by chromosome 10, PPC-1 cells, 2157
- metabolic retinoic acid
- and lung cancer risk, 2692
- metastatic
- PDGF-B/*v-sis* and, T98G cells, 280
 - reversal by anti-CAPL (*mts1*) ribozyme, tumor cells, 5490
- mutator
- inter-Alu polymerase chain reaction, cancer cells, 2733
- neuroendocrine
- IA-2 marker, lung cancer cells, 2742
- replication error, cervical carcinoma, 1427
- reversal
- farnesyl transferase inhibitors, resistance, *ras*-transfected cells, 52626
 - retroviral transduction, malignant melanoma, 3186
 - thioredoxin mutant, breast cancer cells, 5765
- suppression
- chromosome 10, PPC-1 cells, 2157
 - recombinant fibronectin overexpression, fibrosarcoma, 4541
 - reversion by retroviral transduction, malignant melanoma, 3186
- transformed
- reversal by thioredoxin mutant, breast cancer cells, 5765
 - suppression by recombinant fibronectin overexpression, fibrosarcoma, 4541
- tumorigenic
- PDGF-B/*v-sis* and, T98G cells, 280
- 2-Phenylaminopyrimidine**
- derivative
- Abl protein-tyrosine kinase inhibition, 100
- Phlp: see 2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine**
- Phorbol ester**
- MUC18/MCAM regulation, 2218
- Phosphatidylinositol**
- specific phospholipase C
 - dietary fat types and amount effects, colon tumor promotion, 533
 - intestinal, fat effects, 2314
- Phosphatidylinositol 3 kinase**
- inhibitor wortmannin
 - radiosensitization, murine fibroblasts and human tumor cells, 246
- Phosphohexose isomerase polypeptide**
- tumor cell autocrine motility factor, 2960
- Phospholipase A₂**
- colonic mucosal
 - dietary fat types and amount effects, colon tumor promotion, 533 - secretory genes
 - mutations, attenuated adenomatous polypoidosis coli, 955
- Phospholipase C**
- phosphatidylinositol-specific
 - dietary fat types and amount effects, colon tumor promotion, 533
 - intestinal, fat effects, 2314
- N-Phosphonacetyl-L-aspartate**
- p53 induction, 3659
- Phosphoproteins: see also Proteins**
- BRCA1
 - expression and phosphorylation, 3168
 - p18
 - inhibition by antisense RNA, leukemic cells, 1445
- Phosphorus magnetic resonance spectroscopy**
- proton-decoupled
 - soft tissue sarcoma *in vivo* and *in vitro*, 2964
- Phosphorylase**
- thymidine
 - expression, bladder cancers, 4799
- Phosphorylation**
- bcl-2
 - taxol-induced, prostate cancer, 1253
 - taxol-induced, Raf-1 requirement, 1851 - epidermal growth factor receptor
 - MAP kinase signal transduction stimulation by asbestos after, 5334 - heat shock protein 27
 - mediated resistance to actin fragmentation by oxidants, 273 - lymphokine-activated killer proteins, *M_r* 65,000, 127
 - platelet endothelial cell adhesion molecule-2 and TNF α -induced vascular leakage, 3211
 - protein tyrosine
 - protease inhibitor effects, 3909 - p70^{src}
 - inhibition by rapamycin, small cell lung cancer cells, 3895 - topoisomerase II α
 - erythroid differentiation commitment, mouse erythroleukemia cells, 4192
- Photodynamic therapy**
- δ -aminolevulinic and 1,10-phenanthroline tumor necrosis induction, 339
 - combined with *N*-(2-hydroxypropyl)methacrylamide copolymer-bound adriamycin/Mce₆, ovarian carcinoma, 3980
- efficacy
- neutrophils and, 2908
- intraperitoneal, epithelial ovarian carcinoma, 1075
- mediated inactivation
 - leukemia cells, hemin effects, 4636 - mediated oxidative stress
 - heat shock protein induction, 2355
- tumor response
- lymphocytes, mouse EMT6 tumors, 5647
 - potentiation by local GM-CSF treatment, 3281
- Photoimmunoconjugates**
- charged
 - ovarian cancer cell interactions, 5205
- Photokilling**
- leukemia cells
 - hemin effects, 4636
- Photosensitization**
- heat shock protein induction, 2355
- Phytochemicals**
- indole-3-carbinol
 - multidrug resistance reversal, 574
- Piroxicam**
- chemoprevention of spontaneous intestinal adenoma, *Apc*^{Min} mouse, 710
- Pituitary adenylate cyclase activating polypeptide**
- inducible early-response genes
 - PRG1*, pancreatic carcinoma cells, 2641
- Pituitary tumors**
- malignant
 - parathyroid hormone-related peptide inhibition and, rat, 77 - p16 loss, 2493
- PLA: see Phospholipase A**
- Plasma**
- irinotecan metabolite, identification and properties, 3689
- Plasmacytoma**
- J558L
 - peroxide killing, mice, 87
- Plasminogen**
- angiotensin converting enzyme, prostate carcinoma cells, 4887
- Plasminogen activator inhibitor 1**
- mRNA expression
 - del(7)(q22) and, uterine leiomyomas, 3123
- L-Plastin**
- phosphorylated forms, 138
- Platelet-activating factor**
- tumor metastasis augmentation, 2662
- Platelet-derived endothelial cell growth factor**
- expression, bladder cancers, 4799
- Platelet-derived growth factor α**
- receptor
 - expression, 17p loss of heterozygosity and, 164
- Platelet-derived growth factor B/*v-sis***
- and tumorigenic and metastatic phenotype, T98G cells, 280
- Platelet endothelial cell adhesion molecule-2**
- phosphorylation
 - and TNF α -induced vascular leakage, 3211
- Platinum**
- drug resistance
 - DNA mismatch repair and, 4881
- Pluronic L61**
- hypersensitizing effects, MDR cells, 3626
- PMI-retinoic acid receptor α**
- degradation by all-*trans*-retinoic acid, acute promyelocytic leukemia, 2945
- pMV7-4E cells**
- ornithine decarboxylase regulation, 3265
- pO₂: see Oxygen tension**
- Point mutations**
- O⁶-alkylguanine-DNA alkyltransferase and O⁶-benzylguanine sensitization to BCNU killing, 1578
 - topoisomerase II α , small cell lung cancer, 1232
- Poly(ADP-ribosylation)**
- inhibition
 - gene amplification potentiation, SV40-transformed Chinese hamster cells, 2715
- Polyglutamation**
- benzoquinazoline thymidylate synthase inhibitors, 3301
- Polymerase chain reaction**
- fluorescent
 - microsatellite length analysis, 2688 - inter-Alu
 - mutator phenotype detection, cancer cells, 2733 - minisatellite variant repeat
 - Ha-*ras* allele sequence variations, 4773 - quantitative competitive
 - ERCC-2 expression and chloroethylnitrosourea resistance, tumor cells, 2475
- Polymorphic enzymes**
- bladder cancer risk modulation, 3915
- Polymorphisms**
- CYP1A1*
 - C4887A, lung cancer and, 4965
 - lung cancer risk and, African-Americans, 4275
 - non-small cell lung cancer, 3725
 - and p53 mutations, lung cancer, 72 - GSTM1*, non-small cell lung carcinoma, 3725
 - GSTM3*, and cutaneous basal cell carcinoma risk, 1974
 - methylenetetrahydrofolate reductase

- and colorectal cancer risk, 4862
vitamin D receptor gene, prostate cancer, 4108
- Polyoxime chemistry**
trivalent antigen-binding construct preparation, 809
- Polypeptide**
neuroleukin/phosphohexose isomerase tumor cell autocrine motility factor, 2960
pituitary adenylate cyclase activating -inducible early-response gene *PRG1*, pancreatic carcinoma cells, 2641
- Polyploidization**
cell growth rate and, HL60 cells, 5513
premature metaphase exit, staurosporine, 3551
- Posttransplant lymphoproliferative disorders**
microsatellite analysis, 4378
- Potassium oxonate**
1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate antitumor activity, colon carcinoma, 2602
- pp65a protein**
characterization, 138
- pp65b protein**
characterization, 138
- PPC-1 cells**
malignant phenotype
suppression by chromosome 10, 2157
- p18 phosphoprotein**
expression
inhibition by antisense RNA, leukemic cells, 1445
- p15 protein**
gene deletion
sporadic melanoma, 5023
- p16 protein**
accumulation
UV irradiation effects, 2510
gene alterations
glioblastoma, 150
pancreatic cancer, 1137
gene deletion
and chemoselectivity, pancreatic cell carcinoma, 1083
pituitary tumors, 2493
sporadic melanoma, 5023
gene hypermethylation, nasopharyngeal carcinoma, 2721
gene inactivation
advanced-stage esophageal squamous cell carcinoma, 3875
chromosome translocation, B-cell acute lymphoblastic leukemia, 848
head and neck squamous cell carcinoma, 3630
gene mutations
germline, familial malignant melanoma, 2497
growth suppression, head and neck squamous cell carcinoma cells, 4119
-mediated cell cycle arrest
reversible, protection from chemotherapy, 3199
p16-cyclin D/Cdk4-pRb pathway, melanoma, 5475
senescence and immortalization, human uroepithelial cells, 2886
status, non-small cell lung cancer, 5557
- p16 β protein**
growth suppression, head and neck squamous cell carcinoma cells, 4119
- p18 protein**
variant, BT-20 breast cancer cells, 4586
- p21 protein**
and prostaglandin A₂-mediated cellular arrest and death, 475
- p21^{WAF1/CIP1} protein**
posttranscriptional regulation, breast carcinoma cells, 5055
repair defect, -/- cells, 2250
transcriptional activation via mitogen-activated protein kinase, 31
- p27 protein**
and 1,25-dihydroxyvitamin D₃-induced G₁-S block, HL60 cells, 264
- p27^{Kip1} protein**
expression
cyclin E overexpression and, mouse mammary cells, 1389
-mediated G₁ arrest, prostate cancer cells, 3666
mutations, breast cancer, 2400
- p34^{cdc2} protein**
activation
interleukin 1 β -converting enzyme-mediated, Fas-induced apoptosis, 4551
- p53 protein**
accumulation
and response to therapy, advanced ovarian carcinoma, 689
adenovirus-mediated gene transfer
generalized apoptosis, glioma cells, 694
antibodies
circulating, esophageal cancer, 4917
cell growth regulatory gene induction, 5384
c-myc interactions, 1991
-dependent apoptosis
myeloid cells, 2148
suppression by *bfl-1*, 3879
-dependent cell cycle arrests, *scid* mouse fibroblasts, 2940
DNA repair domain, 3324
expression
modulation by rIFN- α 2a, cisplatin-resistant melanoma cells, 2522
ovarian carcinoma, 2178
function
drug-resistant tumor cells, 1374
hypersensitive testicular tumors, 1834
gene alterations, prostate cancers, 3814
gene deletions and insertions, 2130
transgenic mouse skin carcinoma, 4413
gene mutations
bladder tumors, arylamine-exposed workers, 294
chemoresistance and, non-small cell lung cancer, 206
cisplatin resistance and, ovarian carcinoma cells, 556
CYP1A1 polymorphisms and, lung cancer, 72
gain-of-function, and T-cell receptor instability postirradiation, 3862
mammary epithelial cell immortalization, 3129
PTHrP repression, squamous cell carcinoma cells, 4056
transcription, Burkitt's lymphoma cells, 1648
type, and soft tissue sarcoma prognosis, 4134
IGF-II P3 promoter regulation, 1367
inactivation
and chemotherapy sensitivity, 892
-independent apoptosis
mammary tumor progression, 2998
myeloid cells, 2148
induction
ionizing radiation vs PALA, 3659
insulin receptor promoter repression, breast cancer, 2781
manganese superoxide dismutase expression and, radiation therapy, 2771
- null cells
ultraviolet light sensitivity, 5365
pathway abnormality after ionizing radiation, melanoma, 840
proteasome-mediated degradation, 2649
and radiosensitivity, glioblastoma, 500
transcriptional activation
blockade by wortmannin, 246
wild-type
adenovirus-mediated gene transfer, cervical cancer, 3047
and BCNU resistance, mouse astrocytes, 2748
dominant, 158
gene transfer, ovarian tumor radiosensitization, 4891
MGMT transcription inhibition, 2029
p53 pathway abnormality after ionizing radiation, melanoma, 840
and thyroid peroxidase reexpression, thyroid carcinoma cells, 765
- p70^{erk} protein**
phosphorylation
inhibition by rapamycin, small cell lung cancer cells, 3895
- p114 protein**
matrix attachment region-binding activity, breast carcinoma, 457
- p120^{cas} protein**
isoforms, tumor cells, 2633
prognostic value, bladder tumors, 4154
- p130 protein**
pRb2/p130 interactions with cyclins, functional analysis, 2003
- p210^{bcr/abl} protein**
IL-3 receptor interactions, 3426
Src kinase activation, myeloid cells, 3589
- pRb: see Retinoblastoma protein**
- Pregnancy**
-dependent mammary tumor growth
IGF-II overexpression and, 3651
H-ras1 promoter conformation alterations, 4927
- PRG1**
pancreatic carcinoma cells, 2641
- Primitive neuroectodermal tumors**
insulin-like growth factor I receptor-mediated circuit, 4570
- Procarcinogens**
chemical
activation by human P450 1B1, 2979
- Prodrugs: see also specific drugs**
adenovirus-mediated gene therapy
CEA-producing gastric carcinoma, 1341
antibody-directed enzyme prodrug therapy ZD2767 system, colorectal tumor xenografts, 3287
gene-directed enzyme prodrug therapy
mustard prodrug/carboxypeptidase G2 combination, 4728
paclitaxel and camptothecin
rat serum carboxylesterase-mediated activation, 1471
- Proliferating cell nuclear antigen**
regulation by androgens, LNCaP cells, 1539
- Proliferative breast disease**
FHIT and *PTPRG* deletions, 4871
- 1,N²-Propanodeoxyguanosine**
adducts, tissue DNA, 452
- Proprotein convertase**
new gene (*LPC*)
location, lymphoma, 448
- Prostaglandin A₁**
-induced thermotolerance
modulation by quercetin, leukemic cells, 210

- Prostaglandin A₂**
-mediated cellular arrest and death
p21 and, 475
- Prostaglandin H synthase 2:** *see* **Cyclooxygenase-2**
- Δ¹²-Prostaglandin J₂**
cytotoxicity, malignancies, 3866
- Prostate**
cell growth inhibition by novel androgen synthesis inhibitors, 4956
-derived cells
isolation from peripheral blood, 4556
differentially expressed genes, 3634
epithelial cells
apoptosis induction by TGF-β1, 5146
radiation-induced neoplastic transformation, 5
malignant tissue
telomerase activity, 218
- Prostate adenocarcinoma**
allelic imbalance and microsatellite instability, 4475
- Prostate carcinoma**
advanced
endothelin-1 production and endothelin B receptor expression, 663
androgen-dependent and relapsed, 3042
androgen-independent
genetic alterations, comparative genomic hybridization and allelotyping, 3091
arginine-rich protein gene mutations, 5576
chaotic oscillations, cultured rat cells, 3682
chemoprevention
linomide, rodents, 3404
chromosome 6q deletions, 4150
chromosome 8p12-21 allelic loss, 2411
chromosome 10p allelic loss, 2263
chromosome 10q allelic loss, 2263
chromosome 13q allelic loss, 1142
cyclin expression, 4159
differentially expressed genes, 3634
DU145 cells
p27^{Kip1}-mediated G₁ arrest, 3666
DU147 cells
β-L-(-)-dioxolane-cytidine uptake and metabolism, 4180
hyaluronidase levels, 651
αIIbβ3 integrin expression, 5071
KAI1 dysregulation, 4387
LNCaP cells
metastatic, apoptosis resistance, 5594
proliferating cell nuclear antigen regulation by androgens, 1539
tpc/hpr fusion transcript, 728
metastasis
apoptosis resistance, LNCaP cells, 5594
genetic alterations, comparative genomic hybridization and allelotyping, 3091
TGF-β1 effects, 3359
TRAMP model, 4096
p53 alterations, 3814
plasminogen-angiotensin converting enzyme, 4887
PPC-1 cells
malignant phenotype suppression by chromosome 10, 2157
prevention
investigational approaches and opportunities, 5547
R-3327 cells
invasion and metastasis inhibition by PKC-ζ, 4137
taxol-induced bcl-2 phosphorylation and apoptosis, 1253
TGF-β receptor-1 genetic change, 44
TGF-β1 insensitivity, 44
tubulin isotype levels, 2584
- vitamin D receptor gene polymorphisms, 4108
- Prostatic intraepithelial neoplasia**
representative cDNA library, construction, 5380
- Protease**
inhibitors
protein tyrosine phosphorylation effects, 3909
serine
-like gene, down-regulated in breast cancer, 3371
Yama
Ara-C-induced, inhibition by Bcl-2 or Bcl-x_L, 4743
Fas-mediated apoptosis effects, 1713
- Proteinase**
C3-cleaving, metastatic melanoma, 254
- Protein-degrading factor**
and cachexia-inducing tumors, 1256
- Protein kinase C**
activators
bryostatin 1, pharmacokinetics, 802
breast carcinoma cell adhesion regulation, 2206
colonic mucosal
fat effects, 2314
inhibition
apoptosis and ceramide production induction, 2711
P-glycoprotein interactions, MDR cells, 3490
- Protein kinase C-α**
antisense oligonucleotide inhibitor
tumor growth inhibition, mice, 3499
- Protein kinase C-ζ**
invasion and metastasis inhibition, R-3327 cells, 4137
- Protein kinases**
DNA-activated
-deficient mouse fibroblasts, p53-dependent cell cycle arrests, 2940
mitogen-activated
p21^{WAF1/CIP1} transcriptional activation, 31
stress-activated
activation by palytoxin, 637
- Proteins:** *see also* **Oncoproteins; Phosphoproteins**
arginine-rich
gene mutations, cancers, 5576
Bak
expression, *in vivo* patterns, 2849
bcl-2
apoptosis inhibition, epithelial tumor cells, 4006
apoptosis inhibition, HL-60 cells, 4743
Ara-C-induced CPP32/Yama inhibition, HL-60 cells, 4743
enediye-induced apoptosis potentiation, 1199
expression, ovarian carcinoma, 2178
inhibition by KH 1060 and 9-*cis*-retinoic acid, HL-60 cells, 495
nonconserved region deletion, 2506
taxol-induced apoptosis and phosphorylation, prostate cancer, 1253
taxol-induced apoptosis and phosphorylation, Raf-1 requirement, 1851
bcl-X
expression, colorectal adenocarcinoma, 2422
bcl-x_L
apoptosis and Ara-C-induced CPP32/Yama inhibition, HL-60 cells, 4743
Bcl-x_S
apoptosis enhancement, neuroblastoma cells, 5734
- Bcr-abl
tyrosine kinase, inhibition by Bcr, 5120
biomarkers
loss, bladder transitional cell carcinomas, 4782
- BRCA1**
expression and phosphorylation, 3168
truncated, hereditary breast cancers, 3216
- CAAT/enhancer binding**
GADD153/CHOP effects, myeloid cells, 3250
- CCAAT/enhancer-binding**
tumor growth inhibition, 1063
- CCAAT/enhancer-binding, β**
expression, mammary neoplasia, 4382
- cell cycle-regulated**
expression, prostate cancer, 4159
- c-erbB-3 and c-erbB-4**
expression, papillary thyroid carcinomas, 1184
- chimeric Lym-1/IL-2**, 4998
- c-Jun**
expression, lung carcinogenesis, 305
vs v-Jun, 4229
- covalent binding**
proximate intermediate 3,4-Dihydroxytamoxifen, 1283
- Fas-nuclear receptor fusion**
lipophilic hormone-induced apoptosis, 4164
- fatty acid binding, adipocyte-type**
loss, bladder transitional cell carcinomas, 4782
- formamidopyrimidine-DNA glycosylase**
E. coli, thiopeta-induced DNA damage resistance in cells expressing, 3721
- fusion**
lymphotoxin, growth inhibition, melanoma, 1707
- GADD153/CHOP**
CAAT/enhancer binding protein activities and apoptosis effects, myeloid cells, 3250
- glycoprotein 40**
bispecific 1A10 antibody, binding characteristics and antitumor properties, 113
- heat shock**
induction by photosensitization, 2355
- heat shock, 27**
overexpression, testis tumor cells, 2446
- high mobility group, 1**
expression, hepatocellular carcinoma, 5330
- high mobility group HMGI(Y)**
expression, colorectal carcinomas, 1896
- human endogenous retrovirus-K**
expression, antibody reaction, 4362
- human papillomavirus 16 E6**
transformation, IGF-1R and, 5087
- human papillomavirus 16 E7**
transformation, IGF-1R and, 5087
- ubiquitin-dependent Rb degradation induction**, 4620
- insulin-like growth factor binding, 3**
retinoic acid- and TGF-β2-induced growth inhibition mediation, breast cancer cells, 1545
- retinoid X receptor-specific retinoids and, ectocervical epithelial cells**, 1794
- interferon β-inducible**
elevation, ataxia telangiectasia cells, 443
- latent membrane 1**
Mcl-1 upregulation, B-cells, 4610
- liver-enriched inhibiting**
expression, mammary neoplasia, 4382
- low-density lipoprotein receptor-related**
expression, cutaneous melanoma, 1432

low molecular weight
deficiencies, renal cell carcinoma, 1756
lymphokine-activated killer, *M*₁, 65,000
phosphorylation induction by tumor target
binding, 127
pp65a and pp65b, characterization, 138
Mac-2-binding
galectin-3 interactions, 4530
mammaglobin
expression, breast cancer, 860
Mcl-1
B-cell levels, upregulation by latent mem-
brane protein 1, 4610
mitogen-activated
kinase, p21WAF1/CIP1 transcriptional
activation, 31
kinase activation, and substance P-induced
mitogenesis, 4983
kinase activation, butylated hydroxytolu-
ene hydroperoxide, 3480
kinase activation, chromium, 2045
kinase kinase inhibitor PD 098059, inva-
sion and urokinase expression inhibi-
tion, 5369
kinase signal transduction stimulation by
asbestos, 5334
kinase stimulation, small cell lung cancer
cells, 5758
motility-related, 1
prognostic factor, breast cancer, 1244
multidrug resistance
gene expression, colorectal cancers, 3642
gene knockout, double, 5351
-mediated conjugate export, substrates,
988
-specific monoclonal antibody QCRL-1,
epitope mapping, 3307
Myc
-overexpressing small cell lung cancer
cells, gene therapy, 354
nuclear matrix
bladder cancer-associated, 1690
p16
p16-cyclin D/Cdk4-pRb pathway, mela-
noma, 5475
status, non-small cell lung cancer, 5557
p16^{INK4a}
expression, non-small cell lung tumors,
3415
p21
and PGA₂-mediated cellular arrest and
death, 475
p21^{WAF1/CIP1}
posttranscriptional regulation, breast carci-
noma cells, 5055
p27
and 1,25-dihydroxyvitamin D₃-induced
G₁-S block, HL60 cells, 264
p27^{Kip1}
cyclin E overexpression and, mouse mam-
mary cells, 1389
-mediated G₁ arrest, prostate cancer cells,
3666
mutations, breast cancer, 2400
p34^{cdc2}
interleukin 1 β -converting enzyme-medi-
ated activation, Fas-induced apoptosis,
4551
p53
accumulation, and response to therapy,
advanced ovarian carcinoma, 689
c-myc interactions, 1991
expression, ovarian carcinoma, 2178
function, drug-resistant tumor cells, 1374
functional, hypersensitive testicular tu-
mors, 1834
IGF-II P3 promoter regulation, 1367

-null cells, ultraviolet light sensitivity,
5365
proteasome-mediated degradation, 2649
p57^{KIP2}
soft tissue sarcoma and Wilms' tumors,
1219
p114
matrix attachment region-binding activity,
breast carcinoma, 457
p120^{cas}
isoforms, tumor cells, 2633
prognostic value, bladder tumors, 4154
p130
pRb2/p130 interactions with cyclins, func-
tional analysis, 2003
p210 Bcr-Abl
IL-3 receptor interactions, 3426
parathyroid hormone-related
bone metastasis, lung cancer model, 4040
gene expression, and hypercalcemia, 1043
repression by p53 mutants, 4056
psoriasis
expression, breast carcinoma, 4606
receptor-associated
expression, cutaneous melanoma, 1432
Rep78
Sp1 binding, 5299
retinoblastoma
cleavage by ICE-like protease, apoptosis,
438
gene alterations, glioblastoma, 150
p16-cyclin D/Cdk4-pRb pathway, mela-
noma, 5475
pRb2/p130 interactions with cyclins, func-
tional analysis, 2003
status, non-small cell lung cancer, 5557
ubiquitin-dependent degradation, 4620
TAP1 and TAP2
cell cycle-dependent expression, breast
cancer cells, 4358
ubiquitin-conjugated, colorectal carcinomas,
2752
VBP-1
VHL gene product binding, 2881
vitamin D₃-binding
deglycosylation, and immunosuppression,
2827
v-Jun vs c-Jun, 4229
von Hippel-Lindau
VEGF reversion, renal carcinoma cells,
2299
wild-type p53
and BCNU resistance, mouse astrocytes,
2748
dominant, 158
MGMT transcription inhibition, 2029
and thyroid peroxidase reexpression, thy-
roid carcinoma cells, 765
X, hepatitis B virus
IGF-I receptor gene activation, 3831
Y box-binding YB-1
and sensitivity to DNA-damaging agents,
4224
Zic
expression, cerebellar granule cells and
medulloblastoma, 377
Protein tyrosine
phosphorylation
protease inhibitor effects, 3909
Protein-tyrosine kinase
Abl
inhibition by 2-phenylaminopyrimidine
derivative, 100
Protein tyrosine phosphatase
DEP-1
expression, breast cancer cells, 4236
transmembrane IA-2

neuroendocrine marker, lung cancer cells,
2742
Proteoglycans
chondroitin sulfate
PG-M/Versican, identification, 3902
Protoberberine alkaloids
coralyne
topoisomerase I cytotoxic target, 2795
**Proton-decoupled phosphorus magnetic re-
sonance spectroscopy**
soft tissue sarcoma *in vivo* and *in vitro*,
2964
**Proton nuclear magnetic resonance spectro-
scopy**
MDR K562 cells, 3461
Proto-oncogenes: see also Genes; Oncogenes
c-erbB-2
quantitative estimation, breast cancer,
3823
c-myc
p53 interactions, 1991
expression, hamster kidney, 2616
Ha-ras
allele sequence variations, minisatellite
variant repeat PCR, 4773
RET
dominantly transforming *in vivo*, 4853
mutations, inherited medullary thyroid
carcinoma, 1241
mutations, medullary thyroid carcinoma,
2167
Pseudomonas putida
L-methioninase
gene cloning and characterization, 2116
Psoriasis
expression, breast carcinoma, 4606
Psychoneuroimmunology
Fifteenth Sapporo Cancer Seminar, meeting
report, 4278
PTC
mutations
initial screening, bladder cancer, 5039
PTCH
mutations
basal cell carcinoma and Gorlin syn-
drome, 4562
nevroid basal cell carcinoma syndrome,
4599
**PTHrP: see Parathyroid hormone-related
protein**
PTPRG
deletions, proliferative breast disease,
4871

Q

QCRL-1
epitope mapping, 3307
Quantitative ion imaging
boron neutron capture therapy, brain tumor
model, 4302
Quercetin
oral carcinogenesis inhibition, rat, 4904
prostaglandin A₁-induced thermotolerance
modulation, leukemic cells, 210
Quinine
modification, *ras*-transfected cells, 589

R

Radiation
apoptosis
oligodendrocytes, adult rat spinal cord,
5417
DNA damage
flow cytometry, glioma cells, 154
repair inhibition by nicotinamide, SCCVII
murine tumors, 2801

- γ
p53 pathway abnormality after, melanoma, 840
- I Gy
and mitotic inducers, HeLa cells, 2268
-inducible glycosylated early-response gene, identification and characterization, 1498
interstitial pressure and pO₂ after, human tumor xenografts, 964
ionizing
nuclear signaling, 3617
p53 induction, 3659
taxoid interactions, HeLa and SQ20B cells, 1842
neoplastic transformation, prostate epithelial cells, 5
resistance
2-nitroimidazole and, 9L s.c. tumors, 405
synergy with Δ^{12} -prostaglandin I₂, malignancies, 3866
tumor hypoxia
reduction by nicotinamide, SCCVII murine tumors, 2801
ultraviolet
-induced apoptosis, inhibition by tumor promoters, rat hepatocytes, 1272
p16 accumulation effects, 2510
tumorigenesis, dendritic epidermal T lymphocytes and, 2607
- X-ray
-induced cell adhesion molecules, 5150
postmitotic apoptosis after, rec-myc cells, 4116
T-cell receptor instability after, increase by p53 mutants, 3862
tumor blood perfusion and pO₂ after, 3344
- Radicals**
production
and tumor size, 5741
- Radioimmunoconjugates**
metabolism and retention by cancer cells, 2123
- Radioimmunodetection**
carcinoembryonic antigen-expressing tumors, 1805
- Radioimmunotherapy**
carcinoembryonic antigen-expressing tumors, 1805
combined with tumor blood flow-modifying agents, colorectal xenografts, 3293
- Radioiodination**
monoclonal antibody, 4970
- Radiosensitivity**
apoptosis and, ataxia telangiectasia, 1400
p53 and, glioblastoma cells, 500
- Radiosensitization**
fluoropyrimidine-mediated
and cyclin E-dependent kinase, 3203
FTI-277, H-ras-transformed rat embryo fibroblasts, 1727
hyperthermia combined with carbogen breathing, 5590
paclitaxel, head and neck squamous cell carcinoma, 5198
wild-type p53 gene transfer, ovarian tumors, 4891
wortmannin, murine fibroblasts and human tumor cells, 246
- Radiotherapy**
combined with hyperthermia, soft tissue sarcoma, 5347
external beam
local chemotherapy and, metastatic brain tumor models, 5217
genetic
tumor vessel targeting, 4311
- manganese superoxide dismutase expression, 2771
13-*cis*-retinoic acid/ α -2a-IFN, head and neck squamous cell carcinoma, 2277
- Raf-1**
activation
Ral GDP dissociation stimulator like Ras-interacting domain and, NIH3T3 cells, 2387
signal transduction pathway
taxol-induced apoptosis and phosphorylation, bcl-2, 1851
- Ral GDP dissociation stimulator like Ras-interacting domain**
and transformation, NIH3T3 cells, 2387
- Rapamycin**
p70^{s6k} phosphorylation inhibition, small cell lung cancer cells, 3895
- ras**
and Ara-C sensitivity, 5211
fibroblasts
migration, α 6 β 1-integrin and, 1682
-interacting domain, Ral GDP dissociation stimulator like
and transformation, NIH3T3 cells, 2387
and topoisomerase II inhibitor sensitivity, 5211
-transfected cells
queuine modification, 589
-transformed cells
resistance to farnesyl transferase inhibitors, 52626
- RAW117 cells**
liver metastasis
integrin $\alpha_v\beta_3$, murine lymphoma, 3103
- Rb: see Retinoblastoma protein**
- R-3327 cells**
invasion and metastasis inhibition by PKC- ζ , 4137
- RD: see Rhabdomyosarcoma**
- Reaction-diffusion model**
invasion, 5745
- Receptor-associated protein**
expression, cutaneous melanoma, 1432
- Receptors**
APO-1
-induced apoptosis, interleukin 1 β -converting enzyme-mediated p34^{cdc2} activation, 4551
endothelin B
expression, advanced prostate cancer, 663
epidermal growth factor
anti-EGFR mAb 225, p27^{Kip1} upregulation, prostate cancer cells, 3666
antisense transfection, rhabdomyosarcoma, 3898
downregulation by E-cadherin/catenin complex, HPV-transfected keratinocytes, 5285
mutant, tumorigenicity enhancement, 5079
phosphorylation, MAP kinase signal transduction stimulation by asbestos after, 5334
quantitative estimation, breast cancer, 3823
truncated, tyrphostin AG 1478 selectivity, 3859
erbB, breast cancer cells, 899
estrogen
exon 5 variant, effects in MCF-7 cells, 1556
gene methylation, hematopoietic neoplasms, 973
methylation, lung tumors, 3655
regulation, breast cancer cells, 2321
types, and response to antiestrogen therapy, 3883
- variant mRNAs, breast cancer, 4324
glucocorticoid, small cell lung carcinoma cells, 3276
gonadotropin-releasing hormone expression, endometrial carcinoma, 2059
growth hormone
mRNA regulation, liver, 2949
- insulin
promoter repression by p53, breast cancer, 2781
substrate 1, protective effects against TGF- β 1-induced apoptosis, 3391
- insulin-like growth factor I
antisense, adenovirus expressing, antitumor effects, 3038
antisense, and mesothelioma, 4044
apoptosis and neuroblastoma tumorigenesis effects, 4522
dominant negative, 4013
gene activation by hepatitis B virus X protein, 3831
gene expression, hepatocellular carcinoma cells, 3831
Grb10 substrate, 3165
-mediated circuit, Ewing's sarcoma and primitive neuroectodermal tumors, 4570
overexpression, cervical carcinoma, 1761
and transformation by HPV-16 E6 and E7, 5087
- interleukin 2
expression, hematopoietic cells, 2590
interleukin 3
p210 Bcr-Abl interactions, 3426
interleukin 6
superantagonists, myeloma cell apoptosis induction, 4213
low-density lipoprotein
-related protein expression, cutaneous melanoma, 1432
- α_2 -**macroglobulin**
expression, cutaneous melanoma, 1432
macrophage colony-stimulating factor
invasion and clonogenic growth stimulation, 5704
- nuclear
Fas fusion protein, lipophilic hormone-induced apoptosis, 4164
platelet-derived growth factor α
expression, 17p loss of heterozygosity and, 164
- retinoic acid
loss, mouse skin tumors, 4942
-specific retinoids, and IGFBP-3 levels, 1794
- retinoic acid, α
human, gene regulation, 5246
PML-, degradation by all-*trans*-retinoic acid, acute promyelocytic leukemia, 2945
- retinoic acid, γ
and cell growth inhibition by retinoids and interferons, breast cancer, 1571
- retinoid
-mediated gene expression, regulation by 4-HPR vs retinoic acid, breast cancer cells, 1056
- retinoid X
-specific retinoids, and insulin-like growth factor binding protein-3, 1794
- somatostatin
mesenchymal tumors, 1922
scintigraphy, carcinoid tumors, 2561
sst2 gene expression, pancreatic and colorectal cancer, 1823
subtype 2 mRNA, scintigraphy vs *in situ* hybridization, 2561
substance P

- mitogenic, astrocytic cells, 4983
- T cell**
- instability postirradiation, increase by *p53* mutants, 3862
 - repertoire, neuroblastoma, 362
- transferrin**
- bispecific 1A10 antibody, binding characteristics and antitumor properties, 113
- transforming growth factor β , type I**
- genetic change, prostate cancer cells, 44
- transforming growth factor β , type II**
- gene mutations, hereditary nonpolyposis colorectal cancers, 4595
 - gene mutations, sporadic cancer, 5620
 - gene promoter mutations, 4831
- urokinase**
- antagonists, tumor and angiogenesis inhibition, 2428
- vascular endothelial growth factor**
- expression, breast cancer, 2013
- vasoactive intestinal peptide**
- breast cancer, 3486
 - mesenchymal tumors, 1922
- vitamin D**
- gene polymorphisms, prostate cancer, 4108
- rec-myc cells**
- postmitotic apoptosis after X-irradiation, 4116
- Recombinase V(D)J**
- mediated *HPRT* mutations, peripheral blood lymphocytes of children, 1405
- Refractory carcinoma**
- bladder
 - EGF-, rat, 2666 - cytostatic calcium influx inhibitor, 569
- Renal carcinoma**
- inhibition by IL-12 cDNA injection, murine model, 3399
- Renal cell carcinoma**
- advanced
 - human leukocyte antigen loss of allele expression, 826 - cadherin expression, 3234
 - chromophobe
 - loss of heterozygosity pattern, 2927 - comparative genomic hybridization, 27
 - disialosyl galactosylgloboside adhesion molecules, 1932
 - malignant progression by FGF-2 transfection, mouse, 2440
 - transporter associated with antigen processing and low molecular weight protein deficiencies, 1756
 - VEGF expression
 - reversion by von Hippel-Lindau protein, 2299
- Renal collecting duct carcinoma**
- chromosome 1q high-density mapping, 5044
- Renal tumors**
- distal nephron, microsatellite allelotyping, 1892
- Reoxygenation**
- tumor parenchyma, murine breast cancer, 5522
- Rep78**
- Sp1 binding, 5299
- Replication**
- deficient adenovirus
 - modified retinoblastoma gene therapy, 2245
- Replication errors**
- phenotypes, cervical carcinoma, 1427
 - semiautomated assessment, 3331
- Resistance: see also Drug resistance; Multidrug resistance**
- apoptosis
 - HL-60 cell variant, isolation and characterization, 1621
 - metastatic LNCaP cells, 5594
- O⁶-benzylguanine*, 5571
- 1,3-bis(2-chloroethyl)-1-nitrosourea
- mismatch repair mutations and, 5375
 - wild-type *p53* and, mouse astrocytes, 2748
- bleomycin**
- protective effects against bleomycin-induced pulmonary fibrosis, *Sh ble* transgenic mice, 5659
- camptothecin**
- independent of topoisomerase I, 345
 - and topoisomerase I expression, epidermoid cancer cells, 2348
- chemosensitizers**
- cytoplasmic P-glycoprotein and, 5435
- chloroethylnitrosourea**
- ERCC-2* expression and, tumor cells, 2475
- cisplatin**
- acquired, DNA mismatch repair loss, 3087
 - human canalicular multispecific organic anion transporter and, 4124
 - phenotype expression, chromosome segregation, 2256
 - p53* modulation by rIFN- α 2a and, melanoma cells, 2522
 - and *p53* mutation, ovarian carcinoma cells, 556
- drug**
- microsatellite instability, apoptosis, and *p53* function, 1374
 - platinum, DNA mismatch repair and, 4881
- estramustine**
- tubulin isotype levels, prostate carcinoma cells, 2584
- farnesyl transferase inhibitors, *ras*-trans-formed cells**, 2626
- 5-fluorouracil**
- rTS* alternate splicing and overexpression, 3207
- glucocorticoid, CEM-C1 cells**, 5033
- hyperresistance**
- photodynamic inactivation, hemin effects, leukemia cells, 4636
- leukemia**
- multidrug resistance reversal by antisense oligodeoxynucleotides, 4332
- merbarone, leukemic cells**, 2573
- mitomycin C**
- and NAD(P)H:quinone oxidoreductase, HCT 116 cells, 5253
- multidrug**
- cytoplasmic P-glycoprotein and, 5435
 - H19* overexpression, 2904
 - hypersensitization, pluronic L61, 3626
 - and malignancy, osteosarcoma, 2434
 - MDR1 substrates/modulators, protective effects against β -estradiol-17 β -D-glucuronide cholestasis, 4992
 - methods detection workshop, 3010
 - P-glycoprotein and protein kinase C interactions, 3490
 - P-glycoprotein-mediated, methods detection workshop, 3010
 - P-glycoprotein-mediated, reversal by LY335979, 4171
 - protein, -specific monoclonal antibody QCRL-1, 3307
 - protein gene knockout, double, 5351
 - reversal, antisense oligodeoxynucleotides, 4332
 - reversal, indole-3-carbinol, 574
 - reversal, LY335979, 4171
- mycophenolic acid, colorectal carcinoma cells, 984
- paclitaxel, sarcoma, 1091
- radiation**
- 2-nitroimidazole and, 9L s.c. tumors, 405
- saintopin**
- and topoisomerase I expression, epidermoid cancer cells, 2348
- temozolomide**
- mismatch repair mutations and, 5375
- vitamin D₃**
- cell growth rate and polyploidization, HL60 cells, 5513
- Resistance genes**
- pre-B lymphoma, MSM/Ms mouse, 3716
- RET**
- dominantly transforming *in vivo*, 4853
 - mutations
 - inherited medullary thyroid carcinoma, 1241
 - medullary thyroid carcinoma, 2167
- Retinoblastoma protein**
- chromosome 13q allelic imbalance, sporadic breast cancer, 1988
 - cleavage by ICE-like protease, apoptosis, 438
 - cyclin interactions, functional analysis, 2003
 - degradation
 - ubiquitin-dependent, 4620 - gene alterations, glioblastoma, 150
 - gene expression, non-small cell lung tumors, 3415
 - modified
 - gene therapy, 2245 - p16-cyclin D/Cdk4-pRb pathway, melanoma, 5475
 - status, non-small cell lung cancer, 5557
- Retinoic acid**
- induced growth inhibition
 - mediation by IGFBP-3, breast cancer cells, 1545 - metabolic phenotypes
 - and lung cancer risk, 2692 - metabolism
 - and cell proliferation inhibition, 675
- 9-cis-Retinoic acid**
- antiproliferative effects, colon cancer cells, 623
 - combined with KH 1060
 - cell growth inhibition, HL-60 cells, 3570
- 13-cis-Retinoic acid**
- combined with α -2-IFN
 - radiotherapy, head and neck squamous cell carcinoma, 2277
- all-trans-Retinoic acid**
- cell proliferation regulation, breast cancer cells, 1056
 - PML-retinoic acid receptor α degradation, acute promyelocytic leukemia, 2945
- Retinoic acid receptor**
- loss, mouse skin tumors, 4942
 - specific retinoids
 - and IGFBP-3 levels, ectocervical epithelial cells, 1794
- Retinoic acid receptor α**
- human
 - gene regulation, SKBR-3 and MDA-MB-435 cells, 5246 - PML-
 - degradation by all-trans-retinoic acid, acute promyelocytic leukemia, 2945
- Retinoic acid receptor γ**
- and cell growth inhibition by retinoids and interferons, breast cancer, 1571
- Retinoids**
- AP-1 and cell transformation inhibition, 483
 - cell growth inhibition, breast cancer, 1571

- receptors
 -mediated gene expression, regulation by
 4-HPR vs retinoic acid, breast cancer
 cells, 1056
 retinoic acid receptor-specific
 and IGFBP-3 levels, ectocervical epithe-
 lial cells, 1794
 retinoid X receptor-specific
 and insulin-like growth factor binding
 protein-3, ectocervical epithelial cells,
 1794
- Retinoid X receptor**
 selective ligand LGD1069
 chemoprevention, mammary carcinoma,
 5566
 -specific retinoids
 and insulin-like growth factor binding
 protein-3, ectocervical epithelial cells,
 1794
- Retrovirus**
 ecotropic production
 inhibition, MHC class I gene-transfected
 B16BL6 melanoma cells, 4464
 human endogenous retrovirus-K
 protein expression, antibody reaction,
 4362
 -mediated deoxycytidine kinase transfer
 and nucleoside toxicity, tumor cells, 2343
 -mediated gene transfer
 suppressed phenotype reversion, malig-
 nant melanoma, 3186
 TIMP-2 overexpression, 2891
 tetracycline-regulatable
 ICE apoptosis induction, glioma cells,
 5423
- Rhabdomyosarcoma**
 antisense epidermal growth factor receptor
 transfection, 3898
 comparative genomic hybridization analysis,
 3220
 metastasis
 inhibition by CEA transduction, 4503
 postextravasation movement, integrin func-
 tion, 3142
- Rhizomes**
 ginger
 tumor promotion inhibition, SENCAR
 mouse skin, 1023
- Rhodacyanines**
 MKT-077
 anticarcinoma activity, 538
 mitochondrial impairment, 551
 mitochondrial toxicity, 544
- Ribonuclease A**
 biodistribution, 4180
- Ribonucleoside diphosphate reductase**
 inhibitor MDL101731
 glioblastoma and neuroblastoma inhi-
 bition, 359
- Ribonucleotide reductase**
 inhibition by CI-F-ara-A, lymphoblastoid
 cells, 3030
 3' untranslated regions
 malignant suppression, 4366
- Ribozyme**
 anti-CAPL (*mts1*)
 metastatic phenotype reversal, tumor cells,
 5490
- RMP-7**
 blood-brain barrier opening, rat, 3998
- RNA: see also Messenger RNA**
 antisense
 p18 expression inhibition, leukemic cells,
 1445
 antisense gastrin
 expression, antitumorogenicity, 4111
 human telomerase, cell lines and tumors,
 645
 noncoding
 malignant suppression, 4366
 synthesis inhibitors
 and topoisomerase I distribution, 1674
- RNA, transfer**
 queuine modification, *ras*-transfected cells,
 589
- RS-33295-198: see LY335979**
- rTS**
 expression, and thymidylate synthase activ-
 ity, 700
- S**
- Saccharomyces cerevisiae**
 aflatoxin B₁-induced mitotic recombination,
 5457
- Saintopin**
 resistance
 and topoisomerase I expression, epider-
 mold cancer cells, 2348
- Salicylate**
 growth inhibition, colorectal tumor cells,
 2273
- Salivary gland tumors**
 allelotype, 1151
- Sapporo Cancer Seminar**
 Fifteenth, meeting report, 4278
- Sarcoma**
 AIDS-associated Kaposi's
 resistance to Fas-mediated apoptosis, 1874
 DS cells
 oxygen consumption rate, DNA synthesis
 inhibition, 2009
 Ewing's
 insulin-like growth factor I receptor-medi-
 ated circuit, 4570
 metastasis
 inhibition by MMP-9 down-regulation, rat
 model, 5279
 paclitaxel resistance mechanisms, 1091
 rhabdomyosarcoma
 antisense epidermal growth factor receptor
 transfection, 3898
 comparative genomic hybridization analy-
 sis, 3220
 metastasis inhibition by CEA transduction,
 4503
 postextravasation movement, integrin
 function, 3142
 soft tissue
 metastases, tumor oxygenation and, 941
 p57^{KIP2} protein, analysis, 1219
³¹P magnetic resonance spectroscopy *in*
vivo and *in vitro*, 2964
 prognosis, p53 mutation type and, 4134
 radiation therapy and hyperthermia, 5347
 synovial
 SSX-2, HOM-MEL-40 codes, 4766
- Schwann cells**
 transformed, ¹H-NMR spectroscopy, 4630
- Scintigraphy**
 somatostatin receptor, carcinoid tumors,
 2561
- Screening**
GAS1 and *PTC* mutations
 initial, bladder cancer, 5039
- L-Selectin**
 -negative T cells, antitumor reactivity, 4338
- Selenate**
 lymphocyte growth inhibition, 4407
- Selenite**
 lymphocyte growth inhibition, 4407
- Seminal vesicle carcinoma**
 linomide chemoprevention, rodents, 3404
- Senescence**
 chromosome 1q and, hybrid cell clones, 241
- fibroblasts, 4582
 p16, human uroepithelial cells, 2886
- Sensitivity: see also Drug sensitivity**
 Ara-c
ras and, 5211
 chemosensitivity
 enhancement by tyrphostin Ag825, non-
 small cell lung cancer cells, 1068
 methylthioadenosine phosphorylase, A549
 cells, 5653
 chemotherapy
 p53 inactivation and, 892
 cisplatin
 and nm23-transfected tumor cells, 2931
 cisplatin, hepatocellular carcinoma, 5330
 diphtheria fusion toxin DAB₃₈₉IL-2, hemato-
 poietic cells, 2590
 DNA-damaging agents
 YB-1 and, 4224
 drug
 HSP27 overexpression and, testis tumor
 cells, 2446
 increase by GST- π antisense cDNA, co-
 lon cancer cells, 3577
 MRP double knockout ant, 5351
 heat
 HSP27 overexpression and, testis tumor
 cells, 2446
 mitomycin C
 DT-diaphorase determinant, colon and
 gastric carcinoma cells, 2823
 mutagen
 and glioma risk, 1484
 natural killer
 bisecting *N*-acetylglucosamine and, K562
 cells, 412
 O⁶-benzylguanine
 alkyltransferase, mouse model, 1880
 radiosensitivity
 p53 and, glioblastoma cells, 500
 tamoxifen, determinates, 3993
 tirapazamine, comet assay, 4460
 topoisomerase II inhibitors
ras and, 5211
 ultraviolet light
 p53-null cells, caffeine and, 5365
- Sensitization**
 cyclophosphamide and ifosfamide
 P450-based gene therapy, breast cancer,
 1331
 photosensitization
 heat shock protein induction, 2355
 radiosensitization
 fluoropyrimidine-mediated, and cyclin
 E-dependent kinase, 3203
 FTI-277, H-ras-transformed rat embryo
 fibroblasts, 1727
 hyperthermia combined with carbogen
 breathing, 5590
 paclitaxel, head and neck squamous cell
 carcinoma, 5198
 wild-type p53 gene transfer, ovarian tu-
 mors, 4891
 wortmannin, murine fibroblasts and hu-
 man tumor cells, 246
- Serine protease**
 -like gene, down-regulated in breast cancer,
 3371
- Serotonin**
 acetyltransferases that acetylate
 mRNA, histological localization, 1517
- Serum**
 carboxylesterase
 prodrug activation role, rat, 1471
 deprivation
 and mutagenesis, Chinese Hamster G12
 cells, 752

- MMP-2:TIMP-2 ratio
recurrence of urothelial cancer, 3196
vascular endothelial growth factor
brain tumor, 2185
vitamin D₃-binding protein
deglycosylated, and immunosuppression,
2827
- Severe combined immunodeficiency**
cell cycle analyses, *scid* mouse fibroblasts,
2940
skin carcinogenesis, human skin grafted to
SCID mice, 757
- Shock**
heat
M-phase kinase activation, 1770
- Sialyl-Tn antigen**
expression, neoplastic transformation, 2229
- Simian virus 40**
early region T antigen, brain tumors, 4820
large T antigen
brain tumors, 4820
gene inoculation, tumor immunity induction,
1126
prostatic intraepithelial neoplasia and
prostate carcinoma, transgenic mice,
4894
-transformed Chinese hamster cells
gene amplification potentiation by poly-
(ADP-ribosylation) inhibition, 2715
-transformed lung fibroblasts
manganese superoxide dismutase overex-
pression, 2864
- SKBR-3 cells**
human retinoic acid receptor α gene regula-
tion, 5246
- Skin carcinoma**
human skin grafted to SCID mice, 757
MGMT protection against, transgenic mice,
3244
p53 loss, transgenic mice, 4413
vascular endothelial growth factor/vascular
permeability factor upregulation, 5391
- Skin tumors**
inhibition
ginger, SENCAR mouse, 1023
Msh2-deficient mice, 3842
protection against
MGMT, transgenic mice, 3244
retinoic acid receptor loss, mouse, 4942
- Small cell lung carcinoma**
apoptosis
induction, erstatin, 4978
induction, tyrosine kinase inhibitors, 4255
cisplatin and topoisomerase inhibitor syner-
gism, 789
c-kit and stem cell factor, 370
 δ opioid receptors, characterization, 1695
glucocorticoid receptor, 3276
mitogen-activated protein kinase stimulation,
5758
Myc-overexpressing, gene therapy, 354
p70^{src} phosphorylation inhibition by rapa-
mycin, 3895
topoisomerase II α point mutations, 1232
tumor suppressor gene region
600-kb cosmid contig, 1489
- Smoking**
airflow-obstructed patients, sputum cytology,
4673
cigarette
8-hydroxyguanine levels and repair activ-
ity, leukocytes, 2546
mitochondrial DNA damage, 5692
oral cancer risk
gender differences, 5192
- SN-38**
synergism with cisplatin, small cell lung
cancer cells, 789
- Sodium**
erythrocyte transport, cancer patients, 511
- Sodium chloride**
vitamin D₃ chemopreventive effects against,
glandular stomach carcinogenesis, 2767
- Sodium thiosulfate**
carboplatin ototoxicity rescue, 706
- Soft tissue sarcoma**
metastases
tumor oxygenation and, 941
p57^{KIP2} protein, analysis, 1219
³¹P magnetic resonance spectroscopy *in vivo*
and *in vitro*, 2964
prognosis
p53 mutation type and, 4134
radiation therapy and hyperthermia, 5347
- Solid tumors**
advanced
magnetic drug targeting, 4'-epidoxorubi-
cin, 4686
liposomal daunorubicin and local hyperther-
mia, rat, 563
- Somatic cell hybridization**
breast cancer progression regulation by dom-
inant *trans*-acting factors, 3560
- Somatostatin**
receptor
mesenchymal tumors, 1922
scintigraphy, carcinoid tumors, 2561
ss2 gene expression, pancreatic and colo-
rectal cancer, 1823
subtype 2 mRNA, scintigraphy *vs in situ*
hybridization, 2561
- SOS-like response**
abnormal, inheritance, 2621
- Soybean**
-derived Bowman-Birk inhibitor
carcinoma suppression, Min mice intes-
tines, 679
- Sp1**
Rep78 binding, 5299
upregulation
and polyploidization, HL60 cells, 5513
- Special articles**
NIEHS/AACR Task Force on the Advance-
ment of Minorities in Science
model program, 3380
- Special lectures**
Fifteenth Cain Award, K. W. Kohn
DNA-targeted cancer treatment, 5533
- Sperm fluids**
SV40 early region and large T antigen, 4820
- S phase**
BrdUrd cell labeling
histone H3 mRNA *in situ* hybridization
and, rat colonic epithelium, 434
- Spheroids**
multicell
metaiodobenzylguanidine therapeutic ef-
fects, neuroblastoma, 5428
tirapazamine response, comet assay, 4460
- Sphingo(glyco)lipid**
metabolism, tumor malignancy, 5309
- Sphingomyelin**
colon carcinogenesis inhibition, CF1 mice,
4936
- Spinal cord**
oligodendrocytes
radiation-induced apoptosis, adult rat spi-
nal cord, 5417
- Spleen**
K562 cells
natural killer sensitivity, bisecting
N-acetylglucosamine and, 412
zinostatin stimulant cellular effects, 1868
- Spontaneous intestinal adenoma**
piroxicam chemoprevention, *Apc^{Min}* mouse,
710
- Spontaneous intestinal carcinoma**
Msh2-deficient mice, 3842
- Spontaneous metastasis**
batimastat control, rat mammary carcinoma,
2815
- Spontaneous ovarian teratocarcinoma**
genetic traits, LT/Sv mice, 5047
- Sporadic carcinoma**
breast
chromosome 13q allelic imbalance, 1988
cecum
transforming growth factor β type II re-
ceptor gene mutations, 5620
ovarian
BRCA2 mutations, 3622
pancreatic
germline *BRCA2* mutations, 5360
- Sporadic hepatoblastoma**
APC gene mutations, 3320
- Sporadic melanoma**
p16, *p15*, and chromosome 9p21 marker
losses, 5023
- Sprague-Dawley rats**
late-stage colon carcinoma and diet, 2896
- Sputum**
cytology, airflow obstruction, 4673
microsatellite alterations, lung cancer, 2285
- SQ20B cells**
taxoid-ionizing radiation interactions, 1842
- Squamous cell carcinoma**
esophageal
advanced-stage, *p16/CDKN2* inactivation,
3875
deletion mapping, 1629
interleukin 6 serum levels, 2776
head and neck
arginine-rich protein gene mutations, 5576
chromosomal alterations, comparative
genomic hybridization, 5325
chromosome 13q deletion mapping, 1146
DPC4 mutations, 2519
FHIT abnormalities, 5128
genetic progression model, 2488
growth suppressors, *p16* and *p16 β* , 4119
p16 inactivation, 3630
radiosensitization by paclitaxel, 5198
radiotherapy, 13-*cis*-retinoic acid/ α -2a-
IFN, 2277
telomerase activity, 3530, 5600
telomerase activity, oral rinses, 5720
parathyroid hormone-related protein gene
expression
and hypercalcemia, athymic mice, 1043
radiation
tumor hypoxia reduction and repair inhibi-
tion by nicotinamide, SCCVII murine
tumors, 2801
- Src kinases**
activation by *bcr/abl*, myeloid cells, 3589
- SSX-2**
HOM-MEL-40 codes, 4766
- Staphylococcal enterotoxin B**
superantigen
antitumor immunity augmentation, 3731
- Staurosporine**
premature metaphase exit induction, 3551
- Stem cell factor**
small cell lung cancer, 370
- Stomach: see under Gastric**
- Stress**
-activated protein kinase
activation by palytoxin, 637
oxidative
-induced cell death, HSP27 phosphoryla-
tion-mediated resistance, 273
photodynamic therapy-mediated, heat

- shock protein induction, 2355
- Stroma**
hematopoietic progenitor
MDR gene transfer, 2566
tumor
immune destruction, melanoma growth acceleration, 463
tissue factor expression, invasive breast cancer, 5063
- Stromal tumors**
gastrointestinal
chromosome 14q deletions, 3230
- Styrene**
occupational exposure
biomarkers, 5410
- Styrene-7,8-oxide**
occupational exposure
biomarkers, 5410
- Substance P**
receptor
mitogenic, astrocytic cells, 4983
- N-Succinimidyl 5-iodo-3-pyridinecarboxylate**
monoclonal antibody radioiodination, 4970
- Suicide genes: see also Genes**
combined with cytokine genes
therapy for hepatic metastases, colon carcinoma, 3758
E. coli cytosine deaminase
autologous tumor vaccine for pulmonary metastases, 1361
- Sulfatase**
inhibitor *in vivo* activity, 4950
- Sulfate**
MRP-mediated conjugate export, substrates, 988
- Sulfate proteoglycans**
chondroitin
PG-M/Versican, identification, 3902
- Sulfonation**
cyproterone acetate activation, 4391
- Sulfotransferase**
expression, breast cells, 1551
- Sulindac**
tumor formation prevention, murine familial adenomatous polyposis model, 2556
- SUM-52PE cells**
erbB receptors, 899
- Sunlight**
cancer prevention, 925
- Superantigen**
-activated T cells
immunotherapy, brain tumors, 4702
- Superficial bladder tumors**
-associated CEA glycoform, identification by 19A211, 908
- Superoxide dismutase**
manganese
expression, central nervous system tumors, 3192
expression, radiation therapy, 2771
overexpression, SV40-transformed lung fibroblasts, 2864
- Surface epithelial ovarian tumors**
early chromosome 6q activity, 4487
- Susceptibility**
ATM mutations and, breast cancer, 4130
benzo(a)pyrene diol epoxide-DNA adducts and, lung cancer, 3638
CYP1A1 C4887A polymorphism and, lung cancer, 4965
genetic, colonic adenoma, 2382
NAT2 genotype and, lung cancer, 3961
- SV40: see Simian virus 40**
- Sweden**
southern
familial malignant melanoma, *p16* germline mutations, 2497
- Synovial sarcoma**
SSX-2
HOM-MEL-40 codes, 4766
- Synthetic glycoamines**
breast cancer metastasis inhibition, nude mice, 5319
- Synthetic peptides**
immunization, immunization against gp100, 4749
- Synthetic vaccines**
MUC1, mice, 3315
- T**
- TAI/E16**
expression, colon carcinoma, 5012
- TAL-1**
T-cell lymphoma, transgenic mice, 5113
- TALL-104 cells**
phase I clinical trial, advanced canine tumors, 3021
xenogeneic effector, leukemic mice, 4444
- Tamoxifen**
DNA adducts, 53
breast cancer, 4374
identification, rat liver, 66
genotoxicity, endometrium, 1475
hepatocellular carcinoma response
estrogen receptor type and, 3883
metabolic activation, 53
phase II enzyme expression response, rat liver, 3704
sensitivity determinates, 3993
uterine leiomyoma response
IGF-I autocrine loop and, 4049
uterine VEGF expression and, 3954
- Tamoxifen methiodide**
anticancer activity, rodents, 4328
- T antigen**
Simian virus 40 early region, brain tumors, 4820
Simian virus 40 large
brain tumors, 4820
gene inoculation, tumor immunity induction, 1126
prostatic intraepithelial neoplasia and prostate carcinoma, transgenic mice, 4894
- TAP: see Transporter in antigen processing**
- Targretin[®]**
chemoprevention, mammary carcinoma, 5566
- Taxol: see also Paclitaxel**
combined with cremophor EL
pharmacokinetics, mice, 2112
-dependent IL-8 expression activation, ovarian cancer, 1303
-induced apoptosis and mitotic exit, HeLa cells, 816
-induced bcl-2 apoptosis and phosphorylation
prostate cancer, 1253
Raf-1 requirement, 1851
ionizing radiation interactions, HeLa and SQ20B cells, 1842
pharmacodynamics, head and neck tumors, 2086
resistance mechanisms, sarcoma, 1091
- Taxotere**
hepatic CYP3A-mediated metabolism, 1296
ionizing radiation interactions, HeLa and SQ20B cells, 1842
- TBHQ: see tert-Butyl-hydroquinone**
- T cells: see T lymphocytes**
- Tegafur**
1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxanate
antitumor activity, colon carcinoma, 2602
- 5848
- TEL**
alterations, t(12;21) childhood acute lymphoblastic leukemia, 2655
mutations, childhood acute lymphoblastic leukemia, 1413
- Telomerase**
activity
cell lines and tumors, 645
head and neck squamous cell carcinoma, 3530, 5600, 5720
inhibition, differentiation, 3796
malignant prostate tissue, 218
oral leukoplakia, 3530
oral rinses, head and neck squamous cell carcinoma, 5720
tumor cell differentiation, 1503
human
RNA, cell lines and tumors, 645
- Temozolomide**
glioma uptake, rat model, 1983
resistance
mismatch repair mutations and, 5375
- Tempol**
adjunctive 6-hydroxydopamine treatment, murine neuroblastoma, 2336
- Tenascin-C**
expression by astrocytoma and brain endothelial cells, 182
- Teratocarcinoma**
spontaneous ovarian
genetic traits, LT/Sv mice, 5047
- Testicular tumors**
heat shock protein 27 overexpression, 2446
hypersensitive
functional p53, 1834
- Tetracycline**
-regulatable retrovirus
ICE apoptosis induction, glioma cells, 5423
- Tetraploidy**
transition
cell growth rate and, HL60 cells, 5513
- T98G cells**
tumorigenic and metastatic phenotype, PDGF-B/*v-sis* and, 280
- TGF: see Transforming growth factor**
- Thermotolerance**
prostaglandin A₁-induced
modulation by quercetin, leukemic cells, 210
- Thioredoxin**
dominant-negative mutant
phenotype reversal, breast cancer cells, 5765
overexpression, hepatocellular carcinoma, 5330
transfection
cell proliferation and, 5765
- Thiosulfate**
carboplatin ototoxicity rescue, 706
- Thiotepa**
-induced DNA damage
repair, 3721
- Thrombospondin-1**
chromosome 10 induction
angiogenesis inhibition, glioblastoma, 5684
- Thymidine kinase**
herpes simplex virus
gene therapy, Myc-overexpressing small cell lung cancer cells, 354
gene therapy, noninvasive imaging, 4087
-mediated apoptotic death, bystander cells, 2697
- Thymidine phosphorylase**
expression, bladder cancers, 4799

- Thymidylate synthase**
activity
 rTS expression and, 700
 benzoquinazoline inhibitors
 uptake, anabolism and cellular retention, 3301
 rTS gene product
 alternate splicing and overexpression, 5-FU-resistant cells, 3207
- Thyroid carcinoma**
differentiated
 mAb JT-95, production, 1817
medullary
 RET mutations, 1241, 2167
papillary
 CD44 mRNA splicing, 1037
 c-erbB-3 and *c-erbB-4* expression, 1184
thyroid peroxidase reexpression
 wild-type *p53* and, 765
- Thyroid peroxidase**
reexpression
 wild-type *p53* and, thyroid carcinoma cells, 765
- TIMP: see Tissue inhibitor of metalloproteinase**
- Tirapazamine**
DNA strand breaks induction, 1584
tumor response
 comet assay, mice, 4460
- Tissue**
breast
 karyotypic heterogeneity, 855, 5098
colon
 PhlP metabolism, rat, 2550
normal
 cellular pH gradient, 1194
tumor
 cellular pH gradient, 1194
 DaunoXome disposition, fluorescence imaging studies, 2066
 vascular endothelial growth factor levels, brain tumor, 2185
- Tissue factor**
tumor stroma, invasive breast cancer, 5063
- Tissue inhibitor of metalloproteinase 2**
expression, invasive bladder cancer, 1654
membrane-type matrix metalloproteinase 1 complex, 2707
overexpression
 retroviral-mediated, tumors, 2891
serum MMP-2:TIMP-2 ratio, recurrence of urothelial cancer, 3196
- T lymphocytes: see also Cytotoxic T lymphocytes; Lymphocytes**
acute lymphoblastic leukemia
 ALL-1 breakpoint cluster region deletion, 2171
 CEM-C1 cells, glucocorticoid resistance, 5033
adult leukemia
 G_{D3} synthase gene expression, 2844
dendritic epidermal
 and UV radiation tumorigenesis, 2607
helper
 tumor-specific Th2 clone, tumor regression, 5005
human T cell leukemia virus type I cells
 AP-2 binding activity, 779
lymphoma, transgenic tal-1 mice, 5113
melanoma recognition, 2368
receptor instability postirradiation
 increase by *p53* mutants, 3862
receptors
 repertoire, neuroblastoma, 362
 L-selectin-negative, antitumor reactivity, 4338
superantigen-activated
 immunotherapy, brain tumors, 4702
- γδ T lymphocytes**
and heat induction of autologous tumor killing, 1104
- Tn antigen**
expression, neoplastic transformation, 2229
- TNF: see Tumor necrosis factor**
- TNP-470**
and glioma temozolomide uptake, rat model, 1983
- Tobacco**
lung cancer risk
 CYP2D6 activity and, 251
- Tolerance**
thermotolerance
 prostaglandin A₁-induced, modulation by quercetin, 210
- TOP-53**
antitumor activity, lung cancer, 2809
- Topotecan**
-treated anaplastic astrocytoma
 topoisomerase I redistribution, 1664
- Toxic gene therapy**
osteocalcin promoter-based, osteosarcoma, 4614
- Toxicity**
cardiotoxicity
 doxorubicin-induced, dexrazoxane, 4200
cytotoxicity
 gemcitabine-containing regimens, non-small cell lung cancer cells, 794
 natural killer, bisecting *N*-acetylglucosamine and, K562 cells, 412
gastrointestinal
 chemotherapy-induced, prevention by anti-doxorubicin mAb, 2082
genotoxicity
 aflatoxin B₁, *S. cerevisiae*, 5457
 mammary lipid, 5342
 tamoxifen, endometrium, 1475
hepatic
 interleukin-2-induced, mechanisms, 507
 TBHQ-glutathione conjugates, 1006
intestinal
 irinotecan, β-glucuronidase and, 3752
mitochondrial
 MKT-077, 544
nucleoside
 retroviral deoxycytidine kinase transfer and, tumor cells, 2343
ototoxicity
 carboplatin, thiosulfate rescue, 706
TBHQ-glutathione conjugates, kidney and bladder, 1006
vinblastine
 brain-derived neurotrophic factor protective effects against, neuroblastoma cells, 3737
- Toxins**
aflatoxin B₁
 biotransformation, oltipraz-mediated changes, rat liver, 2306
 genotoxicity, *S. cerevisiae*, 5457
 oxidative DNA damage, rat liver and human oral mucosal cells, 683
 circularly permuted IL4-toxin, malignant astrocytoma, 5631
diphtheria fusion toxin DAB₃₈₉IL-2 sensitivity, hematopoietic cells, 2590
genes
 lung adenocarcinoma therapy, 1315
immunotoxins
 advances, Fourth International Symposium on Immunotoxins meeting report, 926
 ochratoxin A
 mutagenicity testing, 299
 palytoxin
 stress-activated protein kinase/c-Jun N-terminal kinase activation, 637
 vascular endothelial growth factor conjugate endothelium targeting, 1324
- Trans-acting factors**
dominant
 breast cancer progression regulation, somatic cell hybridization studies, 3560
- Transcription factors**
AP-1
 inhibition by retinoids, 483
 upregulation, and polyploidization, 5513
AP-2
 binding activity, HTLV-I cells, 779
IRF-1
 Lysyl oxidase gene regulation, 2417
Sp1
 Rep78 binding, 5299
 upregulation, and polyploidization, 5513
- Transferrin**
receptor
 bispecific 1A10 antibody, binding characteristics and antitumor properties, 113
- Transfer RNA**
queuine modification, *ras*-transfected cells, 589
- Transformation**
and choline metabolism alterations, 4630
cyclooxygenase-2 transcription, mammary epithelial cells, 4424
human papillomavirus 16 E6 and E7
 IGF-1R and, 5087
hydrogen peroxide *in vitro*, rat urothelial cells, 4649
induction by *HhaI* methyltransferase, NIH3T3 cells, 616
oncogenic
 synergism with hypoxia, 3437
Ral GDP dissociation stimulator like Ras-interacting domain and, NIH3T3 cells, 2387
reversal by ornithine decarboxylase mutant, 5136
tumor promoter-induced
 inhibition by retinoids, 483
 urate oxidase-mediated, epithelial cells, 4846
- Transforming growth factor β**
growth and differentiation effects, HL-60 cells, 495
inhibition by lisofylline, 105
receptor, type I
 genetic change, prostate cancer cells, 44
receptor, type II
 gene mutations, hereditary nonpolyposis colorectal cancers, 4595
 gene mutations, sporadic cancer, 5620
 gene promoter mutations, 4831
- Transforming growth factor β1**
apoptosis induction, prostatic epithelial cells, 5146
autocrine stimulation of gelatinase B secretion, murine metastatic colon carcinoma cells, 3366
effects in metastatic vs primary mouse prostate cancer cells, 3359
genomic instability suppression, 3645
-induced apoptosis
 inhibition by tumor promoters, rat hepatocytes, 1272
 insulin receptor substrate 1 protection against, hepatocellular carcinoma cells, 3391
insensitivity, prostate cancer, 44
- Transforming growth factor β2**
-induced growth inhibition
 mediation by IGFBP-3, breast cancer cells, 1545

Transgenes: see also Genes

lacI
mutations, ethylnitrosourea-induced, 4654

Transitional cell carcinoma

bladder
adipocyte-type fatty acid binding protein loss, 4782

Translation initiation factors

eIF-4E
overexpression, ornithine decarboxylase regulation and, 3265

Translocations

t(6;16)(p21;q22)
LNCaP cells, 728
t(9;14)(p21-22;q11)
p16 inactivation, B-cell acute lymphoblastic leukemia, 848
t(11;14)(q23;q32)
breakpoint, molecular cloning, 448
t(12;21)
ETV6 and *CDKN1B* alterations, childhood acute lymphoblastic leukemia *CDKN1B*, 2655

Transplantation

posttransplant lymphoproliferative disorders
microsatellite analysis, 4378

Transporter in antigen processing proteins

cell cycle-dependent expression, breast cancer cells, 4358
deficiencies, renal cell carcinoma, 1756

Trichothiodystrophy

DNA repair and mutagenesis
XPD gene and, 5450

***N,N',N''*-Triethylenethiophosphoramidate: see Thiotepe**

Trisomy 7p

and malignant transformation, breast epithelial cells, 2039

Trisomy 11

acute myeloid leukemia
ALL1 partial tandem duplication, 1418

Trivalent antigen

-binding construct
preparation with polyoxime chemistry, 809

Tuberous sclerosis

Tsc2 gene product
transcriptional activation domains, Eker rat model, 429

Tubular invasive breast cancer

grade I
FHIT and *ATM* allele loss, 5484

Tubulin

cryptophycin interactions, 4398

β_{III} -Tubulin

concentrations, prostate carcinoma cells, 2584

β_{IVa} -Tubulin

concentrations, prostate carcinoma cells, 2584

Tumor antigen

carbohydrate, possible roles, 2237
HOM-MEL-40
SSX-2 codes, 4766

large

SV40, gene inoculation, tumor immunity induction, 1126

melanoma

gene, transduced dendritic cells, 5672

MHC class II presentation, vaccine that enhances, 21

mucin

human dendritic cells engineered to express, 3763

pE4

immunoglobulin-like TuAg.I, rat liver, 3934

sialyl-Tn

expression, neoplastic transformation, 2229

Tumor-associated glycoprotein 72

levels

colorectal patients, quantitative CA 72-4 immunoassay, 5293

phosphorylatable MAB-chB72.3-P, construction, 4250

Tumor cells

allogeneic

antitumor immunity, 3782

apoptosis

induction by cytokine-stimulated cells, leukemic cells, 866

autocrine motility factor, 2960

autologous tumor killing

induction by heat, 1104

deoxycytidine kinase overexpression, 2343

differentiation

telomerase activity, 1503

drug-resistant

microsatellite instability, apoptosis, and p53 function, 1374

embolization

galectin-3 and Mac-2-binding protein interactions and, 4530

epithelial

bcl-2 and clonogenic survival, 4006

ERCC-2 expression

and chloroethylnitrosourea resistance, 2475

interleukin 2-transduced

vaccine, adjuvant interleukin 12, 467

metastatic phenotype

reversal by anti-CAPL (*mts1*) ribozyme, 5490

nonhematopoietic

CD43 expression, 3526

opsonization by anti-galactose, 3069

p120cas isoforms, 2633

recombinant fibronectin overexpression, 4541

type II hexokinase gene amplification, 2468

wortmannin radiosensitization, 246

Tumor growth: see also Cell growth; Cell proliferation

acceleration after stroma destruction, mouse melanoma, 463

autocrine

inhibition by triple helix-forming oligodeoxyribonucleotides, glioblastoma, 5156

mediation by *c-kit* and stem cell factor, small cell lung cancer, 370

colonic

apoptosis and mitoses, mouse, 4910

inhibition

antisense gastrin RNA expression, 4111

antisense oligonucleotide PKC- α inhibitor, mice, 3499

anti-VEGF antibody, intravital videomicroscopy, 4032

bis(7-amino-4-azaheptyl)dimethylsilane and bis(7-ethylamino-4-azaheptyl)dimethylsilane, 5624

CCAAT/enhancer-binding protein, 1063

chromosome 6, melanoma, 1635

c-kit kinase defective mutants, 4343

drug-loaded liposomes, lung tumor xenografts, 3743

Flk-1 inhibition, 1615

Flk-1 target, 3540

ginger, SENCAR mouse, 1023

IGF-IR antisense, mesothelioma, 4044

irsogladine, 1512

Lysyl oxidase gene, 2417

retroviral-mediated deoxycytidine kinase overexpression, 2343

urokinase receptor antagonists, 2428

vascular endothelial growth factor inhibition, 921

pregnancy-dependent

IGF-II overexpression and mammary tumors, 3651

vascular permeability factor/vascular endothelial growth factor expression and, melanoma, 172

Tumorigenesis: see also Carcinogenesis

enhancement

IGF-I receptor, neuroblastoma, 4522

inhibition

dominant negative IGF-I receptor, 4013

Tumorigenicity

cholesterol epoxides, estrone-3,4-quinone, rat mammary gland, 1970

Tumorigenic phenotypes

PDGF-B/*v-sis* and, T98G cells, 280

Tumor markers

circulating

vitamin B₆, 3671

Tumor necrosis factor

cell cycle-dependent apoptosis, 1591

inhibition by triple helix-forming oligodeoxyribonucleotides, glioblastoma, 5156

Tumor necrosis factor α

allelic frequency, colorectal cancer, 145

apoptosis induction, leukemic cells, 866

and cell cycle control, keratinocytes, 2452

genetic radiotherapy

tumor vessel targeting, 4311

hyperthermic limb perfusion

and systemic fibrinolysis, 3948

-induced vascular leakage, 3211

inhibition by cancer preventive agents, 3711

targeting

bispecific antibody anti-CEA and TNF α , 4758

Tumor promoters

-induced cell transformation

inhibition by retinoids, 483

liver

apoptosis inhibition, rat hepatocytes, 1272

Tumor promotion

fat types and amount, colon, 533, 2314

Tumors: see also Lesions; Neoplasms

adrenocortical

genetic aberrations, comparative genomic hybridization, 4219

advanced

killer clone therapy, canine, 3021

TALL-104 cells, phase I clinical trial, 3021

amniotic

bone formation induction, 633

ascites

energy metabolism regulation by nitric oxide, 4535

bladder

blood group ABO gene transcription, 1031

cadherin-associated molecules, prognostic value, 4154

p53 mutations, arylamine-exposed workers, 294

superficial, -associated CEA glycoform, 908

blood perfusion

and pO₂, after X-rays, 3344

brain

O⁶-benzyl-2'-deoxyguanosine and BCNU antitumor activity, xenografts, 2076

boron neutron capture therapy, quantitative ion imaging, 4302

carboplatin uptake, RMP-7 and, rat, 3998

carmustine treatment, alkyltransferase, 783

cell migration, 1939

- immunotherapy, superantigen-activated T cells, 4702
- inhibition by MDL101731, 359
- malignant, boron neutron capture therapy, 2017
- malignant, membrane-type matrix metallo-protease expression and gelatinase A activation, 384
- manganese superoxide dismutase expression, 3192
- metastatic, local chemotherapy, 5217
- microvessel permeability mediation by bradykinin, 4027
- peritumoral edema, corticotropin-releasing factor treatment, 1352
- serum and tumor tissue VEGF levels, 2185
- SV40 early region and large T antigen, 4820
- breast
 - adenovirus-mediated gene transfer, gene therapy and bone marrow purging, 1346
 - apoptosis induction by *bcl-x_s* gene therapy, 1965
 - growth regulation by heregulin, erbB2 effects, 1457
 - interleukin 6 expression and response, 3118
 - pregnancy-dependent growth, IGF-II overexpression and, 3651
 - progression, apoptosis suppression, 2998
 - WNT-2* expression, 4320
- cachexia-inducing
 - protein-degrading factor and, 1256
- carcinoembryonic antigen-expressing radioimmunodetection and radioimmunotherapy, 1805
- carcinoid
 - somatostatin receptor scintigraphy *vs in situ* hybridization, 2561
- cell-cell contact
 - gelatinase B expression induction, 5506
- cellular pH gradient, 1194
- central nervous system
 - manganese superoxide dismutase expression, 3192
- colon
 - 2-amino-3-methylimidazo[4,5-f]quinoline-induced, apoptosis inhibition, 4307
 - apoptosis and mitoses, mouse, 4910
 - DT-diaphorase transcript splicing and expression, 1731
 - promotion by fat types and amount, male F344 rats, 533
 - promotion by fat types and amount, mechanisms, 2314
- colorectal
 - growth inhibition by salicylate, 2273
 - radioimmunotherapy plus blood flow modifiers, xenografts, 3293
 - ZD2767 ADEPT system, xenografts, 3287
- DaunoXome disposition
 - fluorescence imaging studies, tissue, 2066
- derived endothelial cells
 - etoposide-induced DNA strand breakage, inhibition by integrins, 4146
 - nitric oxide production, 886
- DPC4* alterations, 2527
- epithelial ovarian
 - borderline, microsatellite instability, 2501
 - surface, early chromosome 6q activity, 4487
- gastrointestinal
 - suppressor locus, potential, 978
- gastrointestinal stromal
 - chromosome 14q deletions, 3230
- germ cell
 - human endogenous retrovirus-K protein expression and antibody reaction, 4362
- head and neck
 - multiple, clonal origin, 2484
 - taxol pharmacodynamics, 2086
- human telomerase RNA and telomerase activity, 645
- hypoxia
 - and malignant progression, cervical cancer, 4509
 - reduction by nicotinamide, SCCVII murine tumors, 2801
- interstitial pressure and pO₂ after radiation, human xenografts, 964
- intestinal
 - MSH2 deficiency and, Min mice, 2922
- killing
 - autologous, induction by heat, 1104
- liver
 - VX2, MRI chemoembolization study, 1863
 - loss of heterozygosity and replication error semiautomated assessment, 3331
- 9L s.c.
 - 2-nitroimidazole and radiation resistance, 405
- lung
 - clonal evolution, 1609
 - estrogen receptor methylation, 3655
 - suppression by drug-loaded liposomes, xenografts, 3743
- malignant
 - 2B1 antigen, identification, 3902
 - endothelial ICAM-1 suppression, 1111
 - glycosylation and sphingo(glyco)lipid metabolism, 5309
- MEN1
 - chromosome 11q13 deletions, 5272
- mesenchymal
 - somatostatin and vasoactive intestinal peptide receptors, 1922
- metastasis
 - augmentation by platelet-activating factor, 2662
- microenvironment
 - genetic instability, 5754
- microsatellite instability
 - hMSH2 and hMLH1 expression, 4836
- microtumors
 - growth inhibition, anti-VEGF antibody, 4032
- necrosis
 - induction by δ -aminolevulinic acid and 1,10-phenanthroline photodynamic therapy, 339
- neovascularization
 - inhibition by irsogladine, 1512
- neuroblastoma multicell spheroids
 - metaiodobenzylguanidine therapeutic effects, 5428
- non-small cell lung
 - Rb* and p16^{INK4a} expression, 3415
- ovarian
 - borderline epithelial, microsatellite instability, 2501
 - growth regulation by heregulin, erbB2 effects, 1457
 - radiosensitization by wild-type *p53* gene transfer, 4891
 - surface epithelial, early chromosome 6q activity, 4487
- oxygenation
 - erythropoietin effects, 4728
 - and metastases, soft tissue sarcoma, 941
- pancreatic
 - chromosome 3p14.2 fragile site *FRA3B* breakpoints, 4347
- parenchyma
 - reoxygenation, murine breast cancer, 5522
- partial pressure of oxygen
 - hyperthermia combined with carbogen and, 5590
- peripheral nerve sheath
 - malignant, genetic changes, 4778
- photodynamic therapy response
 - lymphocytes, mouse EMT6 tumors, 5647
- pituitary
 - malignant, parathyroid hormone-related peptide inhibition and, 77
 - p16* loss, 2493
- prevention by sulindac, murine familial adenomatous polyposis model, 2556
- primitive neuroectodermal
 - insulin-like growth factor I receptor-mediated circuit, 4570
- regression
 - local *vs* systemic IL-12 delivery and, 2531
 - tumor-specific Th2 clone, mice, 5005
- renal
 - distal nephron, microsatellite allelotype, 1892
 - gene expression and, 2616
- salivary gland
 - allelotype, 1151
- size
 - radical production and, 5741
- skin
 - inhibition by ginger, SENCAR mouse, 1023
 - MGMT protection against, transgenic mice, 3244
 - retinoic acid receptor loss, mouse, 4942
- solid
 - liposomal daunorubicin and local hyperthermia, rat, 563
 - magnetic drug targeting, 4'-epidoxorubicin, 4686
- specific CTLs, *in vivo* maintenance, 11
- specific growth hormone receptor mRNA regulation, liver, 2949
- specific Th2 clone
 - tumor regression, mice, 5005
- stroma
 - immune destruction, melanoma growth acceleration, 463
 - tissue factor expression, invasive breast cancer, 5063
- stromal
 - gastrointestinal, chromosome 14q deletions, 3230
- superficial bladder
 - associated CEA glycoform, identification by 19A211, 908
- surface epithelial ovarian
 - early chromosome 6q activity, 4493
- target binding
 - lymphokine-activated killer protein phosphorylation, 127
- testicular
 - heat shock protein 27 overexpression, 2446
 - hypersensitive, functional p53, 1834
 - TIMP-2 overexpression, retroviral-mediated, 2891
 - tirapazamine response comet assay, mice, 4460
- tissue serum vascular endothelial growth factor levels
 - brain tumor, 2185
- vascularization
 - and gastric carcinoma progression, 2671
- vascular permeability
 - chimeric Lym-1/IL-2 fusion protein and, 4998

VX2
MRI chemoembolization study, rabbit liver, 1863

Wilms'
familial, deletion regions, 3837
p57^{KIP2}, analysis, 1219
p57^{KIP2}, G401 assay, 1214
xenografts
potential doubling time, cytokinesis-block measurement, 1660

Tumor suppressor gene products: *see also* **Gene products**

VHL
VBP-1 binding, 2881

Tumor suppressor genes: *see also* **Genes**
chromosome 8p22-23, colorectal cancer, 5238
chromosome 17p13.3 candidate, 1997
chromosome 9 loci, bladder cancer, 5039

DPC4
alterations, various tumor types, 2527
mutations, head and neck squamous cell carcinoma, 2519
somatic alterations, lung cancer, 2718

FHIT
abnormalities, head and neck cancer cells, 5128
gastrointestinal
potential locus, 978
kidney expression, hamster, 2616

KIP1
mutations, childhood acute lymphoblastic leukemia, 1413

MEN1 tumor mapping, 5272

MTS-1
alterations, pancreatic cancer, 1137
ovarian carcinoma
candidate, loss of heterozygosity, endometriosis, 3534
chromosome 22q localization, 729

p16
alterations, pancreatic cancer, 1137
inactivation, head and neck squamous cell carcinoma, 3630

p53
deletions and insertions, cancers, 2130
loss, transgenic mouse skin carcinoma, 4413
parathyroid adenomas
genomic localization, 599
small cell lung cancer region
600-kb cosmid contig, 1489

TEL
mutations, childhood acute lymphoblastic leukemia, 1413

Tumor vaccines
autologous, microscopic pulmonary metastases treatment, 1361

Tyrosine
phosphorylation, protease inhibitor effects, 3909

Tyrosine kinase
Bcr-abl
inhibition by Bcr, 5120
c-Abl
inhibition by Bcr, 5120
inhibitors
apoptosis stimulation, small cell lung cancer cells, 4255

Tyrphostin AG825
chemosensitivity enhancement, non-small cell lung cancer cells, 1068

Tyrphostin AG1478
selectivity for truncated epidermal growth factor receptor, glioma cells, 3859

U

1843U89
uptake, anabolism and cellular retention, 3301

Ubiquitin
-conjugated proteins, colorectal carcinomas, 2752
-dependent Rb degradation, 4620

UDP-glucuronosyltransferase
genoprotection, 1526

Ulcerative colitis
chronic
microsatellite instability, nonneoplastic mucosa, 1237

Ultraviolet radiation
-induced apoptosis
inhibition by tumor promoters, rat hepatocytes, 1272
p16 accumulation effects, 2510
sensitivity
p53-null cells, caffeine and, 5365
YB-1 and, 4224
tumorigenesis
dendritic epidermal T lymphocytes and, 2607

Urate oxidase
-mediated transformation, epithelial cells, 4846

Urinary bladder carcinoma: *see* **Bladder carcinoma**

Uroepithelial cells
human
senescence and immortalization, *p16*, 2886

Urokinase
hepatocyte growth factor activation, rat hepatocytes, 2837
inhibition by PD 098059, 5369

Urokinase plasminogen activator
deficiency
melanocytic neoplasm induction, mice, 3597
receptor antagonists
tumor and angiogenesis inhibition, 2428

Urothelial carcinoma
DNA methylation, 5698
recurrence
serum MMP-2/TIMP-2 ratio, 3196

Urothelial cells
growth-stimulated
blood group ABO gene transcription, 1031
transformation by hydrogen peroxide *in vitro*, rat, 4649

Ursolic acid
anti-invasive activity, HT1080 cells, 2281

Uterine cervix: *see* **Cervix**

Uterine leiomyoma
del(7)(q22) and PAI-1 expression, 3123
tamoxifen response
IGF-I autocrine loop and, 4049

Uteroglobin
gene family member mammaglobin
expression, breast cancer, 860

Uterus
monoclonal endometrial carcinoma precursors, 1917
vascular endothelial growth factor expression, 3954

Uveal melanoma
angiogenesis, 2900

V

Vaccines
GM-CSF plus IL-4 producing, 1828
MAGE-1 peptide-loaded antigen presenting

cell-based
CTLp frequency enhancement, melanoma, 2479
recombinant anticancer
costimulation enhancement, 2832
synthetic MUC1, mice, 3315
tumor
autologous, microscopic pulmonary metastases treatment, 1361
interleukin 2-transduced, adjuvant interleukin 12, 467
tumor antigen MHC class II presentation enhancing, 21
vaccinia-CEA
combined with interleukin-2, immunotherapy, 2361

Vaccinia
-carcinoembryonic antigen vaccine
combined with interleukin-2, immunotherapy, 2361

Variable tandem repeat
Ha-ras
sequence variations, minisatellite variant repeat PCR, 4773

Vascular endothelial growth factor
antisense
growth inhibition, C6 cells, 393
anti-VEGF antibody
angiogenesis inhibition, intravital video-microscopy, 4032
expression
breast cancer, 2013
hepatocellular carcinoma, 3004
modulation by oncogenic transformation and hypoxia, 3437
reversion by von Hippel-Lindau protein, renal carcinoma cells, 2299
tumor growth and vascularization and, melanoma cells, 172
uterine, 3954
inhibition
tumor dissemination suppression, 921
receptor expression, breast cancer, 2013
regulation
cell density, colon carcinoma cells, 3891
iron chelators, 3747
serum levels, brain tumor, 2185
toxin conjugate
endothelium targeting, 1324
tumor tissue levels, brain tumor, 2185
upregulation, mouse skin carcinogenesis, 5391

Vascular endothelium
adhesion
MUC1 adhesion ligand, breast cancer, 4244
radiation-induced, mediation by cell adhesion molecules, 5150

Vascularization
tumor
and gastric carcinoma progression, 2671
vascular permeability factor/vascular endothelial growth factor expression and, melanoma, 172

Vascular leakage
TNF α -induced, 3211

Vascular permeability
tumor
chimeric Lym-1/IL-2 fusion protein and, 4998

Vascular permeability factor
expression
hepatocellular carcinoma, 3004
melanoma cells, tumor growth and vascularization and, 172
upregulation, mouse skin carcinogenesis, 5391

Vasoactive intestinal peptide

- receptor
- breast cancer, 3486
- mesenchymal tumors, 1922

VBP-1

- VHL gene product binding, 2881

V(D)J recombinase

- mediated *HPRT* mutations, peripheral blood lymphocytes of children, 1405

VEGF: see Vascular endothelial growth factor

Versican

- identification, 3902

VHL: see von Hippel Lindau

Videomicroscopy

- intravital
- anti-VEGF antibody angiogenesis inhibition, 4032

Vinblastine

- toxicity
- brain-derived neurotrophic factor protective effects against, neuroblastoma cells, 3737

Viruses

- adenovirus
- antisense IGF-Ir expressing, antitumor effects, 3038
- based gene therapy, CEA-producing gastric carcinoma, 1341
- based *p53* transfer, glioma cells, 694
- based wild-type *p53* transfer, cervical cancer, 3047
- based wild-type *p53* transfer, ovarian tumor radiosensitization, 4891
- melanoma-specific, 5638
- Rep78, Sp1 binding, 5299
- replication-deficient, modified retinoblastoma gene therapy, 2245

Epstein-Barr

- associated neoplasia, targeted therapy, 969
- infection, proliferative response, 5610
- hepatitis B virus X protein
- IGF-I receptor gene activation, 3831
- herpes simplex virus thymidine kinase gene therapy, Myc-overexpressing small cell lung cancer cells, 354
- mediated apoptotic death, bystander cells, 2697

human papillomavirus

- cell cycle control, TNF- α and, keratinocytes, 2452
- cervical lesions, virus-specific memory CTLs, 582
- interleukin 2 response, cervical pathology correlation, 3967
- invasive phenotype reversal by E-cadherin/catenin complex, keratinocytes, 5285
- tumor status, cervical carcinoma, 197

human T cell leukemia, type I cells

- AP-2 binding activity, 779

lysis

- Epstein-Barr virus-targeted therapy, 969

retrovirus

- mediated deoxycytidine kinase transfer, and nucleoside toxicity, 2343
- mediated gene transfer, suppressed phenotype reversion, 3186
- mediated gene transfer, TIMP-2 overexpression, 2891

Simian virus 40

- early region T antigen, brain tumors, 4820
- large T antigen, gene inoculation, tumor immunity induction, 1126
- large T antigen, prostatic intraepithelial neoplasia and prostate carcinoma, 4894

- transformed Chinese hamster cells, gene amplification potentiation by poly-(ADP-ribosyl)ation inhibition, 2715
- specific memory CTLs, cervical carcinoma, 582

Vitamin B₆

- circulating tumor marker, 3671

Vitamin D

- receptor
- gene polymorphisms, prostate cancer, 4108

Vitamin D₃

- analogue effects
- potentiation by antiestrogen, breast cancer cells, 2789
- antiproliferative effects, colon cancer cells, 623
- chemopreventive effects, glandular stomach carcinogenesis, 2767
- 20-*epi*- analogues
- combined with 9-*cis*-retinoic acid, cell growth inhibition, HL-60 cells, 3570

Vitamin D₃-binding protein

- deglycosylated
- and immunosuppression, 2827

Vitronectin

- breast carcinoma cell adhesion regulation, 2206

v-Jun

- comparison with c-Jun, 4229

VLA-2

- postextravasation cell movement function, RD cells, 3142

von Hippel-Lindau protein

- gene product
- VBP-1 binding, 2881
- VEGF reversion, renal carcinoma cells, 2299

von Recklinghausen's neurofibromatosis

- malignant tumors, genetic changes, 4778

v-Ras

- induced transformation
- Ral GDP dissociation stimulator like Ras-interacting domain and, NIH3T3 cells, 2387

VX2 tumors

- liver
- chemoembolization study, MRI, 1863

W

WAP/Int3

- and mammary secretory differentiation, 1775

WBHa-ras cells

- cytogenetic analysis and correlation with IGF-II expression, 2992

WBneo cells

- cytogenetic analysis and correlation with IGF-II expression, 2992

WBrasIIa cells

- cytogenetic analysis and correlation with IGF-II expression, 2992

Weight loss

- protein-degrading factor
- and cachexia-inducing tumors, 1256

Western-style diet

- induced tumorigenesis
- apoptosis and mitoses, mouse colon, 4910
- modulation, colonic epithelial cells, 4644

Whites: see Caucasians

Wild-type p53 protein

- adenovirus-mediated gene transfer
- cervical cancer, 3047
- ovarian tumor radiosensitization, 4891
- and BCNU resistance, mouse astrocytes, 2748
- dominant, 158
- MGMT transcription inhibition, 2029
- p53 pathway abnormality after ionizing radiation, 5853

- ation, melanoma, 840

Wilms' tumors

- familial
- deletion regions, comparative genomic hybridization, 3837
- p57^{KIP2}*
- analysis, 1219
- expression, 5723
- G401 assay, 1214

Withdrawal

- epidermal growth factor
- malignant transformation and, breast epithelial cells, 2039

WNT-2

- expression, breast tumors, 4320

Women

- Jewish
- BRCA1 185delAg* mutations, ovarian cancer, 1250

Workers: see Occupational exposure

Wortmannin

- radiosensitization, murine fibroblasts and human tumor cells, 246

X

Xenogeneic effectors

- TALL-104
- efficacy, leukemic mice, 4444

Xenografts

- androgen-dependent and relapsed prostate cancer, 3042
- anti-CEA antibody fragment rapid targeting, 3055
- bile duct carcinoma
- MUC1-specific targeting immunotherapy, 4205
- brain tumor
- O⁶*-benzyl-2'-deoxyguanosine and BCNU antitumor activity, 2076
- breast cancer
- growth reduction, *lit/lit* hosts, 1509
- inhibition by antisense, nude mice, 1098
- colorectal tumor
- radioimmunotherapy plus blood flow modifiers, 3293
- ZD2767 ADEPT system, 3287
- epithelial ovarian carcinoma
- intraperitoneal photodynamic therapy, murine model, 1075

GS-7

- antibody penetration, mice, 3508

lung tumor

- suppression by drug-loaded liposomes, 3743

orthotopic

- pancreatic carcinomas, 5713

ovarian cancer

- chemotherapy by fatty acid synthase inhibition, 1189

tumor

- interstitial pressure and pO₂ after radiation, 964
- potential doubling time, cytokinesis-block measurement, 1660

Xeroderma pigmentosum

- group A
- oxidative DNA damage repair, mitochondrial, 1262
- SOS-like response
- abnormal, inheritance, 2621

XPD

- DNA repair and mutagenesis and, trichothiodystrophy cells, 5450

X protein

- hepatitis B virus
- IGF-I receptor gene activation, 3831

X-ray irradiation

- induced cell adhesion molecules, 5150

SUBJECT INDEX TO VOLUME 56

postmitotic apoptosis after, rec-myc cells,
4116
T-cell receptor instability after, increase by
p53 mutants, 3862
tumor blood perfusion and pO_2 after, 3344

Y

Yama protease

Ara-C-induced
inhibition by Bcl-2 or Bcl-x_L, HL-60
cells, 4743
Fas-mediated apoptosis effects, 1713

Y box-binding protein YB-1

and sensitivity to DNA-damaging agents,

4224

Yeast

aflatoxin B₁-induced mitotic recombination,
5457
functional topoisomerase II α expression, 91

Yttrium-90

metabolism and retention by cancer cells,
2123

Z

ZD1694

cell cycle perturbations, colon carcinoma
cells, 4715

ZD2767

antibody-directed enzyme prodrug therapy
system, colorectal tumor xenografts,
3287

Zinc finger proteins

Zic

expression, cerebellar granule cells and
medulloblastoma, 377

Zingiber officinale rhizome

tumor promotion inhibition, SENCAR
mouse skin, 1023

Zinostatin stimalamer

-induced antitumor effector cells, 1868

